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ABSTRACT
All-fr<ms-retinoic acid (ATRA) has shown spectacular success in the 
treatment of cancer and leukaemia, however ATRA is rapidly metabolised by the 
P450 enzyme CYP26. In order to enhance endogenous levels of ATRA and/or to 
extend the half life of externally administered ATRA, a CYP26 inhibitor is required.
Two series of CYP26 inhibitors were synthesised: a series of 4-alkyl/aryl- 
substituted 1 -[benzofuran-2-yl-phenylmethyl]-1 //-triazoles and a series of 
benzoxazol-2-yl-[phenylimidazol-l-ylmethyl)phenyl]amines. The triazole 
derivatives were prepared using methodology previously described by our group. 
The aminobenzoxazole derivatives were envisaged from a docking experiment using 
a CYP26A1 homology model (based on CYP3A4) template; docking experiments 
were performed with MOE. The molecular docking of the amino-benzooxazole 
imidazole derivatives indicated multiple hydrogen bonding in addition to 
coordination between the imidazole nitrogen and the P450 haem transition metal. 
The triazole derivatives were evaluated for CYP26A1 inhibitory activity using a 
MCF-7 cell-based assay. The 4-ethyl-1,2,4-triazole and the 4-phenyl-1,2,4-triazole 
derivatives displayed inhibitory activity (ICso= 4.5 and ICso= 7 pM respectively) 
comparable with liarozole (ICso= 7 pM). On the other hand the aminobenzooxazole 
imidazole derivatives were only moderate inhibitors o f the CYP26A1 enzyme in 
MCF-7 cells and did not achieve the promise shown in docking studies. The most 
potent inhibitor was the unsubstituted derivative (IC5o= 0.9 pM).
Studies of the interaction of some of these inhibitors with hemin and TPP 
were also performed using different spectroscopic techniques (mass spectrometry, X- 
ray crystallography, NMR and UV/VIS spectroscopy) and the binding constant 
was determined from the UV/VIS data for the unsubstituted compound of the 
aminobenzoxazole derivative with both hemin (XHi= (1.69 ± 0.31).105 M'1) and TPP 
(Kt2= (1.08 ± 0.18).107 M-2).
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1) GENERAL INTRODUCTION
1.1) The cvtochromc P450 Enzyme
The P450 enzymes consist of a large family of single polypeptide chains in 
the order of 45000 to 55000 Da. All these proteins contain a single iron 
protoporphyrin DC prosthetic group coordinated to the four pyrrole nitrogen atoms as 
a haem1. The fifth coordination site has the thiolate anion from a cysteine residue and
a
the sixth is probably coordinated to the imidazole group from a histidine residue 
(Figure 1.1).
HOOC
COOH
Figurel.l: Structure of protorphyrin DC3
The name cytochrome P450 comes from pigment at 450 nm as their UV/VIS 
spectrum displays a strong absorbance near 450 nm when the haem iron is reduced
1 De Matteis F.; In Iron in biochemistry and medicine, 2 *  Ed. Academic Press, London, New York, 
1980, 5293-324.
2 Poulos T.L.; Cytochrome P450: Molecular architecture, mechanism and prospects for rational 
inhibitor design. Pharm. Res., 1988,5,67-75.
3 McMuny T.J. and Groves J.T.; Metalloporphyrin models for cytochrome P450. In: Ortiz de 
Montellano, P.R., Ed. Cytochrome P450: Structure and biochemistry, New York: Plenum Press, 1986, 
1-28.
1
with sodium dithionate and complexed to carbon monoxide4. This is called a reduced 
CO difference spectrum5.
In mammals, the P450 enzymes can be found in most tissues, except the 
muscles, neurones and red blood cells6. These enzymes are located in the
• * 7endoplasmic reticulum and are highly concentrated in the liver and small intestine .
These enzymes are monooxygenases, able to insert one oxygen atom of the 
oxygen molecule (O2) into a large number of substrates, while reducing the other 
oxygen atom by two electrons to form water .
R-H + 0 2 + 2H+ + 2e' ---------------   R-OH + H2O
Where R-H is a hydrophobic substrate
They are involved in the synthesis or the degradation o f a large number of 
endogenous compounds such as steroids and fatty acids, and can also transform new 
synthesised compounds such as drugs9.
The P450 enzymes are often designated by the abbreviation CYP followed by 
a number indicating their gene family, a capital letter indicating the subfamily and 
another number for the individual gene. Members of the same family should share at 
least 40 % of the amino acids in their protein sequence while members of the same 
subfamily should share at least 55 % of their amino acids in their protein sequence.
In humans, 57 genes and more than 59 pseudogenes divided among 18 
families o f cytochrome P450 genes and 43 subfamilies have been identified10. The 18
4 Meunier B., De Visser S.P. and Shaik S.; Mechanism of oxidation reactions catalysed by cytochrome 
P450 enzymes. Chem. Rev., 2004,104,3947-3980.
5 Omura T. and Sato R.; The carbon monoxide-binding pigment o f liver microsomes. J. Biol. Chem., 
1964,239,2370-2378.
6 Waterman M.R., John M.E. and Simpson E.R.; Regulation o f synthesis and activity of cytochrome 
P-450 enzymes in physiological pathways; In: Ortiz de Montellano, P.R., Ed. Cytochrome P450: 
Structure and biochemistry; New York: Plenum Press, 1986,345-386.
7 Nerbert D.W. and Gonzalez F.J.; P450 genes: structure, evolution and regulation. Ann. Rev. 
Biochem., 1987,56,945-993.
8 Dawson J.H.; Probing structure-function relations in heme-containing oxygenases and peroxidases. 
Science, 1988,240,433-439.
9 Simmons D.L., Lalley P.A. and Kapser C.B.; Chromosomal assignments of genes coding for
components o f the mixed-functkm oxidase system in mice: Genetic localisation of the cytochrome 
P450 PB gene families and the NADPH-cytochrome P450 oxidoreductase and epoxide hydratase 
genes. J. Biol. Chem., 1985,260,515-521.
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families found in human are CYP1, CYP2, CYP3, CYP4, CYP5, CYP7, CYP8, 
CYP11, CYP17, CYP19, CYP20, CYP21, CYP24, CYP26, CYP27, CYP39, CYP46, 
CYP5110.
Their functions and substrates are variable (Table 1.1). The majority of them 
(CYP1, CYP2, CYP3, CYP7, CYP11, CYP17, CYP21, CYP39, CYP46, CYP51) are 
involved in the metabolism of drugs and steroids such as the sex hormone 
(oestrogen, testosterone) and cholesterol which is involved in cardiovascular 
disease11,12. Some others such as CYP4 and CYP5 are involved in the metabolism of
I
fatty acids (especially arachidonic acid) . Some of them also have a very specific 
function and substrate such as CYP24 responsible for the degradation of calcitriol14 
and the CYP26 responsible of the metabolism of retinoic acid15. They can also 
display different functions depending on their subfamily such as the CYP8 and the 
CYP27 families. CYP8A1 is involved in the degradation of prostacyclin, which is a 
metabolite of the arachidonic acid acting as an effective vasodilator16, while 
CYP8B1 is involved in the biosynthesis of bile acid17. Concerning the CYP27 
family, CYP27A1 is involved in bile acid biosynthesis18 while CYP27B1 is 
connected with the degradation of vitamin D19 and the function of the third member
10 Nelson D.R., Zeldin D.C., Hoffinan S.M.G., Maltais L.J., Wain H.M. and Nebert N.W.; 
Comparison o f cytochrome P450 (CYP) genes from the mouse and human genomes, including 
nomenclatures recommandations for genes, pseudogenes and altemative-splice variant. 
Pharmacogenetics, 2004, 74,1-18.
11 Nagata K. and Yamazoe Y.; Genetic polymorphism of human cytochrome P450 involved in drug 
metabolism. Drug Metabol. Pharmacokin., 2002, 77,167-189.
12 Honkakoski P. and Negishi M.; Regulation of cytochrome P450 (CYP) genes by nuclear receptor. 
Biochem. J\, 2000, 347,321-337.
13 Baer B.R. and Rettie A.E.; CYP4B1: an enigmatic P450 at the interface between xenobiotic and 
endobiotic metabolism. Drug Met. Rev., 2006,38,451-476.
14 Schuster I., Egger H., Astecker N., Herzag G., Schussler M. and Vorisek G.; Selective inhibitors of 
CYP24: mechanistic tools to explore vitamin D metabolism in human keratmocytes. Steroids, 2001, 
66,451-462.
15 Abu-Abed S.S., Beckett B.R., Chiba H., Chitalen VJ., Jones G., Metzger D., Chambon P. and 
Petkovic M.; Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid 
metabolism in F9 cells are regulated by retinoic acid receptor y and retinoid X receptor a. J. Biol 
Chem., 1998,273,2409-2415.
16 Chiang C.W., Yeh H.C., Wang L.H. and Chan N.L.; Crystal structure of the human prostacyclin 
synthase. J. Mol. Biol., 2006,364,266-274.
17 Zhang M. and Chiang J.Y.L.; Transcriptional regulation o f die human sterol 12a-hydrolase gene 
(CYP8B1). J. Biol. Chem., 2001,276,41690-41699.
18 Bjorkhem I., Araya Z., Rudling M., Angelin B., Einarsson C. and Wikvall K.; Differences in the 
regulation of the classical and the alternative pathway for bile acid synthesis in human liver. J. Biol. 
Chem., 2002,277,26804-26807.
19 Farhan H., Wahala K. and Cross H.S.; Genistein inhibits vitamin D hydroxylases CYP24 and 
CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. B iol, 2003,84 ,423-429.
3
of the family CYP27C1 is still unknown. The function of the CYP20 family is still to
be discovered.
Table 1.1: Fam ilies and function of the different cytochrome P450 in human20:
Family Function Members Names
CYP1
Drug and steroid 
(especially 
oestrogen) 
metabolism
3 subfamilies, 3 
genes, 1 pseudogenes
CYP1A1, CYP1A2, 
CYP1B1
CYP2 Drug and steroid 
metabolism
13 subfamilies, 16 
genes, 16 
pseudogenes
CYP2A6, CYP2A7, 
CYP2A13, CYP2B6, 
CYP2C8, CYP2C9, 
CYP2C18, CYP2C19, 
CYP2D6, CYP2E1, 
CYP2F1, CYP2J2, 
CYP2R1, CYP2S1, 
CYP2U1, CYP2W1
CYP3
drug and steroid 
(including 
testosterone) 
metabolism
1 subfamily, 4 genes,
2 pseudogenes
CYP3A4, CYP3A5, 
CYP3A7, CYP3A43
CYP4 arachidonic acid or fatty acid metabolism
6 subfamilies, 11 
genes, 10 
pseudogenes
CYP4A11, CYP4A22, 
CYP4B1, CYP4F2, 
CYP4F3, CYP4F8, 
CYP4F11, CYP4F12, 
CYP4F22, CYP4V2, 
CYP4X1, CYP4Z1
CYP5 thromboxane A2 synthase 1 subfamily, 1 gene CYP5A1
CYP7 bile acid biosynthesis 
7-alpha hydroxylase
2 subfamilies, 2 genes CYP7A1, CYP7B1
20 Nebert D.W. and Russell D.W.; Clinical importance of the cytochromes P450. The Lancet, 2002, 
360 ,1155-1162.
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of steroid nucleus
CYP8 varied 2 subfamilies, 2 genes
CYP8A1 (prostacyclin 
synthase), CYP8B1 
(bile acid biosynthesis)
CYP11 steroid biosynthesis 2 subfamilies, 3 genes CYP11A1, CYP11B1, CYP11B2
CYP17 steroid biosynthesis, 17-alpha hydroxylase 1 subfamily, 1 gene CYP17A1
CYP19
steroid biosynthesis: 
aromatase 
synthesizes 
oestrogen
1 subfamily, 1 gene CYP19A1
CYP20 unknown function 1 subfamily, 1 gene CYP20A1
CYP21 steroid biosynthesis 2 subfamilies, 2 genes, 1 pseudogene CYP21A2
CYP24 vitamin D degradation 1 subfamily, 1 gene CYP24A1
CYP26 retinoic acid hydroxylase 3 subfamilies, 3 genes
CYP26A1, CYP26B1, 
CYP26C1
CYP27 varied 3 subfamilies, 3 genes
CYP27A1 (bile acid 
biosynthesis), 
CYP27B1 (vitamin D3 
1-alpha hydroxylase, 
activates vitamin D3), 
CYP27C1 (unknown 
function)
CYP39
7-alpha
hydroxylation of 24- 
hydroxycholesterol
1 subfamily, 1 gene CYP39A1
5
CYP46 cholesterol 24- hydroxylase 1 subfamily, 1 gene CYP46A1
CYP51 cholesterolbiosynthesis
1 subfamily, 1 gene, 3 
pseudogenes
C YP51A1 (lanosterol 
14-alpha demethylase)
The subfamilies CYP1A, CYP2C and CYP3A are the most predominant 
P450 enzymes in humans, representing 65 % of all cytochrome P450 enzymes in the 
liver. The CYP2A (8 %) subfamily as well as the CYP2D6 (4 %) and CYP2E1 (6 %) 
are also highly expressed in the human liver. All the other families are present in low 
concentration and together represent only 17 % of all P450 enzymes (Figure 1.2).
CYP3A4, which is involved in drug metabolism, is the most abundant of all 
the CYPs in the human liver21, and is known to metabolise more than 120 different 
drugs such as codeine, diazepam, erythromycin and taxol and is responsible for many 
drug interactions in humans22.
Others
2E1
6%
Figure 1.2: Distribution of P450 enzymes in human liver23
21 Waxman D.J.; P450 gene induction by structurally diverse xenochemicals: central role of nuclear 
receptors CAR, PXR and PPAR. Archiv. Biochem. Biophys., 1999, 369, 11-23.
22 Kenworthy K.E., Bloomer J.C., Clarke S.E. and Houston J.B.; CYP3A4 drug interactions: 
correlation of 10 in vitro probe substrate. Br. J. Clin. Pharmacol., 1999, 48, 716-727.
23 Guengerich F.P.; Human cytochrome P-450 enzymes; In: Ortiz de Montellano, P.R., Ed. 
Cytochrome P450; New York: Plenum Press, 1995, 473-535.
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1.2) Reactions catalysed by cytochrome P450 and catalytic cycle
H+
ROH
Cys 7
h 2o
OH
/O
b ?
Fe111
I
Cys
N
V
RH
N
Cys
O'
r
N-
'  f t u' '
N
I
Cys
N
/  Fe11
/ f \ N
Cys 5
Figure 1.3: The reaction cycle and enzymatic intermediates known in P450 
reactions; the porphyrin ring is represented by a parallelogram and the intermediate 6 
and 7 are only hypothetical structures24.
The catalytic cycle of cytochrome P450 is shown in Figure 1.3. In its resting 
state, the P450 enzyme generally exists as a hexacoordinate low-spin Fein species 
containing a water molecule trans to its cysteine ligand (1). Binding of a RH
24 Van Vauwe J.P. and Janssen P.A.J.; Is there a case for P450 inhibitors in cancer treatment? J. Med. 
Chem., 1989, 32,2231-2239.
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substrate in the protein site changes the haem system into a pentacoordinate Fem 
complex (2). Then, there is a reduction by an electron to give the pentacoordinated 
Fe11 high spin complex (3). This electron comes from the cofactor of the enzyme, 
which can be NADH or NADPH depending on the type of P450 system.
NADPH ---------------   NADP+ + e
NADH---------------   NAD+ + e
Then in the third step, the ferrous form of the enzyme combines with a 
molecule of oxygen to form a ferric-oxy intermediate (4), which can also be in its 
Fe111 mesomeric form 5. This is followed by a second reduction step that leads to a 
short-lived activated oxygen species. Protonation of the distal oxygen of 5 produces a 
hydroperoxo-iron complex (6), which can then be transformed after losing a water 
molecule into an activated iron-oxo complex (7). Finally the oxygen atom transfers 
from the iron-oxo complex to the substrate yielding the oxidised ROH product and 
the iron complex returns to its resting state.
Although mono-oxygenation of substrate is the main function of P450 
enzymes, some other unusual catalytic functions such as oxidations involving C-C or 
C=N bond cleavage, dehydration, dehydrogenation or isomerisation have also been 
reported (Figures 1.4 and 1.6).25 In some P450s, an oxidase type activity with the 
formation of 02*’, H2O2 and H2O from reduction of O2  could be observed26. This is 
due to a partial decoupling between the electron transfer from NADPH to O2 and the 
transfer o f an oxygen atom to the substrate. Some P450s also have been found to be 
able to act as a peroxidase and catalyse the oxidative coupling of phenol27. This 
involves the oxidation of the phenol function into its phenoxy radical, followed by 
coupling of two of these radicals. Dehydrogenation of alkane CH-CH bonds and
25 Mansuy D.; The great diversity of reactions catalysed by cytochromes P450. Comp. Biochem. 
Biophys. C, 1998,121,5-14.
26 Bast A., Brenninkmeijer J.W., Savenije-Chapel E.M. and Noordhoek J.; Cytochrome P450 oxidase 
activity and its role in NADPH dependent lipid peroxidation. FEBSLett., 1983,151,185-188.
27 Stadler R. and Zenk M.H.; The purification and characterization o f a unique cytochrome P450 
enzyme from Berberis stolonifera plant cell cultures. J. Biol. Chem., 1993,268,823-831.
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formation of the corresponding double bond have also been observed with some
•  28substrates such as testosterone, valproic acid and lovastatm .
Oxidative deformylation Oxidase Dehydrogenation
P450 enzymes + 
NADPH + O?
OH OH
N
RH
ROH
MonooxidationPeroxidase type oxidation NO-synthase type oxidation
Figure 1.4: Atypical oxidation reactions catalysed by cytochrome P45025
The cleavage of a C-C bond via oxidative deformylation has also been 
proven. A good example is the oxidative demethylation observed with P450 
aromatase which is responsible for the last step of the biosynthesis of oestrone 
(Figure 1.5). The oxidative cleavage of C=N-OH bond can also be achieved using 
P450 enzymes. This non-classical monooxygenation has been found to be catalysed 
by liver microsomal P450s29.
P450 enzymes are also able to catalyse non-oxidative reactions (Figure 1.6). 
Two particular P450s, prostacyclin synthase (CYP8A1) and thromboxane synthase 
(CYP5A1) are able to act as an isomerase catalysing the formation of prostacyclin
28 Mansuy D. and Renaud J.P.; Heme-thiolate proteins different from cytochrome P450 catalysing 
monooxygenations; In: Ortiz de Montellano, P.R., Ed. Cytochrome P450: structure, mechanism and 
biochemistry; New York: Plenum Press, 1995,537-574.
29 Andronik-Lion V., Boucher J.L., Delaforge M., Henry Y. and Mansuy D.; Formation of nitric oxide 
by cytochrome P450-catalysed oxidation of aromatic amidoximes. Biochem. Biophys. Res. Commun., 
1992,185,452-458.
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and thromboxane through isomerisation of prostaglandin H230’31. Several P450s are 
also able to catalyse the reduction of azo-compounds, nitroaromatics, 
polyhalogenated compounds, tertiary amine, TV-oxides and arene oxide . This is due 
to the ability of the Fe(II) intermediate in the catalytic cycle to transfer an electron to 
substrates other than O2 containing electron-accepting properties25. Dehydration of 
substrate is also a possible function of P450 enzymes, and can occur on two forms: 
the conversion of hydroperoxides into allenes oxide33 and the transformation of 
aldoximes into nitriles34. In both cases, the reaction is catalysed by the reduced Fe(II) 
species and does not require any reducing agent
HO
Androstendione Oestrone
Figure 1.5: Transformation of androgens to oestrogens catalysed by the P450 
aromatase enzyme, CYP 19 (P450arom)-
The ability of the cytochrome P450 haem iron to exist under different 
oxidation states with different reactivity is one of the main causes of the great 
diversity of reactions catalysed by P450 enzymes35.
30 Wang L.H., Tsai A.L. and Hsu P.Y.; Substrate binding is the rate limiting step in thromboxane 
synthase catalysis. J. Biol. Chem., 2001,276,14737-14743.
3 Chiang C.W., Yeh H.C., Wang L.H. and Chan N.L.; Crystal structure of the human prostacyclin 
synthase. J. Mol. Biol., 2006,364,266-274.
3 Mansuy D., Battioni P. and Battioni J.P.; Chemical model systems for drug -metabolizing 
cytochrome P450-dependant monooxygenase. Eur. J. Biochem., 1989,184,267-285.
3 Song W.C. and Brach A.R.; Purification o f an allene oxide synthase and identification of the 
enzyme as a cytochrome P450. Science, 1991,253,781-784.
34 De Master E.G., Shirota F.N. and Nagasawa H.T.; A Beckmann-type dehydration of n- 
butyraldoxime catalysed by cytochrome P450. J. Org. Chem., 1992, 57, 5074-5075.
35 Pylypenko O. and Schlichting I.; Structural aspects o f ligand binding to and electron transfer in 
bacterial and fungal P450s. Ann. Rev. Biochem., 2004, 73,991-1018.
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(allene oxide synthase)
^OH
PGI2
OOH
PGH2
P450 enzymes OH
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+ NADPH NO
+ NADPH
NzORH
Reductase Nitric oxide reductase Dehydrase
Figure 1.6: Non oxidative reactions catalysed by cytochrome P45025.
1.3) Specific target: the CYP26 enzymes
1.3.1) Retinoid family
Retinoids are chemically derived from vitamin A, including natural 
metabolites and synthetic analogues. Provitamin A (carotenoids) from vegetables 
(carrots, spinach and broccoli) and retinyl esters from animal origin are the main
or
sources of vitamin A . Carotenoids are converted into retinol after a central 
oxidative cleavage in the intestine and then a reduction to retinol. Conversely, lipases 
or esterases from the intestine hydrolyse the retinyl esters into retinol37. Then, in the 
body retinol is converted into retinaldehyde (RAL) and retinoic acids (RAs). 
Cytochrome P450 enzymes (CYPs 1A1, 1A2 and 3A4 particularly) are responsible
36 Underwood B.A. and Arthur P.; The contribution of vitamin A to public health. FASEB, 1996,10, 
1040-1048.
37 Curley R.W. and Robarge M.J.; Retinoid structure, chemistry and biologically active derivatives. In 
G.V. S. (Ed). Retinoids: their physiological Junction and therapeutic potential, 1997, JAI Press Inc, 
London, 1-34.
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for the metabolism of retinaldehyde to ATRA in human38. Then, retinoic acids are 
hydroxylated to 4-hydroxy sd\-trans retinoic acid and more polar metabolites (Figure 
1.7).
Retinyl ester Provitamin A carotenoids Polar metabolites
Upases
Esterases
OH
Retinol
Dehydrogenase
Retinaldehyde
Dehydrogenase 
P450 enzymes
P450 enzymes 
O
4-keto all-tons retinoic acid
P450 enzymes 
O
4-hydroxy all-tons retinoic acid
P450 enzymes 
(CYP26)
OH
all-tons retinoic acid (ATRA)
Isomerase ?
\  HO O
13-c/s retinoic acid9-c/s retinoic acid
Figure 1.7: Biosynthesis and metabolism of a\\-trans retinoic acid.
RAs are the most interesting compounds; they play an important role in 
development, differentiation and homeostasis in our body39. There are three major 
forms: all-fra/w-retinoic acid (ATRA) and its two isomeric forms 9-cw-retinoic acid 
(9-cis-RA) and 13-c/s-retinoic acid (13-cw-RA) (Figure 1.8). The temperature- 
dependent interconversion of these transformations suggests that they may be
38 Zhang Q.Y., Dunbar D. and Kaminsky L.; Human cytochrome P450 metabolism of retinals to 
retinoic acids. Drug Met. Dispo., 2000,28 ,292-297.
39 Chambon P.; A decade of molecular biology of retinoic acid receptors. FASEB, 19%, 10,940-954.
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catalysed by an isomerase40’41, but no specific retinoid isomerase has been identified 
yet (Figure 1.7).
1.3.2) General mode o f action o f retinoic acid
ATRA CRABP CRABP9-cb
ATRA 9-cb
RXR RAR RXRRXR
Retinoic Acid Response Element (RARE) Retinoic X Response Element (RXRE)
DNA DNA
NUCLEUS
CYTOPLASMActivation of RXRa/RARY by 
ATRA or 9-cb RA and 
stimulates transcription of genes 
containing RARE in their promoters
Activation of RXRa/RXRT 
by 9-cb RA stimulates 
transcription of genes 
containing RXRE in 
their promoters
Figure 1.8: The bonding of ATRA and 9-cis RA to the RAR and RXR 
nuclear receptor respectively in the nucleus.
Retinoids are small hydrophobic molecules and are able to cross biological 
membranes and enter cells where they can bind to specific receptors37. These 
receptors are divided into two sub-families: the retinoic acid receptors (RARs) and 
the retinoid X receptors (RXRs). Each receptor is composed of three subtypes (a, p, 
y). The RAR family is activated by both ATRA and 9-cis RA42 whereas the RXR
40 Chen H. and Juchau M.R.; Biotransformation of 13-cis- and 9-cw-retinoic acid to all-fra/as-retinoic 
acid in rat conceptal homogenates. Drug Met. Dispo., 1998,2 6 ,222-228.
41 Giguere V.; Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in 
retinoid signaling. Endocrin. Rev., 1994,15,61-79.
42 Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umenoso K., Blumberg B., 
Kastner P., Mark M., Chambon P. and Evans R.M.; The nuclear receptor superfamily -  the 2nd decade. 
Cell, 1995,83, 835-839.
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family is activated only by 9-cis RA43 (Figure 1.8). The binding of other ATRA 
stereoisomers e.g. 13-cis RA is still unclear; however the reported antitumour 
efficacy of 13-c/s RA44, suggest that 13-cw-RA is isomerised intracellularly to 
ATRA or 9-c/s-RA or acts without obvious interaction with the known retinoid 
receptors45,46.
Most of the action of retinoids is due to their binding to the RAR site of the 
RAR/RXR heterodimer, RXR being the silent partner, as it is not able to activate the 
RAR/RXR heterodimer on its own. However it has been shown that binding of a
ahligand to the RXR allosterically improves the potencies of the RAR ligands . These 
receptors (heterodimer RAR/RXR or homodimer RXR/RXR) bind to DNA as RA- 
inducible transcriptional regulatory proteins in the RAREs (retinoic acid response 
elements) or RXREs (retinoid X response elements) regions39,48.
In the absence of ligand, the RAR/RXR heterodimer binds to the RARE and 
complex with a corepressor protein such as nuclear receptor corepressor (NCoR) 
and/or silencing mediator for retinoid and thyroid receptors (SMRT)47. These 
corepressors by recruiting histone deacetylases which catalyse the removal of acyl 
group from lysine residues cause DNA to be inaccessible to the transcriptional 
machinery49. On the other hand, binding of ATRA or an agonist to the RAR result in 
a conformational change which lead to dissociation of the corepressor and 
recruitment o f a coactivator protein50 which in turn promotes transcriptional 
activation by interacting directly with the basal transcriptional activation or by
43 Heyman R.A., Mangelsdorf DJ., Dyck JA., Stein R.B., Eichele G., Evans RJM. and Thaller C.; 9- 
cis retinoic acid is a high affinity ligand fen* die retinoid X receptor. Cell, 1992, 68,397-406.
44 Steams M.E., Wang M. and Fudge K.; Liarozole and 13-m-retinoic acid anti-prostatic tumor 
activity. Cancer Res., 1993,53,3073-3077.
45 Njar V.C.O., Gediya L., Purushottamachar P., Chopra P., Vasaitis T.S., Khandelwal A., Mehta J., 
Huynh C., Belosay A. and patel J.; Retinoic acid metabolism blocking agent (RAMBAs) for treatment 
of cancer and dermatological diseases. Bioorg. Med Chem., 2006,14,4323-4340.
46 Armstrong J.L., Redfem C.P.F. and Veal GJ.; 13-cis retinoic acid and isomerisation in paediatric 
oncology-is changing shape the key to success? Biochem. Pharm., 2005, 69, 1299-1306.
47 Kurokawa R., Soderstrom M., Horlein A , Halachmi S., Brown M., Rosenfeld M.G. and Glass C.K.; 
Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature, 1995, 377, 
451-454.
48 Altuchi L. and Gronemeyer H.; The promise of retinoids to fight cancer. Nat. Rev. Cancer, 2001,1, 
181-193.
49 Loinder K. and Soderstrom M.; The nuclear corepressor (NCoR) modulates basal and activated 
transcription o f genes controlled by retinoic acid. J. Steroid Biochem. MoLBiol., 2003,8 4 ,15-21.
50 Pogenberg V., Guichou J.F., Vivat-Hannah V., Kammerer S., Perez E., Germain P., De Lera A.R., 
Gronemeyer H., Royer C.A and Bourguet W.; Characterization o f the interaction between retinoic 
acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through 
structural and fluorescence anisotropy studies. J. Biol. Chem., 2005,280 ,1625-1633.
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encoding histone acetyl transferase activity (HAT) which causes chromatin to relax 
and increases the access to DNA51.
RAR RAR
ATRA
Nucleus
CRAPB-II
Cytoplasm
Response
CRAPB-II-
ATRA
complex
Figure 1.9: Mechanism of action of the cellular retinoic acid binding protein 
II (CRABP II)33.
Two binding proteins, CRABP I and CRABP II (cellular retinoic acid-binding 
proteins I and II) are also involved in the mechanism of actions of ATRA. Their role 
is to solubilise and stabilise retinoic acid in aqueous milieu and then to transport it in 
different compartments of the cell . Although they are very similar, the two 
isoforms of CRABP serve different functions in the cell. This might be due to their 
different binding affinity with retinoic acid53. CRABP I has been shown to moderate 
the cellular response to ATRA by facilitating its catabolism. The retinoic acid bound
51 Dilworth F.J., Fromental-Ramain C., Remboutsika E., Benecke A. and Chambon P.; Ligand- 
dependant activation of transcription in vitro by retinoic acid receptor a/retinoid X receptor a 
heterodimers that mimics transactivation by retinoids in vitro. Proc. Natl. Acad. Sci. USA, 1999, 96, 
1995-2000.
52 Noy N.; Retinoid-binding protein: mediators of retinoid action. Biochem. J., 2000, 348,481-495.
53 Norris A.W., cheng L., Giguere V., Rosenberger M. and Li E.; Measurement of subnanomolar 
retinoic acid binding affinities for cellular retinoic acid binding proteins by fluorometric titration. 
Biochim. Biophys. Acta, 1994, 1209, 10-18.
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to CRABP I is metabolised by CYP26 enzymes resulting in the formation of more 
polar metabolites54. While CRABP I acts as a passive vehicle which binds and 
release its ligand, CRABP II delivers retinoic acid to the RAR in a direct collisional 
process39 (Figure 1.9). As a result, the ligation of the RAR by retinoic acid is 
facilitated and it enhances the transcriptional activity of the RAR It has also been 
demonstrated that the expression of CRABP II plays a role in sensitising cells such 
as MCF-7 to retinoic acid55.
1.3.3) Retinoids and cancer
A total of 1,444,920 new cancer cases and 589,650 deaths for cancer are 
projected to occur in the United States in 200756.The most common are lung (31 %), 
bowel (19 %), breast (15 %) and prostate (9 %)56. Therefore, the development of 
drugs involved in cancer therapy and chemoprevention is o f main interest. Retinoids 
and especially retinoic acid have been known to be associated with the development 
and the treatment of cancer in human57.
Retinoic acid (RA) is a naturally occurring retinoid that exists in three 
isomeric forms: s&l-trcms-RA (ATRA), 9-cis-RA (9cRA) and 13-cw-RA (13cRA) 
(Table 1.2). Retinoic acid is an essential regulator o f embryogenesis, high 
concentrations of retinoic acid has shown to be teratogenic (capable of causing 
malformation in the embryo), while insufficient vitamin A concentration can also 
cause severe malformation48.
RA is commonly used as a therapeutic treatment for dermatological disease 
such as acne, psoriasis and ichtyosis58, 59 (Table 1.2). However side effects such as 
skin irritation constitute a limit to their prolonged use60.
54 Fujii H., Sato T., Kaneko S., Gotoh O., Fujii-KuriyainaY., Osawa K., Kato S. and Hamada H.; 
Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse 
embryos. EMBOJ., 1997,16,4163-4173.
55 Manor D., Schmidt E.N., Budhu A., Flesken-Nikitm A., Zgola M., Page R , Nikitin Y.A. and Noy 
N.; Mammary carcinoma suppression by cellular retinoic acid binding protein II. Cancer Res., 2003, 
63,4426-4433.
56 Jemal A., Siegel R., Ward E., Murray T., Xu J. and Thun MJ.; Cancer statistics, 2007. CA Cancer 
J. Clin., 2007,57,43-66.
57 Zanardi S., Serrano D., Argusti A., Barile M., Puntoni M. and Decensi A.; Clinical trials with 
retinoids for breast cancer prevention. Endocrin. Rel. Cancer, 2006,13,51-68.
58 Kuijpers A.L., Van Pelt P.T., Bergers M., Boegheim P.J., Den Bakker J.E., Siegenthaler G., Van der 
Kerkhof P.C. and Achalkwijk J.; The effects of oral liarozole on epidermal proliferation and 
differentiation in severe plaque psoriasis are comparable with those o f acitretin. Br. J. Dermatol., 
1998,139,380-389.
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ATRA has been proven to be an effective treatment in cancer 
chemoprevention and in differentiation therapy of cancer. Clinical studies have
shown the efficacy of RA in reversing human premalignant lesions and in the
61 62prevention of primary tumour of head and neck, liver, skin and breast cancer ’ 
Retinoids have also been known to have anti-proliferative effects on the growth of 
various tumour cells in vitro, including prostate cancer (LNCap) , breast carcinoma 
(MCF-7, ZR-75.1) 64 and human leukaemia cells (HL60)65. The most impressive 
effect o f ATRA therapy has been observed in the treatment of acute promyelocytic 
leukaemia (APL) for which a complete remission was observed with high dose of 
ATRA66’ 67 (Table 1.2).
The two others stereoisomers 13-c/s-RA (Isotretinoin) and 9-cis-RA 
(Alitretinoin) are also used clinically for the treatment o f dennatologic diseases such 
as acne58, psoriasis59 and also in the treatment of APL66 and Kaposi’s sarcoma (KS) 68 
(Table 1.2).
59 Thacher S.M., Vasudenvan J., Tsang K.Y., Nagpal S. and Chandraratna R.A.S.; New 
dennatological agents for the treatment of psoriasis. J. Med. Chem., 2001, 44 ,281-297.
60 Esgleyes-Ribot T., Chandraratna R.A.S., Lew-Kaya D.A., Sefton J. and Du vie M.; Response of 
psoriasis to a new topical retinoid, AGN 190168. J. Am. Acad Dermatol., 1994,30,581-590.
Sun S.Y. and Lotan R.; Retinoids and their receptors in cancer development and chemoprevention. 
Crit. Rev. Oncol. Hematol., 2002,41,41-55.
62 Miller W.H.; The emerging role of retinoids and retinoic acid metabolism blocking agents in the 
treatment o f cancer. Cancer, 1998,8 3 ,1471-1482.
63 Shen J.C., Wang T.T., Chang S. and Hursting S.D.; Mechanistic studies o f the effects of die retinoid 
Y-(4-hydroxyphenyl)retinamide) mi prostate cancer cell growth and apoptosis. Mol. Carcinogen., 
1999,281, 1598-1604.
64 Van Heusden J., Wouters W., Ramakaers F.C.S., Krekels M.D.W.G., Dillen L., Borgers M. and 
Smets G.; Hie anti-proliferative activity of ATRA catabolites and isomers is differentially modulated 
by liarazole-fumarate in MCF-7 human breast cancer cells. Br. J. Cancer, 1998, 77,1229-1235.
6 Fontana J.A., Dawson M.I., Leid M., Rishi A.K., Zhang Y., Hsu C.A., Lu J.S., Peterson V.J., Jong 
L., Hobbs P., Chao W.R., Shroot B. and Reichert U.; Identification of a unique binding protein 
specific for a novel retinoid inducing cellular apoptosis. Int. J. Cancer, 2000,86,414-419.
Huang M., Ye Y., Chen S., Chai J., Lu J., Zhoa L., Gu L. and Wang Z.; Use o f all-/rarcs-retinoic 
acid in the treatment of acute promyelocytic leukaemia. Blood, 1988, 72,567-572.
67 Witcher M. and Miller W.H. Jr; Cytokine and retinoic acid therapy for APL: new tricks from an old 
combination. Leukemia Res., 2004,28,447-448.
68 Guo W.X., Gill P.S. and Antakly T.; Inhibition o f AIDS-Kaposi’s sarcoma cell proliferation 
following retinoic acid receptor activation. Cancer Res., 1995,55, 823-829.
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Table 1.2: Structure and therapeutic application of retinoic acid isomers used 
clinically
Retinoid Structure Target Application
Tretinoin
(ATRA)
RAR agonist APL, Acne
Isotretinoin
(13-cw-RA)
RAR agonist Acne
Alitretinoin
(9-c/s-RA)
RAR and RXR 
agonist
Psoriasis, APL, 
KS
Despite the anti-cancer properties of RA, its use in the therapy of human 
cancer in the clinic has been quite disappointing69. The metabolism and catabolism of 
RA by P450 enzymes seem to be the cause of its reduced therapeutic effects70. 
Although few P450 enzymes are known to be involved in retinoid metabolism71 
(CYP2C8, CYP3A4, CYP2C9 and CYP26), the CYP26 is the only of these enzymes 
to have a high specificity for RA72.
1.3.4) Role o f CYP26
CYP26 is membrane bound and is located in the endoplasmic reticulum, it is 
found in highest levels in adult liver, heart, pituitary gland, adrenal gland, testis, 
duodenum, colon, placenta and regions of the brain73, 74. Studies by Taimi et al. 75
69 Trump D.L., Smith D.C., Stiff D., Adedoyin A., Day R., Banhson R.R., Hofacker J. and Branch 
R.A.; A phase II trial o f all-Zrons-retinoic acid in hormone-refractory prostate cancer a clinical trial 
with detailed pharmacokinetic analysis. Cancer Chem. Pharm., 1997,3 9 ,349-356.
70 Huynh C.K., Brodie A.M.H. and Njar V.C.O.; Inhibitory effects of retinoic arid metabolism 
blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour 
xenografs in SCID mice. Br. J. Cancer, 2006,94, 513-523.
71 Marill J., Cresteil T., Lanotte M. and Chabot G.G.; Identification of human cytochrome P450s 
involved in the formation of all-frans-retinoic acid principal metabolites. Mol. Pharmacol., 2000, 58, 
1341-1348.
72 Njar V.C.O.; Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer 
therapy. Min. Rev. Med Chem., 2002,2 ,261-269.
73 Ray W.J., Bain G., Yao M. and Gottlieb D.I.; CYP26 a novel mammalian cytochrome P450, is 
induced by retinoic arid and defines a new family. J. Biol. Chem., 1997,272 ,18702-18708.
74 Lampen A., Meyer S. and Nau H.; Effects o f receptor-selective retinoids on CYP26 gene expression 
and metabolism of all-/ra/w-retinoic arid in intestinal cells. Drug Met. Dispo., 2001,29, 742-747.
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showed the existence of three different types of CYP26: CYP26A1, CYP26B1 and 
CYP26C1. More recently, a fourth CYP26 enzyme CYP26D1 has also been 
identified in zebrafish76.
CYP26 plays a key role in retinoic acid metabolism. It acts on retinoids, 
including all-/rans-retinoic acid (ATRA) and its stereoisomer 9 -cis-retinoic acid (9- 
cis-RA) and 13-ds-retmoic acid (13-cis-RA) (Figure 1.7), enable of both 4- 
hydroxylation and 18-hydroxylation responsible for the generation of several 
hydroxylated forms of retinoic acid, including 4-hydroxy-retinoic acid, 4-oxo- 
retinoic acid and 18-hydroxy-retmoic add (Figure 1.7). These enzymes exhibit a 
high degree of specifidty for ATRA (ATRA»>9-c/$-RA> 13 -cis- 
RA>retinaldehyde>retinol)77. However CYP26C1, which shares many similarities 
with the other member o f its family CYP26A1 and CYP26B1, is also able to 
metabolise the ATRA stereoisomer 9-cw-RA75. The role o f the CYP26 enzymes is to 
regulate the level of intracellular ATRA in the body and to protect tissues from 
inappropriate level of ATRA78.
Induction of C YP26 enzyme by ATRA has been observed in a large number 
of normal and cancer cells such as MCF-7, T47D, NB4, HepG2, HPK1A and 
LNCaP45. An inappropriate metabolism of ATRA by CYP26 is also related to some 
dermatological diseases such as acne, psoriasis and ichtyosis79.
CYP26 enzymes are involved in the regulation o f both normal and 
therapeutic level of ATRA. They may also be involved in the limited effect of 
retinoic acid treatment observed in the dime. Inhibition o f these enzymes would 
consequently lead to an increase in the level o f endogenous and co-administered 
ATRA. The development o f retinoic add metabolism blocking agents (RAMBAs) or
75 Taimi M., Helvig C., Wisniewski J., Ramshaw H., White J., Amad M., Korczak B. and Petkovich 
M.; A novel human cytochrome P450 CYP26C1, involved in metabolism o f 9-cis and all-tom? 
isomers o f retinoic add. J. Biol. Chem., 2004,279,77-85.
76 Gu X., Xu F., Song W., Wang X., Hu P., Y a $  Y., Gao X. and Zao Q.; A novel cytochrome P450, 
zebrafish Cyp26Dl, is involved in tiie metabolism of aU-jftzm-ietmoic acid. Mol. Endo., 2006, 20, 
1661-1672.
77 Sonneveld E., Van den Brisk C.E., Van der Leede BJ.M., Schulkes RJCAM , Petkovic M., Van 
der Burgh B. and Van der Saag P.T.; Human retinoic add (RA) 4-hydroxyiase (CYP26) is highly 
specific for all-rrarar-RA and can be induced through RA receptors in human breast and colon 
carcinoma cells. Cell Growth Differ., 1998,9,629-637.
78 Perimann T.; Retinoids metabolism: a balancing act Nature Gen., 2002,31 ,7-8.
79 Orfanos C.E., ZoubouKs C.C., Almond-Roestler B. aid GeOen C.C.; Current use and future 
potential role o f retinoids in dermatology. Drug?, 1997,53 ,358-388.
19
CYP26 inhibitors thus emerged as a good therapy for cancer chemoprevention or 
treatment and dermatological disease.
1.3.5) Known CYP26 inhibitors or retinoic acid metabolism blocking agents 
(.RAMBAs)
The development of retinoic acid metabolism blocking agents (RAMBAs) 
has been a major subject of research in the past 2 0  years resulting in an important 
number o f drugs.
(a) Liarozole (Liazal™) and ketoconazole
Well established inhibitors are the two imidazole compounds: ketoconazole80 
and liarozole81 (Figure 1.10).
Ketoconazole was one o f the first oral treatments for fungal infections and is 
still sold as an anti-dandruff shampoo branded Nizoral® by Janssen Pharmaceutica82. 
It is also well-known to be an efficient inhibitor o f some P450 enzymes including 
CYP2683. However it has a poor activity with an IC50 of 18 pM and a very poor 
selectivity for CYP2684.
Liarozole displayed an IC50 of 6  pM for CYP26 inhibition81 and has also 
been proven to be a potent inhibitor of CYP17 (IC5o= 260 nM) and CYP1985’ 86. 
Liarozole remains the only RAMBA so far to have been evaluated clinically for 
cancer and dermatological diseases.
80 Heeres J., Backx L J., Mostmans J.H. and Van Cutsem J.; Antimycotic imidazoles. Part 4. Synthesis 
and antifungal activity o f ketoconazole, anew potent orally active broad-spectznm antifangal agent. J. 
Med Chem., 1979,2 2 ,1003-1005.
81 Freyne E., Raemaekers A., Venet M., Sanz G., Wouters W., De Coster R. and Van Wauwe J.; 
Synthesis of LIAZAL™, a retmoic acid metabolism blocking agent (RAMBA) with potential clinical 
applications in oncology and dermatology. Bioorg. Med Chem. Lett., 1998,8 ,267-272.
Buhner A.C. and Buhner G.S.; The antifungal action o f dandruff shampoo. Afyeopathologia, 1999, 
147,63-65.
83 Van Wauwe JJP., Coene M.C., Goosens J., Van Nigen G., Cools W. and Lauwers W.; Ketoconazole 
inhibits the in vitro and in vivo metabolism o f all-trans-retinoic acid. J. Pharm. Exp. Ther., 1988,245, 
718-722.
84 Yee S.W. and Simons C.; Synthesis and CYP24 inhibitory activity o f 2-substituted-3,4-dihydro-2//- 
naphtalen-l-one (tetralones) derivatives. Bioorg. Med Chem. Lett., 2004,14,5651-5654.
85 Leze MJP., Le Borgne M., Marchand P., Loquet D., Kogler M., Le Baut G., Pahisczak A. and 
Hartmann R.W.; 2- and 3-[(aiylXazolyl>netiiyl]iiidoles as potential non-steroidal aromatase inhibitor. 
J. Em. Inhib. Med Chan., 2004,19,549-557.
86 Van Ginckel R., De Coster R., Wouters W., Vanherck W., Van der Veer R , Goeninne N., Jagers
E., Van Canteen H., Wouters L., Distefanans W. and Janssen P.; Antitummal effects of R75251 on 
the growth of transplantable R3327 prostatic adeiocarcinoinain rats. Prostate, 1990,16,313-323.
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Anti-tumour activity has been observed in the treatment of prostate cancer in 
immunodepressed mice87 and in rat prostate carcinoma44. It has also shown in vivo 
anti-tumour activity for breast cancer therapy88. These studies also revealed that the 
anti-tumour properties of liarozole were correlated to its inhibition of ATRA 
metabolism. Studies have shown that treatment with liarozole will increase the level 
of endogenous ATRA89 and also increase the half-life of exogenous administered 
ATRA90.
As a result, liarozole progressed to a phase in clinical trial tor prostate 
cancer91. The study showed that liarozole was efficient in improving life expectancy, 
pain reduction and maintaining the quality o f life o f patients and was therefore a 
good treatment for prostate cancer.
However, despite these very encouraging results in preclinical and clinical 
studies, side effects due its lack of CYP specificity and moderate potency in CYP26 
inhibition appeared to be a strong limitation for its use in cancer therapy. 
Consequently, the clinical development of liarozole has been stopped92.
87 Smets G., Van Ginckel R., Daneels G., Moeremans M., Van Wauwe J., Coene M.C., Romarehers
F.C., Schalken J.A., Borgers M. and De Coster R.; Liarozole, an antitiimor cfrug, modulates 
cytokeratin expression in the dunning AT-6sq prostatic carcinoma through in situ accumulation of all- 
trans retinoic acid. Prostate, 1995,2 7 ,129-140.
88 Goss P.E., Strasser K., Marques R., Clemons M., Oza A., Goel R., Blackstein M., Kaizer L., Stems 
E.E., Nabholtz J.M., De Coster R., Crump M., Abdolell M. and Qi S.; Liarozole fumarate (R85246): 
in the treatment o f ER negative tamoxifen refractory or chemotherapy resistant postmenoposal 
metastatic breast cancer. Breast Cancer Res. Treat., 2000,6 4 ,177-188.
89 Van Wauwe J.P., Coene M.C., Goosens J., cools W. and Monbaliu J.; Effects o f cytochrome P450 
inhibitors on the in vivo metabolism o f aU-trans retinoic acid in rats. J. Pharmacol. Exp. Ther., 1990, 
252,365-369.
90 Achkar C.C., Bentel JJML, Boylan JJF., Scher H.I., Gudas L.J. and Miller WJL Jr, Differences in the 
pharmacokinetic properties o f orally administrated all-trans retmoic acid and 9-cis-retinoic acid in the 
plasma of nude mice. Biochem. Pharmacol., 1994,47,737-741.
Debruyne FJ.M., Murray R., Fradet Y., Johansson JJL, Tyrrel C., Boccardo F., Denis L., 
Marberger J., Bnme D., Rasswiler J., Vangeneugden T., Bruynseels J., Jansens M. and De Porre P.; 
Liarozote-a novel treatment approach for advance prostate cancer, results o f a large randomized trial 
versus cyproteron acetate. Urology, 1998,52 ,72-81.
92 Goss P.E., Strasser K., Marques R , Clemons M., Oza A., Goel R., Blackstein M., Kaizer L., Stems 
E.E., Nabhohz JJM., Coster RJX, Crump M., Abdoiell M. and Qi S.; Liarozole fumarate (R85246): in 
the treatment o f ER negative, tamoxifen refractory or chemotherapy resistant postmenoposal 
metastatic breast cancer. Breast Cancer Res. Treat., 2800,6 4 ,177-188.
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Figure 1.10: Chemical structure o f ketoconazole80 and liarozole81.
Because o f the contribution of ATRA in some skin disorders, liarozole has 
also been studied for dermatological diseases. Clinical studies showed that liarozole 
was in fact an effective therapy for psoriasis9 3 ,94  and ichtyosis95. As a result liarozole 
has been recently approved (2004) in Europe and in the USA as an orphan drug for 
the treatment of congenital ichtyosis96.
(b) R 115866 and R116010
Two benzothiazolamines compounds with high potency and selectivity for 
CYP26 inhibition have been developed: R11586697 (ICso= 4 nM) and R11601098 
(IC5o= 8.7 nM), (Figure 1.11). They displayed about 1000 fold more potency than 
liarozole (ICso= 6  pM)81.
R 115866 has been shown to be very specific for CYP26 inhibition with 
moderate inhibitory activity versus CYP19 (ICso= 2.6 pM), CYP17 (IC5o= 1.2 pM),
93 Dockx P., Decree J. and Degree H.; Inhibition o f the metabolism of endogenous retmoic acid as 
treatment for severe psoriasis: an open study with oral liarozole. Br. J. Dermatol., 1995,735,426-432.
94 Berth-Jones J., Todd G., Hutchinson P.E., Thestnip-Petersen K. and Vanhotrtte F.P.; Treatment of 
psoriasis with oral liarozole: a dose-ranging study. Br. J. Dermatol., 2000,143,1170-1176.
Lucker G.P.H., Heremans A.M.C., Boegheim PJ., Van der Kerkhof P.C.M. and Steijlen P.P.M.; 
Oral treatment o f ichtyosis by the cytochrome p450 inhibits liarozole. Br. J. Dermatol, 1997,136, 
71-75.
96 Lucker G.P.H., Verfaille C.J., Heremans A.M.C., Vanhoutte F.P., Boegheim PJ. and Steijlens 
P.P.M.; Topical liarazole in ichtyosis: a double-blind, left-right comparative study followed by a long 
term open maintenance study. Br. J. Dermatol., 2005,152,566-568.
97 Stoppie P., Borgers M., Boighraef P., Dillen L., Goossens J., Sanz G., Szel H., Van Hove C., Van 
Nyen G., Nobels G., Van den Bossche H., Venet M., Willemsens G. and Van Wauwe J.; R115866 
inhibits aH-^am-retinoic acid metabolism and exarts retinoidal effects in rodents. J. Pharmacol. Exp. 
Ther., 2000,293,304-312.
98 Van Heusden J., Van Ginckel R., Bruwiere H., Moelans P., Janssen B., Floren W., Van des Leede 
B.J., Van Dun J., Sanz G., Venet M., Dillen L., Van Hove C., Willemsens G., Jankot M. and Wouters 
W.; Inhibition o f ah-tamsHnetinoic acid metabolism by R116010 induces antitumour activity. Brit. J. 
Cancer, 2002,86 ,605-611.
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CYP2C11 (ICso= 12  pM), CYP2A1 (ICstr 9.1 pM) and CYP3A4 (20 % inhibition 
at 10 pM) 97 and should thus be less likely to show any unwanted side effects. In vivo 
studies have also proved that R115866 is able to enhance endogenous retinoic acid 
levels and also to mimic the effects o f retinoic acid83. As a result, R115866 was 
found to exert retinoidal activities and displayed some potential in dermatological 
therapy: in the treatment of severe facial acne vulgaris and plaque-type psoriasis 
R115866 exhibited a  modulating effect on epithelial growth and differentiation in 
various animal models of keraHnisation99,100’101.
R116010 also displayed specificity for CYP26 inhibition. R116010 inhibition 
activity versus other CYPs is quite low. It is superior at 10 pM for CYP2A1, 
CYP2B1, CYP2B2, CYP2C11, CYP3A and CYP19 and moderate for CYP17 (ICso=
0.25 pM)98. R116010 has shown anti-tumour activity as a  single agent and enhanced 
the anti-proliferative property of retinoic acid both in vitro and in vivo98. R116010 
has also shown potency in the treatment o f neuroblastoma while co-administrated 
with 13-c/j-RA102.
99 Verfaille C.J., Coel M., Boersma I.H., Mertens J., Borgers M. and Roseeuw D.; Oral R115866 in 
the treatment o f moderate to severe facial acne vulgaris: an exploratory study. Br. J  Dermatol, 2007, 
157,122-126.
100 Verfaille CJ., Thissen C.A.C.B., Bovenshen HJ., Mertens J., Steijlen P.M. and Van der Kerkhof 
P.C.M.; Oral R115866 in the treatment o f moderate to severe plaque-type psoriasis. J. Ear. Acad. 
Dermatol Venereol, 2007,2 1 ,1038-1046.
101 Bovenschen HJ., Otero M.E., Langewouters A.M.G., Van Vlijmen-Willems I.M.J.J., Van Rens 
D.W.A., Seyger M.M.B. and Van der Keikhof P.C.M.; Oral retinoic acid metabolism blocking agent 
Rambazole™ for plaque psoriasis: an immunohistochemical study. Br. J. Dermatol, 2007,156,263- 
270.
102 Armstrong J.L., Taylor GA^ Thomas HJ)., Boddy A.V., Redfem CJP.F. and Veal GJ.; Molecular 
targeting o f retinoic acid metabolism in neuroblastoma: the role o f CYP26 inhibitor R116010 in vitro 
and in vivo. Br. J. Cancer, 2007,9 6 ,1675-1683.
HH
R115866 R116010
Figure 1.11: Chemical structure of R11586697 and R11601098.
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R115866 and R116010 are thus two very interesting RAMBAs showing both 
high potency and high specificity for CYP26 inhibition. They also displayed 
promising results in cancer and dermatological therapy.
(c) RAMBAs recently developed
Few very potent RAMBAs displaying activities in the nanomolar range have 
been developed in the last few years. Three series o f compounds hold our attention: a 
series of benzeneacetic acid103’104, a series o f 2 ,6 -disubstituted naphthalene1 0 5 ,106 and 
a series of azolyl retinoids107 (Figure 1.12).
im
A series of benzeneacetic acid derivatives have recently been developed ’ 
m . The most potent inhibitor of the series containing an acetylene linker between an 
aromatic moiety and a substituted chiomain as well as two cyclopropyl rings (Figure
1.12) displayed a CYP26 inhibitory activity of 14 nM in HeLa cells.
Mulvihil et a/.105, 106 proposed a series o f 2,6-disubstituted naphthalenes 
which m im ic the haem-binding imidazolyl-propylamino moiety of R116010 with a 
naphthalene core substituted at the 6 -position by an ether group. The most potent 
inhibitor of the series displayed a very potent activity (ICso= 1.3 nM in T47D cells) 
as well as a high specificity over CYP3A4 enzyme (IC5o= 3300 nM) 105 (Figure 1.12). 
The potent activity o f these 2,6-disubstituted naphthalenes as well as their selectivity
103 Vasudevan J., Jonhsoo A.T., Huang D. and Chadraratna R.A.; Preparation of compounds having 
activity as inhibitors o f cytochrome P450RAI. U.S. Patent, 2001,68 pp.
104 Vasudevan J., Johnson A.T., Huang D., Wang L. and Chandraratna R.A.; Preparation of 
tetrahydronaphtalenes, tetrahydroisoquinolines, chromans, spirobenzopyrancyclopropanes and related 
compounds as cytochrome P450RAI inhibitors. U.S. Patent, 2002,269 pp.
105 Mulvihil M J., Kan J.L.C., Cooke A., Bhagwat S., Beck P., Bittner M., Cesario C., Keane D., 
Lazarescu V., Nigro A., Nillson C., Panicker B., Smith V., Srebemak M., Sun F.L., O’Connor M., 
Russo S., Fischetti G., Vridjan M., Winski S., Castelhano AJL, Emerson D. and Gibson N.W.; 3-[6- 
(2-Dimethylamino-l-imida7nl-l-yl-butyl)-naphtalen-2-yloxy}-2,2-dimethyl-propionic acid as a highly 
potent and selective retinoic acid metabolism blocking agent Bioorg. Med. Chem. Lett., 2006, 16, 
2729-2733.
106 Mulvihil M J., Kan J.L.C., Beck P., Bittner M., Cesario C., Cooke A., Keane D id., Nigro A.I., 
Nillson C., Smith V., Srebemak M., Sim FX., Vrkljan M., Winski S.L., Castelhano A.L., Emerson D. 
and Gibson N.; Potent and selective [2-imidazol-1 -yl-2-{6-alkoxy-naphtaleii-2-yl)-1 -methyl-ethyl]- 
dimethyl-amines as retinoic acid metabolism blocking agents. Bioorg. Med Chem. Lett., 2005, 15, 
1669-1673.
107 Patel J.B., Huynh CJL, Handratta V.D., Gediya L., Brodie A.M.H., Goloubeva O.G., Clement 
O.O., Nnane I.P., Sopranoo D.R. and Njar V.C.O.; Novel retinoic acid metabolism blocking agents 
endowed with multiple biological activities are efficient growth inhibitors o f human breast and 
prostate cancer cells in vitro aid a human breast tumor xenograft in nude mice. J. Med Chem., 2004, 
47 ,6716-6729.
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for CYP26 over CYP3A4 make them good candidates for further development as 
therapeutic agents in dermatology and oncology.
OH
HOOC
2,6-disubstituted naphtalene (1C 5 0 = 3.3 nM)Benzeneacetic acid derivatives (1C5 0 = 14 nM)
OH
: 0.009 nM)
Figure 1.12: Chemical structure of the most potent compound of the
benzeneacetic derivatives103, 104, the 2 ,6 -disubstituted naphthalene derivative105, 106 
and the azolyl derivative107.
The most potent CYP26 inhibitor to date has been described by the Njar 
group107. As the presence of an azole ring seems to be essential in the design of 
RAMBAs, their compounds have been designed by introducing an azole ring at the 
C-4 position of ATRA, which is the position of the initial enzymatic hydroxylation 
(Figure 1.12). Compound VN/14-1 with an imidazole ring as a substituted appeared 
to be the most potent inhibitor of CYP26 with an inhibitory activity of 0.009 nM so 
almost 100000 fold the activity of liarozole (IC5o= 6000 nM)81. These compounds as 
well as being potent inhibitors of ATRA metabolism exhibited multiple biological 
activities such as induction of apoptosis and differentiation and antiproliferative 
activity on a number of human cancer cells108,70.
108 Belosay A , Brodie A.M.H. and Njar V.C.O.; Effects o f novel retinoic acid metabolism blocking 
agent (VN/14-1) on letrozole-insensitive breast cancer cells. Cancer Res, 2006,6 6 ,11485-11493.
^  ^  azolyl retinoid VN/14-1 (IC,
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(ch RAMBAs previously developed in our laboratory
•  109Our group has been interested in inhibition of CYPs including CYP19 , 
C YP2484 and CYP26 for a number of years. However the emerging role of RAMBAs 
as potential anti-cancer agents focussed our interest in the development of CYP26 
inhibitors. Two main type of structures were investigated: a series of pyrrolidin-2,5- 
diones derivatives110 and a series of tetralone derivatives111 (Figure 1.13).
A series of pyrrolidin-2,5-dione derivatives substitututed by a long alkyl 
chain or an aryl group at the 1-, 3- or 1,3-position was first investigated. They 
appeared to be weak inhibitors of ATRA metabolism against rat liver microsomes 
(68-80 % inhibition at 100 pM) compared to ketoconazole (85 % inhibition at 100 
pM)110. The most potent compound II of the series contained a long alkyl chain 
(C6H13) in position -1 and no substitution in position -3.
The tetralone derivatives displayed more promising results. The tetralone 12 
(IC5o= 12.75 pM) was 2 fold more potent than ketoconazole (IC5o= 22.15 pM) 
against rat liver microsomal RA-metabolising enzymes111. Also no difference in the 
activity was observed between the two isomer (+) and (-). A later study by Angotti et 
al.n i also showed that tetralone 1 2  was able to enhance the endogenous plasma 
concentration of retinoic acid and that the tetralone inhibitory activity was 
comparable to ketoconazole. Transformation of the tetralone derivatives into a 
benzylidene tetralone 13 or a benzyltetralone derivatives 14 increased the activity to a 
level comparable with liarozole with measured IC50 of 5 to 9 pM in MCF-7 cells 
(liarozole IC50= 7 (iM)113.
109 Saberi M.R., Vinh T.K., Yee S.W., Griffiths B.J.N., Evans P.J. and Simons C.; Potent CYP19 
(aromatase) 1 [(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: 
synthesis and biological evaluation. J. Med Chem., 2006,4 9 ,1016-1022.
Kirby A.J., Le Lain R., Mason P., Maharlouie F., Nicholls P.J., Smith HJ. and Simons C.; Some 3- 
(4 -aminophenyl)pyrrolidine-2,5 -dinones as all-tra/is-retinoic acid metabolizing enzyme inhibitors 
(RAMBAs). J. Em. Inhib. Med Chem., 2002,17,321-327.
111 Kirby AJ., Le Lain R., Maharlouie F., Mason P., Nicholls P.J., Smith H.J. and Simons C.; 
Inhibition of retinoic acid metabolizing enzymes by 2-{4-aminophenylmethyI)-6-hydroxy-3,4- 
dihydronaphtalen-l(2H)-one and related compounds. J. Em. Inhib. Med Chem., 2003,18,27-33.
112 Angotti M., Hartmann R.W., Kirby AJ., Simons C., Nicholls PJ., Sewell R.D.E. and Smith H.J.; 
Effect of 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphtalen-1 (2H)-one on all-trans and 13- 
cis retinoic acid levels in plasma quantified by high performance liquid chromatography coupled to 
tandem mass spectrometry. J. Enz. Inhib. Med Chem., 2005,20 ,219-226.
113 Yee S.W., Jamo L., Gomaa M.S., Elford C., Ooi L.L., Coogan M.P., McClelland R., Nicholson 
R.I., Evans B.A.J., Brancale A. and Simons C.; Novel tetralone-derived retinoic acid metabolism 
blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell 
assays. J. Med Chem., 2005,48, 7123-7131.
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Figure 1.13: Chemical structure of the most potent compounds previously 
developed in our laboratory.
In conclusion, the pyrrolidin-2,5-dione derivatives and the tetralone 
derivatives displayed a weak to moderate activity towards CYP26 inhibition. The 
tetralone derivatives were the most interesting compounds (IC5o= 5-9 pM) displaying 
results comparable with liarozole (ICso= 7 pM). These structures were consequently 
not investigated further as they seem unlikely to lead to potent inhibitors.
2) AIMS AND OBJECTIVES
The inhibition of C YP26 enzyme responsible for the metabolism of ATRA is 
an important target for the treatment of several cancers, leukaemia and some 
dermatological diseases and the use of RAMBAs has been proven to be effective in 
inhibiting the CYP26 enzyme and thus increasing the endogenous levels of ATRA.
Our research focussed on the design, synthesis and biological evaluation of 
new inhibitors for the C YP26 enzyme as well as a study o f their binding interactions 
with a mimic of the active site of the enzyme using different spectroscopic 
techniques.
Some compounds have been previously synthesised in our group at the Welsh 
School of Pharmacy which affect activity of cytochrome P450 enzymes involved in 
retinoic acid catabolism110, in . However, they displayed a low activity compared to 
the best known inhibitors and the design of a new series of inhibitor is clearly, 
needed.
Two new series of compounds were thus developed: a series of benzofiiran 
derivatives and a series of benzoxazole derivatives. The first series of compounds is 
based on the l-[benzofiiran-2-yl-(4-alkylphenyl)methyl]triazole derivatives described 
by Vinh et al.n4’115. A lipophilic alkyl chain attached to the 4-position of the phenyl 
ring of the benzofiiran derivatives may mimic the lipophilic chain structure of ATRA 
(Figure 1.13).
The second series, the benzoxazol-2-yl-[phenylimidazol-1 -
ylmethyl)phenyl]amine (Figure 1.13), is based on docking studies performed with 
R11586697 using a model of the CYP26A1 enzyme. As they display multiple 
hydrophobic interactions and hydrogen bonding with the active site, the benzoxazole
114 Vinh T.K., Ahmadi M., Delgado P.O., Perez S.F., Walters H.M., Smith H.J., Nicholls P.J. and 
Simons C.; 1 -[(Benzofiiran-2-yl)phenylmethyl]-triazoles and tetrazoles -  potent inhibitors of 
aromatase. Bioorg. Med Chem. Lett., 1999,9,2105-2108.
115 Vinh T.K., Yee S.W., Kirby AJ., Nicholls PJ. and Simons C.; l-[(Benzofuran-2-yl)- 
methylphenyl] triazoles as stereoidogenic inhibitors: synthesis ami in vitro inhibition of human 
placental CYP19 aromatase. Anti-cancer Drug Des., 2001,16,217-225.
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derivatives were scheduled for synthesis with various substituents on the 4-position 
of the phenyl ring including CQzMe, COOH, CONH2, OMe, OH ,CH3 , F and H.
These two new series of compounds were then to be evaluated for CYP26 
inhibition against MCF-7 cells using a method previously developed in our 
laboratory.
y —Z
X, Y, Z= N, CH
Lipophilic alkyl chain
X, Y, Z= N, CH
R= H, F, CH3, OH, OMe, 
CONH2, C 0 2 Me, COOH
Figure 1.13: l-[Benzofuran-2-yl-(4-alkylphenyl)methyl]triazole and
benzoxazol-2 -yl-[phenylimidazol- 1 -ylmethyl)phenyl]amine derivatives
The second part of our work was to study the interaction of some of our drugs 
with a model of the haem enzyme active site. Different techniques such as X-ray 
crystallography, mass spectrometry, NMR spectroscopy and UV/VIS 
spectroscopy will be investigated in order to determine the binding constant of our 
inhibitors. A crystal structure of the haem-drug complex could also allow us to study 
the length and the angle of the Fe-N bond. The aim of this study was to correlate the 
binding properties of the drugs in the active site with their activity and therefore 
determine which type of azole ring or substituent is the more appropriate to enhance 
the activity.
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CHAPTER 2
FIRST SERIES: l-tbenzofuran-2-vl- 
(4-alkvlphen vDmeth vl 1 triazole and
l-[benzofuran-2-vl-(4- 
alkylphenvDmethyll tetr azole
1) SYNTHESIS AND DISCUSSION
1.1) General chemistry
HO
OH
N
R= F, i-Pr, t-Bu, cyclohexyl, /-Bu, n-Pr 
X, Y, Z= N, CH
Scheme 2.1: General reaction scheme for the synthesis of 1 -[benzofuran-2-yl- 
(4-alkylphenyl)methyl]triazole and l-[benzofuran-2-yl-(4-
alkylphenyl)methyl]tetrazole. Reagents and conditions: (i) Br2 , AICI3 , Et2 0 , 0 °C, 1 
h; (ii) NaH, DMF, 80 °C, 1.5 h, then NaOCH3, 80 °C, 1 h; (iii) NaBft*, dioxan, rt, 3- 
6  h; (iv) SOCI2 , triazole or tetrazole, CH3CN, 10 °C, 1 h, then K2CO3, 3-7 days.
The synthesis of l-[benzofuran-2-yl-(4-alkylphenyl)methyl]triazole and 1- 
[benzofuran-2-yl-(4-alkylphenyl)methyl]tetrazole involved a sequence of four steps 
(Scheme 2.1):
30
- The generation of 4’-alkylacetophenone bromide by reaction of the appropriate 
acetophenone with bromine and aluminium trichloride.
- The preparation of the ketones by the Rap-Stormer reaction involving reaction of 
saiicylaldehyde with the corresponding 4’-alkylacetophenone bromide.
- The reduction of the ketones to alcohols in quantitative yield using sodium 
borohydride.
- The addition of the aza-ring (triazole or tetrazole) using N-N ’-thionyldi-triazole or - 
tetrazole.
The reactions shown in Scheme 2.1 involve a procedure described previously 
in the laboratory by Vinh et a l114’115.
1.2) Preparation of the 4’-alkvIacetophenone bromide
1, R= F
2, R= /-Pr
3, R= f-Bu
4, R= cyclohexyl
5, R= i-Bu
6 , R= n-Pr
Scheme 2.2: Reagents and conditions (i) Br2 , AICI3 , Et2 0 , 1-2 h, rt, 58-100
%.
In this reaction, bromine was added dropwise over 20 min to the mixture 
composed of 4-substituted acetophenone and aluminium chloride as catalyst in 
anhydrous ether (Scheme 2.2)116. The reaction time was shorter than 2 h to prevent 
the formation of any side products and particularly the di-brominated products, but 
this time was enough to complete the reaction. The mechanism of the reaction 
reviewed by Fieser117 is described in Figure 2.1.
116 Cowper R.M. and Davidson L.H.; Phenacyl bromide (Acetophenone, a-bromo-). Org. Synth., Coll. 
VolII, 1943,480-481.
117 Fieser L.F. and Fieser M.; Reagents for organic synthesis. USA: John Wiley and Sons, Inc. 1967.
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Figure 2.1: Proposed mechanism of the bromination of acetophenone by 
AICI3 catalyst.
In the first step, aluminium chloride, acting as a Lewis acid, forms a complex 
with the oxygen to give the enolate. Then, this enolate attacks bromine yielding the 
2-bromoacetophenone and liberating the catalyst AICI3 and hydrogen bromide. The 
di-brominated product can also be formed during this reaction. The ratio of mono- 
brominated/di-brominated was calculated by proton NMR. The mono-brominated 
products were confirmed by the presence of a CH2 singlet at approximately 8  4.5 
ppm and the di-brominated products by a CH singlet about 8  6.7 ppm. The crude 
product was used for the next reaction.
Table 2.1: Yield of the bromination in mono-brominated product:
1 R YIELD(*} COMPOUND NUMBER
F 65% 1
I Isopropyl 1 0 0  % 2
Tert-\mty\ 1 0 0 % 3
I Cyclohexyl 58%
I . 4
I Isobutyl 75%
1 . 5
I n-propyl 95%
1
(a) Yield of the crude mono-brominated product only.
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The proportion of di-brominated product was very variable (Table 2.1). None 
was detected in 2, 3 and 6  while the ratio was about 1:2 (di:mono) in 1 and 5 and 
about 1:1 in 4.
1.3) Preparation of the benzofurans
8 , R= #-Pr
9, R= f-Bu
10, R= cyclohexyl
11, R= /-Bu 
^  12, R= n-Pr
Scheme 2.3: Reagents and conditions (i) (a) NaH, salicylaldehyde, DMF, 2-3 
h, 80 °C (b) NaOCH3, 3-5 h, 80 °C, 29-50 %.
The formation of these a-ketones was achieved by a Rap-St6 ermer reaction
lift(Scheme 2.3), which involved two steps , the mechanism of which is shown in 
Figure 2.2.
In the first step, salicylaldehyde is mixed with sodium hydride and DMF as 
solvent. Sodium hydride, which is a strong base, deprotonates the alcohol to form the 
sodium salt (a) and hydrogen gas. Nucleophilic substitution between the sodium salt 
and the 2 -bromoacetophenone results in the non- cyclic compound (b).
In the second step, NaOCH3 deprotonates the acidic a-proton of the ketone
(b), with the resulting carbanion (c) attacking the aldehyde carbonyl to close the 
benzofiiran ring (d). Then the molecule loses water to form the more stable 
conjugated product (f).
In conclusion, the synthesis of these a-ketones showed usually a moderate 
yield (29-50 %, Table 2.2). This may be due to the difficulty in purification of the 
product. In some case, the starting material was not pure (1, 4 and 5) and the two 
steps of the reactions were generally not complete. As a result the product was
118 Buu-Hoi N.P., Bisagni E., Royer R., Routier C.; Oxygen related compounds. J. Chem. Soc., 1957, 
625-628.
BrCH (0
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obtained with purification by recrystallisation from methanol (7, 8 , 9,11 and 12) or 
ethyl acetate (1 0 ).
NaH
NaOCH.
OCH.
R
R
Figure 2.2: Mechanism of a-ketone formation by a Rap-Stoermer reaction
Table 2.2: Results of the preparation of benzofurans:
R MELTING
POINT
YIELD(a) COMPOUND
NUMBER
F
132-134 °C 42% 7
1 Isopropyl 93-95 °C 44% 8
tert- Butyl 103-105 °C 32% 9
Cyclohexyl 92-94 °C 29% 1 0
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Isobutyl 62-63 °C 50% 1 1
w-Propyl 64-66 °C 42% 1 2
(a) Yield calculated after recrystallisation from methanol or ethyl acetate.
1.4) Reduction of the a-ketones
( 0
7-12
14, R= i-Pr
15, R= f-Bu
16, R= cyclohexyl
17, R= /-Bu
18, R= n-Pr
—
Scheme 2.4: Reagents and conditions (i) NaBFLj, dioxan, 2-3 h, rt, 90-99 %.
The reduction was achieved in mild conditions and very high yields (Table
2.3) using the reducing agent NaBR* and anhydrous dioxane as solvent (Scheme
2.4)119. The reactions were complete after 2 to 4 h. The reduction involved the 
transfer o f one hydride ion H" from NaBR* to the carbonyl carbon. Then, the excess 
NaBFL* was quenched with 1 M HC1 and the product obtained after extraction was 
pure enough for the next step.
Table 2.3: Results of the reduction:
R MELTING
POINT
YIELD COMPOUND
NUMBER
F - 99% 13
Isopropyl 69-70 °C 96% 14
ter/-Butyl 87-88 °C 99% 15
Cyclohexyl 67-68 °C 98% 16
119 Ghelardoni M., Russo F. and Pestellini V.; Derivati del benzofurano ad attivita’ 
coronarodilatatrice. Boll. Chim. Farm., 1970,109,45-58.
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Isobutyl - 98% 17
«-Propyl - 90% 18
1.5) Addition of the aza-ring (triazole or tetrazole)
H
*5Y -N
X, Y= CH or N
(0 N i \ N
Y ^ X  A-^ry
Scheme 2.5: Reagents and conditions (i) SOCI2 , CH3CN, 1 h, 10 °C.
The required triazole and tetrazole compounds were prepared by using the 
10(\ •Staab method . In this reaction, it is necessary to form in situ the reactive species 
N-N -thionyldiaza-ring by coupling the aza-ring (triazole or tetrazole, 4 equivalents) 
and thionyl chloride (2 equivalents) during 1 h at 10 °C with anhydrous acetonitrile 
as solvent121 (Scheme 2.5).
(i)
13-18 Y -N
19, R= F, X, Y= N
20, R= f-Pr, X= N, Y= CH 
20*. R= /-Pr, X= CH, Y= N
21, R= t-Bu, X= N, Y= CH 
21’, R= f-Bu, X= CH, Y= N
22, R= cyclohexyl, X= N, Y= CH
23, R= /-Bu, X= N, Y= CH
24, R= n-Pr, X= N, Y= CH
Scheme 2.6: Reagents and conditions (i) N-N ’-thionylditriazole or N-N’- 
thionylditetrazole, K2C03, CH3CN, 3-5 days, rt, 4-78 %.
120 Staab A.H.; New methods of preparative organic chemistry IV. Syntheses using heterocyclic 
amides (azolides). Angew. Chem. Int. Ed., 1962,1, 351-367.
121 Humburg G., Mildenberger H. and Hoechst A.G.; 1,5-Disubstituted 1,2,4-triazole compounds. 
Liebigs Ann. Chem., 1982, 7,1387-1393.
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Then, a solution of the carbinol (13-18) in dry CH3CN was added to the 
mixture, followed by activated potassium carbonate. Next, the suspension was stirred 
under nitrogen at room temperature for 3 to 5 days (Scheme 2.6). The mechanism of 
the reaction is described in Figure 2.3.
The carbinol is first attacked by the base (K2CO3) to form the potassium salt 
of the carbinol. Then, this salt attacks the thionyl group of the N-N -thionyldiazaring 
previously formed in situ, producing the carbinol with a very good leaving group in 
place of the hydroxyl. Then the aza-ring in the reaction can substitute the leaving 
group to form the final product and liberate SO2 and triazole or tetrazole.
k2c o 3
R
Y -N
Y -N
Figure 2.3: General mechanism of the formation of l-[benzofuran-2-yl-(4- 
alkylphenyl)methyl]triazole and l-[benzofijran-2-yl-(4-alkylphenyl)methyl]tetrazole.
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Table 2.4: Results of the addition of the aza-ring
R X Y YIELDW COMPOUND
NUMBER
F N N 41% 19
i-Pr N CH 78% 2 0
/-Pr CH N 7% 2 0 ’
/-Bu N CH 62% 2 1
/-Bu CH N 4% 2 1 ’
Cyclohexyl N CH 14% 2 2
Cyclohexyl CH N 0 % 2 2 ’
/-Bu N CH 56% 23
/-Bu CH N 0 % 23’
«-Pr N CH 59% 24
n-Pr CH N 0 % 24’
(a) Yield calculated after purification by flash column chromatography
The final compounds with 1,2,4-triazole (20, 21) and 1,3,4-triazole (20% 21’) 
are formed together in the same reaction with /-Pr and /-Bu as substituents. The 
1,3,4-triazole compounds were not formed with the cyclohexyl, the isobutyl and the 
n-propyl derivatives (Table 2.4). Flash column chromatography was used to separate 
the regioisomer mixture, a 9:1 v/v petroleum ether/ethyl acetate mixture was used for 
the 1,2,4-triazole products while a 95:5 v/v dichloromethane/methanol mixture was 
used to obtain the 1,3,4-triazole products. The ratio of 1,3,4-triazole compounds was 
generally very low (4 to 7 %) however this was adequate for biological evaluation. 
The 1,2,4-triazole compounds were obtained generally with a good yield (Table 2.4), 
except for 22 (14 %).
After purification the products were confirmed by proton NMR. One proton 
at about 8  8 . 8  ppm was observed for the tetrazole compound 19 and two protons 
about 8  8 . 2  and 8  8 . 1  ppm respectively were observed for the 1 ,2 ,4 -triazole 
compounds 20, 21, 22, 23 and 24 instead of one two protons singlet at about 8  8.3 
ppm for the 1,3,4-triazole compounds 20’ and 21’.
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2) BIOLOGICAL ASSAY
These assays were performed using all-trans retinoic acid as substrate and 
used methods previously developed by our group122,123
2.1) M aterials and equipment
Matenal/Chemical/Equipment Source
A\\-trans retinoic acid Sigma Chemicals (Dorset, UK)
[JH-11,12]-ATRA (9.25 MBq, 250 nCi) Perkin Elmer Life Science Ltd. 
(Massachussets, USA)
HPLC grade solvent (acetonitrile, 
methanol)
Fisher Scientific (Leicestershire, UK)
Ethyl acetate, ethanol, ammonium acetate Sigma Chemicals, UK
Optiflow Safe 1 liquid scintillation 
cocktail
Fisons Chemical, UK
Ketoconazole Sigma Chemicals (Dorset, UK)
Borosilicate tubes (12 x 75 mm and 13 x 
1 0 0  mm)
Coming (New York, USA)
Centrifuge MSE Harrier 18/80, Santo, Japan
Pump Milton-Roy
Water bath with shaker Grant, UK
Rotating evaporator Christ Alpha RVC (Germany)
10 pm Cig pBondapak® 309 x 300 mm 
column
Waters, UK
122 Yee S.W.; PhD thesis: Synthesis and evaluation of inhibitors against vitamin D3 and all-trans 
retinoic acid metabolising enzymes as potential therapy for androgen-independent prostate cancer. In 
Welsh School o f Pharmacy, Cardiff University, Cardiff, 2005.
123 Jamo L.; PhD diesis: Studies on the action and metabolism of retinoic acid in MCF-7 human breast 
cancer cells. In Welsh School of Pharmacy, Cardiff University, Cardiff, 2003.
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Beta-Ram online scintillation detector LKB Wallace 1217 Rackbeta
Computer Compaq ™
Laura data acquisition and analysis 
software
Lablogic Ltd
[3H-11,12]-ATRA stock solution was prepared using the following method: 
100 pL of 1.2 nM ATRA in EtOH was diluted with 900 pL of iPrOH:EtOH 1:1 v/v. 
To this was added 10 pL of [3H-11,12] ATRA (9.25 MBq, 250 pCi).
The HPLC system was equipped with a high pressure pump (Milton-Roy 
pump), injector with a 50 pL loop connected to a p-RAM radioactivity detector, 
connected to a Compaq™ computer running Laura® data acquisition and analysis 
software. This enabled on-line detection and quantification of radioactive peaks. The 
HPLC column (10 pM Cis pBondapak™ 3.9 * 300 mm HPLC column from Waters, 
UK) operating at ambient temperature was used to separate the metabolites which 
were eluted with acetonitnle/1 % ammonium acetate in water/acetic acid (75:25:0.1
T p W
v/v/v) at a flow rate of 1.9 mL/min. Ecoscint was used as the flow scintillation 
fluid.
2.2) Cell-lines used
Retinoids have been known to have anti-proliferative effects on the growth of 
breast carcinoma cells (MCF-7, ZR-75.1)61. The wild type MCF-7 cell lines were 
chosen because of their availability at the Welsh school of Pharmacy from the 
Tenovus group.
The MCF-7 wild type cell line is also known as the MCF-7 human 
mammary-carcinoma cell line and is oestrogen receptor-positive. These cells were 
grown in RPMI medium with 5 % (v/v) foetal calf serum (FCS), antibiotics 
(streptomycin and penicillin) and fugizone at a concentration of 10 iU/mL.
The MCF-7 cells are cultured in 75 cm2 sterile flasks and are passaged every 
7 days. To work on the retinoic acid metabolism, the cells are seeded at 1 x 106 cells 
per well plate ( 1 2  wells).
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2,3) General method for the MCF-7 wild type ATRA assay
- On the dav of the assay:
1. Place PBS (phosphate buffer solution) in a water bath at 37 °C.
2. Prepare the experimental media solution as follow in the laminar flow.
3. Add 20 pL of EtOH or MeCN as control or inhibitor to labelled glass tubes.
4. Add the media (white RPMI + 5 % stripped-charcoal foetal calf serum +
antibiotics). Need 1 mL of this media per well.
5. Cover each tube before removing it from the laminar flow to keep the
experimental media as sterile as possible.
6 . Add the [3H] ATRA to the tubes (20 pL per tube) in a dark room.
7. Place the tubes in the water bath and shake gently for about 10-15 min.
8 . Take the MCF-7 cells from the incubator.
9. Remove the media from each well and then add 1 mL PBS.
10. Remove the PBS from the wells and add the corresponding experimental
media to the corresponding well.
11. Incubate the plate in the incubator for 24 hours.
- After 24 h incubation time:
1. Remove the cells from the incubator.
2. Add 100 pL of 1 % acetic acid to each well. Shake it gently.
3. Add 2 mL of ethyl acetate/0.05 % butylated hydroxyanisole (BHA) into 
each labelled glass tube.
4. Remove the media from each well.
5. Add 200 pL of distilled water into each well.
6 . Scrap the cells using the rubber end of the 1 mL syringe.
7. After scrapping the cells from each well, wash the rubber end with 200 pL 
of distilled water. Remove this 400 pL of distilled water with cells into the 
corresponding glass tube.
8 . Vortex each tube for 15 s.
9. Remove 1 mL from each glass tube into the corresponding glass tube.
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10. Add 1 mL ethyl acetate/ 0.05 % BHA and 100 pL of MeOH into each tube. 
Vortex it for 10 s.
11. Place the glass tube in the centrifuge for 15-18 min, the cells/serum in the 
media will settle in between the organic and water layer.
12. Remove the organic layer and place it in corresponding tubes.
13. Centrifuge the tube with the pump switched on for about 60 min.
14. Add 60 pL of MeOH to each tube and vortex.
15. Inject to the HPLC, run it for 20 min, flow rate 1.9 mL/min. Psi is usually 
around 115-117.
2.4) Experimental results
The ICso of our final compounds can be measured using HPLC and Laura 
data acquisition software. Two major peaks can be observed on the HPLC. The first 
peak (retention time about 2 min) corresponds to the metabolites of ATRA (4-oxo- 
ATRA, 4-hydroxy-ATRA and other polar metabolites) which are metabolised by the 
action of CYP26 on ATRA and the second peak (retention time about 5.5 min) 
corresponds to the ATRA itself.
Consequently, a disappearance of the first peak would be observed if an 
inhibitor is added to the media The separated metabolites were quantitatively 
calculated from the area under the curves and the percentage inhibition was 
calculated from: 100[metabolites (control) -  metabolites (inhibitors) / metabolites 
(control)].
The tested compounds were the l-[benzofuran-2-yl-(4- 
alkylphenyl)methyl]triazole and l-[benzofuran-2-yl-(4-alkylphenyl)methyl]tetrazole:
Y -N
X, Y= CH, N R= A Pr, f-Bu, ABu, 
cyclohexyl, n-Pr
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Table 2.5: ICUn of the 1 -rbenzofiiran-2-vl-(4-alkvlphenvl>)methvlltriazolc and 1-
rbenzofuran-2-vl-(4-alkvlDhenvDmethvl]tetrazole:
R X Y ICso COMPOUND
NUMBER
/-Pr N CH 20-40 pM 20
/-Pr CH N 50-100 pM 20’
/-Bu N CH 10-25 pM 21
/-Bu CH N - 21’
Cyclohexyl N CH 5-15 pM 22
/-Bu N CH 30-40 pM 23
n-Pr N CH 50-100 pM 24
Me N CH > 40 pM124 25
Me CH N > 40 pM124 25’
Et N CH 4.5 pM124 26
Et CH N 5 pM124 26’
Ph N CH 7 pM124 27
Ph CH N 9 pM124 27’
/7-Cl-C6H5 N CH 20-40 pM 28
/7-Cl-C6H5 CH N 20-40 pM 28’
Compounds 25,25’, 26,26’, 27,27’, 28 and 28’ were synthesised previously 
in the laboratory by Sook-Wah Yee124.
The 4-ethyl (26, IC50 = 4.5 pM and 26’, IC50 = 5 pM) and the 4-phenyl (27, 
IC50 = 7 pM and 27’, IC50 = 9 pM) derivatives displayed inhibitory activity of 
CYP26 comparable with that of liarozole (IC50 = 7 pM), and the cyclohexyl (22, IC50 
= 5-15 pM) and the /-Bu (21, IC50 = 10-25 pM) derivatives displayed moderate 
activity, the remaining alkyl/aryl derivatives were all poor CYP26 inhibitors of 
retinoic acid metabolism (IC50 > 20 pM) (Table 2.5). All the l-[benzofuran-2-yl-(4-
1 Pautus S., Yee S.W., Jayne M., Coogan M.P. and Simons C.; Synthesis and CYP26A1 inhibitory 
activity of 1 -[benzofuran-2-yl-(4-alkyl/aryl-phenyl>methyl]- l//-triazoles. Bioorg. Med Chem., 2006
14, 3643-3653.
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alkyl/arylphenyl)methyl]-1 //-triazoles were considerably less active than R11586694 
(IC5o= 5 nM).
The 4-methyl derivative 25 has previously been evaluated as an aromatase 
(CYP19) inhibitor (IC50 = 0.59 pM)106. The 4-ethyl 26 and the 4-phenyl 27 
derivatives were also screened against CYP19 to determine selectivity, both having 
an inhibitory IC50 > 100 pM. The negligible CYP19 inhibitory activity of 26 and 27 
was expected from SAR studies103 which had shown that only small substituents, for 
example, F, Cl, CH3 and CN were tolerated at the 4-position of the phenyl ring for 
CYP19 inhibitors.
2.51 Molecular modeling
In order to rationalise the results obtained, MOE (Molecular Operating 
Environment) 125 docking studies of the inhibitors were performed using a human 
CYP26A1 model126, built using the recently crystallised human CYP3A4127 as a 
template. Docking interactions at the enzyme active site were shown to be 
comparable with those of the CYP26 inhibitor liarozole with the benzofurans 
positioned above the haem with multiple hydrophobic interactions. The inhibitor 
compounds are all racemic therefore both enantiomers of all the compounds were 
docked to determine any preference for (R)- or (^-configuration; no preference was 
observed with both enantiomers exhibiting a similar ‘fit’ in the active site with the 
nitrogen of the heterocyclic ring coordinating with the Fe o f the haem.
Docking of the 4-alkyl derivatives with a chain length of >2 indicated that 
steric hindrance was encountered preventing close (2.5-3.5 A) interaction with the 
haem. The phenyl derivatives (27 and 27’, IC5o= 7-9 pM) have a greater inhibitory 
activity despite its size owing to favourable conformation and enhanced hydrophobic
125 Molecular Operating Environment (MOE). Chemical Computing Group, Inc. Montreal, Quebec, 
Canada, http://www.chemcomp.com. Code ‘scoring svP obtained from SVL Exchange website 
http://svl.chemcomp.com.. Chemical computing Group, Inc. Montreal, Canada.
126 Gomaa M.S., Yee S.W., Milboume C.E., Barbera M., Simons C. and Brancale A.; Homology 
model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site 
architecture and ligand binding. J. Em. Inhib. Med Chem. 2006,21,361-369.
127 Yano J.K., Wester M.R., Schoch G.A., Griffin K.J., Stout C.D. and Johnson E.F.; The structure of 
human microsomal cytochrome P450 3A4 determinated by X-ray crystallography to 2.05- A 
resolution. J. Biol. Chem., 2004,279,38091-38094.
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bonding (Figure 2.4). This may strengthen the interaction of the phenyl derivative 
increasing its potency as an inhibitor of the enzyme; however, the unsubstituted 
phenyl was the limit with the introduction of the chloro substituent (28, IC50 = 20-40 
pM) resulting in a reduction of inhibitory activity owing to steric/electronic factors.
The docking studies however failed to shed any light on the poor results 
obtained for the methyl compound (25, I C 5 0  > 40 pM), which was expected to 
possess potency similar to that of the ethyl derivative.
A series of 4-alkyl/aryl benzofuran phenyl triazole derivative has been 
successfully prepared with the ethyl and phenyl derivatives shown to possess 
comparable inhibitory activity with that of the known CYP26 inhibitor liarozole.
a
45
bFigure 2.4: Active site region of CYP26A1 model showing (a) 5-26 and (b) 
5-27 in ball and stick form. The distance from the haem is indicated with a green 
line, transition metal interaction with a purple line. Amino-acid residues identified 
are involved in hydrophobic interactions124.
46
3) EXPERIMENTAL
3.1) General materials and methods
All reactions were carried out under an atmosphere of nitrogen when 
necessary. All reagents and solvents employed were of general purpose or analytical 
grade and purchase from Fluka, Agros chemicals and Sigma-Aldrich Chemical 
Company. Then solvents were appropriately dried over molecular sieves (3 A) or 
when necessary by distillation.
N.M.R. spectra were recorded on a Bruker Advance 500 MHz. The chemical 
shifts are given in parts per million (ppm) relative to the internal standard tetramethyl 
silane (TMS), the coupling constants (J) are in Hertz and the multiplicity is denoted 
as s (singlet), d (doublet), t (triplet) and m (multiplet).
Silica gel Fluka Kieselgel 60 was used for column chromatography in a glass 
column. Flash column chromatography was performed with the aid of a pump.
Thin layer chromatography was achieved on pre-coated silica plates (Merck 
Kieselgel 60 F254) and visualised with UV light (254 nm) and/or vanillin stain.
Melting points were determinate using a Gallenkamp melting point apparatus 
and are uncorrected. Mass spectroscopy was performed at the EPSRC National Mass 
Spectrometry Service Centre Swansea and microanalyses were obtained from Medac 
Ltd., Brunei Science Centre Surrey.
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3.2) Experimental results
3.2.1) General procedure for the preparation of the 4 ’-alkvlacetoDhenone bromide 1- 
6
Br2, AICI3
E tp
1: R= F 
2: R= hPr 
3: R= f-Bu 
4: R= cyclohexyl 
5: R= /-Bu 
6: R= D-Pr
To a cooled solution (0 °C) of 4’-alkylacetophenone (30.82 mmol) in 
anhydrous Et2<3 (50 mL) was added a catalytic amount of aluminium chloride (3.08 
mmol). Bromine (30.82 mmol) was added dropwise to the solution (to give an orange 
solution) over a period of 2 0  min and the reaction was stirred for further 1 h until the 
orange solution faded to a yellow coloration. The reaction mixture was then 
quenched with H2O (100 mL) and stirred for 10 min. H2O was separated from the 
ether and the organic layer was dried with MgSC>4 , filtered and reduced in vacuo.
3.2.1.1) 4’-Fluoroacetophenone bromide (1, R= F )128
Green syrup (65 % mono-brominated product), ratio monobrominated 
product-dibrominated product 3:1. t.l.c system petroleum ether-ethyl acetate 4:1, Rf= 
0.89.
*HNMR: 8  (CDCI3): 7.89 (d, 2H, J= 8.4 Hz, Ar), 7.09 (d, 2H, J= 8.3 Hz, Ar),
6.76 (s, 2H, CH2Br).
3.2.1.2) 4’-Isopropylacetophenone bromide (2, R= i-P r)129
Brown syrup (100 %). t.l.c system: petroleum ether-ethyl acetate 4:1, Rf=
0.74.
128 Bahner C.T., Easley W.K., Walden B.G., Lyons H.D. and Biggerstaff G.E.; p-Fluorophenacyl 
bromide salts. J. Am. Chem. Soc., 1952, 74,3960.
129 Rebstock M.C. and Stratton C.D.; Some compound related to Chloromycetin. J. Am. Chem Soc 
1955, 77,4054-8.
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*H NMR: 8 (CDC13): 7.96 (d, 2H, J= 8.2 Hz, Ar), 7.37 (d, 2H, J= 8.1 Hz,
Ar), 4.48 (s, 2H, CH2Br), 3.01 (m, 1H, i-Pr), 1.29 (d, 6H, J= 6.9 Hz, i-Pr).
3.2.1.3) 4’-7er/-butylacetophenone bromide (3, R= t -  B u)130
Yellow syrup (100 %). t.l.c system: petroleum ether-ethyl acetate 4:1, Rf=
0.63.
*H NMR: 8  (CDCI3): 7.92 (d, 2H, J= 8.4 Hz, Ar), 7.56 (d, 2H, J= 8.4 Hz, Ar),
4.48 (s, 2H, CH2Br), 1.38 (s, 9H, /-Bu).
3.2.1.4) 4’-Cyclohexylacetophenone bromide (4, R= Cyclohexyl)128
Yellow syrup (58 % in mono-brominated product), ratio monobrominated 
product-dibrominated product 1 :1 . t.l.c system: petroleum ether-ethyl acetate 4:1, Rf= 
0.66.
*H NMR: 8  (CDC13): 8.01 (d, 2H, J= 8.3 Hz, Ar), 7.33 (m, 2H, J= 8.4 Hz, 
Ar), 4.46 (s, 2H, CH2Br), 2.18 (m, 1H, cyclohexyl), 1.58 (m, 10H, cyclohexyl).
3.2.1.5) 4’Isobutylacetophenone bromide (5, R= i-B u)131
Yellow solid (75 % in mono-brominated product), ratio mono-brominated 
product-di-brominated product 3:1. tl.c  system: petroleum ether-ethyl acetate 4:1, 
Rf= 0.69.
*H NMR: 8  (CDC13): 7.83 (d, 2H, J= 8.3 Hz, Ar), 7.19 (m, 2H, J= 8.3 Hz, 
Ar), 4.36 (s, 2H, CH2Br), 2.49 (d, J= 8.04 Hz, 2H, i-Bu), 1.72 (m, 1H, i-Bu), 0.83 (d, 
6 H, J= 6 . 8  Hz, /-Bu).
3.2.1.6) 4’/i-Propylacetophenone bromide (6, R= #i-Pr)132
Yellow solid (95 %). tl.c  system: petroleum ether-ethyl acetate 4:1, R f = 0.66.
130 Pesson M., Antoine M., Girard P., Benichon J.L., Chabassier S., De Lajudie P., Patte S., Roquet F. 
and Montay G.; Synthetic antibacterial agents. Pipemidic acid derivatives. Eur. J. Med. Chem., 1980, 
15,263-8.
131 Pal M., Batcher V.R., Khanna S. and Yeleswaparu K.R.; Regioselective aluminium chloride 
induced heteroacylation of pyrrolo[ 1 ^ -bjpyridazines: its scope and application. Tetrahedron, 2002, 
58, 9933-9940.
132 Zaschke H., Nitsche K., Schubert H.; Liquid-crystalline 3,6-diphenyl-1,2,4-triazines. J. Prak. 
Chem., 1977, 319,475-484.
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*H NMR: 8 (CDCI3): 7.90 (d, 2H, J= 8.3 Hz, Ar), 7.29 (d, 2H, J= 8.3 Hz, Ar),
4.44 (s, 2H, CH2Br), 2.65 (m, 2H, w-Pr), 1.67 (m, 2H, «-Pr), 0.94 (m, 3H, n-Pr).
3.2.2) General procedure for the preparation o f the Benzofuran-2-vl-(4- 
alkvlnhenvl)methanone 7-12
(i) NaH, DMF
(ii) NaOCH,
7: R= F 
8: R= /-Pr 
9: R= f-Bu 
10: R= Cyclohexyl 
11: R= /-Bu 
12: R= n-Pr
To a solution of sodium hydride (60 % in mineral oil, 11 mmol) in dry DMF 
(10 mL) was added a solution of salicylaldehyde (10 mmol) in diy DMF ( 6  mL) 
dropwise. Hydrogen gas was liberated to give a yellow solution of the sodium salt. A 
solution of the 4’alkylacetophenone bromide 1-6 (10 mmol) in dry DMF (10 mL) 
was then added dropwise and the reaction mixture was heated under nitrogen at 80 
°C for 1.5-3 h. Sodium methoxide (2.5 mmol) was added to the mixture and heating 
was continued for 2-4 h. After cooling, the reaction mixture was evaporated to about 
a third its volume, diluted with CH2CI2 (100 mL), washed with H20  (100 mL), dried 
(MgSC>4) and concentrated under reduced pressure.
3.2.2.1) Benzofuran-2-yI-(4-fluoro-phenyl)-methanone (7, R= F ) 133
Light yellow crystalline solid (55 %) after recrystallisation from MeOH, mp: 
132-134 °C (lit mp 133-135 °C)133. tl.c  system: petroleum ether-ethyl acetate 4:1, 
Rf= 0.62.
'HNMR: 8  (CDCI3): 7.90 (m, 2H, Ar), 7.52 (m, 2H, Ar), 7.34 (m, 4H, Ar),
7.33 (s, 1H, H-7).
133 Clementi S., Linda P. and Marino G.; Electrophilic substitutions in five membered heteroaromatic 
systems. Part XII. A quantitative study on the reactives o f the a- and 0- positions of benzofuran and 
benzothiophen in electrophilic substitutions. J. Chem. Soc., 1971, (B), 79-82.
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3.2.2.2) Benzofuran-2-yl-(4-isopropylphenyl)methaiione (8, R= i- Pr)
Pale orange solid (44 %) after recrystallisation from MeOH, mp: 93-95 °C. 
t.l.c system: petroleum ether-ethyl acetate 4:1, Rf= 0.64.
*H NMR: 8 (CDC13): 7.85 (m, 2H, Ar), 7.53 (m, 2H, Ar), 7.35 (m, 2H, Ar),
7.34 (s, 1H, H-7), 7.32 (m, 2H, Ar) 3.05 (m, 1H, z-Pr), 1.32 (d, 6H, J= 6.9 Hz, z-Pr).
13C NMR: 8 (CDC13): 186.36 (C, C-9), 155.81 (C, C-15), 154.60 (C, C-6), 
154.39 (C, C-10), 152.39 (C, C-8), 134.89 (C, C-5), 131.15 (CH, C -ll, C-12), 
129.74 (CH, C-13, C-14), 126.62 (CH, C -l), 124.22 (CH, C-2), 123.27 (CH, C-3),
115.76 (CH, C-4), 111.20 (CH, C-7), 34.24 (CH, z-Pr), 23.82 (CH3 x 2, z-Pr).
Microanalvsis: Calculated for C18H16O2 . theoretical: %C 81.79, %H 6.10, 
found %C 81.58, %H 6.07.
3.2.2.3) Benzofuran-2-yl-(4-/CT7-butylphenyl)methaiione (9, R= /-Bn)
Yellow solid (32 %) after recrystallisation from MeOH, mp: 103-105 °C. t.l.c 
system: petroleum ether-ethyl acetate 4:1, Rf= 0.58.
*H NMR: 8 (CDC13): 7.87 (m, 2H, Ar), 7.67 (m, 2H, Ar), 7.53 (m, 2H, Ar),
7.34 (s, 1H, H-7), 7.32 (m, 2H, Ar), 1.35 (s, 9H, H-17, H-18, /-Bu).
13C NMR: 8 (CDC13): 184.08 (C, C-9), 167.76 (C, C-15), 156.77 (C, C-6), 
155.95 (C, C-10), 155.95 (C, C-8), 134.54 (C, C-5), 130.89 (CH, C -ll, C-12),
129.51 (CH, C-13, C-14), 127.09 (CH, C-l), 125.55 (CH, C-2), 123.92 (CH, C-3),
116.14 (CH, C-4), 112.57 (CH, C-7), 68.17 (C, /-Bu), 31.15 (CH3 x 3 , /-Bu).
Microanalvsis: Calculated for C19H18O2 . 0.5 H2O; theoretical: %C 78.92, %H 
6.69, found: %C 79.17, %H 7.06.
3.2.2.4) Benzofuran-2-yl-(4-cyclohexylphenyl)methanone (10, R= cyclohexyl)134
Light yellow crystalline solid (29 %) after recrystallisation from EtOAc, mp: 
92-94 °C. t.l.c system: petroleum ether-ethyl acetate 4:1, Rf= 0.71.
*HNMR: 5 (CDCfe): 7.93 (m, 2H, Ar), 7.24 (m, 2H, Ar), 7.19 (m, 4H, Ar), 
6.62 (s, 1H, H-7), 2.51 (m, 1H, cyclohexyl), 1.56 (m, 10H, cyclohexyl).
13C NMR: 8 (CDC13): 184.08 (C, C-9), 155.94 (C, C-6), 153.70 (C, C-15),
152.52 (C, C-8), 134.94 (C, C-10), 129.76 (CH, C-13, C-14), 128.17 (CH, C -ll, C-
134 Richter P.H., Eisner H. and Vogt B.; Preparation of benzo[b]furan-derived ketone 
amidinohydrazome classIII antiarrhythmic agents. Eur. Pat. Appl, 1997, 32 pp.
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12), 127.07 (CH, C-2), 123.91 (CH, C-l), 123.23 (CH, C-3), 116.06 (CH, C-4), 
112.56 (CH, C-7), 44.78 (CH, C-16), 34.17 (CH2, C-17, C-18), 26.76 (CH2, C-19, C- 
20), 26.07 (CH2, C-21).
H^MSJEI): Found: 305.1537(M)+, Calculated: 305.1536.
3.2.2.5) Benzofuran-2-yl-(4-isobutylphenyl)methanone (11, R= i-Bu)
White solid (50 %) after recrystallisation from MeOH, mp: 62-63 °C. t.l.c 
system: petroleum ether-ethyl acetate 4:1, Rf= 0.63.
*H NMR: 6  (CDC13): 7.90 (m, 2H, Ar), 7.59 (m, 2H, Ar), 7.52 (m, 2H, Ar),
7.34 (m, 2H, Ar), 7.32 (s, 1H, H-7), 2.56 (d, J= 8.06 Hz, 2H, /-Bu), 1.96 (m, 1H, /- 
Bu), 1.01 (d, 6 H, J= 6 . 8  Hz, /-Bu).
13C NMR: 8  (CDC13): 184.08 (C, C-9), 155.95 (C, C-6 ), 152.50 (C, C-8 ),
147.55 (C, C-10), 134.86 (C, C-15), 129.63 (CH, C -ll, C-12), 129.30 (CH, C-13, C- 
14), 128.19 (CH, C-l), 127.08 (CH, C-5), 123.92 (CH, C-2), 123.25 (CH, C-3),
116.09 (CH, C-4), 112.55 (CH, C-7), 45.48 (CH2, /-Bu), 30.16 (CH, /-Bu), 22.39 
(CH3 x 2, /-Bu).
Microanalvsis: Calculated for Ci9Hig0 2; theoretical: %C 81.99, %H 6.52, 
found %C 81.55, %H 6.45.
3.2.2.6) Benzofuran-2-yl-(4-propylphenyl)methanone (12, R= it-Pr)
Cream crystalline solid (42 %) after recrystallisation from MeOH, mp: 64-66 
°C. tl.c  system: petroleum ether-ethyl acetate 4:1, Rf= 0.52.
*HNMR: S (CDC13): 7.92 (d, 2H, J= 8.2 Hz, Ar), 7.65 (d, 2H, J= 7.9 Hz, Ar),
7.57 (m, 1H, Ar), 7.46 (m, 1H, Ar), 7.42 (m, 1H, Ar), 7.26 (m, 3H, Ar), 2.62 (m, 2H, 
H-16), 1.64 (m, 2H, H-17), 0.91 (t, 3H, J= 7.3 Hz, H-18).
13C NMR: 5 (CDCI3): 184.09 (C, C-9), 155.95 (C, C-6 ), 152.51 (C, C-8 ), 
148.50 (C, C-10), 134.84 (C, C-15), 129.67 (CH, C -ll, C-12), 128.68 (CH, C-13, C- 
14), 128.19 (CH, C-l), 127.08 (CH, C-5), 123.92 (CH, C-2), 121.71 (CH, C-3),
116.07 (CH, C-4), 112.56 (CH, C-7), 38.12 (CH2, C-16), 24.25 (CH2, C-17), 13.75 
(CH3, C-l 8 ).
HRMS (ED: Found: 265.1224 (M)+, Calculated: 265.1223.
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3.2.3) General procedure for the preparation o f the Benzofuran-2-vl-(4-
alkvlDhenvDmethanol 13-18
NaBH4
dioxan
15 . R
13: R= F 
14: R= /-Pr 
15: R= f-Bu 
16: R= Cyclohexyl 
17: R= /-Bu 
18: R= n-Pr
To a cooled (0 °C) solution of benzofuran-2-yl-(4-alkyl-phenyl)-methanone 
(5 mmol) in anhydrous dioxane (15 mL) was added sodium borohydride (5 mmol) 
and then the mixture was allowed to stir at room temperature under nitrogen for 2-4 
h. The solvent was concentrated under reduced pressure and aqueous HC1 (1 M, 10 
mL) was added to the residue. The oil formed was extracted with Et2 0  or EtOAc (2 x 
50 mL), the organic layers were combined and dried (MgS0 4 ) and the solvent 
concentrated under reduced pressure.
3.2.3.1) Benzofuran-2-yl-(4-fluorophenyl)methanol (13, R= F) 135
Yellow-brown oil (99 %). t.l.c system: petroleum ether-ethyl acetate 4:1 v/v, 
Rf= 0.67.
*H N.M.R.: 8  (CDC13): 7.54 (m, 4H, Ar), 7.30 (m, 2H, Ar), 7.13 (m, 2H, Ar),
6.57 (s, 1H, H-7), 5.98 (s, 1H, H-9), 3.74 (bs, 1H, OH).
3.2.3.2) Benzofuran-2-yl-(4-isopropylphenyl)methanol (14, R= i-Pr)
White solid (96 %), mp: 69-70 °C. tl.c  system: petroleum ether-ethyl acetate 
4:1, Rf= 0.74.
‘H NMR: 8  (CDCI3): 7.42 (m, 2H, Ar), 7.34 (m, 2H, Ar), 7.16 (m, 2H, Ar),
7.11 (m, 2H, Ar), 6.45 (s, 1H, H-7), 5.81 (s, 1H, H-9), 2.82 (m, 1H, i-Pr), 2.59 (bs, 
1H, OH), 1.18 (d, 6 H, J= 6.9 Hz, /-Pr).
135 Vinh K.T.; Design and synthesis of inhibitors o f steroidogenesis. PhD Thesis, Cardiff University, 
2001
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13C NMR: 8  (CDCI3): 157.64 (C, C-8 ), 154.03 (C, C-15), 148.10 (C, C-10),
136.71 (CH, C -ll, C-12), 127.03 (CH, C-13, C-14), 125.81 (CH, C-2), 125.65 (CH, 
C-l), 123.16 (CH, C-3), 110.28 (CH, C-4), 102.82 (CH, C-7), 69.54 (CH, C-9),
32.84 (CH, /-Pr), 22.93 (CH3 x 2, z-Pr).
Microanalvsis: Calculated for C18H19O2 . 0.5 H2O; theoretical: %C 78.23, %H 
7.29, found %C 78.14, %H 7.05.
3.2.3.3) Benzofuran-2-yl-(4-/er/-butylphenyl)methanoI (15, R= /-Bu)
White solid (99 %), mp: 87-88 °C. tl.c  system: petroleum ether-ethyl acetate 
4:1, Rf= 0.72.
*H NMR: 8  (CDC13): 7.39 (m, 2H, Ar), 7.34 (m, 2H, Ar), 7.30 (m, 2H, Ar),
7.12 (m, 2H, Ar), 6.41 (s, 1H, H-7), 5.78 (s, 1H, H-9), 2.58 (bs, 1H, OH), 1.21 (s, /- 
Bu).
13C NMR: 8  (CDCI3): 158.74 (C, C-8 ), 155.14 (C, C-15), 151.24 (C, C-10),
130.72 (CH, C -ll, C-12), 129.36 (CH, C-13, C-14), 128.15 (CH, C-2), 126.64 (CH, 
C-l), 125.93 (CH, C-3), 111.39 (CH, C-4), 103.92 (CH, C-7), 70.57 (CH, C-9),
34.66 (C, /-Bu), 31.39 (CH3 * 3, /-Bu).
Microanalvsis: Calculated for C19H20O2 ; theoretical: %C 81.40, %H 7.19, 
found %C 81.22, %H 7.01.
3.2.3.4) Benzofuran-2-yl-(4-cyclohexylphenyl)methanol (16, R= cyclohexyl)
White solid (98 %), mp: 67-68 °C. tl.c  system: petroleum ether-ethyl acetate 
4:1, Rr= 0.63.
*H NMR: 8  (CDCI3): 7.59 (m, 1H, Ar), 7.48 (m, 3H, Ar), 7.25 (m, 4H, Ar),
6.58 (s, 1H, H-7), 5.89 (s, 1H, H-9), 3.72 (bs, 1H, OH), 2.61 (m, 1H, cyclohexyl),
1.58 (m, cyclohexyl).
13C NMR: 8  (CDClj): 159.28 (C, C-4), 155.46 (C, C-8 ), 144.09 (C, C-15), 
134.90 (C, C-10), 128.72 (CH, C -ll, C-12), 128.59 (CH, C-13, C-14), 124.00 (CH, 
C-l), 122.77(CH, C-2), 120.91 (CH, C-3), 111.25 (CH, C-4), 103.24 (CH, C-7),
67.63 (CH, C-9), 45.00 (CH, cyclohexyl), 35.40 (CH2, cyclohexyl), 27.65 (CH2, 
cyclohexyl), 26.95 (CH2, cyclohexyl).
HRMS (ED: Found: 306.1612(M)+, Calculated: 306.1614.
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3.2.3.5) Benzofuran-2-yl-(4-isobutylphenyl)methanol (17, R= i-Bu)
Yellow syrup (99 %). t.l.c system: petroleum ether-ethyl acetate 4:1, Rf=
0.73.
*H NMR: 6  (CDC13): 7.53 (m, 1H, Ar), 7.48 (m, 1H, Ar), 7.41 (m, 2H, Ar), 
7.20 (m, 4H, Ar), 6.57 (s, 1H, H-7), 5.95 (s, 1H, H-9), 3.72 (bs, 1H, OH), 2.52 (d, J=
8.06 Hz, 2H, /-Bu), 1.91 (m, 1H, /-Bu), 0.96 (d, 6 H, J= 6 . 8  Hz, z-Bu).
13C NMR: 8  (CDC13): 158.74 (C, C-8 ), 155.12 (C, C-6 ), 142.05 (C, C-10),
137.66 (C, C-15), 129.38 (CH, C -ll, C-12), 128.10 (CH, C-5), 126.63 (CH, C-13, C- 
14), 124.23 (CH, C-2), 122.81 (CH, C-l), 121.12 (CH, C-3), 111.34 (CH, C-4),
103.89 (CH, C-7), 70.66 (CH, C-9), 45.16 (CH2, C-16), 30.21 (CH, C-17), 22.38 
(CH3, C-18, C-19).
Microanalvsis: Calculated for C19H20O2 . 0.5 H20 ; theoretical: %C 81.40, %H 
7.19, found %C 81.07, %H 7.43.
3.2.3.6) Benzofuran-2-yl-(4-propylphenyl)methanol (18, R= iz-Pr)
Yellow syrup (90 %). t.l.c system: petroleum ether-ethyl acetate 4:1, Rf=
0.64.
*H NMR: 8  (CDCI3): 7.50 (m, 4H, Ar), 7.26 (m, 4H, Ar), 5.70 (s, 1H, H-9), 
2.64 (m, 2H, n-Pr), 2.50 (bs, 1H, OH), 1.69 (m, 2H, n-Pr), 0.10 (m, 3H, n-Pr).
13C NMR: 8  (CDCI3): 157.20 (C, C-8 ), 155.25 (C, C-6 ), 142.95 (C, C-15),
135.72 (C, C-10), 128.76 (CH, C-13, C-14), 128.15 (CH, C -ll, C-12), 127.57 (CH, 
C-5), 126.78 (CH, C-2), 124.25 (CH, C-l), 122.82 (CH, C-3), 111.48 (CH, C-4),
105.09 (CH, C-7), 75.22 (CH, C-9), 37.85 (CH2, n-Pr), 24.51 (CH2, n-Pr), 13.93 
(CH3, n-Pr).
Microanalvsis: Calculated for Ci9H20O2; theoretical: %C 81.17, %H 6.81, 
found %C 80.87, %H 6.92.
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3.2.4) Preparation o f thel-{Benzofuran-2-vlf4-fluoroDhenvllmethvl}-lH-tetrazole 19
135
1
OH
, SOCI.
F KaCOa, CH3CN
Thionyl chloride (0.17 g, 1.43 mmol) in anhydrous CH3CN (2 mL) was added 
dropwise to a stirred solution of l/f-tetrazole (0.40 g, 5.71 mmol) in anhydrous 
CH3CN (5 mL) at a temperature of 10 °C. The white suspension formed was allowed 
to stand for 1 h at 10 °C. A solution of 3 (0.34 g, 1.43 mmol) in anhydrous CH3CN 
(5 mL) was added to the mixture followed by activated potassium carbonate (0.40 g, 
2.86 mmol). The suspension was stirred under nitrogen at room temperature for 3 to 
5 days. The resulting suspension was filtered and the filtrate was evaporated in vacuo 
to yield a brownish oil. The oil was extracted with CH2CI2  (50 mL) and washed with 
H2O (3 x 50 mL). The organic layer was dried (MgSC>4), filtered and reduced in 
vacuo to give an orange oil. The crude product was purified by flash column 
chromatography (CHCL-MeOH 99:1 v/v increasing to 97:3 v/v) to give the crude 
product as a yellow syrup. Preparative TLC was performed on glass plates (CHCI3- 
MeOH 95:5 v/v). The product was collected and washed with CH2CI2 (2 x 20 mL), 
CHCI3 (3 x 20 mL) and then with MeOH (3 x 20 mL), filtered and reduced in vacuo 
to give a yellow syrup. Yield: 0.18 g (41 %). tl.c  system: petroleum ether-ethyl 
acetate 1:1, R f = 0.63.
'HN.M .R:5 (CDCI3): 8.16 (s, 1H, H-16), 7.47 (m, 2H, Ar), 7.35 (m, 4H, Ar), 
7.30 (m, 2H, Ar), 6.31 (s, 1H, H-7), 5.48 (s, 1H, H-9).
13C NMR: 8  (CDC13): 167.04 (C, C-15), 157.42 (C, C-6 ), 143.85 (CH, C-16), 
139.77 (C, C-8 ), 134.90 (CH, C -ll, C-12), 130.38 (C, C-5), 123.37 (CH, C-2),
122.14 (CH, C-l), 119.91 (CH, C-3), 119.09 (CH, C-13, C-14), 110.25 (CH, C-4),
98.76 (CH, C-9).
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3.2.5) General procedure for the preparation o f the 1- (Bemofuran-2-vl)4-
alkvl(Dhenvl)methvl)-lH-fl.2.47 triazole 20-24 and 7- (benzofuran-2-vl)4- 
alkvl(Dhenvl)methvI)-lH-fl.3.41 triazole 209 and 21*
fi—N 
N
k  , SOCI2
R k2c o 3, c h 3c n
20, R= hPr
21, R= f-Bu
22, R= cyclohexyl
23, R= f-Bu
24, R= n-Pr
N -N 20’; R= /-Pr 
21*, R= f-Bu
1
42
Thionyl chloride (4 mmol) in anhydrous CH3CN (10 mL) was added 
dropwise to a stirred solution of 1,2,4-triazole (16 mmol) in anhydrous CH3CN (10 
mL) at a temperature of 10 °C. The white suspension formed was stirred for 1 h at 10 
°C. A solution of benzofuran-2-yl-(4-alkyl-phenyl)-methanol (13-18) (4 mmol) in 
anhydrous CH3CN (10 mL) was added to the mixture followed by activated 
potassium carbonate ( 8  mmol). The suspension was stirred under nitrogen at room 
temperature for 4 days. The resulting suspension was filtered and the filtrate was 
evaporated in vacuo to yield a light brown oil. The oil was extracted with CH2CI2 
(150 mL) and washed with H2O (3 x 100 mL). The organic layer was dried 
(MgSC>4), filtered and reduced in vacuo.
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3.2.5.1) 1- (Benzofiiran-2-yl)4-isopropyl(phenyl)methy l)-l/7- [1,2,4] triazole (20, 
R= z-Pr) and 1- (benzofuran-2-yl)4-isopropyl(phenyl)methyl)-l//-[l,3,4] triazole 
(20% R= i-Pr).
Purified by column chromatography (hexane/EtOAc, 9:1 v/v) to give the
[l,2,4]triazole 20, further elution (CHhCh/MeOH, 9:1 v/v) gave the [l,3,4]triazole 
20’.
Data for 20: Yellow syrup (78 %). tl.c  system: petroleum ether-ethyl acetate 
1:1, Rf= 0.72.
*H NMR: 8  (CDCk): 8.42 (s, 1H, H-17), 8.33 (s, 1H, H-16), 7.31 (m, 1H, Ar), 
7.24 (m, 2H, Ar), 7.06 (m, 5H, Ar), 6.62 (s, 1H, H-7), 6.37 (s, 1H, H-9), 2.73 (m, 1H, 
/-Pr), 1.05 (d, 6 H, J= 6.9 Hz, z-Pr).
13C NMR: 8  (CDC13): 155.25 (C, C-6 ), 153.15 (CH, C-16), 152.11 (CH, C- 
17), 149.79 (C, C-15), 143.35 (C, C-8 ), 133.09 (C, C-10), 127.76 (CH, C -ll, C-12),
126.84 (CH, C-13, C-14), 125.04 (CH, C-2), 123.22 (CH, C -l), 112.44 (CH, C-3), 
111.42 (CH, C-4), 107.07 (CH, C-7), 62.03 (CH, C-9), 34.47 (CH, z-Pr), 24.16 (CH3 
x 2, z-Pr).
HRMS^EQ: Found: 318.1601(M)+, Calculated: 318.1601.
Data for 20': Yellow syrup (7 %). t.l.c system: petroleum ether-ethyl acetate 
1:1,Rr= 0.11.
*H NMR: 8  (CDC13): 8.12 (s, 2H, H-16, H-17), 7.47 (m, 1H, Ar), 7.39 (m, 
1H, Ar), 7.27 (m, 1H, Ar), 7.20 (m, 3H, Ar), 7.13 (m, 2H, Ar), 6.56 (s, 1H, H-7),
6.49 (s, 1H, H-9), 2.75 (m, 1H, z-Pr), 1.18 (d, 6 H, J= 6.9 Hz, z-Pr).
13C NMR: 8  (CDC13): 155.39 (C, C-6 ), 152.30 (C, C-15), 150.63 (CH, C-8 ), 
142.47 (CH, C-16, C-17), 132.46 (C, C-6 ), 127.72 (C, C-5), 127.52 (CH, C-13, C- 
14), 127.21 (CH, C -ll, C-12), 125.58 (CH, C-2), 123.58 (CH, C-l), 121.59 (CH, C- 
3), 111.64 (CH, C-4), 107.67 (CH, C-7), 58.08 (CH, C-9), 33.89 (C, z-Pr), 23.85 
(CH3 x 2, z-Pr).
HRMSIEI): Found: 318.1601(M)+, Calculated: 318.1603.
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3.2.5.2) 1- (Benzofuran-2-yl)4-/£r/-butyl(phenyl)methyl)-l//-[l,2,4] triazole (21, 
R= /-Bu) and 1- (benzofuran-2-yl)4-/er/-butyl(phenyl)methyl)-l//-[l,3»4] triazole 
(21’, R= /-Bu).
Purified by column chromatography (hexane/EtOAc, 9:1 v/v) to give the
[l,2,4]triazole 21, further elution (C^Ch/M eOH, 9:1 v/v) gave the [l,3,4]triazole 
21’.
Data for 21: Yellow syrup (62 %). t.l.c system: petroleum ether-ethyl acetate 
1:1, Rf= 0.61.
*H NMR: 5 (CDCh): 8.15 (s, 1H, H-17), 8.01 (s, 1H, H-16), 7.49 (m, 1H, Ar),
7.40 (m, 3H, Ar), 7.25 (m, 3H, Ar), 7.19 (m, 3H, Ar), 6.76 (s, 1H, H-7), 6.57 (s, 1H, 
H-9), 1.32 (s, 9H, /-Bu).
13C NMR: 6  (CDC13): 156.98 (C, C-6 ), 154.16 (CH, C-17), 150.30 (C, C-15),
148.52 (CH, C-16), 136.47 (C, C-8 ), 132.56 (CH, C -ll, C-12), 129.94 (C, C-5),
129.08 (C, C-10), 127.92 (CH, C-13, C-14), 123.37 (CH, C-2), 122.14 (CH, C-l),
120.55 (CH, C-3), 110.82 (CH, C-4), 101.37 (CH, C-7), 61.90 (CH, C-9), 34.80 (C, 
/-Bu), 31.41 (CH3 x 3, /-Bu).
HRMS (ED: Found: 332.1761 (M)+, Calculated: 332.1757.
Data for 21': Yellow syrup (4 %). t.l.c system: petroleum ether-ethyl acetate 
1 :1 , Rf= 0.08.
*H NMR: 5 (CDCI3): 8.12 (s, 2H, H-16, H-17), 7.47 (m, 1H, Ar), 7.39 (m, 
3H, Ar), 7.25 (m, 1H, Ar), 7.18 (m, 2H, Ar), 7.10 (m, 1H, Ar), 6.56 (s, 1H, H-7),
6.51 (s, 1H, H-9), 1.24 (s, 9H, /-Bu).
13C NMR: 8  (CDC13): 158.26 (C, C-6 ), 150.02 (C, C-15), 158.22 (CH, C-16, 
C-17), 140.15 (CH, C-8 ), 131.84 (CH, C -ll, C-12), 131.22 (C, C-5), 129.20 (CH, C- 
13, C-14), 127.93 (C, C-10), 123.49 (CH, C-2), 122.25 (CH, C-l), 120.28 (CH, C-3),
111.63 (CH, C-4), 107.64 (CH, C-7), 62.05 (CH, C-9), 34.71 (C, /-Bu), 31.23 (CH3 x 
3, /-Bu).
HRMS (ED: Found: 332.1762 (M)+, Calculated: 332.1757.
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3.2.5.3) 1- (Beiizofuran-2-yl)4-cyclohexyl(pheiiyl)methyl)-lir-[l,2,4] triazole (22, 
R= cyclohexyl).
Purified by column chromatography (hexane/EtOAc, 9:1 v/v) to give the
[1.2.4]triazole 22 as a yellow syrup (14 %). tl.c  system: petroleum ether-ethyl 
acetate 1 :1 , Rf= 0.70.
*H NMR : 8  (CDC13): 8.12 (s, 1H, H-17), 7.99 (s, 1H, H-16), 7.50 (m, 2H, 
Ar), 7.41 (m, 2H, Ar), 7.26 (m, 2H, Ar), 7.20 (m, 2H, Ar), 6.71 (s, 1H, H-7), 6.55 (s, 
1H, H-9), 2.50 (m, 1H, cyclohexyl), 1.54 (m, 10H, cyclohexyl).
13C NMR: 8  (CDC13): 156.98 (C, C-6 ), 154.16 (CH, C-17), 148.52 (CH, C- 
16), 143.74 (C, C-15), 136.47 (C, C-8 ), 131.56 (CH, C -ll, C-12), 129.81 (CH, C-13, 
C-14), 128.64 (C, C-10), 123.37 (CH, C-l), 122.14 (CH, C-2), 120.55 (CH, C-3),
110.89 (CH, C-4), 101.37 (CH, C-7), 56.50 (CH, C-9), 45.00 (CH2, cyclohexyl),
35.40 (CH2 x 2, cyclohexyl), 27.65 (CH2 x 2, cyclohexyl), 26.95 (CH2, cyclohexyl). 
HRMS (ED: Found: 358.1910 (M)+, Calculated: 358.1914.
3.2.5.4) 1- (Benzofuran-2-yl)4-isobutyl(phenyl)methyI)-l//-[l,2,4] triazole (23, 
R= i-Bu).
Purified by column chromatography (hexane/EtOAc, 9:1 v/v) to give the
[1.2.4]triazole 23 as a yellow syrup (56 %). tl.c  system: petroleum ether-ethyl 
acetate 1:1, Rf= 0.63.
*H NMR: 8  (CDC13): 8.28 (s, 1H, H-17), 8.22 (s, 1H, H-16), 7.60 (m, 2H, 
Ar), 7.40 (m, 2H, Ar), 7.31 (m, 2H, Ar), 7.23 (m, 2H, Ar), 6.82 (s, 1H, H-7), 6.54 (s, 
1H, H-9), 2.54 (d, J= 8.06 Hz, 2H, /-Bu), 1.95 (m, 1H, /-Bu), 1.02 (d, 6 H, J= 6.9 Hz, 
/-Bu).
13C NMR: 8  (CDCb): 155.27 (C, C-6 ), 153.21 (CH, C-17), 152.11 (CH, C- 
16), 136.47 (C, C-8 ), 132.51 (CH, C -ll, C-12), 131.47 (CH, C-13, C-14), 131.36 (C, 
C-15), 129.94 (C, C-5), 128.88 (C, C-10), 123.37 (CH, C-2), 122.14 (CH, C-l),
120.55 (CH, C-3), 110.89 (CH, C-4), 101.37 (CH, C-7), 56.50 (CH, C-9), 45.54 
(CH2, /-Bu), 27.57 (CH, Z-Bu), 22.23 (CH3 x 2, /-Bu).
Microanalvsis: Calculated for C2 iH2 iN30 . 0.3 H20 ; theoretical: %C 74.89, 
%H 6.46, %N 12.48, found %C 74.87, %H 6.45, %N 12.15.
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3.2.5.5) 1- (Benzofunm-2-yl)4-propyl(phenyl)methyl)-l/iF-[l,2,4] triazole (24, R= 
n-Pr).
Purified by column chromatography (hexane/EtOAc, 9:1 v/v) to give the
[l,2,4]triazole 24 as a yellow syrup (59 %). t.l.c system: petroleum ether-ethyl 
acetate 4:1, Rf= 0.25.
*H NMR: 8  (CDC13): 8.03 (s, 1H, H-17), 7.94 (s, 1H, H-16), 7.46 (d, 1H, J=
7.7 Hz, Ar), 7.38 (d, 1H, J= 8.3 Hz, Ar), 7.23 (m, 1H, Ar), 7.16 (m, 5H, Ar), 6.74 (s, 
1H, H-7), 6.49 (s, 1H, H-9), 2.53 (t, 2H, J= 7.6 Hz, n-Pr), 1.57 (m, 2H, n-Pr), 0.87 (t, 
3H, J= 7.3 Hz, n-Pr).
13C NMR: 8  (CDC13): 154.32 (C, C-8 ), 151.92 (C, C-6 ), 151.17 (CH, C-17), 
148.22 (CH, C-16), 142.96 (C, C-5), 131.77 (C, C-10), 128.17 (CH, C -ll, C-12), 
126.61 (CH, C-13, C-14), 126.53 (C, C-15), 124.13 (CH, C-2), 122.27 (CH, C-l), 
120.46 (CH, C-3), 110.52 (CH, C-4), 106.55 (CH, C-7), 61.11 (CH, C-9), 36.68 
(CH2, n-Pr), 23.34 (CH2, n-Pr), 12.79 (CH3, n-Pr).
HRMS (ED: Found: 318.1601 (M)+, Calculated: 318.1601.
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CHAPTER 3
SECOND SERIES: Benzoxazol-2-vl- 
[phenvlimidazol-1-
vlmethvDphenvll amine
1) MOLECULAR DOCKING
1.1) Introduction
The active site of the P450 enzyme is composed of a single iron 
protoporphyrin IX prosthetic group coordinated to the four pyrrole nitrogen atoms as 
a haem1 as shown previously in Figure 1.1.
Our group recently constructed a three-dimensional model of CYP26A1 
based on the three known crystal structures of membrane bound human cytochrome 
P450: P450 2C9136, P450 2C8137 and P450 3A4127. Molecular Operating 
Environment (MOE) 125 and FLEXX (TRIPOS Inc. ) 138 software were used to build 
the three models based on the templates, P450 2C8 (PDB code: 1PQ2), P450 2C9 
(1R90), P450 3A4 (ITQN). After performing docking with known CYP26 inhibitors 
such as liarozole and R115866, the model based on the P450 3A4 template was 
chosen. Further active site optimisation generated a final CYP26A1 model.
The CYP26A1 active site in human contains 497 amino-acids in its chain; the 
full sequence is given in Figure 3.1. The protein residues within a 7 A radius of the 
haem were selected (Figure 3.2). All the other residues in the active site were too far 
to interact with a ligand. These residues formed a large hydrophobic pocket above 
the haem molecule which will be able to accommodate the substrate.
136 Williams P.A., Cosme J., Ward A., Angrove H.C., Vinkovic D.M. and Johti H.; Crystal structure 
of human cytochrome P450 2C9 with bound warfarin. Nature, 2003,424,464-468.
137 Schoch G.A., Yano J.K., Wester M.R., Griffin K.J., Stout C.D. and Johnson E.F.; Structure of 
human microsomal cytochrome P450 2C8. J. Biol Chem., 2004,279,9497-9503.
138 Tripos SYBYL 7.0; Tripos Inc., 1699 South Hanley Rd, St Louis, Missouri 63144, USA. 
http://www. tripos.com.
62
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1 Met Gly Leu Pro Ala Leu Leu Ala Ser Ala Leu Cys Thr Phe Val 15
16 Leu Pro Leu Leu Leu Phe Leu Ala Ala lie Lys Leu Trp Asp Leu 30
31 Tyr Cys Val Ser Gly Arg Asp Arg Ser Cys Ala Leu Pro Leu Pro 45
46 Pro Gly Thr Met Gly Phe Pro Phe Phe Gly Glu Thr Leu Gin Met 60
61 Val Leu Gin Arg Arg Lys Phe Leu Gin Met Lys Arg Arg Lys Tyr 75
76 Gly Phe lie Tyr Lys Thr His Leu Phe Gly Arg Pro Thr Val Arg 90
91 Val Met Gly Ala Asp Asn Val Arg Arg lie Leu Leu Gly Asp Asp 105
106 Arg Leu Val Ser Val His Trp Pro Ala Ser Val Arg Thr lie Leu 120
121 Gly Ser Gly Cys Leu Ser Asn Leu His Asp Ser Ser His Lys Gin 135
136 Arg Lys Lys Val lie Met Arg Ala Phe Ser Arg Glu Ala Leu Glu 150
151 Cys Tyr Val Pro Val lie Thr Glu Glu Val Gly Ser Ser Leu Glu 165
166 Gin Trp Leu Ser Cys Gly Glu Arg Gly Leu Leu Val Tyr Pro Glu 180
181 Val Lys Arg Leu Met Phe Arg lie Ala Met Arg lie Leu Leu Gly 195
196 Cys Glu Pro Gin Leu Ala Gly Asp Gly Asp Ser Glu Gin Gin Leu 210
211 Val Glu Ala Phe Glu Glu Met Thr Arg Asn Leu Phe Ser Leu Pro 225
226 H e Asp Val Pro Phe Ser Gly Leu Tyr Arg Gly Met Lys Ala Arg 240
241 Asn Leu lie His Ala Arg lie Glu Gin Asn lie Arg Ala Lys lie 255
256 Cys Gly Leu Arg Ala Ser Glu Ala Gly Gin Gly Cys Lys Asp Ala 270
271 Leu Gin Leu Leu lie Glu His Ser Trp Glu Arg Gly Glu Arg Leu 285
286 Asp Met Gin Ala Leu Lys Gin Ser Ser Thr Glu Leu Leu Phe Gly 300
301 Gly His Glu Thr Thr Ala Ser Ala Ala Thr Ser Leu lie Thr Tyr 315
316 Leu Gly Leu Tyr Pro His Val Leu Gin Lys Val Arg Glu Glu Leu 330
331 Lys Ser Lys Gly Leu Leu Cys Lys Ser Asn Gin Asp Asn Lys Leu 345
346 Asp Met Glu lie Leu Glu Gin Leu Lys Tyr lie Gly Cys Val lie 360
361 Lys Glu Thr Leu Arg Leu Asn Pro Pro Val Pro Gly Gly Phe Arg 375
376 Val Ala Leu Lys Thr Phe Glu Leu Asn Gly Tyr Gin lie Pro Lys 390
391 Gly Trp Asn Val lie Tyr Ser lie Cys Asp Thr His Asp Val Ala 405
406 Glu lie Phe Thr Asn Lys Glu Glu Phe Asn Pro Asp Arg Phe Met 420
421 Leu Pro His Pro Glu Asp Ala Ser Arg Phe Ser Phe lie Pro Phe 435
436 Gly Gly Gly Leu Arg Ser Cys Val Gly Lys Glu Phe Ala Lys lie 450
451 Leu Leu Lys lie Phe Thr Val Glu Leu Ala Arg His Cys Asp Trp 465
466 Gin Leu Leu Asn Gly Pro Pro Thr Met Lys Thr Ser Pro Thr Val 480
481
496
Tyr
Glu
Pro
lie
Val Asp Asn Leu Pro Ala Arg Phe Thr His Phe His Gly 495
Figure 3.1: Sequence of the 497 amino acid of the CYP26A1 enzyme in 
human139.
In order to find new potent C YP26 inhibitors, ligand docking was performed 
on this CYP26A1 model using the MOE software. These ligands should fit in the 
active site (have no steric clashes), have optimal binding with the protein residues by 
forming hydrogen and hydrophobic bonds and coordinate with the iron atom from 
the haem at a distance of 3 A or less.
139http://www.expasy.org/uniprot/043174
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GLU303
ALA114
ARG86
GLY300?481
PR0478
THR304
ASN426
GLJC372
Figure 3.2: 3D Structure of the CYP26A1 model based on P450 3A4 template 
with residues within 7 A radius of the haem molecule. These residues may form the 
main skeleton of the active site. Colour coding of the atoms: grey= carbon, red= 
oxygen, blue= nitrogen and brown= iron .
1.2) D ocking studies
1.2.1) Dockins o f A TRA
ATRA is the natural substrate of the CYP26A1 enzyme. The result of the 
docking study is shown on Figure 3.3. The C-4 atom is positioned perpendicular at a 
distance of 5.3 A from the haem iron. This distance would accommodate a molecule 
of water which will then be responsible for the 4-hydroxylation of the substrate. 
ATRA also interacts with the protein residues by forming multiple hydrophobic 
interactions as well as a hydrogen bond between its carboxylic acid group and 
ARG 86 which will hold the molecule in the active site126.
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Figure 3.3: ATRA docked in the CYP26A1 active site, hydrogen bond 
between ATRA and ARG 86 is represented by a dashed line126.
1.2.2) Dockins o f R115866
The triazole compound R115866 synthesised by Stoppie et a l91 is one of the 
most potent CYP26 inhibitors (ICso= 4 nM). Therefore the interaction of this drug 
with our active site model was evaluated.
As observed with other triazole and imidazole derivative inhibitors, the 
nitrogen atom of the aza-ring of both R115866 enantiomers is coordinated to the iron 
atom of the haem with a distance of 2.13 A (S-) and 2.38 A (R-). Multiple 
hydrophobic interactions with the side chains residues were observed (TRP112, 
ALA114, SER115, MET_217, ARG_219, PHE_222, TYR_234, GLU_296, 
LEU 297, PHE 299, GLU_303, THR_304, PRO_369, VAL_370, PRO_371, 
PHE 374, THR 479) as well as a very interesting hydrogen bonding interaction 
between the secondary nitrogen of the S'-enantiomer and the peptide carbonyl group
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of ALA I 14 (Figure 3.4). This hydrogen bond could contribute to the potent activity 
of these compounds.
TYR234
ARC219
MET217
ALA114
GLU303
THR304
Figure 3.4: Active site region of CYP26A1 model after dynamics showing 
the S-enantiomer of the inhibitor ligand R115866 as a ball and stick form. Hydrogen 
bonding interactions are shown as green lines and distance from the haem is 
indicated with a purple line. Colour coding of the atoms: grey= carbon, red= oxygen, 
blue= nitrogen, brown= iron and yellow= sulphur. Amino-acid residues identified are 
involved in hydrophobic interactions.
As a consequence a new series of compounds which interact closely with the 
haem (less than 3 A) and keep the hydrogen bonding of R115866 with ALA114 
was envisaged.
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1.2.3) Dockins o f  benzoxazol-2-vl-Fphenvlimidazol-l -vlmeihvDvhenvl 1 amine
derivatives
CYS
C02H
ch2oh
C02Me
CONH2
haem
Hydrophilic domain 
H-bonding
Haem-binding 
Azole group
H-bond 
NH essential
Hydrophobic domain 
Bicyclic aryl optimal
Figure 3.5: Structure and key binding interactions of the benzoxazol-2-yl- 
[phenylimidazol-1 -ylmethyl)phenyl]amine derivatives
A new molecule with hydrogen bonds on both sides of the active site was 
investigated. These two hydrogen bonds could hold the molecule in the hydrophobic 
tunnel of the active site and thus increase the activity. After further investigations, 
the replacement of the alkyl chain of R115866 by a substituted phenyl ring showed 
interesting results with OH, OMe, OAc, CN, CH2 OH, COOH, COOMe and CONH2 
as substituents (Figure 3.5).
In some cases, the hydrogen bond, observed in R115866 docking, between 
the benzooxazole nitrogen and ALA I 14 was kept (B and K’) or replaced by another 
hydrogen bond with the next peptide SER I 15 (B’, H, H ’ and J).
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ARG219
. TYR44!
PR0113
A) /?-enantiomer
ff-enantiomer
PR0478
ALA114
THR304
^ > © -Y S 4 4 2
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Figure 3.6: Diagram showing both enantiomers R (H ) and S (H ’) of 4-{[4- 
(benzoxazol-2-ylamino)phenyl]imidazol-l-yhnethyl} benzoic acid docked at the 
active site region of the CYP26A1 model. Hydrogen bonding interactions are shown 
as green lines and co-ordination with the transition metal is indicated with a purple 
line. Colour coding of the atoms: grey= carbon, red= oxygen, blue= nitrogen, 
brown= iron and yellow= sulphur. Amino-acid residues identified are involved in 
hydrophobic interactions.
In the example shown in Figure 3.6 with COOH as a substituent, several 
hydrophobic interactions as well as hydrogen bonds on both sides of the active site 
are observed with both enantiomers. The i?-enantiomer H  is forming a hydrogen 
bond between the oxygen of the benzoxazole ring and SER115 on one side and 
between the carboxylic acid group and THR 479, PRO_369, SER 307 and 
GLU 303 on the other side. Hydrophobic interactions are observed with the side 
chains of PHE_84, TRP_112, PRO_l 13, SER_115, VAL_116, ARG_219, PHE_222, 
PHE 299, GLU 303, THR_304, SER_307, PRO_369, VAL_370, PRO_371, 
PHE 374, TYR 442, PRO_478 and THR_479.
The S-enantiomer H ’ displayed also interesting results (Figure 3.5), 
hydrogen bonds were observed on one side between the benzoxazole nitrogen and 
SER115 and on the other side between the carboxylic acid and MET 217, 
HIS 302, PHE 299. A large number of hydrophobic interactions are also observed 
with the residues LEU_83, PHE_84, TRP_112, PRO_113, ALA_114, SER_115, 
VAL116, MET 217, ARG_219, PHE_222, PHE_274, PHE_299, HIS_302, 
GLU 303, THR 304, PRO_369, VAL_3770, PRO_371, ILE_395, PRO_478 and 
THR 479. Both enantiomers are also interacting closely with the haem with a 
distance of respectively 2.88 A for H  and 2.29 A for H \
The docking of the other para-substituted compounds displayed also 
interesting results (Table 3.1). They all showed a good interaction with the haem iron 
atom between 1.85 A and 3.40 A, except the methoxy derivative (E, E’) and the R- 
enantiomer of the methyl derivative (C) that fit in the active site but don t show any 
interaction with the haem (Table 3.1). They also display a large number of
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hydrophobic interactions and most of them form hydrogen bonds with the protein 
residues.
Although they show good interaction with the haem, the small substituents 
(H, F, Me, OH, OMe and CN) seem to be too far from the edge of the active site to 
form any hydrogen bond with the protein residues. The only one observed is with the 
hydroxy group of compound D’ and HIS_271. The presence of larger substituents 
seems to be required.
In fact, the use of larger substituents (C0 2 Me, COOH, CH2OH, CONH2 , 
OAc), as expected, allowed the formation of hydrogen bonds with different protein 
residues (SER_307, ARG_219, THR_479, PRO_369, SER_307, GLU_303, 
MET_217, HIS_302, PHE_299) depending on the orientation of the molecule and 
the enantiomer. However only compounds H, H% J  and K’ are able to hold the 
molecule on both sides of the active site.
Table 3.1: Interactions observed between the different inhibitors and the active site:
R Enantiom er Distance from  
haem (A)
Hydrogen
bonding
Name
H R 2.57 - A
H S 2.77 - A’
F R 2 . 1 2 A L A I 14 B
F S 3.16 SER_115 B’
Me R - - C
Me S 2 . 1 1 - C’
OH R 2.78 - D
OH S 2.73 HIS271 D’
OMe R - - E
OMe S - - E’
CN R 2.98 - F
CN S 2.26 - F’
C02Me R 3.12 SER307 G
C02Me S 1.85 ARGJ219 G’
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COOH R 2 . 8 8 SER115,
THR_479,
PRO_369,
SER_307,
GLU_303
H
COOH S 2.29 M ET217, 
HIS_302, 
PHE 299, 
SER115,
H’
CH2OH R 3.28 PRO_369 I
CH2OH S 3.28 ARG_219,
GLU303
r
CONH2 R 2.84 SER115,
ARG_219
J
CONH2 S 2.31 - J’
OAc R 2.94 HIS_302 K
OAc S 3.40 A L A I  14, 
A RG 219
K’
These substituents are also convenient because it is possible to synthesise a 
large variety of compounds from the same skeleton by simple reactions such as 
oxidation, reduction, esterification and amidation (Figure 3.7).
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CONH
reductionamidation
COOH 
esterification
CH2OH
COOMe
Figure 3.7: Possible transformation of the substituents by simple reactions.
1.2.4) Investigation o f other substitutions
After the interesting results observed for the benzoxazol-2-yl- 
[phenylimidazol-l-ylmethyl)phenyl]amine derivatives with a para substituent, ortho 
and meta substitution as well as a di-substitution on the phenyl ring were also 
investigated. As examples, three substituents o f different size and properties were 
employed: CH2OH, OH and Me. Results are reported in Table 3.2.
Table 3.2: Interactions observed on the other positions:
R Position Enantiomer Distance from  
haem (A)
Hydrogen
bonds
Name
Me Ortho R 2.85 - L
Me Ortho S 1.49 - L’
OH Ortho R 2.87 GLU_303 M
OH Ortho S 1.82 GLU296 M’
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c h 2o h Ortho R 1.82 - N
c h 2o h Ortho S 2 . 0 2 - N’
Me Meta R 2.25 GLUJ296 O
Me Meta S 1.73 - O’
OH Meta R 1.57 PHE_299 P
OH Meta S 2.17 - P’
CH2OH Meta R - - Q
CH2OH Meta S 1 . 8 6 - Q’
Me 2,3 R 2.98 - R
Me 2,3 S 2 . 1 0 - R’
OH 2,3 R 1.91 PHE_299 S
OH 2,3 S 1.35 GLY_372 S’
CH2OH 2,3 R - - T
CH2OH 2,3 S 1.82 - T’
Me 2,4 R - - U
Me 2,4 S 1.63 GLU_296 U’
OH 2,4 R 1 . 6 6 - V
OH 2,4 S 1.96 - V’
CH2OH 2,4 R - - w
CH2OH 2,4 S - - W’
Me 2,5 R 2.74 - X
Me 2,5 S 3.75 - X’
OH 2,5 R 1.54 - Y
OH 2,5 S 2.63 - Y’
CH2OH 2,5 R 1.33 GLU_296 Z
CH2OH 2,5 S 2.64 PHE_299
GLU303
Z’
Me 2 , 6 R 2.14 - AA
Me 2 , 6 S 3.49 - AA’
OH 2 , 6 R 1.80 - AB
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OH 2 , 6 S 1.80 - AB’
CH2OH 2 , 6 R 1.36 GLY_300
PHE_299
AC
CH2OH 2 , 6 S 2.08 - AC’
Me 3,4 R - - AD
Me 3,4 S - - AD’
OH 3,4 R 1.35 GLU_303 AE
OH 3,4 S 1.60 PRO_338 AE’
CH2OH 3,4 R 3.31 - AF
CH2OH 3,4 S 4.02 - AF’
Me 3,5 R 2.03 - AG
Me 3,5 S 2.36 - AG’
OH 3,5 R 1.99 GLU_296 AH
OH 3,5 S 1 . 8 8 - AH’
CH2OH 3,5 R 1.98 PRO_369
PHE_299
GLU303
AI
CH2OH 3,5 S 2 . 0 2 PRO_369 AI’
In the ortho position (compounds L, L \  M, M \ N, N’), the 6  compounds 
showed a good coordination with the haem (1.49 A to 2.87 A). However, only the 
compounds with the hydroxy substituent are able to form some hydrogen bonds, 
between the benzoxazole nitrogen and GLU_296 for the S-enantiomer and between 
the OH substituent and GLU_303 for the j?-enantiomer.
Concerning the meta derivative (O, O’, P, P’, Q, Q’), The ^-enantiomer of 
both small substituent CH3 and OH (O and P) gave the best results. They are 
respectively 2.25 A and 1.57 A from the haem and formed hydrogen bonds with 
GLU 296 (secondary amine of O) and PHE 299 (OH substituent of P). The 4 others 
compounds interact also well with the haem, except Q’ but do not form any 
hydrogen bonds with the protein residues. In conclusion, the size of the substituent 
may be an issue in this position especially with the i?-enantiomer.
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Then compounds with a di-substitution were investigated using the same 
three substituents. The 2,3-substitution (compounds R, R \ S, S’, T , T’) gave similar 
results than die single ortho and meta substitution, die compounds of most interest 
were the OH-derivatives S and S’ which are respectively 1.91 A and 1.35 A from the 
haem and form hydrogen bond with their OH substituent and PH E299 for S and 
GLY 372 for S’. Compounds R, R’ and T’ are also quite close to the haem, 
respectively 2.98 A, 1.91 A and 1.82 A although they do not form hydrogen bonds 
with the protein residues. As for the meta substitution, the jR-enantiomer of the 
CH2OH compound fitted in the active site but did not interact with the haem. It 
confirms that a large substituent in the meta position may not be tolerated.
The ortho-para (2,4) substituted compounds (U, U \ V, V’, W, W’) did not fit 
as well in the active site. Although U, W  and W  fit in the active ate, they do not 
form any interaction with the haem. Large substituents do not seem to be tolerated in 
these positions. The OH derivatives V and V’ and the S-enantiomer of the methyl 
derivative U’ are interacting strongiy with the haem with transition metal 
coordination at 1 . 6 6  A, 1.96 A and 1.63 A respectively. However, the methyl 
compound U’ is the only one forming a hydrogen bond on GLU_296 using its 
secondary amine.
The 2,5-substituted compounds (X, X’, Y, Y’, Z, Z’) interacted with the 
haem iron between 1.33 A and 3.75 A. Compounds with a methyl or a hydroxy 
substitution (X, X’, Y, Y’) did not form any hydrogen bonds with the protein 
residues. The presence o f a larger group seems to be required. Compounds Z  and Z’ 
with CH2OH as a substituent had transition metal coordination with the haem and 
formed hydrogen bonding: the S-enantiomer with GLU 296 using its secondary 
amine and the i?-enantiomer with PHE 299 and GLU303 using one of its OH 
substituents.
Compounds with a di-ortho (2,6) substitution (AA, AA’, AB, AB’, AC, AC’) 
also allow the three different substituents. They displayed very similar results to the 
2,5-derivatives, interacting well with the haem (between 3.49 A and 1.36 A) but only 
the introduction of a CH2OH subsituent allowed formation of hydrogen bonding. The 
CH2OH substituent o f the J?-enantiomer AC interacts with GLY300 and PHE 299.
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In the 3,4 position, the presence of an electron donating substituent seems to 
be essential. Both enantiomers of the methyl substituted compounds (AD, AD’) are 
not able to interact with the haem. The presence of the CH2OH substituent as well 
gave disappointing results. Although they fit in the active site, both enantiomers are 
quite far to the haem (3.31 A for the ^-enantiomer AF and 4.02 A for the S- 
enantiomer AF’) and no hydrogen bonds were observed. On the other hand, the OH 
substituted compounds AE and AE’ displayed interesting results. They are both very 
close to the haem, respectively 1.35 A and 1.60 A and form hydrogen bonds with 
some protein residues with their OH groups (GLU_303 for AE and PRO_369 for 
AE’).
The di-meta derivatives (AG, AG’, AH, AH’, AI, AI’) are the most 
promising compounds. They are all at a short distance from the haem (between 2.36 
A and 1 . 8 8  A). The presence of a large electron donating substituent (CH2OH) also 
seems to improve their correlation in the active site by forming some hydrogen bonds 
with the protein residues. The R-enantiomer AI formed hydrogen bonds with each of 
its CH2OH group and the amino-acid PRO_369, PHE 299 and GLU_303, these two 
hydrogen bonds are able to hold the molecule on two different sides of the 
hydrophobic pocket The S-enantiomer AI’ interacts with only one of its CH2OH 
substituents and PRO_369 (Figure 3.8). The OH derivative AH was also able to form 
hydrogen bond with the protein residue GLU 296. However di-meta compounds AI
(TRP_112, ALA I 14, VAL_116, ARG_219, TYR_234, GLU_296, PHE_299,
GLU 303, THR_304, PRO_369, VAL_370, PHE_374 and THR_479) and AI’ 
(TRP112, ALA_114, VAL_116, ARG_219, PHE_222, TYR_234, GLU_296,
PHE_299, GLU 303, THR_304, PRO_369, VAL_370, PRO_371, PHE_374,
THR 479) do not display as many hydrophobic interactions with the protein residues 
as the para-substituted compounds H and H ’.
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i?-enantiomer AI
ARG219 TYR234
(M370
^-enantiomer AI
ARG21!
'AL116
TYR234
THR304 !LU296
Figure 3.8: Diagram showing both enantiomers R-(AT) and S-^AT) of (3-{[4- 
(benzoxazol-2-ylamino)phenyl] imidazol-1 -ylmethyl} -5-
hydroxymethylphenyl)methanol docked at the active site region of the CYP26A1 
model. Hydrogen bonding interactions are shown as green lines and co-ordination 
with the transition metal is indicated with a purple line. Colour coding of the atoms: 
grey= carbon, red= oxygen, blue= nitrogen, brown= iron and yellow= sulphur. 
Amino-acid residues identified are involved in hydrophobic interactions.
Although most of these compounds displayed interesting results and 
especially a very close interaction with the haem iron, none was able to keep the 
hydrogen bond observed in R115866 with SER_115 and thus to hold the molecule on 
both sides of the active site. They also appear to be very challenging to synthesise, 
our effort will thus focus on the synthesis o f para-derivatives.
1.2.5) Substitution on the benzoxazole ring and change in the aza-rim
After looking at different substituents on the phenyl ring of the molecule, 
other changes such as a halogen substitution of the benzooxazole ring and a change 
of the imidazole ring into a triazole or tetrazole ring were investigated. The results 
are reported in Tables 3.3 and 3.4.
ci
In the case of the halogen substitution on the benzoxazole ring, the chlorine 
atom was used as an example (Table 3.3). This substitution seemed to be tolerated; 
all compounds except the 4-substituted AM’ fitted nicely in the active site. Though 
none were able to form any hydrogen bonds with the protein residues, they appear to 
be closer to the haem than the unsubstituted compounds A and A’ which displayed a 
distance of respectively 2.57 A and 2.77 A. Consequently, a chlorine substitution on
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position 4, 5 and 6  of the benzoxazole ring (compounds AJ, AJ’, AK, AK’, AL, 
AL’) could improve the activity.
Table 3.3: Effects of a chlorine substitution on the benzooxazole ring:
Position Enantiomer Distance from  
haem (A)
Hydrogen
bonds
Name
4 R 1.97 - AJ
4 S 1.92 - AJ’
5 R 2 . 2 0 - AK
5 S 1.62 - AK’
6 R 1.92 - AL
6 S 2 . 0 0 - AL’
7 R 1.99 - AM
7 S • - - AM’
The replacement of the imidazole ring by a 1,2,4-triazole, a 1,3,4-triazole and 
a tetrazole ring also seems to decrease the distance between the aza-ring nitrogen and 
the haem (Table 3.4). All compounds are very close to the haem iron (between 2.47 
A and 1.26 A), even if, as the imidazole compounds, they are not able to form any 
hydrogen bonds with the amino-acid residues.
However because of its enhanced binding properties with the haem114, the 
imidazole ring should display a lower IC50 than the other azoles, especially the 1,3,4- 
triazole and the tetrazole ring.
Table 3,4: Effects o f a change in the aza-ring:
X Y Enantiomer Distance from  
haem (A)
Hydrogen
bonds
Name
CH CH R 2.57 - A
CH CH S 2.77 - A’
N CH R 1.91 - AN
N CH S 2.47 - AN’
CH N R 1.56 - AO
CH N S 1.26 - AO’
N N R 1.56 - AP
N N S 1.39 - AP’
This new series of benzoxazole derivatives showed very promising results on 
docking studies with our CYP26A1 active site model. They displayed close 
interaction with the haem iron as well as multiple hydrophobic interactions and 
hydrogen bonds with the protein residues. A method for their synthesis was thus 
investigated, starting with the para-substituted compounds.
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2) SYNTHESIS AND DISCUSSION
2.1) Retrosvnthesis
NH NH R
SCN
BA
Scheme 3.1: Disconnective strategy toward substituted N-
phenylbenzo[<f]oxazolamines
The benzoxazol-2-yl-[phenylimidazol-1 -ylmethyl)phenyl] amine could be 
envisaged from the corresponding benzophenone C. This benzophenone could be 
transformed, as in the first series, by a reduction of the ketone followed by the 
addition of the triazole ring using the Staab method120 (Scheme 3.1).
The benzoxazole ring of C could be obtained by the reaction of the 
isothiocyanate B and 2-hydroxyaniline with nickel peroxide as a catalyst140.
Then, the isothiocyanate B could be prepared by the action of di-2-pyridyl 
thionocarbonate (DPT) 141 or thiophosgene142 on the aminobenzophenone A.
140 Ogura H., Mineo S. and Nakagawa K.; Studies on heterocyclic compounds. Synthesis of 2- 
substituted aminobenzoxazoles with nickel peroxide. Chem. Pharm. Bull., 1981,2 9 ,1518-1524.
141 Kim S. and Yi K.Y.; Di-2-pyridyl thionocarbonate. A new reagent for die preparation of 
isothiocyanates and carbodiimides. Tetrahedron Lett., 1985,2 6 ,1661-1664.
142 Bertha F., Homyak G., Lempert K.Z.K. and Toht EJP.G.; Benzoxadiazocines, benzothiadiazocines 
and benzotriazocines-III: The synthesis o f 2-(subst.)amino- and 2-(2-subst.hydrazino)-6-(alkylsulfonyl 
and aiylsulfonyl)-5,6-dihydro-4H-3,l,6-benzodiiadiazocines. Tetrahedron, 1983,3 9 ,1203.
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2.2) Synthesis of the 4-substituted aminobenzophenone A
Three methods were envisaged to synthesise these aminobenzophenones: a 
Friedel-Crafts acylation, a Negishi coupling and a method developed by Samietz in 
1895143.
2.2.1) Formation o f A  bv a Friedel-Crafts deviation
The Friedel-Crafts acylation is the most important method for the preparation 
of aryl ketones. This electrophilic aromatic substitution allows the synthesis of 
monoacylated products from the reaction between arenes and acyl chlorides.
a ic l
ArH + RCOCI ---------- ArCOR
The mechanism of this reaction involves the formation of the acyl cation by 
the action of the Lewis acid (generally aluminum chloride) on the acyl chloride. This 
acyl cation is then attacked by an ion pair of the aryl ring to form the aryl ketone 
(Figure 3.9).
O
A ,
+0 -AICl3
A , X +  aici4
+  IT
Figure 3.9: Mechanism of the Friedel-Crafts acylation144
The Friedel-Crafts acylation was applied to the synthesis of the 
aminobenzophenone A.
143 Samietz E.;p-N itropheny 1-tolylketon. Ann. Chem., 1895,321-332.
144 Smith M.B. and March J.; March’s advanced organic chemistry: reactions, m echanism s and 
structure 5th edition. John Wiley and Sons, Inc. 2001, 712-715.
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The first attempt was the reaction between methyl-4 -chlorocarbonylbenzoate 
and aniline with an excess of AICI3 (3 equivalents) and CH2CI2 as solvent. This 
reaction did not form the aminobenzophenone but resulted in the N-acylated product 
29 with a low 20 % yield (Scheme 3.2).
O
Me02C
MeOzC
aminobenzophenone
NH2  \ ( i )
MeOzC
W-acylated product
Scheme 3.2: Reagents and Conditions (i) AICI3 , CH2CI2 , o/n, rt, 20 %.
The problem of the TV-acylation could be solved by protecting the amino 
group of the aniline. The protecting group should be stable to the conditions of the 
Friedel-Crafts acylation (Lewis acid) and subsequently cleaved easily without loss of 
the ester. The MMT (monomethoxytrityl) group was suitable for these conditions.
MeOzC
(0
*
MeOzC
R =NHMMT
R =NH3+ Ch
R =NHMMT
r = n h 3 +ci-
Scheme 3.3: Reagents and Conditions (i) AICI3, CH2CI2, o/n, rt.
The MMT protected aniline was prepared by reaction of aniline with 4- 
monomethoxytrityl chloride in anhydrous pyridine and Et3N overnight145. The 
reaction did not go to completion resulting in a 34 % yield (Scheme 3.3). The poor 
yield could be explained by steric limitations.
145 Will D.W., Breipohl G., Langner D., Knolle J. and Uhlmann E.; Two recent examples of the use of 
MMT as an amino protecting group. Tetrahedron, 1995,57,12069-12082.
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Then, the Friedel-Crafts acylation was attempted again using the protected 
aniline; however no reaction was observed (Scheme 3.3).
The size of the protecting group could be a problem to achieve the acylation. 
So, a reaction with a smaller group was envisaged: the aniline hydrochloride. The 
chloride salt should be a good enough protection for this type of reaction. 
Unfortunately no reaction was observed with this amine salt (Scheme 3.3). The 
reason could be the problem of solubility of the aniline hydrochloride in 
dichloromethane.
A new method with different starting material (protected benzyl alcohol and 
4-nitrobenzoyl chloride) was then investigated146.
The acetyl protecting group was chosen for the benzyl alcohol as it is stable 
to the Friedel-Crafts conditions and to the hydrogenation envisaged at the next step 
to reduce the nitro group to an amino group.
OR
R = Ac
AcO
NO.
Scheme 3.4: Reagents and Conditions (i) AC2O, pyridine, DMAP, o/n, rt, 98 
%; (ii) AICI3 , CH2CI2 , o/n, rt then reflux, 2h; (iii) AICI3 , CS2 , o/n, rt.
Acetic anhydride was added to a solution of benzyl alcohol and DMAP in dry 
pyridine and the mixture was stirred at room temperature overnight (Scheme 3.4). 
The reaction went to completion with a 98 % yield, and the product could be used in 
the next step without any chromatographic purification147.
Then for the Friedel-Crafts acylation, an excess of benzylacetate and 
aluminum chloride (two equivalents) were added to a solution of 4-nitrobenzoyl
146 Carrol R.D., Miller M.W., Mylari B.L., Chappel L.R., Howes H.L., Lynch M.J., Lynch J.E., Gupta 
S.K., Rash J.J. and Koch R.C.; Anticoccidial derivatives o f 6-azauracil. 5. Potentiation by 
benzophenone side chains. J. Med. Chem., 1983,26, 96-100.
147 Weber H. and Khorana H.G.; CIV. Total synthesis o f the structural gene for an alanine transfer 
ribonucleic acid from yeast. Chemical synthesis o f an iscosadesoxyribonucleotide corresponding to 
the nucleotide sequence 21 to 40. J. Mol. Biol., 1972, 72,219-249.
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chloride and dichloromefhane as solvent. The reaction was stirred at room 
temperature overnight and refluxed for two hours, but again no reaction was 
observed. Employing carbon disulphide instead of dichloromethane as solvent148 was 
also unsuccessful (Scheme 3.4).
No efficient methods to synthesise the aminobenzophenone A by a Friedel- 
Crafts acylation could be found, so a new method using a Negishi coupling was 
investigated.
2.2.2) Formation o f A  by a Nezishi coupling
R'XR-R’
PdLn oxidative
addition
reductive
elimination
R'-Pd-XL-Pd-R
trans/cis 
isomerisation R'-Pd-R
RZnX
transmetaiation
ZnX,
Ni(PPh3)4
R-X +  R’-Z n -X ------- ► R-R'
or Pd(PPh3)4
Figure 3.10: Mechanism of the Negishi coupling
148 De Souza A.O., Hemerly F.P., Busallo A.C., Melo P.S., Machado G.M.C., Miranda C.C., Santa- 
Rita R.M., Haun M., Leon L.L., Sato D.N., De Castro S.L. and Duran N.; 3-[4’-bromo-(l,l’- 
biphenyl)-4-yl]-jV,A-dimethyl-3-(2-thienyl)-2-propen-l-amine: synthesis, cytotoxicity, and
leishmanicidal, trypanocidal and antimycobacterial activities. J. Antimicrob. Chemother., 2002, 50, 
629-637.
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The Negishi Coupling, published in 1977, was the first reaction that allowed 
the preparation of unsymmetrical biaryls in good yields. It is a Pd- or Ni-catalysed 
cross-coupling reaction forming a carbon-carbon bond149.
The mechanism of this reaction involves four steps (Figure 3.10):
- The oxidative addition: The alkyl halide R’X coordinates to the metal which 
looses two of its ligand.
- The transmetalation: The alkyl o f the zinc metal is exchanged with the 
halide of the palladium to form the four coordinated palladium with two ligands and 
the two alkyl groups R and R \
- The trans/cis isomerisation: The two alkyl groups are transformed from the 
trans to the cis conformation.
- The reductive elimination: The palladium is reduced to its second oxidative 
state by loosing the two alkyl groups which form the expected product RR\
The Negishi coupling was attempted to synthesise the aminobenzophenone 
A. A protection of the alcohol function was needed to avoid the possible 
esterification, again the acetyl protecting group was chosen. The acetylation was
1 AHperformed using acetic anhydride with DMAP and pyridine and the product 32 
was obtained pure with 99 % yield (Scheme 3.5).
34
Scheme 3.5: Reagents and Conditions (i) AC2O, pyridine, DMAP, o/n, rt, 99 
%; (ii) (a) nBuLi, THF, -78 °C, (b) ZnCh, -78 °C to rt, (c) Pd(PPh3)4 ,4-nitrobenzoyl 
chloride, o/n, rt, 85 %; (iii) TBDMSC1, imidazole, DMF, 4 h, rt, 95 %.
149 Huo S.; Highly efficient, general procedure for Ihe preparation of alkylzinc reagents from 
unactivated alkyl bromides and chlorides. Org. Lett., 2003,5,423-425.
O
OTBDMSTBDMSO
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The Negishi coupling was performed in three steps150. In the first step, n- 
butyllithium was added dropwise to a solution of 4-bromobenzylacetate in 
tetrahydrofuran at -78 °C. Then a THF solution of zinc chloride was added to the mix 
and the reaction allowed warming to room temperature. Finally, the reaction was 
cooled to 0 °C and a catalytic amount of tetrakis(triphenylphosphine)palladium(0) 
was added followed by the addition of 4-nitrobenzoyl chloride (Scheme 3.5). The 
reaction mixture was stirred overnight. Unfortunately, the acetyl group was not stable 
under these conditions and as a result the ester 33 was formed with 85 % yield.
A new protecting group was consequently envisaged. A silyl group such as 
TBDMS (tert-butyldimethylsilyl) was considered as quite stable to a variety of 
organic reactions and particularly to basic conditions. It is also quite easy to 
introduce and can be removed under mild conditions151.
The TBDMS protection was performed using /er/-butyldimethylsilyl chloride 
in dry DMF and imidazole as a catalyst152 (Scheme 3.5). The mixture was allowed to 
stir at room temperature during four hours. This reaction resulted in 95 % yield of 
pure product 34 after the extraction, no further purification was required.
Then the Negishi coupling was applied to this protected 4-bromobenzyl 
alcohol 34 following the same method previously described (Scheme 3.5). The 
TBDMS protection was stable to the reaction conditions, however no reaction was 
observed.
The Negishi cross-coupling reaction was thus not suitable for the formation 
of the required benzophenone A; therefore the method developed by Samietz in 1895 
was attempted.
2.2.3) Formation o f A  bv Samietz method143
This method allowed the synthesis of A in three steps: (1) a Friedel-Crafts 
acylation between toluene and nitrobenzoyl chloride in order to form 4-Methyl-
150 Ottosen E.R., Sorensen M.D., Bjdrkling F., Skak-Nielsen T., Fjording M.S., Aaes H. and Binderup 
L.; Synthesis and structure-activity relationship o f aminobenzophenones. A novel class of p38 MAP 
kinase inhibitors with high antiinflammatory activity. J. Med. Chem., 2003,46 ,5651-5662.
151 Greene T.W. and Wuts P.G.M.; Protective groups in organic synthesis. John Wiley and Sons, Inc., 
1991,77-79.
152 Ogilvie K.K., Schifinan A.L. and Penney C.L.; The synthesis of oligoribonucleotides HI. The use 
of silyl protecting groups in nucleoside and nucleotides chemistry VIII. Can. J. Chem., 1979, 57, 
2230-2238.
87
4’nitrobenzophenone, (2) a Jones oxidation to the carboxylic acid, and (3) a selective 
reduction of the nitro group (Scheme 3.6).
For the Friedel-Crafts acylation, an excess of aluminium chloride was added 
to a mixture of p-nitrobenzoyl chloride dissolved in toluene. After one hour stirring, 
water was added to the mix to precipitate the catalyst. After extraction the product 
was recrystallised from a mixture of chloroform and hexane to give the product as a 
single isomer with 92 % yield. The mechanism of this reaction is similar to the one 
shown in Figure 3.9.
CH.CH.
OH
COOH
COOH
COOH
Scheme 3.6: Reagents and Conditions (i) AICI3, toluene, 2 h, rt, 92 %; (ii) 
C 1 O 3 ,  AcOH, H2 0 , 1 h, reflux, 93 %; (iii) SnCh, EtOH, rt, 95 %.
The second step involved the oxidation of the methyl group into a carboxylic 
acid, using a mixture of chromium oxide with acetic acid and sulphuric acid known 
as Jones reagent. The mixture was stirred under reflux for 1 h. After cooling, cold 
water was added into the flask and the solid that precipitated was collected and 
washed with cold water until perfectly white to give the expected carboxylic acid 36 
with 93 % yield. This result was confirmed by proton NMR by the disappearance of 
the methyl peak at 8  2.49 ppm and the presence of a broad singlet at 8  13.35 ppm, 
which corresponds to the acid proton.
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Selective reduction of the nitro group into an am ino group using tin chloride 
as a catalyst was unsuccessful. After 30 min stirring at 70 °C, it afforded a mixture of 
three different compounds, the starting material, the expected compound and the 
“amino-alcohol” product (Scheme 3.6). Owing to the limited solubility of the 
mixture, further purification was not attempted.
2.2.4) Reduction o f the nitro-zroup
Scheme 3.7: Reagents and Conditions (i) H2SO4, M eO H , 30 m in, reflux, 89 
%; (ii) NaBHU, d ioxane , 5 h, rt, 99 %; (iii) SnCh, EtO H , rt, 76 %; (iv) Pd/C, H2 (1 
atm ), E tO H , 30 m in , rt, 80 %.
Before investigating other routes, the carboxylic acid was transformed to a 
methyl ester 37, using standard methodology, to improve solubility (Scheme 3.7). 
Attempts to selectively reduce the nitro group of the ester derivative using SnCb, 
H2/Pd on C, nickel-catalysed formic acid reductions were all unsuccessful. 
According to the literature, this latter method should be selective for the reduction of
O O
C 0 2Me
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nitro compounds over carbonyl substituents153. However in all cases complex 
mixtures and over reduction were observed. After the lack of success of selective 
reduction of the nitro group the selective reduction of the carbonyl group was 
performed in very high yield using NaBH4  and dioxane as solvent (38). The reaction 
was complete after 5 h stirring at room temperature and the result confirmed by 
proton NMR by the CH singlet peak at 8 5.88 ppm and the disappearance of the 
carbonyl peak in the carbon NMR.
Reduction of the nitro group using catalytic tin chloride resulted in a 
surprising 0-alkylation by the solvent ethanol (41). However Pd/C hydrogenation 
using a hydrogen balloon at atmospheric pressure instead of the hydrogenator at 20- 
30 psi resulted in a complete and selective reduction of the nitro group (40) after 30 
min stirring at room temperature (Scheme 3.7). If the reaction was left for longer 
removal of the hydroxy group was observed. The same type of result was obtained 
with an acetyl protection of the alcohol; the acetyl protection was cleaved under 
these conditions.
2.3) Formation o f the benzoxazole ring C
The benzoxazole ring could be attached by a simple nucleophilic substitution 
between 2-chlorobenzoxazole and the amine (40). Two different methods have been 
found to execute this reaction (1) using 2 equivalents of diisopropylethylamine as a 
base and dichloromethane as a solvent154, and (2) using 2 equivalents of EtaN as a 
base and dioxane as a solvent (Scheme 3.8)155. Both reactions have been shown to 
work with a primary amine as the nucleophilic species, but unfortunately in this case 
no reaction was observed presumably owing to the reduced nucleophilicity of the 
aromatic amine.
153 Gowda D.C., Gowda A.S.P., Baba A.R. and Gowda S.; Nickel-catalysed formic acid reductions. A 
selective method for die reduction o f nitro compounds. Synth Com., 2000,30,2889-2895.
154 Lazer E.S., Miao C.K., Wang H.C., Sorcek R., Spero D.M., Gilman A., Pal K., Behuke M., 
Graham A.G., Watraus J.M., Homan C.A., Nagel J., Shah A., Guindon Y., Farina P.R. and 
Adams J.; Benzoxazolamines and benzothiazolamines: potent, enantioselective inhibitors of 
leukotriene biosynthesis with a novel mechanism o f action. J. Med Chem., 1994,37,913-923.
155 Haviv F., Ratajczyk J.D., De Net R.W., Kerdesky F.A., Walters R.L., Schmidt S.P., Holms J.H., 
Young P.R. and Carter G.W.; 3-[ 1 -(2-Benzoxazolyl)hydrazine]propanenitrile derivatives: Inhibitors of 
immune complex induced inflammation. J. Med Chem., 1988,3 1 ,1719-1728.
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Scheme 3.8: Reagents and Conditions (i) 2-chlorobenzoxazole, DIEA, 
CH2CI2 , o/n, rt; (ii) 2-chlorobenzoxazole, Et3N, dioxane, o/n, rt.
However, studies by Ogura et a /140 have shown that the benzoxazole ring 
could also be formed by attaching 2-aminophenol to an isothiocyanate. This leads to 
a thiourea derivative that can then be cyclisised using nickel peroxide as a catalyst.
o h  4 s o h
Me02C
OH
Me02C
NCS
Figure 3.11: Mechanism of the formation of the isothiocyanate using 
thiophosgene as a reagent
The isothiocyanate (42) could be formed by two different methods: one 
employing expensive di-pyridyl-thiocarbonate (DPT)140 and the other involving 
thiophosgene141 (Scheme 3.9). The DPT reaction was performed by adding DPT to 
the amine (40) in dichloromethane, the mixture was left overnight at room 
temperature, washed with water and then purified by column chromatography to give 
the product 42 in 78 % yield. The thiophosgene reaction was performed by adding 
thiophosgene to a mixture o f amine (40), dichloromethane, ice and water, the
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reaction was stirred overnight at 0 °C then the thiophosgene residue and the 
hydrochloric acid formed during the reaction were removed by washing the organic 
layer thoroughly with water and sodium bicarbonate. The product 42 was obtained in 
89 % yield and could be used in the next step without further purification.
The mechanism of the thiophosgene reaction (Figure 3.11) involves the attack 
of the nitrogen lone pair on the thiophosgene thiocarbonyl group. The chloride 
released during this process is then acting like a base and catch the hydrogen on the 
nitrogen atoms. The electrons are then coming between the nitrogen and the carbon 
to form the isothiocyanate and the last chloride is released. The mechanism of the 
DPT reaction is similar.
OH OH
Scheme 3.9: Reagents and Conditions (i) DPT, CH2CI2 , 12 h, rt, 78 %; (ii) 
CSCI2 , CH2CI2 , H2O, 12 h, rt, 89 %; (iii) 2-aminophenol, EtOH, 12 h, rt, then (iv) 
NiPO, CH3CN, 24 h, rt, 61 %; (v) l,r-carbonyldiimidazole, imidazole, CH3CN, 12 
h, rt, 89 %; (vi) l/f-l,2,4-triazole, SOCl2, K2C 03, CH3CN, 72 h, rt, 43 %.
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The isothiocyanate (42) derivative was then reacted with 2-aminophenol at 
room temperature overnight. On a small scale (100 mg), the thiourea product (43) 
could be isolated after purification by column chromatography with 76 % yield. On a 
large scale (9 g), a mixture of the thiourea derivative (43) and the cyclised 
benzoxazole (44) was observed; this mixture was difficult to separate by column 
chromatography and was used as a mixture for the cyclisation. After the nickel 
peroxide cyclisation140, the product (44) was formed with an overall 61 % yield 
(Scheme 3.9).
The difference between the thiourea and the benzoxazole could be seen by 
NMR; the thiourea gave 2 broad NH protons at 8h 8.09 ppm and 7.79 ppm instead of 
only one for the benzoxazole at 8h 7.92 ppm. In the 13C NMR, the thiourea C=S 
signal of 43 was observed at 8c 178.96 ppm while the quaternary carbon of 44, 
which links the benzoxazole ring to the rest o f the molecule was observed at 8c 
158.13 ppm.
Figure 3.13: Proposed mechanism for the radical cyclisation of the 
benzoxazole by Ni-PO.
The mechanism of the reaction involved radical species. The reaction starts 
by a redox reaction involving a one-electron transfer generating the hydroxy radical
156 Sykes P.; A guidebook to mechanism in organic chemistry 6 ed. Longman Singapore publishers 
PteLtd. 1986, p 306.
H20 2 + Ni2+ , .....£ OH +% H  + Ni3+
Figure 3.12: Redox reaction between the peroxide and the nickel156
H H
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OH (Figure 3.12). This radical will be able to react with the molecule to form a 
phenoxy radical which will then attack the thiourea function to close the ring. Then 
the ring is stabilised by aromatisation and the thiyl radical SH' is released (Figure 
3.13).
2.4) Addition o f the aza-ring
The imidazole compound (45) was prepared in 89% yield by direct reaction 
of the carbinol (44) with 1,1 ’-carbonyldiimidazole in the presence of excess 
imidazole as previously reported157 (Scheme 3.8). The addition of the triazole ring 
employed the Staab method120, i.e. reaction o f the carbinol (44) with in situ prepared 
N,N -di(\H -\,2,4-triazol-1 -yl)sulphoxide. After purification by column 
chromatography the triazole benzoxazole (46) was obtained in 43% yield (Scheme 
3.9). The 1,2,4-triazole isomer was confirmed by NMR with the presence of the 
two singlet protons o f the triazole at approximately 6  7.97 and 8.02, no 1,3,4-triazole 
isomer was formed during the reaction.
The mechanism of the imidazole reaction is described in Figure 3.14. This 
mechanism is similar to the triazole reaction mechanism previously described. In this 
case the reagent 1 ,1 * carbonyl diimidazole is commercially available and does not 
need to be prepared in situ.
The carbinol (44) is first attacked by the imidazole to form the anion species. 
Then, the negatively charged oxygen attacks the carbonyl of the 1-1* carbonyl 
diimidazole yielding the product with a very good leaving group instead of the 
hydroxyl and releasing 1 mole o f imidazole anion. Finally the leaving group is 
substituted by the imidazole anion to form the product and liberate carbon dioxide 
and another mole of imidazole.
157 Aelterman W., Lang Y., Willemsens B., Vervest I., Leurs S. and De Knaep F.; Conversion of the 
laboratory synthetic route o f the A-aryl-2-benzothiazolamine R116010 to a manufacturing method. 
Org. Proc. Res. Dev. 2001,5,467-471.
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Figure 3.14: Mechanism o f the addition o f the imidazole ring
2.5) Synthesis o f the other substituents
The previous docking experiments have shown interesting results for three 
other substituents other than the ester: the carboxylic acid COOH, the alcohol 
CH2OH and the amide CONH2 .
The saponification of the ester 45 to the carboxylic acid 47 was achieved 
using a solution of 2 M aqueous NaOH and methanol as solvent in a 1:2 ratio. This 
allowed the compound to be synthesised after 30 min reflux with 62 % yield 
(Scheme 3.10).
Then the reduction o f both the ester 45 and the carboxylic acid 47 into the 
alcohol was investigated. Several methods have been found to perform this reaction 
(Scheme 3.10).
MeOzC
) (  (ii)or(iii) X (iv), (v) or (vi)
H2NOC
Scheme 3.10: Reagents and Conditions (i) 2 M aq. NaOH, MeOH, 30 min, 
reflux, 62 %; (ii) 28 % NH4OH aq., o/n, rt; (iii) NHh/MeOH, o/n, rt; (iv) UAIH4, 
THF, 4 h, 0 °C; (v) NaBHU, ethane dithiol, THF, 4 h, reflux; (vi) NaBHU, BFs/E^O, 
THF, 5 h, rt.
The conventional method using the reductive agent LLMH4 in THF158 was 
attempted but no reaction was observed. In the other methods, sodium borohydride 
was used as the reducting agent. Sodium borohydride cannot reduce carboxylate 
ester and carboxylic acid on its own, however some studies have shown that its 
reducing power can be increased. It has been shown that the addition of ethanedithiol 
to sodium borohydride leads to a sulfurated sodium borohydride species with a 
stronger reducing power159,16°. The mixture NaBH4/BF3‘Et2 0  in THF has also been
158 Hartmann R.W., Palusczak A., Lacan F., Ricci G. and Ruzziconi R.; CYP 17 and CYP 19 
inhibitors. Evaluation of fluorine effects on the inhibiting activity o f regioselectively fluorinated 1- 
(naphtalen-2-ylmethyl)imidazoles. J. Enz. Inh. Med Chem., 2004,1 9 ,145-155.
159 Guida W.C., Entreken E.E. and Guida A.R.; Reduction of esters and otto ’ carboxylates by sodium 
borohydride/ethandithiol: Improved procedures and an investigation into the nature of the reducing 
species. J. Org. Chem., 1984,49, 3024-3026.
Maki Y. and Kikuchi K.; Thiol-activated sodium borohydride reduction of carboxylate ester. 
Tetrahedron Lett., 1975,3 8 ,3295-3296.
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1shown to reduce carboxylic acids and esters161, 162. The treatment of sodium 
borohydride with boron trifluoride etherate produces borane which is a good 
reducing agent. Unfortunately both of these methods were ineffective in that case and 
no reaction was observed (Scheme 3.10).
The transformation of either 45 or 47 into the amide derivative was also 
attempted (1) using a 28 % ammonium hydroxide aqueous solution163 and (2) using a 
saturated methanolic ammonia solution. Unfortunately no reaction was observed in 
both cases (Scheme 3.10).
2.6) Synthesis o f the unsubstituted, m ethyl, methoxv and hydroxy 
substituted phenyl derivatives
2.6.1) Synthesis______ o£_______the______ benzoxazol-2-vl-f4-substituted-l-
vlvhenvlmethvllvhenvllamine (52). (S3). (S39). (54).
The unsubstituted derivative was prepared using the same strategy as seen 
before for the methyl ester derivative. However as the 4-aminobenzophenone is 
commercially available the synthesis was much easier with only 4 steps instead of 8 
(Scheme 3.11).
4-aminobenzophenone was first transformed into the corresponding 
isothiocyanate 49 with 99 % yield using thiophosgene. Then the benzoxazole ring 
was added. As seen previously 2-aminophenol reacted on 49 to form the thiourea. 
For the cyclisation step, the expensive nickel peroxide reaction (Scheme 3.9) has 
been changed by a cheap mercury (II) oxide reaction in ethanol catalysed by a small 
amount of sulphur powder164. This allowed the formation of 50 with an overall yield 
of 54 %. The reduction o f the ketone 50 to the alcohol 51 was performed using
161 Cho S., Park Y., Kim J., Falck J.R. and Yoon Y.; Facile reduction o f carboxylic acids, esters, acid 
chloride, amides and nitriles to alcohols or amines using NaBH4/BF3*Bt20 . Bull. Korean Chem. Soc., 
2004,25,407-409.
162 Brown H.C. and Subba Rao B.C.; Hydroboration. III. The reduction of organic compounds by 
diborane, an acid-type reducing agent. J. Am. Chem. Soc., 1960,82 ,681-686.
163 Pan Y., Holmes C.P. and Tumelty D.; Novel a,a-Difluorohomophthalimides via Copper-Catalyzed 
Tandem Cross-Coupling-Cyclization o f 2-Halobenzamides with tt,cc-Difluoro Reformatskii Reagent. 
J. Org. Chem., 2005, 70,4897-4900.
164 Janssens F., Torremans J., Janssen M., Stokbroekx R.A., Luyckx M. and Janssen P.A.J.; New 
antihistaminic N-heterocyclic 4-piperidinamines. Synthesis and antihistaminic activity of N-(4- 
piperidiny 1)-1 i/-benzimidazol-2-amines. J. Med. Chem., 1985,2 8 ,1925-1933.
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NaBKU in dioxane. Because of the poor solubility of 50 in dioxane, the reaction had 
to be left overnight to give 51 in 8 6  % yield. The imidazole (52), 1,2,4 triazole (53),
1,3,4 triazole (53’) and tetrazole (54) ring were then added to the carbinol 50 using 
methods previously described (Scheme 3.9 and Figure 3.14) with variable yield (12 
to 74 %) depending on the azole ring (Table 3.5).
(iv), (v) 
or (vi) Y—z 52: X= CH, Y= N, Z= CH 
53: X= N, Y= CH, Z= N 
53': X= CH, Y= N, Z= N 
54: X= N, Y= N, Z= N
Scheme 3.11: Reagents and Conditions (i) CSCI2 , CH2CI2 , H2O, 12 h, rt, 99 
%; (ii) (1) 2-aminophenol, EtOH, 12 h, rt (2) HgO, S, EtOH, 4 h, reflux, 54 %; (iii) 
NaBHt, dioxane, o/n, 8 6  %; (iv) l , l ’-carbonyldiimidazole, imidazole, CH3CN, 12 h, 
rt, 74 %; (v) ltf-l,2,4-triazole, SOCl2, K2C 03, CH3CN, 72 h, rt, 53: 35 %, 53’: 12 %; 
(vi) 17/-tetrazole, SOCI2 , K2C0 3, CH3CN, 72 h, rt, 54: 32 %.
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Table 3.5: Results o f the addition o f the aza-ring
X Y Z YIELD(*} COMPOUND
NUMBER
CH N CH 74% 52
N CH N 35% 53
CH N N 1 2 % 53’
N N N 32% 54
(a) Yield calculated after purification by flash column chromatography
2.6.2) Synthesis o f the methyl derivative (59)
The synthesis o f the methyl derivatives could be achieved in 6  steps (Scheme 
3.12). This method followed the procedure used for the synthesis of the methyl ester 
derivative. 35 formed by a Friedel-Crafts acylation between 4-nitro-benzoyl chloride 
and toluene was reduced to the corresponding alcohol 55 using NaBH* in methanol. 
Then the nitro group was reduced to an amino group using a hydrogen atmosphere 
(P= 1 atm). This reduction was performed on a large scale ( 6  g), and after 1.5 h 
stirring at room temperature the reaction was still not complete however reduction of 
the alcohol was occurring leading to a mixture of three different compounds. The 
expected product could be isolated by column chromatography in only 48 % yield.
The benzoxazole ring was attached using the mechanism described in 
Scheme 3.10 for 50. The formation o f the isothianocyanate 57 was completed using 
thiophosgene with 8 8  % yield. Then 2-aminophenol was added and after an 
overnight stirring at room temperature, mercury oxide and sulphur were added to the 
mixture and left under reflux for 2 h to form 58 with 35 % yield (Scheme 3.12).
The imidazole was finally attached to 58 using the conventional method with 
l,r-carbonyldiimidazole and imidazole to give, after overnight stirring at room 
temperature, 59 with 6 6  % yield.
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Scheme 3.12: Reagents and Conditions (i) AICI3 , toluene, 2 h, rt, 92 %; (ii) 
NaBH4 , MeOH, 1 h, rt, 8 6  %; (iii) Pd/C, H2  balloon, EtOH, 1.5 h, rt, 48 %; (iv) 
CSCI2 , CH2CI2 , H20 , 12 h, rt, 8 8  %; (v) (1) 2-aminophenol, EtOH, 12 h, rt (2) HgO, 
S, EtOH, 4 h, reflux, 35 %; (vi) l,r-carbonyldiimidazole, imidazole, CH3CN, 12 h, 
rt, 6 6  %.
2.6.3) Synthesis o f the methoxv (67) and the hvdroxv (68) derivatives
The synthesis o f the methoxy derivative was performed in 6  steps following 
the method for the synthesis o f the unsubstituted compound 52; the reduction of the 
ketone took place after the formation of the benzoxazole ring (Scheme 3.13). The 
benzophenone 60 was formed by a Friedel-Crafts acylation between p-nitrobenzoyl 
chloride and anisole. In contrast with the methyl derivative, the nitro group of 60 was 
first reduced to the amine. Only 10 min under a hydrogen atmosphere (1 atm) and 
Pd/C catalyst afforded the corresponding amine 61 with 95 % yield.
After transformation into the isothiocyanate 62 using thiophosgene with 97 % 
yield, the benzoxazole ring was attached using the same method seen previously. 62
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was stirred overnight with 2 -aminophenol in toluene instead of ethanol because of its 
poor solubility and then sulphur and HgO were added to the mixture which was 
refluxed for 1.5 h to give 63 with 46 % yield. The carbinol 65 was then formed by a 
reduction of the ketone using NaBH4  in methanol with 91 % yield.
Scheme 3.13: Reagents and Conditions (i) AICI3 , anisole, CH2CI2 , 12 h, rt, 69 
%; (ii) Pd/C, H2  balloon, EtOH, 10 min, rt, 95 %; (iii) CSCI2 , CH2CI2 , H20 , 12 h, rt, 
97 %; (iv) (1) 2-aminophenol, EtOH, 12 h, rt (2) HgO, S, toluene, 4 h, reflux, 46 %;
(v) HBr, AcOH, 6  h, reflux then 12 h, rt, 77 %; (vi) NaBFU, MeOH, 1 h, rt, 65: 91 %, 
6 6 : 44 %; (vii) l,r-carbonyldiim idazole, imidazole, CH3CN, 12 h, rt, 67: 38 %, 6 8 : 
74 %.
The imidazole was finally attached to 65 using the conventional method with 
l,r-carbonyldiimidazole and imidazole to give, after overnight reflux, 67 with only
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38 % yield. The poor yield of this reaction could be explained by the fact that the 
reaction did not go to completion because o f the poor solubility of 65 in CH3CN.
The hydroxy derivative 6 8  was formed in 3 steps after deprotection of the 
methoxy function of 63 (Scheme 3.13). A first attempt using a 1 M solution of BBr3 
in CH2CI2 was found unsuccessful165. Then, another method involving a 48 % 
solution of HBr in acetic acid gave the hydroxy product 64 in 77 % yield after 6  h 
reflux followed by overnight stirring166. This product was then reduced to the alcohol 
6 6  using NaBFL* in methanol. In that case the reaction did not go to completion and 
afforded the product after purification by column chromatography with a moderate 
44 % yield. The imidazole ring was then attached using the usual method to form 6 8  
with 74 % yield.
2. 7)  Substitution on the other positions o f the phenyl ring
Docking studies in the previous chapter showed that substitution on the ortho 
and the meta positions of the phenyl ring could be of interest. Better results were also 
observed in the case of a di-substitution; however the synthesis o f these compounds 
appeared to be very challenging.
2.7.1) Synthesis o f a di-meta derivative
R= R ' = C O ,M e o r CN
R
+
R ’ R'
Scheme 3.14: Reagents and Conditions (i) AICI3, CH2CI2, rt; (ii) AICI3, DCE, reflux.
165 Grieco P.A., Nishizawa M., Oguri T., Burke S.D. and Marinovic N.; Sesquiterpene lactones: total 
synthesis o f vemolepin and vemomenin. J. Am. Chem. Soc., 1977,99, 5773-5780.
Plattner J.J., Martin Y.C., Smital J.R., Lee C.M., Fung A.K.L., Horram B.W., Orowley S.R., Pemet 
A.G., Bunnel P.R. and Kim K.H.; [(Aminomethyl)aryloxy]acetic acid esters. A new class of high- 
ceiling diuretics. 3. Variation in the bridge between the aromatic rings to complete mapping of the 
receptor. J. Med. Chem., 1985,2 8 ,79-93.
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Synthesis o f a di-meta derivative by a Friedel-Crafts acylation requires 
having 2  withdrawing groups on the 2  meta positions.
Friedel-Crafts acylation were attempted with 4-nitrobenzoyl chloride and 
both dimethyl isophtalate and 1,3-dicyanobenzene with CH2CI2 as a solvent at room 
temperature and with dichloroethane as a solvent at reflux (Scheme 3.14). 
Unfortunately no reaction was observed.
2.7.2) Synthesis o f the dimethyl derivatives 84. 85 and 86
A simple method to obtain some di-substituted compounds was to perform a 
Friedel-Crafts acylation between 4-nitrobenzoyl chloride and ortho, meta and para- 
xylene. This led to the formation o f three dimethyl derivatives, the 3,4-dimethyl 84, 
the 2,4-dimethyl 85 and the 2,5-dimethyl 8 6 . Their synthesis is described in Scheme 
3.15.
The Friedel-Crafts acylation was performed at room temperature for 3-4 h 
and gave the products 69, 70 and 71 respectively with 41 %, 85 % and 90 % yield. 
These products were obtained pure as a single isomer after extraction except 69 
which required purification by column chromatography (PE/EtOAc 80:20 v/v). 
Formation of 69 and 70 was confirmed by proton NMR with the presence of 
respectively an aromatic singlet at 7.46 ppm and two aromatic doublets at 7.34 ppm 
and 7.10 ppm integrating for one proton for 69 and an aromatic singlet at 6 . 8 6  ppm 
and 2 aromatic doublets at 7.04 and 6 . 8 6  integrating for one proton for 70. Because 
of the symmetry o f the para-xylene compound 71 was the only possible product of 
the reaction.
The rest of the synthesis involved the usual method for this type of compound 
(Scheme 3.15) with first a reduction of the nitro-group which led to the amino- 
benzophenone 72 (94 %), 73 (96 %) and 74 (94 %) followed by a transformation of 
the amino group into an isothiocyanate (compound 76 was pure enough after 
extraction and obtained with 96 % yield while compounds 75 and 77 required 
purification by column chromatography (petroleum ether/ethyl acetate 80:20 v/v) and 
were respectively obtained with 75 % and 61 % yield). Then the benzoxazole ring 
was added in high yield to give compounds 78 (87 %), 79 ( 6 6  %) and 80 (64 %), the
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ketone was reduced (compounds 81, 82 and 83) and finally the imidazole ring 
attached to give the three dimethyl derivatives 84,85 and 86.
[78: R1= R4= H, 
R2= R3= CH3 
79: R2= R4= H, 
R1= R3= CH3 
80: R2= R3= H, 
R1=R4CH
*69: R1=
rXii2
R2= R3= CH3
70: R2= R4= H,
R1= R3= CH3
71: R2= R3= H,
R1= R4 CHg v (Hi)
"72: R1= R4= H, %
R2= R3= CH3
73: R2= R4= H,
R1= mX
0IIs
74: R2= R3= H,
R1= R4CH,
75: R1= R4= H, 
R2= R3= CH3 
76: R2= R4= H, 
R1= R3= CH3 
77: R2= R3= H,
OH R1
81: R1= R4= H, 
R2= R3= CH3 
82: R2= R4= H, 
R1= R3= CH3 
83: R2= R3= H, 
R1=R4CH,
84: R1= R4= H, 
R2= R3= CH3 
85: R2= R4= H, 
R1= R3= CHa 
86: R2= R3= H, 
R1= R4 CH,
Scheme 3.15: Reagents and Conditions (i) AICI3 , o,m or p-xylene, CH2CI2 , 3- 
4 h, rt, 69: 41 %, 70: 85 %, 71: 90 %; (ii) Pd/C, H2  balloon, EtOH, 20-25 min, rt, 72: 
94 %, 73: 96 %, 74: 94 %; (iii) CSC12, CH2C12, H2 0 , 12 h, rt, 75: 75 %, 76: 96 %, 77: 
61 %; (iv) (1) 2-aminophenol, EtOH, 12 h, rt (2) HgO, S, EtOH, 4-6 h, reflux, 78: 87 
%, 79: 6 6  %, 80: 64 %; (v) NaBEU, MeOH, 3-4 h, rt, 81: 73 %, 82: 97 %, 83: 99 %;
(vi) l,r-carbonyldiimidazole, imidazole, CH3CN, 12 h, rt, 84: 78 %, 85: 84 %, 86: 
72 %.
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2.8) Biological evaluation
The biological activity of the benzoxazole derivatives was measured 
following the same procedure as previously described with the MCF-7 cell line and 
[3H-11,12] -al\-trans retinoic acid. The results are reported in Table 3.6.
Compounds 45, 46, 47 and 48 which showed very interesting results in the 
docking studies were unfortunately not as active as expected (IC50 > 20 pM), and 
were 2 to 3 times less active than the most potent 1 -[(benzofuran-2- 
yl)phenylmethyl]triazole series previously described (IC50 = 5 pM) and liarozole 
(IC50 = 6 pM)81. On the other hand 52 which is the same compound with no 
substituent showed a good activity (0.9 pM) as well as the methyl derivative (59, 
IC50 = 8  pM) and the hydroxy derivative (68, IC50 = 12 pM). Also the presence of a 
methoxy (67) or a dimethyl substitution (84, 85 and 86) gave disappointing results. 
The accurate IC50 of compounds 53% 54, 65, 84, 85 and 86 were not calculated as 
they appeared to be weak inhibitors o f CYP26 and showed less than 50 % inhibition 
at a 20 pM concentration. Their percentage inhibition at 20 pM is showed in Table 
3.7.
Y------Z
O
N
H
Table 3.6: ICsn of the benzoxazole derivatives
R X Y Z IC 50 (pM) COMPOUND
NUM BER
4-C 02Me CH N CH 20 45
4-C 02Me N CH N 50 46
4-COOH CH N CH 50 47
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4-COOH N CH N 50 48
H CH N CH 0.9 52
H N CH N 18 53
H CH N N >20 53’
H N N N >20 54
4 -CH3 CH N CH 8 59
4-OMe CH N CH >20 67
4-OH CH N CH 12 68
3,4-CH3 CH N CH >20 84
2,4-CH3 CH N CH >20 85
2,5-CH3 CH N CH >20 86
A large drop in the activity can also be observed when the imidazole ring (52, 
IC5o= 0.9 pM) is replaced by a triazole ring (53, ICso= 18 pM for the 1,2,4 triazole 
and > 20 pM for the 1,3,4 triazole 53’) or a tetrazole ring (54, IC50 > 20 pM).
Table 3.7: % inhibition at 20 ttM
COMPOUND NUMBER %  INHIBITION AT 20 pM
53’ 19.12%
54 39.32 %
67 40.5 %
84 34.62 %
85 31.82%
86 36.15%
Consequently, comparison between the activity of the unsubstituted 
compound (52, IC5o= 0.9 pM) and the different substituted ones (45, ICso= 20 pM; 
47, IC50= 50 pM; 59, IC5o= 8 pM; 67, IC50 > 20 pM; 68, IC50= 12 pM) showed that 
no substitution on the phenyl ring seem to be tolerated at the para-position. The 
moderate activity observed for the small substituent CH3 (59, IC5o= 8 pM) and OH 
(IC5o= 12 pM) suggests that this is due to steric limitations with the active site. The
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poor activity of the three dimethyl compounds 84, 85 and 86 (IC50 > 20 pM) also 
showed that substitution on the other position of the phenyl ring did not need to be 
investigated further. The imidazole ring also appears to be the best choice in the 
azole ring as the unsubstituted compounds appeared to be much more potent with an 
imidazole ring than a triazole or a tetrazole.
As a result, the presence o f a substituted phenyl ring displayed disappointing 
results. The difference observed in the docking studies and the activity also showed 
the limitations of our CYP26A1 model. The model should consequently be improved 
and the replacement o f the phenyl ring by a more flexible alkyl chain should now be 
considered in the design of new potential C YP26 inhibitors.
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3) EXPERIMENTAL
3.1) Experimental results for the preparation o f the methvi ester 
derivatives 45 and 46 and the carboxylic acid derivatives 47 and 48
3.1.1) Terephtalanilic acid (29)167
To a suspension o f aniline (38 mg, 0.41 mmol) in CffeCfe (10 mL), was 
added aluminum chloride (0.16 g, 1.23 mmol) at 0 °C. The reaction mixture was 
stirred for 30 min, during which time the reaction temperature was allowed to rise to 
room temperature. Methyl-4-chlorocarbonylbenzoate (0.10 g, 0.45 mmol) was added 
over a period of 1 h maintaining the temperature below 30 °C. The reaction mixture 
was stirred overnight at room temperature and then 2 N aqueous HC1 (2 mL) was 
slowly added. The solvent was removed and water was added. The resulting 
precipitate was filtered, washed with FfeO (3 x 20 mL) and dried to give the N- 
acylated product as a yellow syrup. Yield: 21 mg (20 %). t.l.c system: petroleum 
ether-ethyl acetate 1:1, Rf= 0.83.
*H NMR: 8 (DMSO-4*): 8.09 (m, 2H, Ar), 7.84 (m, 2H, Ar), 7.61 (m, 2H,
167 Schoenberg A. and Heck R.F.; Palladium-catalyzed amidation o f aryl, heterocyclic, and vinylic 
halides. J. Org. Chem., 1974,59,3327-3331.
MeOOC MeOOC
Ar), 7.31 (m, 2H, Ar), 7.13 (m, 1H, Ar), 3.88 (s, 3H, CH3).
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3.1.2) f(4-Methoxvphenvl)diphenvlmethvllDhenvlamine (30)168
Aniline (1.33 g, 14.25 mmol) was dissolved in anhydrous pyridine (27 mL) 
and triethylamine (0.6 mL). To this solution was added a solution of 4- 
monomethoxytrityl chloride (4 g, 12.95 mmol) in anhydrous pyridine (15 mL) in 3 
aliquats at 45 min intervals. The reaction was stirred at room temperature for 3 h then 
quenched by the addition of MeOH (3 mL). The solution was evaporated to give a 
yellow syrup and coevaporated 3 times with toluene to remove traces of pyridine. 
The residue was dissolved in EtOAc (30 mL) and washed with saturated aqueous 
KC1 solution (2 x 25 mL). The organic phase was dried (MgSC>4), filtered and 
evaporated in vacuo. The residue was purified by column chromatography (hexane: 
EtOAc: diethylamide 49.5: 49.5: 1) to give the product as a yellow syrup. Yield: 1.59 
g (34 %). t.l.c system: dichloromethane, Rf = 0.89.
*H NMR: 6 (CDC13): 7.56 (m, 3H, Ar), 7.43 (m, 2H, Ar), 7.39 (m, 5H, Ar), 
7.35 (m, 2H, Ar), 7.09 (m, 2H, Ar), 6.98 (m, 2H, Ar), 6.72 (m, 1H, Ar), 6.54 (m, 2H, 
Ar), 5.28 (bs, 1H, NH), 3.87 (s, 3H, CH3).
3.1.3) Benzyl acetate (31)169
OH (Ac)20
DMAP, pyridine
168 Moises Comle L., Demirtas I. and Maskill H.; Substituent effects upon rates deamination and base 
strengths of substituted JV-tritylamines. J. Chem. Soc., Perkin Transactions 2 ,2001, 9, 1748-1752.
169 Bryant D.R., McKeon J.E. and Ream B.C.; Palladium-catalyzed synthesis o f benzyl esters from 
methyl benzenes. J. Org. Chem., 1968,33 ,4123-4127.
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To a solution o f benzyl alcohol (15 g, 0.14 mol) and DMAP (1.86 g, 15.26 
mmol) in dry pyridine (150 mL) was added acetic anhydride (42.48 g, 0.42 mol) and 
the reaction was stirred under nitrogen at room temperature overnight. EtOH (60 mL) 
was added to quench the reaction, and the solvent concentrated under reduced 
pressure. The residue was then diluted with CH2CI2 (100 mL) and washed with 
saturated aqueous NaHC0 3  (2 x 100 mL) and 10 % aqueous NaCl (2 x 100 mL) 
solution. The organic layer was dried with MgS0 4  to give a yellow syrup. Yield: 
20.40 g (98 %). t.l.c system: petroleum ether-ethyl acetate 4:1, Rf= 0.51.
'HNM R: 5 (CDCI3): 7.39 (m, 5H, Ar), 5.13 (s, 2H, CH2), 2.11 (s, 3H, CH3).
3.1.4) 4-Bromobenzvl acetate (32),?0
To a solution o f 4-bromobenzyl alcohol ( 6  g, 32.07 mmol) and DMAP (0.43 
g, 3.53 mmol) in dry pyridine (50 mL) was added acetic anhydride (6.55 g, 64.14 
mmol) and the reaction was stirred under nitrogen at room temperature overnight. 
EtOH (30 mL) was added to quench the reaction, which was then diluted with 
CH2CI2 (60 mL). The solution was washed with saturated aqueous NaHCOs (2 x 50 
mL) and 10 % NaCl solution (2 x 50 mL). The organic layer was dried with MgS0 4  
to give a yellow syrup. Yield: 7.30 g (99 %). tl.c  system: petroleum ether-ethyl 
acetate 3:1, Rf= 0.59.
'HNM R: 5 (CDC13): 7.47 (d, J= 8.1 Hz, 2H, Ar), 7.22 (d, J= 8.1 Hz,2H, Ar), 
5.05 (s, 2H, CH2), 2.10 (s, 3H, CH3).
170 Gilman H. and Helstrom D.S.; Organolithium compounds with hydroxyl, nitrilo and sulfonamido 
groups. J. Am. Chem. Soc., 1948, 70,4177-4179.
DMAP, pyridine Br
32
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3.1.5) 4-Bromobenzvl 4-nitrobenzoate (S3)171
2) ZnCI2, -78 °C to r.t.
3) 4-nitro benzoyl chloride, 
PdCPPhg),
«-Butyllithium (5.86 mL, 8.73 mmol) was added dropwise (10 min) to a 
solution of 4-bromobenzyl acetate (2 g, 8.73 mmol) in THF (20 mL) at -78 °C, and 
the resulting mixture was stirred for 30 min. A THF solution of dry ZnCfe (1.0 M, 12 
mL) was added with a syringe and the reaction mixture was allowed to warm to room 
temperature. After 2 h the reaction mixture was cooled to 0 °C, and 
tetrakis(triphenylphosphine)palladium(0) (0.49 g, 0.43 mmol) was added followed by 
the addition of 4-nitrobenzoyl chloride (1.78 g, 9.6 mmol) in THF (5 mL). The 
stirring mixture was allowed to warm to room temperature overnight The reaction 
was concentrated under reduced pressure. The residue was partitioned between 
EtOAc (50 mL) and 1 N HC1 (100 mL) and the aqueous phase was extracted with 
EtOAc (50 mL). The combined organic extracts were washed with brine (3 x 50 
mL), dried over MgSC>4 and concentrated in vacuo. The residue obtained was washed 
with MeOH to give a white solid. Yield: 2.56 g (85 %). t.l.c analysis was impossible 
owing to limited solubility.
'HNM R: 8 (DM SO-*): 8.41 (d, J= 7.8 Hz, 2H, Ar), 8.29 (d, J= 7.8 Hz, 2H, 
At), 7.67 (d, J= 8.1 Hz, 2H, Ar), 7.54 (d, J= 8.1 Hz, 2H, Ar), 5.42 (s, 2H, H-8).
I3C NMR: 6 (DMSO-rf«): 164.07 (C, C=0), 150.33 (C, C-4), 135.06 (C, C- 
1’), 135.84 (C, C -l), 131.48 (CH, C-2, C-6), 130.74 (CH, C -3\ C-5’), 130.35 (CH, 
C-2’, C-6’), 123.91 (CH, C-3, C-5), 121.52 (C, C-4’), 66.25 (CH2).
IR (NaCiy cm '1 1714 (C=0); 1524.7 (NOz); 1348.8 (NQz).
Melting point: 106-108 °C.
Microanalvsis: Calculated for Ci4HioBrN0 4 ; theoretical: %C 50.03, %H 3.00, 
%N 4.17, found %C 49.80, %H 3.14, %N 3.95.
171 Bowie J.H. and Nussey B.; Electron-impact studies. LXXXIV. Substituent effects in the negative 
ion mass spectra o f aryl esters. Org. Mass Spec., 1974,9, 310-320.
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3.1.6) (4-BromoDhenoxv)-tert-butvldimethvl-silane 134)172
Br Si-CI Br
HO TBDMSOimidazole, DMF
34
TBDMSC1 (1.01 g, 6.68 mmol) in dry DMF (5 mL) was added to a dry DMF 
(25 mL) solution of 4-bromo-benzylalcohol (1 g, 5.35 mmol) and imidazole (0.91 g,
13.36 mg). The mixture was stirred at room temperature for 4 h and then quenched 
with MeOH (10 mL). The solvent are removed under reduced pressure and the 
residue diluted with EtOH (30 mL). The mixture was washed with H2O (3 x 20 mL) 
and the recombined organic layers were dried (MgSC>4), filtered and concentrated in 
vacuo to give a pure yellow syrup. Yield: 1.54 g (95 %). t.l.c system: petroleum 
ether-ethyl acetate 2:1, Rf= 0.75.
'HNM R: 5 (DMSCWtf): 6.61 (d, J= 8.1 Hz, 2H, Ar), 6.48 (d, J= 8.1 Hz, 2H,
To a solution of p-nitrobenzoyl chloride (1 g, 5.39 mmol) in toluene (40 mL) 
was added AICI3 (1 g, 7.54 mmol) and the resulting red solution stirred at room 
temperature for 2 h. H2O (4 mL) was added dropwise and the resulting mixture was 
stirred for 15 min and then extracted with H2O (50 mL) and 10 % NaHCOs (2 x 50 
mL). The organic layer was dried (MgSO^, filtered and evaporated to give a pale 
yellow solid. Recrystallisation from CHCL/hexane gave the product as pale yellow 
needles. Yield: 1.2 g (92 %). t.l.c system: dichloromethane-hexane 1:1, Rf= 0.27.
172 Sessler J.L., Wang B. and Harriman A.; Photoinduced energy transfer in associated, but 
noncovalent-linked photosynthetic model system. J. Am. Chem. Soc., 1995,117,704-714.
173 Findeis M.A. and Kaiser E.T.; Nitrobenzophenone oxime based resins for the solid phase synthesis 
of protected peptide segments. J. Org. Chem., 1989,54 ,3478-3482.
Ar), 3.82 (s, 2H, CH2), 2.10 (s, 3H, Me), 2.05 (s, 3H, Me), 0.14 (s, 9H, tBu).
3.1.7) 4-Methvl-4 ’nitrobenzovhenone (35)173
O  14
toluene
112
*HNMR: 8  (CDCI3): 8.36 (d, 2H, J= 8 . 8  Hz, Ar), 7.92 (d, 2H, J= 8.0 Hz, Ar),
7.70 (d, 2H, J= 8 . 8  Hz, Ar), 7.24 (d, 2H, J= 8.0 Hz, Ar), 2.49 (s, 3H, CH3).
Melting point: 112-114 °C (lit m.p. 120-120.5 °C)173.
3.1.8) 4-(4-Nitrobemovl)benzoic acid (36)174
CrO.
COOH0,N 35
(4-Nitrophenyl)(p-tolyl)methanone (35) (2.35 g, 9.74 mmol) was dissolved in 
warm acetic acid (14 mL). A solution of chromic acid (3.41 g, 34.10 mmol) in H2O/ 
acetic acid/^SQ* (8/14/2.6 mL) was added slowly through the condenser while the 
reaction was kept just below boiling point. When all the oxidizing mixture had been 
added the preparation was refluxed gently for 1 h and the liquid portion then 
decanted into cold H2O. The precipitated solid was collected and washed thoroughly 
with cold H2O, then dried at 70 °C in vacuo to give the product as a white crystalline 
solid. Yield: 2.45 g (93 %). t.l.c analysis was impossible owing to limited solubility.
'HNM R: 8 (DMSO-<4): 13.35 (bs, 1H, COOH), 8.40 (d, 2H, J= 8.4 Hz, Ar), 
8.12 (d, 2H, J= 8.0 Hz, Ar), 7.98 (d, 2H, J= 8.4 Hz, Ar), 7.77 (d, 2H, J= 8.0 Hz, Ar). 
Melting noint: 243-244 °C (lit m.p. 255 °C)174.
/ 7?3.1.9) 4-(4-Nitrobenzovl)benzoic acid methyl ester (37)
O
H2 S 0 4, MeOH r Y V 1
COOH reflux OzN ^ ^  3 7  ^ ^ C O O M e
4-(4-Nitrobenzoyl)benzoic acid (36) (1 g, 3.68 mmol) was dissolved in 
H 2 S O 4  (6 mL) with cooling (ice-bath), and the solution poured into dry MeOH (25
174 Werther E.; Benzylbenzaldoxime. J. Am. Chem. Soc., 1933,55 ,2540.
175 Danishefsky S., Hirama H., Gombatz K., Harayama T., Berman E. and Schuda P.; The use of 
trans-methyl ^ -nitroacrylate in Diels-Alder reaction. J. Am. Chem. Soc., 1978,100,6536.
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mL). The mixture was refluxed for 30 min and then allowed to cool to room 
temperature. The precipitated solid was filtered and washed with MeOH (2 x 20 mL) 
to give the product as a white solid. Yield: 0.94 g (89 %). t.l.c system: petroleum 
ether-ethyl acetate 1 :1 , Rf= 0.79.
'HNM R: 8  (DMSO-rf*): 8.41 (d, 2H, J= 8.7 Hz, Ar), 8.16 (d, 2H, J= 8.4 Hz, 
Ar), 8.03 (d, 2H, J= 8.7 Hz, Ar), 7.90 (d, 2H, J= 8.4 Hz, Ar), 3.96 (s, 3H, CH3). 
Melting noint: 141-142 °C (lit m. p. 174-175 °C)176.
3.1.10) Methyl 4-(hvdroxv(4-nitroDhenvl)methvl)benzoate (38)
NaBH.
dioxan
COOMe37
To a cooled (0 °C) solution of 37 (5.84 g, 20 mmol) in anhydrous dioxane 
(100 mL) was added sodium borohydride (0.77 g, 20 mmol), then the mixture was 
allowed to stir at room temperature under nitrogen for 5 h. The solvent was 
concentrated under reduced pressure and aqueous HC1 (1 M, 10 mL) added to the 
residue. The oil formed was extracted with Et2 0  (2 x 50 mL) and washed with H2O 
(2 x 50 mL), the organic layers were combined and dried with MgSC>4 and the 
solvent concentrated under reduced pressure to give a white solid. Yield: 5.74 g (99 
%). t.l.c system: petroleum ether-ethyl acetate 1:1, R f = 0.62.
*H NMR: 5 (CDC13): 8.12 (d, 2H, J= 8.7 Hz, Ar), 7.94 (d, 2H, J= 8.3 Hz, Ar), 
7.52 (d, 2H, J= 8.7 Hz, Ar), 7.39 (d, 2H, J= 8.3 Hz, Ar), 5.88 (s, 1H, H-7), 3.87 (s, 
3H, CH3).
13C NMR: 8  (CDC13): 167.87 (C, C=0), 150.52 (C, C -l’), 148.13 (C, C-4),
147.25 (C, C-4’), 130.41 (CH, C-2, C-6 ), 129.51 (C, C -l), 127.46 (CH, C-2’, C-6 ’),
126.48 (CH, C-3, C-5), 123.72 (CH, C-3’, C-5’), 74.80 (CH, C-OH), 52.18 (CH3).
Melting point: 122-124 °C.
HRMS (ED: Found: 287.0786 (M)+, Calculated: 287.0788.
176 Salem O.A.I., Frotscher M., Scherer C., Neugebauer A., Biemel K., Streiber M., Maas R. and 
Hartmann R.W.; Novel 5a-reductase inhibitors: synthesis, structure -activity studies, and 
pharmacokinetic profile o f phenoxybenzoylphenyl acetic acid. J. Med Chem., 2096,49,748-759.
114
3.1.11) 4-FAcetoxv-(4-nitronhenvl)methvllbenzoic acid methvl ester (39)
AcgO
COOMe P y ^ '06- DMAP o oN .0,
O
To a solution of 38 (1 g, 3.48 mmol) and DMAP (46 mg, 0.38 mmol) in dry 
pyridine (25 mL) was added acetic anhydride (0.71 g, 6.96 mmol) and the reaction 
was stirred under nitrogen at room temperature overnight. EtOH (10 mL) was added 
to quench the reaction, which was then diluted with CH2CI2  (40 mL). The solution 
was washed with saturated aqueous NaHCC>3 (2 x 25 mL) and 10 % NaCl solution (2 
x 25 mL). The organic layer was dried with MgSC>4 to give a yellow syrup. Yield: 
1.07 g (93 %). t.l.c system: petroleum ether-ethyl acetate 1:1, Rf= 0.68.
*H NMR: 8  (CDC13): 8.11 (m, 2H, Ar), 7.97 (m, 2H, Ar), 7.50 (m, 2H, Ar), 
7.39 (m, 2H, Ar), 6.90 (s, 1H, H-7), 3.83 (s, 3H, H-15), 2.16 (s, 3H, H-17).
13C NMR: 8  (CDCI3): 169.50 (C, OAc), 166.29 (C, Ar-C=0), 148.39 (C, C- 
1’), 147.53 (C, C-4), 146.61 (C, C-4’), 130.53 (CH, C-2, C-6 ), 130.38 (C, C-l), 
128.17 (CH, C-2’, C-6 ’), 127.77 (CH, C-3, C-5), 123.83 (CH, C-3’, C-5’), 75.71 (C- 
OAc), 52.43 (CH3, OCH3), 21.32 (CH3, CO-CH3).
HRMSIEH: Found: 329.0895(M)+, Calculated: 329.0894.
3.1.12) 4-[(Aminovhenvl)ethoxvmethvllbenzoic acid methvl ester (40) 
OH
33 ^ ^ X O O M e
A mixture o f38 (0.20 g, 0.69 mmol) and SnCL, 2 H2O (0.47 g, 2.09 mmol) in 
20 mL of absolute EtOH was heated at 70 °C under nitrogen. After 3 h, the starting 
material has disappeared and the solution was allowed to cool down and then poured 
into ice. The pH was made slightly basic (pH 8-9) by addition of 5 % aqueous
SnCI2
EtOH
40
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sodium bicarbonate. The product was then extracted with EtOH (20 mL) and the 
organic phase was thoroughly washed with brine (3 x 50 mL), treated with charcoal 
and dried over MgSC>4 . After filtration, the solvent was removed under reduced 
pressure to give an orange solid which was washed with hot H2O (2 x 30 mL) and 
MeOH (2 x 30 mL) to give the product as a yellow solid. Yield: 0.15 g (76 %).
‘HNMR: 8  (CDCb): 7.78 (d, 2H, J= 8.3 Hz, Ar), 7.31 (d, 2H, J= 8.3 Hz, Ar),
H-17).
13C NMR: 8  (CDC13): 166.06 (C, C=Q), 147.39 (C, C-4), 144.99 (C, C-4’),
To a solution of 38 (5 g, 17.40 mmol) in EtOH (70 mL) was added Pd/C 
catalyst (1 g) and the reaction stirred under a H2  atmosphere (H2 balloon) for 30 min. 
The reaction was filtered through celite and the filtrate concentrated under reduced 
pressure. The resulting oil was extracted with CH2CI2  (50 mL), washed with H2O (2 
x 50 mL), dried (MgSQO and concentrated in vacuo to give a yellow solid. 
Purification by column chromatography (petroleum ether/EtOAc 50:50) gave the 
product as a white solid. Yield: 3.38 g (76 %). t.l.c system: petroleum ether-ethyl 
acetate 1:1, Rf= 0.23.
177 Bridger G J., Zhou Y. and Skerlj R.; Preparation o f piperidines as chemokine receptor, particularly 
CCR5, modulators for treatment o f inflammatory and autoimmune diseases. PCT Int. Appl., 2005,384
pp.
6.96 (d, 2H, J= 8.5 Hz, Ar), 6.52 (d, 2H, J= 8.5 Hz, Ar), 5.19 (s, 1H, H-7), 3.79 (s, 
3H, H-15), 3.55 (bs, 2H, NH2), 3.40 (q, 2H, J= 7.0 Hz, H-16), 1.13 (t, 3H, J= 7.0 Hz,
130.66 (C, C -l’), 129.01 (CH, C-2, C-6 ), 127.34 (C, C -l), 127.07 (CH, C-2’, C-6 ’),
125.47 (CH, C-3, C-5), 114.36 (CH, C-3’, C-5’), 82.03 (CH, CH-O), 63.35 (CH2), 
51.15 (CH3, OCH3), 14.27 (CH3).
Melting noint: 114-115 °C.
HRMS (ED: Found: 285.1361 (M)+, Calculated: 285.1365.
3.1.13) Methvl 4-((4-aminoDhenvl)(hvdroxv)methvl)benzoate (41)177
OH OH
COOMe EtOH, 1 atm
H2, Pd cat
O
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'HNMR: 5 (CDCI3): 7.91 (d, 2H, J= 7.3 Hz, Ar), 7.39 (d, 2H, J= 7.2 Hz, Ar),
7.04 (d, 2H, J= 7.3 Hz, Ar), 6.56 (d, 2H, J= 7.2 Hz, Ar), 5.70 (s, 1H, H-7), 3.83 (s, 
3H, CH3), 3.61 (bs, 2H, NH2), 2.09 (bs, 1H, OH).
13C NMR: 5 (CDCI3): 167.06 (C, C=0), 149.33 (C, C-4), 146.16 (C, C-4’), 
133.63 (C, C -l’), 129.76 (CH, C-2, C-6 ), 128.91 (C, C -l), 128.08 (CH, C-2’, C-6 ’),
126.21 (CH, C-3, C-5), 115.48 (CH, C-2, C-6 ), 75.59 (CH, CH-OH), 52.05 (CH3). 
Melting point: 117-118 °C.
3.1.14) Methvl 4-(hvdroxv(4-isothiocvanatODhenvl)methvl)benzoate (42)
OHOH
B) CSCI2, CH2 CI2, H20
SONCOOMe 42
Method A: Di-pyrimidyl-thiocarbonate (0.18 g, 0.76 mmol) was added to a 
solution of 41 and CH2CI2 (25 mL) as a solvent. The mixture was stirred overnight at 
room temperature and then extracted with H2O (2 x 25 mL). The recombined organic 
layers were dried on MgSC>4 and after filtration the solvent was reduced under 
reduced pressure to give an oil which was purified by column chromatography 
(petroleum ether/EtOAc 4:1) to obtain the product as a yellow syrup. Yield: 0.16 g 
(78 %).
Method B: To a solution o f (41) (8.83 g, 34.50 mmol) in CH2CI2  (100 mL) 
was added a mixture of ice (100 g) and H2O (50 mL). Thiophosgene (3.16 mL, 41.40 
mmol) was then added dropwise with vigorous stirring and the mixture stirred for 2  h 
at 0 °C and kept overnight in a refrigerator. The organic layer was separated and 
extracted successively with H2 O (2 x 50 mL), 10 % aqueous NaHCC>3 (50 mL) and 
H2O again (50 mL), dried (MgSC>4) and concentrated under reduced pressure to 
obtain the pure product as a yellow solid. Yield: 9.17 g (89 %). t.l.c system: 
petroleum ether-ethyl acetate 1:1, Rf= 0.59.
'HNM R: 8  (CDC13): 7.90 (d, 2H, J= 7 .9Hz, Ar), 7.31 (d,2H, J= 7.9Hz, Ar), 
7.25 (d, 2H, J= 8.1 Hz, Ar), 7.09 (d, 2H, J= 8.1 Hz, Ar), 5.75 (s, 1H, H-7), 3.80 (s, 
3H, CH3), 2.51 (bs, 1H, OH).
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13C NMR: 8  (CDC13): 166.83 (C, C O ), 148.17 (C, C-4). 142.48 (C, C -l’), 
135.72 (C, NCS), 130.71 (C, C -l), 129.96 (CH, C-2, C-6 ), 129.90 (C, C-4’), 128.62 
(CH, C-2’, C-6 ’), 126.57 (CH, C-3, C-5), 125.92 (CH, C-3’, C-5’), 75.18 (CH, CH- 
OH), 52.19 (CH3).
Melting point: 114-115 °C.
HRMStED: Found: 299.0610(M)+, Calculated: 299.0610.
3.L15)Methvl-4-(hvdroxv(4-(3-(2-hvdroxvDhenvl)thioureido)Dhenvl)methvl)benzoate
(43)
OH
OH
NH2
EtOHSCN
4342
2-Aminophenol (38 mg, 0.24 mmol) was added to a solution of 42 (103 mg, 
0.34 mmol) in absolute EtOH (10 mL). The mixture was then stirred overnight at 
room temperature. EtOH was removed under reduced pressure and the yellow oil 
was extracted with CH2CI2 (20 mL) and washed with H2O (2 x 20 mL). The 
recombined organic layers were dried (MgS0 4 ) and the solvent evaporated in vacuo 
to give an oil which was purified by column chromatography (hexane/ EtOAc 100:0 
to 50:50) to give a yellow syrup. Yield: 106 mg (76 %). t.l.c system: petroleum ether- 
ethyl acetate 1 :1 , Rf= 0.15.
'HNM R: 8 (CDC13): 8.09(bs, 1H,NH), 7.84 (d, 2H, J= 8.1 Hz, Ar), 7.79(bs, 
1H, NH), 7.30 (d, 2H, J= 7.9 Hz, Ar), 7.23 (d, 2H, J= 7.7 Hz, Ar), 7.16 (d, 2H, J= 7.0 
Hz, Ar), 7.07 (d, 2H, J= 8.3 Hz, Ar), 6.90 (d, 1H, J= 8.0 Hz, Ar), 6.71 (m, 1H, Ar),
5.71 (s, 1H, H-7), 3.82 (s, 3H, CH3), 3.23 (bs, 1H, OH).
13C NMR: 8  (CDC13): 178.96 (C, C=S), 166.95 (C, C=0), 150.59 (C, C -l”),
142.48 (C, C-4’), 148.15 (C, C-4), 142.52 (C, C -l’), 134.44 (C, C-l), 129.92 (CH, C- 
2, C-6 ), 129.44 (CH, C-6 ”), 129.02 (CH, C-2”), 128.08 (CH, C-2’, C-6 ’), 126.34 
(CH, C-3, C-5), 126.15 (CH, C-4”), 125.48 (CH, C-3’, C-5’), 121.40 (CH, C-3”),
119.26 (CH, C-5”), 75.22 (CH, CH-OH), 52.21 (CH3).
HRMS (EH: Found: 409.1224 (M )+, Calculated: 409.1222.
118
3.1.16) Methvl-4- ((4-(benzoxazol-2-vlamino)vhenvl) (hvdroxv)methvl)benzoate (44)
OH44
Ni-PO
S
AN
H
N
H 43
To a solution o f (43) (0.35 g, 0.86 mmol) in CH3CN (25 mL) was added 
nickel peroxide (0.29 g). The heterogeneous solution was stirred at room temperature 
overnight then the reaction mixture was filtered and washed repeatedly with CH3CN. 
After evaporation of the solvent, the oil was extracted with CH2CI2 (25 mL) and 
washed with H2O (2 x 25mL). The organic layer was dried (MgSC>4), concentrated 
under reduced pressure and the resulting oil purified by column chromatography 
(petroleum ether/EtOAc 80:20 v/v) to give the product as a yellow syrup. Yield: 0.19 
g (61 %). tl.c  system: petroleum ether-ethyl acetate 1:1, Rf= 0.45.
*H NMR: 6  (CDC13): 7.92 (bs, 1H, NH), 7.91 (d, 2H, J= 8.1 Hz, Ar), 7.48 (d, 
2H, J= 8.1 Hz, Ar), 7.38 (m, 3H, Ar), 7.25 (m, 3H, Ar), 7.12 (m, 1H, Ar), 7.03 (m, 
1H, Ar), 5.77 (s, 1H, H-7), 3.81 (s, 3H, CH3), 2.60 (bs, 1H, OH).
13C NMR: 6  (CDC13): 166.94 (C, C=0), 158.13 (C, C-2”), 148.70 (C, C-8 ”), 
142.10 (C, C-4), 138.32 (C, C-4’), 137.53 (C, C-9”), 129.81 (CH, C-2, C-6 ), 129.27 
(C, C -l’), 127.81 (CH, C-2’, C-6 ’), 126.31 (CH, C-3, C-5), 124.35 (CH, C-6 ”),
122.01 (CH, C-5”), 118.65 (CH, C-3’, C-5’), 117.18 (CH, C-7”), 109.14 (CH, C-4”),
75.45 (CH, CH-OH), 52.10 (CH3).
HRMS (ED: Found: 375.1337(M)+, Calculated: 375.1339.
3.1.17) 4-{[4-(Benzoxazol-2-vlamino)Dhenvl 7 imidazol-1-vlmethvl} benzoic acid
methvl ester (4 5 )
AT 8'1 -1 '-carbodiimidazole
imidazole, CH3CN ®
OH44 45
119
To a solution of 44 (2.28 g, 6.08 mmol) in CH3CN (40 mL) was added 
imidazole (1.24 g, 18.25 mmol) and l,rcarbodiimidazole (1.18 g, 9.13 mmol). The 
mixture was heated under reflux for 2  h, then the reaction mixture was allowed to 
cool and the solvent removed under reduced pressure. The oil formed was then 
extracted with CH2CI2  (50 mL) and washed with H2O ( 2  * 50 mL). The organic layer 
was dried (MgSQ*), filtered and reduced in vacuo. Purification by column 
chromatography (EtOAc) gave the product as a yellow syrup. Yield: 2.33 g (90 %). 
t.l.c system: ethyl acetate, Rf= 0.21.
'HNM R: 8  (CDCfe): 8.52 (bs, 1 H,NH), 7.96 (d, 2H, J= 8 .2Hz, Ar), 7.59 (d, 
2H, J= 8.5 Hz, Ar), 7.38 (d, 2H, J= 7.5 Hz, Ar), 7.22 (d, 1H, J= 7.9 Hz, Ar), 7.18 (m, 
1H, Ar), 7.08 (m, 6 H, Ar), 6.79 (m, 1H, Ar), 6.45 (s, 1H, H-7), 3.86 (s, 3H, CH3).
13C NMR: 6  (CDC1V): 166.47 (C, C=0), 157.82 (C, C-2”’), 147.78 (C, C-8 ’”), 
144.19 (C, C-4), 142.21 (C, C-4”), 139.82 (CH, C-2’), 138.67 (C, C-9”’), 132.46 (C, 
C -l”), 130.28 (C, C -l), 130.18 (CH, C-2, C-3), 129.57 (CH, C-2”, C-6 ”), 127.78 
(CH, C-3, C-5), 125.94 (CH, C-5’), 124.32 (CH, C-6 ’” ), 122.63 (CH, C-4’), 122.13 
(CH, C-5’”), 119.33 (CH, C-3”, C-5”), 117.36 (CH, C-7’” ), 109.12 (CH, C-4’”),
64.37 (CH, CH-N), 52.29 (CH3).
HRMSfEI): Found: 425.1610 (M)+, Calculated: 425.1608.
3.1.18) Methvl 4-((4-(benzoxazol-2-vlamino)Dhenvl){lH-1.2.4-triazol-l-
vl)methvl)benzoate (46)
OH44
1,2,4 triazole
5"
To a cooled (0 °C) solution of 1,2,4-triazole (0.22 g, 3.20 mmol) in 
anhydrous CH3CN (10 mL) was added thionyl chloride (0.12 mL, 1.60 mmol) in 
anhydrous CH3CN ( 6  mL) and the reaction stirred at 10 °C for 1 h. Potassium 
carbonate (0.22 g, 1.60 mmol) was then added followed by a solution of 44 (0.30 g, 
0.80 mmol) in anhydrous CH3CN (10 mL) and the reaction allowed to stir at room
120
temperature for 3 days. The suspension was filtered and the solution concentrated 
under reduced pressure to produce a mixture which was extracted with EtOAc (2 x 
25 mL) and washed with H2O (2 x 25 mL). The organic layers were dried with 
MgS0 4  and the solvent evaporated to give a yellow solid. Purification by flash- 
chromatography (EtOAc) gave the product as a yellow solid. Yield: 0.15 g (43 %). 
tl.c  system: ethyl acetate Rf= 0.10.
*H NMR: 5 (CDC13): 8.69 (bs, 1H, NH), 8.02 (m, 1H, Ar), 8.00 (d, 2H, J= 7.4 
Hz, Ar), 7.97 (m, 1H, Ar), 7.68 (d, 2H, J= 8.2 Hz, Ar), 7.33 (d, 1H, J= 6.3 Hz, Ar),
7.27 (m, 6H, Ar), 6.79 (m, 1H, H-7), 3.91 (s, 3H, CH3).
13C NMR: 6 (CDC13): 165.63 (C, 0= 0), 157.03 (C, C-2”’), 151.64 (CH, C- 
5’), 146.95 (C, C-8’”), 142.75 (CH, C-3’), 142.27 (C, C-4), 141.18 (C, C-4”), 138.03 
(C, C-9’”), 130.54 (C, C -l”), 129.51 (C, C -l), 129.35 (CH, C-2, C-6) , 128.78 (CH, 
C-2”, C-6”), 126.93 (CH, C-3, C-5), 123.58 (CH, C-6’”), 121.35 (CH, C-5’”), 117.78 
(CH, C-3”, C-5”), 116.45 (CH, C-7’” ), 108.34 (CH, C-4’” ), 66.26 (CH, CH-N),
51.46 (CH3).
Melting point: 192-194 °C.
HRMStEH: Found: 426.1559 (M)+, Calculated: 426.1561.
3.1.19) 4-{F4-(Benzoxazol-2-vlamino)Dhenvnimidazol-l-vlmethvUbenzoic acid (47)
OH
5 "NaOH
MeOH
45 47
To a suspension of 45 (0.30 g, 0.7 mmol) in MeOH (6 mL) was added a 2 M 
solution of aqueous NaOH (3 mL) and the mixture was refluxed for 30 min. The 
mixture was then allowed to cool and was diluted with H2O (5 mL), HC1 was added 
until pH 1. After removing the solvent under reduced pressure, MeOH (5 mL) was 
added to the mix to precipitate the NaCl formed during the reaction. Hie solid was
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removed by filtration and the filtrate reduced in vacuo to give a yellow syrup. Yield: 
0.18 g (62 %). t.l.c system: dichloromethane-methanol 98:2, Rf= 0.16.
'HNM R: 8  (DMSO-rftf): 13.11 (bs, 1H, COOH), 11.02 (bs, 1H,NH), 9.21 (s, 
1H, Ar), 8.01 (m, 2H, Ar), 7.87 (m, 2H, Ar), 7.79 (m, 2H, Ar), 7.50 (m, 1H, Ar), 7.43 
(m, 1H, Ar), 7.32 (m, 5H, Ar), 7.22 (m, 1H, Ar), 6.95 (s, 1H, H-7).
13C NMR: 8  (DMSO-ds): 169.14 (C, C=0 ), 159.69 (C, C-2’”), 148.% (C, C- 
8 ’”), 143.75 (C, C-4), 143.45 (C, C-4”), 141.13 (C, C-9’”), 132.74 (C, C -l”), 131.72 
(C, C-l), 131.60 (CH, C-2’), 130.65 (CH, C-2, C-6 ), 129.03 (CH, C-2”, C-6 ”), 
125.33 (CH, C-3, C-5), 123.34 (CH, C-4’), 123.22 (CH, C-6 ’” ), 122.89 (CH, C-5’”), 
120.23 (CH, C-5’), 120.23 (CH, C-3”, C-5”), 117.89 (CH, C-7”’), 110.11 (CH, C- 
4’”), 67.19 (CH, CH-N).
HRMS (ED: Found: 411.1452 (M)+, Calculated: 411.1449.
3.1.20) 4-{f4-(Benzoxazol-2-vlamino)Dhenvll-lH-L2.4-triazol-l -vlmethvUbenzoic
acid (48)
5■NaOH
9*"
MeOH
46
To a suspension o f 46 (50 mg, 0.12 mmol) in MeOH (2 mL) was added a 2M 
solution of aqueous NaOH (1 mL) and the mixture was refluxed for 30 min. The 
mixture was then allowed to cool and was diluted with H2O (2 mL), HC1 was added 
until pH 1. After removing the solvent under reduced pressure, MeOH (3 mL) was 
added to the mix to precipitate the NaCl formed during the reaction. The solid was 
removed by filtration and the filtrate reduced in vacuo to give a yellow syrup. Yield: 
28 mg (56 %). t.l.c system: dichloromethane-methanol 98:2, Rf= 0.20.
'H N M R: 8  (MeOD): 8.99 (s, 1H, Ar), 8.31 (s, 1H, Ar), 7.88 (m, 2H, Ar), 
7.56 (m, 2H, Ar), 7.25 (m, 5H, Ar), 7.13 (m, 1H, Ar), 7.09 (m, 2H, Ar), 6.82 (s, 1H, 
H-7).
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13C NMR: 6  (MeOD): 169.08 (C, C=0), 159.37 (C, C-2”’), 148.26 (C, C- 
8 ’”), 143.96 (C, C-4), 138.96 (C, C-4”), 138.72 (C, C-9”’), 134.45 (C, C -l”), 132.26 
(C, C-l), 131.30 (CH, C-5’), 131.09 (CH, C-2, C-3), 130.98 (CH, C-2”, C-6 ”),
129.47 (CH, C-3, C-5), 126.85 (CH, C-3’), 124.46 (CH, C-6 ”’), 122.86 (CH, C-5’”), 
121.61 (CH, C-3”, C-5”), 116.40 (CH, C-7’” ), 110.89 (CH, C-4’”), 6 8 . 6 6  (CH, CH- 
N).
HRMS (ED: Found: 412.1415 (M)+, Calculated: 412.1410.
3.2) Experimental results for the preparation o f the iinsnbstituted 
derivatives 52. S3. S3’ and 54
ryo
3.2.1) 4-Isothiocvanatobenzophenone (49)
CSCIj
SCN 49
To a solution of 4-amino-benzophenone (10 g, 50.70 mmol) in CH2CI2 (10 
mL) was added a mixture of ice (30 g) and H2O (70 mL) and subsequently dropwise 
with vigorous stirring thiophosgene (4.64 mL, 60.84 mmol). The mixture was stirred 
for 2 h at 0 °C and kept overnight in a refrigerator. The organic layer was separated 
and extracted successively with H2O (2 x 50 mL), 10 % NaHC0 3  aq. (50 mL) and 
H2O again (50 mL), dried (MgS0 4 ) and evaporated to dryness to obtain the pure 
product as a yellow syrup. Yield: 12 g (99 %). t.l.c system: petroleum ether-ethyl 
acetate 2 :1 , Rf= 0 .8 8 .
'HNMR: 8  (CDCI3): 7.83 (d, 2H, J= 8.3 Hz, At), 7.79 (d, 2H, J= 7.2 Hz, Ar), 
7.64 (m, 1H, Ar), 7.51 (m, 2H, Ar), 7.33 (m, 2H, Ar).
178 Horakova K., Drobnica L. and Nemec P.; Cytotoxic and cancerostatic activity o f isothiocyanates 
and related compounds. VI. Isothiocyanates of the R-C6H4-X-C6H4-NCS type. Neoplasma, 1970, 77, 
9-14.
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3.2.2) f  4-(Bemoxazol-2-vlamino)phenvlIphenvlmethanone (SO)
SCN
1) 2-aminophenol / /  \ \  8"
toluene * < { V -
2) HgO, S, EtOH
2-Aminophenol (5.48 g, 50.21 mmol) was added to a solution of 49 (12 g,
50.21 mmol) in toluene (150 mL). The mixture was then refluxed for 1 h and left to 
stir overnight at room temperature. The solvent was removed under reduced pressure 
and the crude product was used for the cyclisation. The crude thiourea was then 
dissolved in EtOH (150 mL), mixed with HgO (16.94 g, 78.21 mmol) and sulphur 
(0.25 g, 7.82 mmol) and refluxed for 4 h. The cooled reaction mixture was filtered 
through a celite pad and then the dark residue was dissolved in THF and filtered 
again through celite to give the pure product as a yellow solid. Yield: 6.89 g (54 %). 
t.l.c system: petroleum ether-ethyl acetate 2:1, R*= 0.56.
‘HNMR: 8 (DMSO-efc): 11.12 (bs, 1H, NH), 7.94 (d, 2H, J= 8.2 Hz, Ar), 
7.83 (d, 2H, J= 8.2 Hz, Ar), 7.72 (d, 2H, J= 7.7 Hz, Ar), 7.67 (m, 1H, Ar), 7.55 (m, 
4H, Ar), 7.26 (m, 1H, Ar), 7.18 (m, 1H, Ar).
13C NMR: 8 (DMSO-d<): 194.35 (C, C=0), 157.28 (C, C-2”), 147.00 (C, C- 
4’), 142.89 (C, C-8”), 141.98 (C, C-9”), 137.68 (C, C -l), 132.12 (CH, C-4), 131.48 
(CH, C-2’, C-6’), 130.25 (C, C -l’), 129.35 (CH, C-2, C-6), 129.03 (CH, C-2’, C-6’), 
128.43 (CH, C-3, C-5), 122.25 (CH, C-5”), 117.02 (CH, C-7”), 116.81 (CH, C-3’, C- 
5’), 109.20 (CH, C-4”).
Melting point: 193-194 °C.
HRMS (ED: Found: 315.1135 (M)+, Calculated: 315.1134.
3.2.3) f4-(Benzoxazol-2-vlamino)phenvlIphenvlmethanol (SI)
NaBH4
dioxan = \  11 2" 4’9"
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To a cooled (0 °C) solution of 50 (6.78 g, 20.86 mmol) in anhydrous dioxan 
(100 mL) was added sodium borohydride (0.79 g, 20.86 mmol), then the mixture was 
allowed to stir at room temperature under nitrogen overnight. The solvent was 
concentrated under reduced pressure and aqueous HC1 ( 1  M, 10 mL) added to the 
residue. The oil formed was extracted with Et2 0  (2 x 50 mL) and washed with H2O 
( 2  x 50 mL), the organic layers were combined and dried with MgSC>4 and the 
solvent concentrated under reduced pressure to give a white solid. Yield: 5.84 g ( 8 6  
%). t.l.c system: petroleum ether-ethyl acetate 2:1, Rf= 0.28.
*H NMR: 8  (DMSO-<fc): 10.52 (bs, 1H, NH), 7.51 (d, 2H, J= 8.1 Hz, Ar), 
7.45 (m, 4H, Ar), 7.40 (m, 2H, Ar), 7.22 (m, 2H, Ar), 7.14 (m, 1H, Ar), 5.83 (bs, 1H, 
OH), 5.20 (s, 1H, H-7).
13C NMR: 8  (DMSO-*/*): 158.04 (C, C-2”), 147.00 (C, C-8 ”), 145.84 (C, C- 
4’), 142.44 (C, C-l), 139.59 (C, C-9”), 137.31 (C, C -l’), 128.45 (CH, C-2’, C-6 ’), 
127.99 (CH, C-3, C-5), 126.86 (CH, C-2, C-6 ), 126.17 (CH, C-4), 123.94 (CH, C- 
6 ”), 121.54 (CH, C-5”), 117.39 (CH, C-3’, C-5’), 116.51 (CH, C-7”),108.87 (CH, C- 
4”), 73.92 (CH, CH-OH).
Melting point: 160-162 °C.
HRMStED: Found: 317.1287 (M)+, Calculated: 317.1285.
3.2.4) Bemoxazol-2-vl-r4-imidazol-l-vlnhenvlmethvllDhenvllamine (52)
OH 4-
^>1 1,1'-cart>odiimidazole 
s ' )  imidazole, CH3CN 7" 9"N
H 51
To a solution of 51 (5.84 g, 17.85 mmol) in CH3CN (100 mL) was added 
imidazole (3.67 g, 53.58 mmol) and 1,1’carbodiimidazole (4.34 g, 26.78 mmol). The 
mixture was heated under reflux overnight, then the reaction mixture was allowed to 
cool and the solvent removed under reduced pressure. The oil formed was then 
extracted with CH2CI2 (100 mL) and washed with H2O (2 x 100 mL). The organic 
layer was dried (MgSCL), filtered and reduced in vacuo. Purification by column
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chromatography (EtOAc) gave the product as a pale yellow solid. Yield: 4.98 g (74 
%). t.l.c system: ethyl acetate, Rf= 0.11.
!H NMR: 8  (CDC13): 10.70 (bs, 1H, NH), 7.76 (m, 2H, Ar), 7.64 (s, 1H, Ar),
7.49 (m, 1H, Ar), 7.40 (m, 4H, Ar), 7.19 (m, 3H, Ar), 7.12 (m, 4H, Ar), 6.97 (s, 1H, 
Ar), 6.84 (s, 1H, H-7).
13C NMR: 8  (CDC13): 157.85 (C, C-2’”), 147.00 (C, C-8 ’”), 142.28 (C, C-4”),
140.27 (C, C-l), 138.42 (C, C-9’”), 137.13 (CH, C-2’), 133.39 (C, C -l”), 128.74 
(CH, C-2”, C-6 ”), 128.26 (CH, C-3, C-5), 127.81 (CH, C-4), 127.54 (CH, C-2, C-6 ),
124.01 (CH, C-5’), 122.06 (CH, C-4’), 121.74 (CH, C-6 ’”), 119.14 (CH, C-5’”),
117.74 (CH, C-3”, C-5”), 116.64 (CH, C-7’”), 108.98 (CH, C-4’”), 62.98 (CH, CH- 
N).
Melting point: 214-216 °C.
HRMSfED: Found: 367.1555 (M)+, Calculated: 367.1553.
3.2.5) Benzoxazol-2-vl-r4-(phenvl-[1.2.41triazol-l-vlmethvl)Dhenvnamine (53) and 
Benzoxazol-2-vl-f4-fohenvl-f1.3.4Itriazol-l-vlmethvDphenvl 1amine (53 *)
1,2,4-triazole
SOCI* CH3CN
T  9”
i 5" 5
+
2
N -N
N
53
2"
1 M
2
,^ U u
1 5" 5
53'
To a cooled (0 °C) solution of 1,2,4-triazole (1.76 g, 6.39 mmol) in 
anhydrous CH3CN (50 mL) was added thionyl chloride (0.94 mL, 12.78 mmol) in 
anhydrous CH3CN ( 6  mL) and the reaction stirred at 10 °C for 1 h. Potassium 
carbonate (1.77 g, 12.78 mmol) was then added followed by a solution of 51 (2.09 g,
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6.39 mmol) in anhydrous CH3CN (10 mL) and the reaction allowed to stir at room 
temperature for 3 days. The suspension was filtered and the solution concentrated 
under reduced pressure to produce a mixture which was extracted with EtOAc (2 x 
50 mL) and washed with H2O (2 x 50 mL). The organic layers were dried with 
MgS0 4  and the solvent evaporated to give a yellow solid. Purification by flash- 
chromatography (EtOAc) gave the first product as a white solid. Yield: 0.85 g (35 
%). t.l.c system: petroleum ether/ethyl acetate 2 :1 , Rf= 0.32. Purification with flash- 
chromatography (C^Cfe-MeOH 9:1 v/v) gave the second as a brown-orange solid. 
Yield: 0.28 g ( 1 2  %). tl.c  system: ethyl acetate, Rf= 0.08.
- Benzoxazol-2-vl-f4-(phenvl-rL2.41triazol-l-vlmethvHphenvl)amine
*H NMR: 8  (CDC13): 8.18 (bs, 1H, NH), 8.10 (s, 1H, Ar), 7.99 (s, 1H, Ar), 
7.67 (m, 2H, Ar), 7.48 (m, 1H, Ar), 7.39 (m, 4H, Ar), 7.28 (m, 1H, Ar), 7.17 (m, 5H, 
Ar), 6.80 (s, 1H, H-7).
13C NMR: 5 (CDC13): 157.80 (C, C-2*”), 152.31 (CH, C-5’), 147.81 (C, C- 
8 ”’), 143.59 (CH, C-3’), 142.10 (C, C-4”), 138.30 (C, C -l), 138.03 (C, C-9’”),
132.46 (C, C -l”), 129.35 (CH, C-2”, C-6 ”), 128.99 (CH, C-3, C-5), 128.62 (CH, C-
4), 127.98 (CH, C-2, C-6 ), 124.39 (CH, C-6 ”’), 122.16 (CH, C-5”’), 118.50 (CH, C- 
3”, C-5”), 117.34 (CH, C-7”’), 109.17 (CH, C-4”’), 67.45 (CH, CH-N).
Melting point: 150-151 °C.
HRMSflED: Found: 368.1510 (M)+, Calculated: 368.1511.
- Benzoxazol-2-vl-|4-(phenvl-fl.3.41triazol-l-vlmethvl)phenvnamine (53*1
*H NMR: 8  (CDCI3): 9.73 (bs, 1H, NH), 8.04 (s, 2H, Ar), 7.68 (m, 2H, Ar),
7.47 (m, 1H, Ar), 7.26 (m, 3H, Ar), 7.18 (m, 1H, Ar), 7.10 (m, 1H, Ar), 7.00 (m, 5H, 
Ar), 6.48 (s, 1H, H-7).
13C NMR: 8  (CDC13): 158.23 (C, C-2”’), 147.72 (C, C-8 ’”), 142.22 (C, C-4”),
139.42 (C, C -l), 137.76 (C, C-9”’), 131.26 (C, C -l”), 129.27 (CH, C-2’, C-5’), 
128.97 (CH, C-2”, C-6 ”), 128.86 (CH, C-3, C-5), 128.67 (CH, C-4), 128.44 (CH, C- 
2, C-6 ), 124.34 (CH, C-6 ’”), 121.96 (CH, C-5’”), 118.78 (CH, C-3”, C-5”), 117.12 
(CH, C-7’”), 109.10 (CH, C-4’”), 63.57 (CH, CH-N).
Melting point: 118-119 °C.
HRMS (ED: Found: 735.2940 (2M + H+)+, Calculated: 735.2944.
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3.2.6) Bemoxazol-2-vl-F4-(Dhenvltetrazol-l-vlmethvl)phenvll amine (54)
1 H-tetrazole
SO C I2, c h 3c n  7 - P ' q
Thionyl chloride (0.4 mL, 4.89 mmol) in anhydrous CH3CN (5 mL) was 
added dropwise to a stirred solution of l//-tetrazole (0.45 M in CH3CN, 22 mL) at a 
temperature of 10 °C. The white suspension formed was allowed to stand for 1 h at 
10 °C. A solution of 51 (0.80 g, 2.44 mmol) in anhydrous CH3CN (5 mL) was added 
to the mixture followed by activated potassium carbonate (0.68 g, 4.89 mmol). The 
suspension was stirred under nitrogen at room temperature for 3 days. The resulting 
suspension was filtered and the filtrate was evaporated in vacuo to yield a brownish 
oil. The oil was extracted with CH2 CI2  (50 mL) and H2O (3 x 50 mL). The organic 
layer was dried with MgSC>4, filtered and reduced in vacuo to give an orange oil. The 
crude product was purified by flash column chromatography (petroleum ether/EtOAc 
70:30 v/v) to give the product as a brown solid. Yield: 0.29 g (32 %). t.l.c system: 
petroleum ether-ethyl acetate 1:1, Rf= 0.68.
'HNM R: 8  (CDCb): 8.49 (s, 1H, tetrazole), 7.52 (m, 2H, Ar), 7.34 (m, 1H, 
Ar), 7.20 (m, 4H, Ar), 7.14 (m, 3H, Ar), 7.07 (m, 3H, Ar), 7.01 (s, 1H, H-7), 6.85 
(bs, 1H,NH).
13C NMR: 8  (CDCI3): 157.28 (C, C-2’”), 152.01 (CH, C-5’), 147.02 (C, C- 
8 ’”), 140.46 (C, C-4”), 137.52 (C, C-l), 135.94 (C, C-9”’), 130.35 (C, C -l”), 128.44 
(CH, C-2”, C-6 ”), 127.81 (CH, C-3, C-5), 127.74 (CH, C-4), 126.94 (CH, C-2, C-6 ),
123.46 (CH, C-6 ’”), 121.02 (CH, C-5’”), 117.51 (CH, C-3”, C-5”), 115.83 (CH, C- 
7’”), 108.27 (CH, C-4”’), 69.66 (CH, CH-N).
Melting point: 116-118 °C.
HRMS (ED: Found: 369.1468 (M)+, Calculated: 369.1464.
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3.3) Experimental results for the preparation of the methyl
derivative 59
3.3.1) (4-Methvlnhenvl)-(4-nitrophenvl)methanol (55)179
NaBH4
MeOH
To a cooled (0 °C) solution of 35 (7 g, 29.02 mmol) in anhydrous MeOH 
(100 mL) was added sodium borohydride (1.10 g, 29.02 mmol), then the mixture was 
allowed to stir at room temperature under nitrogen for 1 h. The solvent was 
concentrated under reduced pressure and aqueous HC1 (1 M, 10 mL) added to the 
residue. The oil formed was extracted with EtOAc (2 x 50 mL) and washed with 
H2O (2 x 50 mL), the organic layers were combined and dried with MgS0 4  and the 
solvent concentrated under reduced pressure to give a white solid. Yield: 6.02 g ( 8 6  
%). t.l.c system: petroleum ether-ethyl acetate 2:1, R f = 0.70.
'HNMR: 8  (CDC13): 8.12 (d, 2H, J= 9.0 Hz, Ar), 7.48 (d, 2H, J= 9.0Hz, Ar), 
7.15 (d, 2H, J= 8.5 Hz, Ar), 7.08 (d, 2H, J= 8.5 Hz, Ar), 5.79 (s, 1H, CH), 2.29 (s, 
3H,CH3).
Melting point: 95-96 °C.
3.3.2) (4-MethvlDhenvl)-(4-aminoDhenvl)methanol (56)
OH
H2, Pd cat 
EtOH, 1atm
179 Massa S., Stefancich G., Corelli F., Silvestri R., Mai A., Artico M., Panico S. and Simonetti N.; 
Researches on antibacterial and antifungal agents, X. synthesis and antifimgal activities of \-\p- 
methyl-a-[4-( 1 //-pyrrol-1 -yl)phenyl]-benzyl]azoles and some related products. Archiv. Pharm., 1989, 
322,369-73.
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To a solution of 55 (6.02 g, 24.77 mmol) in EtOH (150 mL) was added Pd/C 
catalyst (1 g) and the reaction stirred under a H2 atmosphere (H2 balloon) for 1 h. The 
reaction was filtered through celite and the filtrate concentrated under reduced 
pressure. The resulting oil was extracted with CH2CI2 (100 mL), washed with H2O (2 
x 100 mL), dried (MgS0 4 ) and concentrated in vacuo to give a yellow solid. 
Purification by column chromatography (petroleum ether/EtOAc 70:30 v/v) gave the 
product as a white crystalline solid. Yield: 2.55 g (48 %). t.l.c system: petroleum 
ether-ethyl acetate 3:2, Rf= 0.21.
*H NMR: 8  (CDC13): 7.13 (d, 2H, J= 8 . 8  Hz, Ar), 7.03 (m, 4H, Ar), 6.50 (d, 
2H, J= 8 . 8  Hz, Ar), 5.59 (s, 1H, CH), 3.11 (bs, 3H, NH2 + OH), 2.21 (s, 3H, CH3).
13C NMR: 8  (CDCI3): 144.22 (C, C -l), 140.74 (C, C-8 ), 132.43 (C, C-13),
131.82 (C, C-6 ), 124.57 (CH, C -ll, C-12), 122.49 (CH, C-4, C-5), 117.17 (CH, C-9, 
C-10), 113.57 (CH, C-2, C-3).
Melting point: 97-98 °C.
HRMS fED: Found: 196.1125 (M-H20 )+, Calculated: 196.1126.
3.3.3) (4-Methvlphenvl)-(4-isothiocvanatophenvl)methanol (57)
OH OH
To a solution of 56 (1.9 g, 8.92 mmol) in CH2CI2 (50 mL) was added a 
mixture of ice (5 g) and H2 O (30 mL) and subsequently dropwise with vigorous 
stirring thiophosgene (0.82 mL, 10.70 mmol). The mixture was stirred 2 h at 0 °C 
and kept overnight in a refrigerator. The organic layer was separated and extracted 
successively with H2O (2 x 50 mL), 10 % NaHCC>3 aq. (50 mL) and H2O again (50 
mL), dried (MgS04) and evaporated to dryness to obtain the pure product as a brown 
syrup. Yield: 2.01 g ( 8 8  %). t.l.c system: petroleum ether-ethyl acetate 2:1, Rf= 0.81.
*H NMR: 8  (CDC13): 7.33 (m, 2H, Ar), 7.22 (m, 4H, Ar), 7.16 (m, 2H, Ar), 
5.57 (s, 1H, CH), 3.56 (bs, 1H, OH), 2.44 (s, 3H, CH3).
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13C NMR: 8  (CDClj): 143.43 (C, C-6 ), 140.48 (C, C-8 ), 137.70 (C, C-13),
135.42 (C, C -l5), 130.07 (C, C -l), 129.48 (CH, C -ll, C-12), 127.68 (C, C-4, C-5), 
126.71 (C, C-9, C-10), 125.77 (C, C-2, C-3), 75.36 (CH, C-7), 21.37 (CH3, C-14). 
HRMS (ED: Found: 255.0718 (M)+, Calculated: 255.0718.
3.3.4) f  4-(Benzoxazol-2-vlamino)Dhenvl 1-p-tolvlmethanol (58)
OH OH
1) 2-aminophenol 
toluene
2) HgO, S, EtOH T  9"SON
2-Aminophenol (0.68 g, 6.30 mmol) was added to a solution of 57 (1.61 g, 
6.30 mmol) in EtOH (80 mL). After stirring overnight at room temperature, HgO 
(2.73 g, 12.60 mmol) and sulphur (40 mg, 1.26 mmol) were added to the crude 
thiourea and refluxed for 2 h. The cooled reaction mixture was filtered through a 
celite pad and the solvent evaporated. Purification by column chromatography 
(petroleum ether/EtOAc 60:40 v/v) gave the product as an orange solid. Yield: 0.75 g 
(35 %). t.l.c system: petroleum ether-ethyl acetate 1 :1 , Rf= 0.76.
*H NMR: 6  (CDC13): 8 . 8 8  (bs, 1H, NH), 7.86 (m, 4H, Ar), 7.47 (m, 2H, Ar), 
7.28 (m, 2H, Ar), 7.12 (m, 1H, Ar), 6.98 (m, 5H, Ar), 5.59 (s, 1H, H-7), 3.34 (bs, 1H, 
OH), 2.22 (s, 3H, CH3).
13C NMR: 5 (CDC13): 147.89 (C, C-2”), 141.84 (C, C-4’), 141.00 (C, C-8 ”),
139.17 (C, C-9”), 137.25 (C, C -l), 137.16 (C, C -l’), 135.29 (CH, C-4), 129.21 (CH, 
C-3, C-5), 127.59 (CH, C-2’, C-6 ’), 126.55 (CH, C-2, C-6 ), 124.39 (CH, C-5”),
121.78 (CH, C-6 ”), 118.77 (CH, C-3’, C-5’), 116.81 (CH, C-7”), 109.23 (CH, C-4”), 
75.63 (CH, CH-OH), 21.17 (CH3).
Melting point: 157-158 °C.
HRMS (ED: Found: 331.1443 (M)+, Calculated: 331.1447.
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3.3.5) Benzoxazol-2-vl-f 4-imidazol-l -vl-p-tolvlmethvDphenvl 1amine (59)
OH
1,1'-carbodiimidazole
imidazole, CH3CN 7" 9”N
H
To a solution of 58 (0.25 g, 0.73 mmol) in CH3CN (20 mL) was added 
imidazole (0.15 g, 2.19 mmol) and l,rcarbodiim idazole (0.18 g, 1.09 mmol). The 
mixture was then heated under reflux overnight, then the reaction mixture was 
allowed to cool and the solvent removed under reduced pressure. The oil formed was 
extracted with CH2CI2 (50 mL) and washed with H2O (2 x 50 mL). The organic layer 
was dried (MgS0 4 ), filtered and reduced in vacuo. Purification by column 
chromatography (EtOAc) gave the product as a yellow syrup. Yield: 0.19 g ( 6 6  %). 
t.l.c system: ethyl acetate, Rf= 0.08.
NMR: 8  (CDC13): 10.27 (bs, 1H, NH), 7.58 (m, 2H, Ar), 7.41 (s, 1H, Ar), 
7.36 (m, 1H, Ar), 7.18 (m, 1H, Ar), 7.08 (m, 1H, Ar), 7.02 (m, 3H, Ar), 6.95 (m, 3H, 
Ar), 6 . 8 8  (m , 2H, Ar), 6.76 (s, 1H, Ar), 6.37 (s, 1H, H-7), 2.25 (s, 3H, CH3).
13C NMR: 8  (CDCLV. 157.00 (C, C-2”’), 148.82 (C, C-8 ’”), 141.23 (C, C-4”),
137.29 (C, C-9’”), 137.25 (C, C -l), 135.09 (C, C-4), 132.63 (C, C -l”), 129.87 (CH, 
C-2’), 128.55 (CH, C-3, C-5), 127.96 (CH, C-2”, C-6 ”), 127.79 (CH, C-5’), 126.91 
(CH, C-2, C-6 ), 123.24 (CH, C-5’”), 122.06 (CH, C-4’), 120.98 (CH, C-6 ’”), 117.43 
(CH, C-3”, C-5”), 116.24 (CH, C-7’”), 108.08 (CH, C-4”’), 63.49 (CH, CH-N),
21.96 (CH3).
HRMS (ED: Found: 381.1712 (M)+, Calculated: 381.1715.
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3.4) Experimental respite for the preparation o f the methoxy 
derivative 67 and the hydroxy derivative 68
3.4.1) 4-Methoxv-4 ’-nitrobenzophenone (60)180
AICI3
anisote, CHjC^ OMe
cr a
To a solution of p-nitrobenzoyl chloride (2.5 g, 13.37 mmol) in CH2CI2 (50 
mL) was added aluminum chloride (3.59 g, 26.94 mmol) and anisole (1.74 g, 16.16 
mmol). The mixture was then stirred overnight at room temperature. HC1 1 M (10 
mL) was then added to the mix before washing with H2O (2 x 5 0  mL) and NaHCC>3 
(50 mL). The organic layer was dried (MgSC>4), filtered and reduced in vacuo. 
Recrystallisation from EtOAc/petroleum ether gave the product as a pale yellow 
solid. Yield: 2.4 g (69 %). tl.c  system: petroleum ether-ethyl acetate 2:1, Rf= 0.61.
'HNMR: 8 (CDClj): 8.28 (d, 2H, J= 8.5 Hz, Ar), 7.81 (d, 2H, J= 9.0 Hz, Ar),
7.75 (d, 2H, J= 9.0 Hz, Ar), 6.92 (d, 2H, J= 8.5 Hz, Ar), 3.83 (s, 3H, CH3).
Melting noint: 108-109 °C (lit m.p. 123 °C)181.
3.4.2) 4-Methoxv-4 ’-aminobenzophenone (61)182
OMe
Pd cat 
EtOH, 1atm
OMe
180 Gorvin J.H. and Whalley D.P.; Aromatic nitro-group displ^ement reactions. Part 1. A novel route 
to substituted 10-phenylacridones. J. Chem. Soc. Per. Trans. 1: Org and Bio-org Chem..1979, 5, 
1634-70.
181 Shani J., Gazit A., Livshitz T. and Biran S.; Synthesis and receptor-binding affinity of 
fluorotamoxifen, a possible estrogen-receptor imaging agent J. Med. Chem., 1985,2 8 ,1504-1511.
182 Kaslow C.E. and Stayner R.D.; Substituted 4-aminodiphenylmethanes. J. Am. Chem. Soc., 1946 
68,2600-2.
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To a solution of 60 (1 g, 3.88 mmol) in EtOH (50 mL) was added Pd/C 
catalyst (0 . 2  g) and the reaction stirred under a H2 atmosphere (H2 balloon) for 1 0  
min. The reaction was filtered through celite and the filtrate concentrated under 
reduced pressure. The resulting oil was extracted with EtOAc (50 mL), washed with 
H2O (2 x 50 mL), dried (MgS0 4 ) and concentrated in vacuo to give the pure product 
as a yellow syrup. Yield: 0.84 g (95 %). tl.c  system: petroleum ether-ethyl acetate 
2:1, Rf= 0.32.
*HNMR: 8  (CDCI3): 7.68 (d, 2H, J= 8 . 8  Hz, Ar), 7.58 (d, 2H, J= 8 . 6  Hz, Ar), 
6.84 (d, 2H, J= 8 . 8  Hz, Ar), 6.59 (d, 2H, J= 8 . 6  Hz, Ar), 4.07 (bs, 2H, NH), 3.79 (s, 
3H, CH3).
100
3.4.3) 4-Methoxv-4,-isothiocvanatobenzoDhenone (62)
CSCI2
OMe CH2 C,2 > H2 °  SCN OMeH,N 62
To a solution of 61 (0.84 g, 3.70 mmol) in CH2CI2  (50 mL) was added a 
mixture of ice (2 g) and H2O (20 mL) and subsequently dropwise with vigorous 
stirring thiophosgene (0.34 mL, 4.44 mmol). The mixture was stirred for 2 h at 0 °C 
and kept overnight in a refrigerator. The organic layer was separated and extracted 
successively with H2O (2 x 50 mL), 10 % NaHC03 aq. (50 mL) and H2O again (50 
mL), dried (MgSCL*) and evaporated to dryness to obtain the pure product as an 
orange solid. Yield: 0.97 g (97 %). t.l.c system: petroleum ether-ethyl acetate 2:1, 
Rf= 0.72.
‘HNMR: 8  (CDC13): 7.68 (d, 2H, J= 9.0 Hz, Ar), 7.66 (d, 2H, J= 8.5 Hz, Ar),
7.19 (d, 2H, J= 8.5 Hz, Ar), 6.81 (d, 2H, J= 9.0 Hz, Ar), 3.73 (s, 3H, CH3).
13C NMR: 8  (CDCI3): 193.68 (C, C-7), 163.45 (C, C-13), 137.52 (C, C-15), 
136.70 (C, C-6 ), 134.59 (C, C -l), 132.43 (CH, C-4, C-5), 131.21 (CH, C-9, C-10), 
129.60 (C, C-8 ), 125.54 (CH, C-2, C-3), 113.76 (CH, C -ll, C-12), 55.58 (CH3, C- 
14).
183 Antos K., Sura J., Kuoppova V. and Prochozka J.; Synthesis and properties of 4 ’-substituted 4-
isothiocyanatobenzophenone. Coll Czech Chem. Com., 1973,3 8 ,1609-13.
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Melting point: 112-114 °C.
3.4.4) r4-(Benzoxazol-2-vlamino)phenvll(4-methoxvphenvl)methanone (63)
2) HgO, S, EtOH
OMeSCN 62
2-Aminophenol (0.39 g, 3.59 mmol) was added to a solution of 62 (0.97 g, 
3.59 mmol) in toluene (50 mL). After stirring overnight at room temperature, HgO 
(2.73 g, 12.60 mmol) and sulphur (40 mg, 1.26 mmol) were added to the crude 
thiourea and refluxed for 1.5 h. The cooled reaction mixture was filtered through a 
celite pad and the solvent evaporated. Purification by column chromatography 
(petroleum ether/EtOAc 60:40 v/v) gave the product as an orange solid. Yield: 0.57 g 
(46 %). t.l.c system: petroleum ether-ethyl acetate 2:1, Rf= 0.41.
*H NMR: 6  (CDC13): 8.62 (bs, 1H, NH), 7.80 (m, 4H, Ar), 7.67 (d, 2H, J= 8.5 
Hz, Ar), 7.46 (d, 1H, J= 7.5 Hz, Ar), 7.32 (d, 1H, J= 8.0 Hz, Ar), 7.20 (d, 1H, J= 8.5 
Hz, Ar), 7.11 (m, 1H, Ar), 6.92 (m, 2H, Ar), 6 . 8 8  (d, 2H, J= 9.0 Hz, Ar), 3.83 (s, 3H, 
CH3).
13C NMR: 6  (CDC13): 188.04 (C, C=0), 163.09 (C, C-l), 152.63 (C, C-2”), 
149.35 (C, C-9”), 141.36 (C, C-4’), 139.65 (C, C-8 ”), 132.43 (CH, C-3, C-5), 131.83 
(CH, C-2’, C-6 ’), 130.46 (C, C-4), 129.52 (C, C -l’), 125.44 (CH, C-5”), 124.79 (CH, 
C-6 ”), 120.96 (CH, C-4”), 117.17 (CH, C-3’, C-5’), 113.57 (CH, C-2, C-6 ), 110.07 
(CH, C-7”), 55.53 (CH3).
Melting point: 143-144 °C.
HRMS (ED: Found: 345.1236 (M)+, Calculated: 345.1239.
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3.4.5) (4-(Benzoxazol-2-vlamino)Dhenvl)(4-hvdroxvDhenvl)methanone (64)
HBr
AcOH
OHOMeN
H 63 64
A mixture of 63 (0.46 g, 1.33 mmol) in 20 mL of a 48 % solution of HBr in 
acetic acid and 10 mL of acetic acid was heated at reflux for 6  h and then left to stir 
overnight at room temperature. The mixture was then evaporated to one-half the 
original volume on the rotary evaporator. The residue was diluted with H2O (30 mL) 
and extracted with EtOAc (50 mL). The organic extract was washed with aq. 
NaHCC>3 (2 x 30 mL) and evaporated to give a yellow oil. Purification by column 
chromatography (petroleum ether/EtOAc 60:40 v/v) gave the product as a yellow 
syrup. Yield: 0.34 g (77 %). t.l.c system: petroleum ether-ethyl acetate 1:1, Rf= 0.37.
*H NMR: 6  (CD3OD): 7.76 (d, 2H, J= 9.0 Hz, Ar), 7.71 (d, 2H, J= 9.0 Hz,
Ar), 7.62 (d, 2H, J= 8 . 6  Hz, Ar), 7.39 (d, 1H, J= 7.8 Hz, Ar), 7.33 (d, 1H, J= 8.2 Hz,
Ar), 7.18 (m, 1H, Ar), 7.10 (m, 1H, Ar), 6.81 (d, 2H, J= 8 . 6  Hz, Ar).
13C NMR: 6  (CD3OD): 196.81 (C, C=0), 163.43 (C, C -l), 152.79 (C, C-2”),
144.04 (C, C-9”), 143.91 (C, C-4’), 139.06 (C, C-8 ”), 133.94 (CH, C-3, C-5), 133.26 
(C, C-4) 132.57 (CH, C-2’, C-6 ’), 130.36 (C, C -l’), 125.37 (CH, C-5”), 125.12 (CH, 
C-6 ”), 123.53 (CH, C-4”), 118.18 (CH, C-3’, C-5’), 116.14 (CH, C-2, C-6 ), 110.11 
(CH, C-7”).
HRMS (ED: Found: 330.1004 (M)+, Calculated: 330.1004.
3.4.6) General procedure for the preparation o f f 4-(Benzoxazol-2-vlamino)Dhenv 1 (4- 
substitutedphenvDmethanol 65 and 66
65, R= OMe
66, R= OH
NaBK
MeOH
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To a cooled (0 °C) solution of 63-64 (1.20 mmol) in anhydrous MeOH (30 
mL) was added sodium borohydride (53 mg, 1.20 mmol), then the mixture was 
allowed to stir at room temperature under nitrogen for 4 h (R= OMe) or 12 h (R= 
OH). The solvent was concentrated under reduced pressure and aqueous HC1 (1 M, 5 
mL) added to the residue. The oil formed was extracted with EtOAc (2 x 30 mL) and 
washed with H2O (2 x 50 mL), the organic layers were combined and dried with 
MgS0 4  and the solvent concentrated under reduced pressure.
3.4.6.1) [4-(Benzoxazol-2-ylamino)pheny](4-methoxyphenyl)methanol (65)
Orange solid (91 %), mp: 123-124 °C. t.l.c system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.38.
*HNMR: 6  (CDCI3): 8.74 (bs, 1H, NH), 7.38 (d, 2H, J= 8.0 Hz, Ar), 7.33 (d, 
1H, J= 8.0 Hz, Ar), 7.20 (m, 3H, Ar), 7.15 (m, 2H, Ar), 7.10 (m, 1H, Ar), 7.01 (m, 
1H, Ar), 6.76 (d, 2H, J= 8.5 Hz, Ar), 5.68 (s, 1H, H-7), 3.69 (s, 3H, CH3).
13C NMR: 8  (CDC13): 157.67 (C, C -l), 156.74 (C, C-2”), 146.76 (C, C-9”),
142.56 (C, C-4’), 140.73 (C, C-8 ”), 138.18 (C, C-4), 135.11 (C, C -l’), 129.00 (CH, 
C-5”), 127.21 (CH, C-3, C-5), 126.87 (CH, C-2’, C-6 ’), 123.31 (CH, C-6 ”), 120.84 
(CH, C-4”), 117.87 (CH, C-3’, C-5’), 112.99 (CH, C-2, C-6 ), 108.10 (CH, C-7”),
76.96 (CH, CH-OH), 54.20 (CH3).
HRMSJEI): Found: 347.1395 (M)+, Calculated: 347.1396.
3.4.6.2) [4-(Benzoxazol-2-ylamino)pheny](4-hydroxyphenyl)methanol (66)
Purification by column chromatography (petroleum ether/EtOAc 60:40 v/v) 
gave the product as a yellow syrup (42 %). t.l.e system: petroleum ether-ethyl acetate 
1:1, Rf= 0.51.
*H NMR: 8  (CD3OD): 9.96 (bs, 1H, OH), 9.07 (bs, 1H, NH), 7.48 (d, 2H, J= 
8 . 6  Hz, Ar), 7.22 (m, 4H, Ar), 7.11 (m, 3H, Ar), 6.95 (m, 1H, Ar), 6.65 (d, 2H, J= 8 . 6  
Hz, Ar), 5.60 (s ,1H, H-7), 4.58 (bs, 1H, OH).
13C NMR: 8  (CD3OD): 160.34 (C, C-l), 157.68 (C, C-2”), 148.98 (C, C-9”), 
143.50 (C, C-4’), 140.98 (C, C-8 ”), 138.72 (C, C-4), 136.96 (C, C -l’), 129.18 (CH, 
C-3, C-5), 128.46 (CH, C-2’, C-6 ’), 125.25 (CH, C-5”), 123.02 (CH, C-6 ”), 119.48
137
(CH, C-4”), 117.54 (CH, C-3’, C-5’), 116.07 (CH, C-2, C-6 ), 109.94 (CH, C-7”),
76.34 (CH, CH-OH).
HRMS (ED: Found: 333.1238 (M)+, Calculated: 333.1239
3.4.7) General procedure for the preparation o fBenzoxazol-2-vl-{4-Fimidazole-1 -vl- 
(4-substitutedDhenvl)methvnphenyl}amine 67 and 68
67, R= OMe
68, R= OH
gm
l.l'-carbodiimidazoie 1 
p  imidazote, CH3CN T  9'N
H 65-66
To a solution of 65-66 (0.94 mmol) in CH3CN (50 mL) was added imidazole 
(2.82 mmol) and 1,1’carbodiimidazole (1.41 mmol). The mixture was heated under 
reflux overnight, then the reaction mixture was allowed to cool and the solvent 
removed under reduced pressure. The oil formed was then extracted with CH2CI2 (50 
mL) and washed with H2O (2 * 50 mL). The organic layer was dried (MgSCU), 
filtered and reduced in vacuo.
3.4.7.1) Benzoxazol-2-vl-(4-[imidafrol-l-yl-(4-
metho xv phcnvfimeth v H phenvll amine 67
Purification by column chromatography (EtOAc) gave the product as a 
yellow syrup (38 %). tl.c  system: ethyl acetate, Rf= 0.09.
‘HNMR: 8  (CDCb): 9.62 (bs, 1H, NH), 7.60 (d, 2H, J= 8.5 Hz Ar), 7.45 (s, 
1H, Ar), 7.39 (d, 1H, J= 7.5 Hz, Ar), 7.23 (d, 1H, J= 8.0 Hz, Ar), 7.16 (m, 1H, Ar),
7.08 (m, 1H, Ar), 7.01 (m, 6 H, Ar), 6.78 (d, 2H, J= 9.0 Hz, Ar), 6.39 (s, 1H, H-7),
3.75 (s, 3H, CH3).
13C NMR: 6  (CDCI3): 158.59 (C, C-l), 157.28 (C, C-2’”), 146.77 (C, C-9’”),
141.29 (C, C-4”), 139.84 (CH, C-2’), 137.56 (C, C-8 ’”), 132.51 (C, C-4), 130.00 (C,
138
C -l’), 128.34 (CH, C-3, C-5), 127.72 (CH, C-2”, C-6 ”), 125.92 (CH, C-5’), 123.18 
(CH, C-5”’), 122.61 (CH, C-4’), 120.86 (CH, C-6 ”’), 117.47 (CH, C-3”, C-5”), 
116.11 (CH, C-4”’), 113.24 (CH, C-2, C-6 ), 108.05 (CH, C-7”’), 63.31 (CH, CH-N), 
54.33 (CH3).
HRMS (ED: Found: 397.1667 (M)+, Calculated: 397.1665.
3.4.7.2) Benzoxazol-2-vl-(4-[imidazol-l-vl-(4-
hvdroxvphenvDmethvllphenvll amine 68
Purification by column chromatography (EtOAc) gave the product as a 
colourless oil (74 %). t l x  system: ethyl acetate, Rf= 0 .1 0 .
*H NMR: 8  (CD3OD): 7.56 (d, 2H, J= 8 . 6  Hz, Ar), 7.45 (s, 1H, Ar), 7.26 (d, 
1H, J= 7.4 Hz, Ar), 7.20 (d, 1H, J= 7.4 Hz, Ar), 7.07 (m, 1H, Ar), 6.98 (m, 5H, Ar),
6.80 (d, 2H, J= 8.2 Hz, Ar), 6.63 (d, 2H, J= 8 . 6  Hz, Ar), 6.46 (s, 1H, H-7).
13C NMR: 8  (CD3OD): 159.89 (C, C -l), 158.76 (C, C-2’”), 148.98 (C, C- 
9”’), 143.50 (C, C-4’), 139.90 (CH, C-8 ’”), 135.41 (C, C-4), 131.37 (C, C -l’), 
130.58 (CH, C-3, C-5), 130.25 (CH, C-2’), 130.13 (CH, C-5’), 129.74 (CH, C-2’, C- 
6 ’), 125.28 (CH, C-5’”), 123.28 (CH, C-6 ’”), 122.68 (CH, C-4’), 119.68 (CH, C-3’, 
C-5’), 117.82 (CH, C-4’”), 116.68 (CH, C-2, C-6 ), 110.01 (CH, C-7 ’”), 65.48 (CH, 
CH-OH).
HRMS (Ell: Found: 315.1130 (M-imidazole)+, Calculated: 315.1134.
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3.5) Experimental results for the preparation of the dimethyl 
derivatives 84 .85 and 86
3.5.1) General procedure for the preparation o f the dimethvl-4 '-nitrobenzovhenone 
69. 70 and 71
AlClg
R1
R2
R3
R4
69, R1= H, R2= CH3, 
R3= CH3, R4= H
70, R1= CH3, R2= H 
R3= CH3, R4= H
71, R1=CH3, R2= H 
R3= H, R4= CH3
CT Cl
To a solution of p-nitrobenzoyl chloride (10.77 mmol) in 0 , m or p-xylene (25 
mL) was added AICI3 (15.15 mmol) and the resulting black solution stirred at room 
temperature for 3 h. H2O (4 mL) was added dropwise and the resulting mixture was 
stirred for 15 min and then extracted with H2O (50 mL) and 10 % NaHC(> 3  (2 x 50 
mL). The organic layer was dried (MgSC>4), filtered and evaporated.
3.5.1.1) 3,4-Dimethyl-4’-nitrobenzophenone 69184
Purification by column chromatography (petroleum ether/EtOAc 80:20 v/v) 
gave the product as a white solid (41 %), mp: 114-115 °C (lit m.p. 82-83 °C)185. t.l.c 
system: petroleum ether-ethyl acetate 2:1, Rf= 0.66.
!HNMR: 6  (CDCI3): 8.13 (d, 2H, J= 9.0 Hz, Ar), 7.78 (d, 2H, J= 9.0 Hz, Ar),
7.46 (s, 1H, Ar), 7.34 (d, 1H, J= 7.8 Hz, Ar), 7.10 (d, 1H, J= 7.8 Hz, Ar), 2.22 (s, 6 H, 
2  x CH3).
3.5.1.2) 2,4-Dimethyl-4’-nitrobenzophenone 70184
184 Kuhnis H. and De Diesbach H.; Quinolyl ketones and their reduction products. Hel. Chim. Acta, 
1958,41, 894-903.
185 Jin T.S., Yang M.N., Feng G.L. and Li T.S.; Synthesis o f diaryl ketones catalysed by A120 3- 
Zr02/S20 2-8 solid superacid. Synth. Com., 2004,34,479-485.
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White solid (85 %), mp: 80-81 °C (lit m.p. 87-88 °C)185. t.l.c system: 
petroleum ether-ethyl acetate 2:1, Rf= 0.72.
*H NMR: 5 (CDC13): 8.01 (d, 2H, J= 8.6 Hz, Ar), 7.70 (d, 2H, J= 8.6 Hz, Ar),
7.04 (d, 1H, J= 7.8 Hz, Ar), 6.92 (s, 1H, Ar), 6.86 (d, 1H, J= 7.8 Hz, Ar), 2.19 (s, 6H,
2 x CH3).
3.5.1.3) 2,5-Dimethyl -4*-nitrobenzophenone 71184
Yellow solid (90 %), mp: 72-74 °C (lit m.p. 84-86 °C)185. t.l.c system: 
petroleum ether-ethyl acetate 2:1, Rf= 0.81.
*HNMR: 8 (CDCI3): 8.09 (d, 2H, J= 8.6 Hz, Ar), 7.78 (d, 2H, J= 8.7 Hz, Ar),
7.09 (d, 1H, J= 7.7 Hz, Ar), 7.02 (d, 1H, J= 7.7 Hz, Ar), 6.95 (s, 1H, Ar), 2.13 (s, 6H,
2 x CH3).
3.5.2) General procedure for the preparation o f the dimethvl-4 ’-aminobenzophenone 
72. 73 and 74
N
72, R1= H, R2= CH3, 
R3= CH3, R4= H
73, R1= CH3> R2= H, 
R3= CHg, R4= H
74, R1= CH3, R2= H,
EtOH, 1 atm
To a solution of 69-71 (9.75 mmol) in EtOH (70 mL) was added Pd/C 
catalyst (0.4 g) and the reaction stirred under a H2  atmosphere (H2 balloon) for 25 
min. The reaction was filtered through celite and the filtrate concentrated under 
reduced pressure. The resulting oil was extracted with EtOAc (50 mL), washed with 
H2O (2 x 5 0  mL), dried (MgSO^ and concentrated in vacuo.
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3.5.2.1) 3,4-Dimethyl-4’-aminobeiizopheiioiie 72186
Yellow solid (94 %), mp: 96-97 °C. t.l.c system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.47.
*H NMR: 8  (CDC13): 7.59 (d, 2H, J= 8 . 6  Hz, Ar), 7.38 (s, 1H, Ar), 7.33 (d, 
1H, J= 7.7 Hz, Ar), 7.07 (d, 1H, J= 7.7 Hz, Ar), 6.49 (d, 2H, J= 8 . 6  Hz, Ar), 4.02 (bs, 
2 H, NH2), 2.17 (s, 6 H, 2  x CH3).
13C NMR: 8  (CDC13): 197.89 (C, C=0), 151.27 (C, C-4’), 140.77 (C, C-4), 
136.99 (C, C-3), 136.52 (C, C -l), 132.87 (CH, C-2’, C-6 ’), 130.70 (CH, C-2), 129.29 
(CH, C-5), 127.76 (CH, C-6 ), 127.39 (C, C -l’), 113.94 (CH, C-3’, C-5’), 19.77 (CH3 
x 2).
3.5.2.2) 2,4-Dimethyl-4’-aminobeiizophenone 73186
Yellow solid (96 %), mp: 119-120 °C. t.l.c system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.59.
*H NMR: 8  (CDCI3): 7.56 (d, 2H, J= 8.7 Hz, Ar), 7.08 (d, 1H, J= 7.7 Hz, Ar),
6.98 (s, 1H, Ar), 6.93 (d, 1H, J= 7.8 Hz, Ar), 6.52 (d, 2H, J= 8 . 6  Hz, Ar), 4.14 (bs, 
2 H, NH2), 2.29 (s, 3H, CH3), 2.19 (s, 3H, CH3).
13C NMR: 8  (CDC13): 197.15 (C, C=0), 151.36 (C, C-4’), 139.51 (C, C-4), 
136.86 (C, C-2), 136.17 (C, C-l), 132.76 (CH, C-2’, C-6 ’), 131.68 (CH, C-6 ), 128.17 
(CH, C-3), 128.02 (C, C -l’), 123.58 (CH, C-5), 113.65 (CH, C-3’, C-5’), 21.31 
(CH3), 19.74 (CH3).
3.5.2.3) 2,5-Dimethyl-4’-aminobeiizophenone 74186
Yellow solid (94 %), mp: 130-131 °C. t.l.c system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.48.
*H NMR: 8  (CDC13): 7.57 (d, 2H, J= 8.7 Hz, Ar), 7.05 (m, 2H, Ar), 6.97 (s, 
1H, Ar), 6.53 (d, 2H, J= 8 . 8  Hz, Ar), 4.13 (bs, 2H, NH2), 2.22 (s, 3H, CH3), 2.14 (s, 
3H, CH3).
13C NMR: 8  (CDC13): 197.38 (C, C=0), 151.56 (C, C-4’), 139.80 (C, C-l),
134.69 (C, C-2), 133.00 (CH, C-2’, C-6 ’), 132.57 (C, C-5), 130.77 (CH, C-4), 129.93 
(CH, C-6 ), 128.12 (CH, C-3), 127.36 (C, C -l’), 112.08 (CH, C-3’, C-5’), 20.89 
(CH3), 19.20 (CH3).
186 Ernst M.; Isoindole pigments made from tetraphenylketazine and their use. Ger. Offen., 1979,42
pp.
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3.5.3) General procedure for the preparation of the dimethvl-4
isothiocvanatobenzophenone 75. 76 and 77
75, R1= H, R2= CH3, 
R3= CH3, R4= H
76, R1= CH3, R2= H, 
R3= CH3, R4= H
77, R1= CH3, R2= H,
To a solution of 72-74 (2 g, 8.87 mmol) in CH2CI2 (70 mL) was added a 
mixture of ice (2.5 g) and H2O (30 mL) and subsequently dropwise with vigorous 
stirring thiophosgene (0.80 mL, 10.65 mmol). The mixture was stirred for 2 h at 0 °C 
and kept overnight in a refrigerator. The organic layer was separated and extracted 
successively with H2O (2 x 50 mL), 10 % NaHCCb aq. (50 mL) and H2O again (50 
mL), dried (MgSC>4) and evaporated to dryness.
3.5.3.1) 3,4-Dimethyl-4’-isothiocyanatobenzophenone 75
Purification by column chromatography (petroleum ether/EtOAc 80:20 v/v) 
gave the product as an orange solid (75 %), mp: 81-82 °C. t.l.c system: petroleum 
ether-ethyl acetate 2:1, Rf = 0.85.
*H NMR: 8  (CDCI3): 7.63 (d, 2H, J= 8.2 Hz, Ar), 7.42 (s, 1H, Ar), 7.32 (d, 
1H, J= 7.8 Hz, Ar), 7.14 (d, 2H, J= 8 . 6  Hz, Ar), 7.08 (d, 1H, J= 7.4 Hz, Ar), 2.18 (s, 
3H, CH3), 2.14 (s, 3H, CH3).
13C NMR: 8  (CDC13): 195.10 (C, C=0), 142.42 (C, C-4), 137.00 (C, C-3),
136.49 (C, C -l’), 134.92 (C, C-4’), 134.84 (C, C-l), 133.60 (C, NCS), 131.44 (CH, 
C-2’, C-6 ’), 131.07 (CH, C-2), 129.61 (CH, C-5), 127.89 (CH, C-6 ), 125.54 (CH, C- 
3’, C-5’), 20.09 (CH3), 19.82 (CH3).
HRMS (ED: Found: 268.0791 (M)+, Calculated: 268.0796.
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3.5.3.2) 2,4-Dimethyl-4’>lsothiocyanatobeiizophenone 76
Orange solid (96 %), mp: 39-40 °C. tl.c  system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.85.
*H NMR: 8 (CDC13): 7.59 (d, 2H, J= 8.6 Hz, Ar), 7.08 (d, 2H, J= 8.6 Hz, Ar), 
7.02 (d, 1H, J= 7.4 Hz, Ar), 6.95 (s, 1H, Ar), 6.88 (d, 1H, J= 7.8 Hz, Ar), 2.21 (s, 3H, 
CH3), 2.16 (s, 3H, CH3).
13C NMR: 8 (CDC13): 196.86 (C, C=0), 141.13 (C, C-4), 137.89 (C, NCS),
137.43 (C, C-2), 136.61 (C, C -l’), 135.50 (C, C -l), 134.94 (C, C-4’), 132.12 (CH, C- 
6), 131.56 (CH, C-2’, C-6’), 129.22 (CH, C-3), 125.95 (CH, C-5), 125.69 (CH, C-3’, 
C-5’), 21.44 (CH3), 20.14 (CH3).
HRMS (ED: Found: 268.0792 (M)+, Calculated: 268.0796.
3.5.3.3) 2,5-Dimethyl-49 -isothiocy anatobenzophenone 77
Purification by column chromatography (petroleum ether/EtOAc 80:20 v/v) 
gave the product as an orange solid (61 %), mp: 49-50 °C. tl.c  system: petroleum 
ether-ethyl acetate 2:1, R f = 0.88.
*H NMR: 8 (CDC13): 7.71 (d, 2H, J= 8.6 Hz, Ar), 7.18 (d, 2H, J= 8.6 Hz, Ar),
7.10 (m, 2H, Ar), 6.97 (s, 1H, Ar), 2.24 (s, 3H, CH3), 2.17 (s, 3H, CH3).
13C NMR: 8 (CDC13): 197.17 (C, C=0), 137.95 (C, C-l), 137.24 (C, NCS), 
136.20 (C, C-2), 135.71 (C, C-4’), 134.99 (C, C-5), 133.60 (C, C -l’), 131.56 (CH, C- 
2’, C-6’), 131.35 (CH, C-4), 131.09 (CH, C-6), 128.89 (CH, C-3), 125.78 (CH, C-3’, 
C-5’), 20.93 (CH3), 19.55 (CH3).
HRMS (ED: Found: 268.0791 (M)+, Calculated: 268.0796.
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3.5.4) General procedure for the vrevaration o f the f4-(Benzoxazol-2-vlamino)-
nhenvn(dimethvlDhenvl)methanone 78. 79 and 80
(78, R1= H, R2= CH3,^  
R3= CH3, R4= H
79, R1= CH3, R2= H, 
R3= CH3, R4= H
80, R1= CH3, R2= H,
^ R3= H, R4= CH3 ^
R2 1) 2-aminophenol 
EtOH
2) HgO, S, EtOH 7" 9"R3 R3SCN 75-77
R4 R4
2-Aminophenol (5.12 mmol) was added to a solution of 75-77 (5.12 mmol) in 
EtOH (100 mL). After stirring overnight at room temperature, HgO (10.24 mmol) 
and sulphur (1.02 mmol) were added to the crude thiourea and refluxed for 4-6 h. 
The cooled reaction mixture was filtered through a celite pad and the solvent 
evaporated.
3.5.4.1) [4-(Benzoxazol-2-ylamino)phenyl]-(3,4-dimethylphenyI)methanone 78
Purification by column chromatography (petroleum ether/EtOAc 70:30 v/v) 
gave the product as an orange solid (87 %), mp: 154-155 °C. tl.c  system: petroleum 
ether-ethyl acetate 2:1, Rf= 0.73.
*H NMR: 8 (CDC13): 8.94 (bs, 1H, NH), 7.81 (d, 2H, J= 9.0 Hz, Ar), 7.69 (d, 
2H, J= 9.0 Hz, Ar), 7.53 (s, 1H, Ar), 7.45 (d, 2H, J= 7.8 Hz, Ar), 7.30 (d, 1H, J= 8.2 
Hz, Ar), 7.14 (m, 3H, Ar), 2.29 (s, 3H, CH3), 2.26 (s, 3H, CH3).
13C NMR: 8 (CDC13): 194.63 (C, C=0), 156.82 (C, C-2”), 146.12 (C, C-4’),
140.70 (C, C-9”), 138.04 (C, C-8”), 135.71 (C, C-4), 134.58 (C, C-3), 132.06 (C, C- 
1), 131.27 (C, C -l’), 130.99 (CH, C-2’, C-6’), 130.04 (CH, C-2), 128.39 (CH, C-5), 
126.81 (CH, C-6), 123.54 (CH, C-5”), 121.41 (CH, C-6”), 116.30 (CH, C-4”),
116.10 (CH, C-3’, C-5’), 108.36 (CH, C-7”), 18.99 (CH3), 18.77 (CH3).
HRMS (El): Found: 343.1446 (M)+, Calculated: 343.1447.
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3.5.4.2) [4-(Benzoxazol-2-ylamino)phenyl]-(2,4-dimethylphenyl)methanone 78
Purification by column chromatography (petroleum ether/EtOAc 70:30 v/v) 
gave the product as a pale yellow solid (66 %), mp: 164-165 °C. tl.c  system: 
petroleum ether-ethyl acetate 2:1, R f = 0.69.
*HNMR: 5 (CDC13): 7.79 (d, 2H, J= 8.6 Hz, Ar), 7.63 (d, 2H, J= 8.6 Hz, Ar), 
7.45 (d, 1H, J= 7.8 Hz, Ar), 7.32 (d, 1H, J= 7.8 Hz, Ar), 7.16 (m, 3H, Ar), 7.03 (s, 
1H, Ar), 6.98 (d, 2H, J= 7.8 Hz, Ar), 3.80 (bs, 1H, NH), 2.32 (s, 3H, CH3), 2.28 (s, 
3H, CH3).
13C NMR: 8 (CDC13): 196.54 (C, C=0), 156.64 (C, C-2”), 146.73 (C, C-4’), 
141.38 (C, C-9”), 140.26 (C, C-4), 139.35 (C, C-8”), 135.79 (C, C-2), 134.82 (C, C-
1), 131.47 (C, C -l’), 131.02 (CH, C-2’, C-6’), 130.76 (CH, C-6), 127.78 (CH, C-3),
124.78 (CH, C-5), 123.61 (CH, C-5”), 121.46 (CH, C-6”), 116.27 (CH, C-3’, C-5’), 
116.14 (CH, C-4”), 108.42 (CH, C-7”), 20.33 (CH3), 18.95 (CH3).
HRMS (ED: Found: 343.1443 (M)+, Calculated: 343.1447.
3.5.43) [4-(Beiizoxazol-2-ylammo)phenylJ-(2,5-dimethyIphenyl)methanone 79
Purification by column chromatography (petroleum ether/EtOAc 70:30 v/v) 
gave the product as a light brown solid (64 %), mp: 173-174 °C. tl.c  system: 
petroleum ether-ethyl acetate 2:1, R f = 0.67.
*H NMR: 8 (CDC13): 7.80 (d, 2H, J= 8.6 Hz, Ar), 7.64 (d, 2H, J= 9.0 Hz, Ar),
7.43 (m, 1H, Ar), 7.31 (d, 1H, J= 7.8 Hz, Ar), 7.19 (d, 1H, J= 7.8 Hz, Ar), 7.09 (m, 
3H, Ar), 7.04 (s, 1H, Ar), 3.85 (bs, 1H, NH), 2.27 (s, 3H, CH3), 2.19 (s, 3H, CH3).
13C NMR: 8 (CDC13): 195.67 (C, C=0), 156.22 (C, C-2”), 145.97 (C, C-4’),
141.18 (C, C-9”), 137.95 (C, C-8”), 133.80 (C, C -l), 132.13 (C, C-2), 131.85 (C, C-
5), 131.46 (C, C -l’), 131.04 (CH, C-2’, C-6’), 129.78 (CH, C-4), 128.86 (CH, C-3),
127.57 (CH, C-6), 123.71 (CH, C-5”), 121.66 (CH, C-6”), 116.34 (CH, C-3’, C-5’), 
116.24 (CH, C-4”), 108.47 (CH, C-7”), 19.87 (CH3), 18.39 (CH3).
HRMS (El): Found: 343.1444 (M)+, Calculated: 343.1447.
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3.5.5) General procedure for the preparation o f the f4-(Benzoxazol-2-
v la m in o )D h e n v ll(d im e th v lD h e n v l)m e th a n o l 81. 82 a n d  83
81, R1= H, R2= CH3, 
R3= CH3, R4= H
82, R1= CH3> R2= H, 
R3= CH3, R4= H
83, R1= CH3, R2= H, 
R3= H, R4= CH3 J
R1
R2
NH R3R4
NaBH4
MeOH
OH R1
To a cooled (0 °C) solution of 78-80 (2.07 mmol) in anhydrous MeOH (50 
mL) was added sodium borohydride (2.07 mmol), then the mixture was allowed to 
stir at room temperature under nitrogen for 4 h. The solvent was concentrated under 
reduced pressure and aqueous HC1 (1 M, 5 mL) added to the residue. The oil formed 
was extracted with EtOAc (2 x 50 mL) and washed with H2O (2 x 50 mL), the 
organic layers were combined and dried with MgS0 4  and the solvent concentrated 
under reduced pressure.
3.5.5.1) [4-(Benzoxazol-2-ylamino)phenyl]-(3,4-dimethylphenyl)methanol 81
Orange solid (73 %), mp: 125-126 °C. tl.c  system: petroleum ether-ethyl 
acetate 2:1, Rf = 0.50.
*H NMR: 5 (CDCI3): 7.70 (bs, 1H, NH), 7.33 (d, 2H, J= 8.6 Hz, Ar), 7.27 (m, 
4H, Ar), 7.14 (m, 1H, Ar), 7.02 (m, 4H, Ar), 6.11 (s, 1H, H-7), 2.12 (s, 6H, 2 x CH3).
13C NMR: 6 (CDC13): 158.03 (C, C-2”), 146.84 (C, C-9”), 143.24 (C, C-4’),
140.30 (C, C -l), 138.23 (C, C-8”), 135.79 (C, C-3), 134.97 (C, C-4), 129.96 (C, C- 
1’), 126.75 (CH, C-4), 126.50 (CH, C-2’, C-6’), 123.45 (CH, C-2), 122.92 (CH, C-
6), 122.61 (CH, C-5”), 120.85 (CH, C-6”), 117.63 (CH, C-3’, C-5’), 115.65 (CH, C- 
4”), 108.24 (CH, C-7”), 74.67 (CH, CH-OH), 18.83 (CH3), 18.43 (CH3).
HRMS (ED: Found: 345.1604 (M)+, Calculated: 345.1603.
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3.5.5.2) [4-(Benzoxazol-2-ylamino)phenyl]-(2,4-dimethylphenyl)methanol 82
White solid (97 %), mp: 153-154 °C. tl.c  system: petroleum ether-ethyl 
acetate 2:1, Rr= 0.45.
*H NMR: 8  (CDC13): 7.56 (d, 2H, J= 8 . 6  Hz, Ar), 7.34 (m, 2H, Ar), 7.29 (m, 
3H, Ar), 7.13 (m, 1H, Ar), 7.08 (m, 1H, Ar), 6.99 (d, 1H, J= 7.8 Hz, Ar), 6.90 (s, 1H, 
Ar), 5.89 (s, 1H, H-7), 2.27 (s, 3H, CH3), 2.16 (s, 3H, CH3).
13C NMR: 5 (CDC13): 160.27 (C, C-2”), 148.99 (C, C-9”), 143.54 (C, C-4’),
140.34 (C, C-l), 139.59 (C, C-8 ”), 138.89 (C, C-2), 137.84 (C, C-4), 136.31 (C, C- 
1’), 132.19 (CH, C-3), 129.27 (CH, C-2’, C-6 ’), 127.56 (CH, C-6 ), 127.52 (CH, C-
5), 125.23 (CH, C-5”), 123.00 (CH, C-6 ”), 119.40 (CH, C-3’, C-5’), 117.61 (CH, C- 
4”), 109.96 (CH, C-7”), 73.54 (CH, CH-OH), 21.33 (CH3), 19.72 (CH3).
HRMS (ED: Found: 345.1603 (M)+, Calculated: 345.1603.
3,5.53) [4-(Benzoxazol-2-ylamino)phenyl]-(2^-dimethylphenyl)metlianol 83
White solid (99 %), mp: 157-158 °C. tl.c  system: petroleum ether-ethyl 
acetate 2:1, Rf= 0.54.
*H NMR: 8  (DMSO-*/*): 10.54 (bs, 1H, NH), 7.71 (d, 2H, J= 8.4 Hz, Ar),
7.49 (d, 1H, J= 7.7 Hz, Ar), 7.45 (d, 1H, J= 7.7 Hz, Ar), 7.36 (s, 1H, Ar), 7.30 (d, 
2H, J= 8.4 Hz, Ar), 7.22 (m, 1H, Ar), 7.17 (m, 1H, Ar), 7.02 (m, 2H, Ar), 5.84 (s, 
1H, H-7), 5.70 (bs, 1H, OH), 2.32 (s, 3H, CH3), 2.20 (s, 3H, CH3).
13C NMR: 8  (DMSO-d6): 158.04 (C, C-2”), 147.00 (C, C-9”), 142.97 (C, C- 
4’), 142.42 (C, C -l), 138.32 (C, C-8 ”), 137.25 (C, C-5), 134.32 (C, C-2), 131.38 (C, 
C -l’), 129.94 (CH, C-3), 127.51 (CH, C-2’, C-6 ’), 127.14 (CH, C-6 ), 126.93 (CH, C- 
4), 123.92 (CH, C-5”), 121.53 (CH, C-6 ”), 117.31 (CH, C-3’, C-5’), 116.48 (CH, C- 
4”), 108.85 (CH, C-7”), 71.06 (CH, CH-OH), 20.81 (CH3), 18.57 (CH3).
HRMS (ED: Found: 345.1599 (M)+, Calculated: 345.1603.
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3.5.6) General procedure for the preparation o f the Benzoxazol-2-vl- {-
4rdimethvlDhenvI)imidazol-l-vlmethvllDhenv}amine 84. 85 and 86
r 94, R1= H, R2= CH3^  
R3= CH3, R4= H
85, R1= CHg, R2= H, 
R3= CH3, R4= H
86, R1= CH3, R2= H,
1 -1'-carbodiim idazole 
imidazole, CH3CN
81-83
To a solution of 81-83 (1.89 mmol) in CH3CN (70 mL) was added imidazole 
(5.66 mmol) and L l’carbodiimidazole (2.83 mmol). The mixture was heated under 
reflux overnight, then the reaction mixture was allowed to cool and the solvent 
removed under reduced pressure. The oil formed was extracted with CH2CI2 (50 mL) 
and washed with H2O (2 * 50 mL). The organic layer was dried (MgSC>4), filtered 
and reduced in vacuo.
3.5.6.1) Benzoxazol-2-yl-{-4[3,4-dimethylphenyl)imidazol-l-
ylmethyl]phenyl}amine (84)
Purification by column chromatography (EtOAc) gave the product as a white 
solid (78 %), mp: 238-239 °C. tl.c  system: ethyl acetate, Rf= 0.18.
*H NMR: 6  (CDC13): 10.11 (bs, 1H, NH), 7.58 (d, 2H, J= 8 . 6  Hz, Ar), 7.42 (s, 
1H, Ar), 7.33 (d, 1H, J= 7.8 Hz, Ar), 7.19 (d, 1H, J= 7.8 Hz, Ar), 7.06 (m, 2H, Ar),
6.98 (m, 4H, Ar), 6.76 (m, 2H, Ar), 6.70 (d, 1H, J= 7.8 Hz, Ar), 6.30 (s, 1H, H-7), 
2.13 (s, 3H, CH3), 2.09 (s, 3H, CH3).
13C NMR: 8  (CDCI3): 157.60 (C, C-2’”), 146.68 (C, C-9’”), 141.11 (C, C-4 ”),
137.74 (C, C-8 ’” ), 136.18 (C, C -l), 135.88 (CH, C-2’), 135.41 (C, C-3), 132.18 (C, 
C-4), 129.02 (C, C -l”), 128.15 (CH, C-5), 127.83 (CH, C-2”, C-6 ”), 127.51 (CH, C-
2), 124.34 (CH, C-5’), 124.21 (CH, C-4’), 123.12 (CH, C-6 ), 122.65 (CH, C-5’”),
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120.70 (CH, C-6”’), 117.44 (CH, C-3”, C-5”), 115.85 (CH, C-7”’), 108.01 (CH, C- 
4’”), 63.59 (CH, CH-N), 18.80 (CH3), 18.41 (CH3, C).
HRMS (ED: Found: 395.1874 (M)+, Calculated: 395.1872.
3.5.6.2) Benzoxazol-2-yl-{-4[2,4-dimethylphenyl)imidazol-l-
ylmethyl]phenyl}amine (85)
Purification by column chromatography (EtOAc) gave the product as a 
colourless oil (84 %). tl.c  system: ethyl acetate, R f = 0.11.
*HNMR: 6 (CDC13): 10.32 (bs, 1H, NH), 7.62 (m, 2H, Ar), 7.33 (m, 2H, Ar),
7.19 (m, 1H, Ar), 7.09 (m, 2H, Ar), 6.96 (m, 4H, Ar), 7.85 (m, 1H, Ar), 6.77 (s, 1H, 
Ar), 6.55 (m , 1H, Ar), 6.48 (s, 1H, H-7), 2.20 (s, 3H, CH3), 2.08 (s, 3H, CH3).
13C NMR: 6 (CDC13): 157.50 (C, C-2’” ), 146.70 (C, C-9’”), 141.32 (C, C-4’), 
137.90 (C, C-8’”), 137.13 (CH, C-2’), 136.41 (C, C -l), 134.91 (C, C-2), 133.52 (C, 
C-4), 131.38 (C, C -l”), 130.68 (CH, C-3), 127.90 (CH, C-2”, C-6”), 127.67 (CH, C-
6), 126.44 (CH, C-5), 126.00 (CH, C-5’), 123.07 (CH, C-4’), 120.69 (CH, C-5’”),
118.83 (CH, C-6’”), 117.44 (CH, C-3”, C-5”), 115.95 (CH, C-4’”), 107.98 (CH, C- 
7’”), 60.69 (CH, CH-N), 20.02 (CH3, C), 18.02 (CH3, C).
HRMS (ED: Found: 395.1871 (M)+, Calculated: 395.1872.
3.5.63) BenzoxazoI-2-y 1- {-4 12,5-d i m ethy lpheny I )im idazol-1 -
ylmethyl]phenyl} amine (86)
Purification by column chromatography (EtOAc) gave the product as a 
colourless oil (72 %). tl.c  system: ethyl acetate, Rf= 0.09.
*H NMR: 8 (CDC13): 9.82 (bs, 1H, NH), 7.63 (d, 2H, J= 8.6 Hz, Ar), 7.36 (d, 
2H, J= 8.2 Hz, Ar), 7.22 (d, 1H, J= 7.8 Hz, Ar), 7.11 (m, 2H, Ar), 6.99 (m, 5H, Ar),
6.80 (s, 1H, Ar), 6.54 (s, 1H, Ar), 6.47 (s , 1H, H-7), 2.15 (s, 3H, CH3), 2.07 (s, 3H, 
CH3).
13C NMR: 8 (CDC13): 157.36 (C, C-2’”), 146.71 (C, C-9’”), 141.24 (C, C-4”),
137.74 (C, C-8’”), 136.42 (C, C -l), 136.16 (CH, C-2’), 135.02 (C, C-5), 131.90 (C, 
C-2), 131.25 (C, C -l”), 129.81 (CH, C-3), 129.18 (CH, C-6), 128.08 (CH, C-2”, C- 
6”), 127.67 (CH, C-4), 126.88 (CH, C-5’), 123.14 (CH, C-4’), 120.79 (CH, C-5’”),
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118.89 (CH, C-6”’), 117.40 (CH, C-3”, C-5”), 116.01 (CH, C-4”’), 108.03 (CH, C- 
7”’), 60.89 (CH, CH-N), 20.15 (CH3), 17.69 (CH3).
HRMS (ED: Found: 395.1868 (M)+, Calculated: 395.1872.
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CHAPTER 4
Haem and haem model binding
studies
1) INTRODUCTION
The geometrical relationship between the iron atom of the haem and the 
nitrogen donor atom of the axial ligand acts as a major factor for the P450 inhibitors 
activity187. Nitrogen donor ligands can form covalent complexes with the iron atom 
of porphyrins188; it has consequently been proposed that some CYP26 drugs 
containing an aza-ring might coordinate to a porphyrin haem iron via a Fe-N 
covalent bond. It is well established that this coordination can be studied using 
NMR189, mass spectrometry190,191, UV-VIS spectroscopy192 and X-ray 
crystallography193. This field has been especially investigated to study the 
mechanism of antimalarial drug-haem complex194,195.
The haem of the P450 enzymes active site is a ferriprotoporphyrin IX 
(Fe(III)PPIX) containing a single iron coordinated to four planar pyrrole nitrogen 
atoms (Figure 4.1). This complex is commercially available with either chlorine 
(hemin) or hydroxyl group (hematin) coordinated in the axial position to the iron 
atom. The complex with the chlorine substituent has been chosen because it appeared
187 Kkins S., De Groot M.J. and Jones J.P.; Pharmacophore and three-dimensional quantitative 
structure activity relationship methods for modeling cytochrome P450 active sites. Drug Met. Dispo., 
2001,29, 936-944.
188 Munro O.Q., Madlala P.S., Warby R.A.F., Seda T.B. and Madsen S.K.; Structural, 
Conformational, and Spectroscopic Studies o f Primary Amine Complexes o f Iron(II) Porphyrins. 
Inorg. Chem., 1999, 38,4724-4736.
189 Alam S.L. Volkman B.F., Markley J.L. and Satterlee J.D.; Detailed NMR analysis of the heme- 
protein interactions in component IV Gtyceria dibranchiate monomeric hemoglobin-CO. J. Biomol. 
NMR, 1998,11 ,119-133.
190 Vinokur N. and Ryzhov V.; Using collision-induced dissociation with corrections for the ion 
number of degrees o f freedom for quick comparisons of relative bonding strength. J. Mass Spec., 
2004, 3 9 ,1268-1274.
191 Breuker K.; New mass spectrometric methods for the quantification o f protein-ligand binding in 
solution. Angew. Chem. Int. Ed., 2004,43,22-25.
192 Kelly J.X., Winter R., Riscoe M. and Peyton D.H.; A spectroscopic investigation of the binding 
interactions between 4,5-dihydroxyxanthone and heme. J. Inorg. Biochem., 2001,86,617-625.
193 Little R.G., Dymock K.R. and Ibers J.A.; The crystal and molecular structure of the 
ferrihemochrome bis( 1 -methylimidazole)-(protoporphyrin DQiron-methanol-water. J. Am. Chem 
.Soc., 1975,97,4532-4539.
194 Leed A., Du Bay K., Ursos L.M.B., Sears D., De Dios A.C. and Roepe P.D.; Solution structures of 
antimalarial drug-heme complexes. Biochem., 2002,4 1 ,10245-10255.
193 Egan TJ.; Interactions of quinoline antimalarials with hematin in solution. J. Inorg. Biochem., 
2006,5 ,916-926.
152
to be more soluble (and thus easier to study) than the hydroxyl analogue. It has 
shown good solubility in DMF and DMSO.
A study of the binding of the benzoxazol-2 -yl-[phenylimidazol-1 - 
ylmethyl)phenyl]amine inhibitors to this complex could provide a rich source of 
information on the nature of the metal-ligand bonding involved in inhibition. It could 
show the influence of the type of aza-ring (imidazole, 1,2,4 triazole, 1,3,4 triazole 
and tetrazole) and the type of substituents (hydrogen, methyl, methyl ester and 
carboxylic acid) on the interaction between the drug and the haem. The data could 
then be correlated with the inhibitory activity of these compounds in order to 
determine the relative importance of ligand-iron interaction compared with the non- 
covaient ligand-protein interactions (e.g. 7i-stacking, hydrogen bonding and 
hydrophobic interactions).
HOOC
COOH
Figure 4.1: Structure of the haem used for this study (hemin).
A useful data on the haem-ligand binding interaction will be the 
determination of the ligand binding constant (or equilibrium constant) K  which 
expresses the balance between the binding and dissociation processes after infinite 
reaction time (Figure 4.2) and has long been employed as an effective measure of the 
affinity of a ligand for a metal ion in solution196. In order to determine the binding 
constant of the ligand, it is necessary to first determine the stoichiometry of the
196 Martell A.E. and Motekaitis R.J.; Determination and use o f stability constants. VCH Publishers, 
Inc, New York, 1988, p .l.
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reaction and the number of species present in solution. In the case of haem, the 
central iron atom has two available binding sites; so it is possible to form the mono­
substituted complex HL, the di-substituted complex HL2 (Figure 4.3) or even to have 
a mixture of both.
H + nL HLn binding constant
„  L= ligand
[HL] *
K= ---------------  H= haem
[H ][Lf
Figure 4.2: Expression of the binding constant K.
HL
Figure 4.3: Structure of the haem-ligand complex HL and HL2 .
To determine the binding constant of the different ligands, a few different 
spectroscopy techniques were investigated: mass spectrometry, X-ray
crystallography, lH NMR and UV/VIS spectroscopy. Because the analysis is 
performed in the gas phase, the mass spectra do not provide an accurate description 
of the haem-ligand binding in solution; however it provided useful data on the 
different species formed during the reaction. X-ray analysis of a haem-ligand crystal 
will be the most useful and accurate source of information especially on the 
properties (length, angle) of the Fe-N covalent bond and the stoichiometry of the 
reaction. Formation of the complex should also be easily identified by !H NMR and 
UV/VIS spectroscopy. The addition of a haem solution into a ligand solution or the 
inverse should lead to the progressive appearance of new peaks or new bands 
corresponding to the haem-ligand complex189. The ratio observed between the bound
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and unbound ligand or haem in NMR and UV/VIS spectrometry at different 
concentrations could then be used to determine the value of the binding constant K.
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2) MASS SPECTROMETRY STUDIES
The formation of the haem-ligand complexes for 52, 53, 53’ and 54 was first 
studied using mass spectrometry. The mass spectrometry study presents some 
limitations. The presence of a complex in solution is not always correlated with the 
observation of the corresponding species in the gas-phase spectrum197. Also, as 
dissociation processes could emerge during the ionisation process, the intensity of 
the peaks is not always correlated with the real concentration of the species. 
However, it will allow us to clearly identify (although it will be difficult to quantify) 
the products formed during the reaction (HL, HL2) as well as the interaction of the 
haem with the different solvents. Thus it will be a good technique to study the 
stoichiometry of the reaction.
2.1) Material and method
Because of its poor solubility (only soluble in DMSO and DMF), hemin 
could not be used in these experiments in our laboratory, it was replaced by a similar 
and more soluble iron porphyrin: 5,10,15,20-tetraphenyl-2lH,23H-porphine- 
iron(III)-chloride or TPP (Figure 4.4) which showed good solubility in chlorinated 
solvents. Spectra were recorded on a Micromass LCT premier XE using an electro­
ionisation technique (ESI-MS).
A titration of TPP using four different ligands (52, 53, 53’ and 54) was 
performed. Eleven samples each containing a 50 pL mixture of a 2 mM solution of 
TPP in CH2CI2 and a 2 mM solution of ligand in CH2CI2 diluted in 1 mL of a 50:50 
mixture of acetonitrile and water with 1 % of formic acid were used for this study.
197 Clark M.S. and Konermann L.; Diffusion measurements by electrospray mass spectrometry for 
studying solution-phase noncovalent interactions. J. Am. Soc. Mass Spec from., 2003,14,430-441.
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Figure 4.4: Structure of 5,10,15,20-tetraphenyl-21H,23H-porphine-iron(III)- 
chloride or TPP.
2.2) Experimental results and discussion
Although the mass spectra are difficult to interpret because of the molecular 
dissociation observed during the ionisation process, the experiments clearly showed 
the presence of haem-ligand species (HL and HL2) for all the ligands (52,53,53’ and 
54) and could provide a rich source o f information on the stoichiometry of the 
reaction and on the affinity between the haem and the different solvents (CH2CI2, 
CH3CN, H2O, HCOOH) used for the experiment.
The TPP spectrum, shown on Figure 4.5, displayed 5 characteristic peaks. 
The presence of the TPP peak at 6 6 8  Da instead of 704 Da showed that the chloride 
ion is lost during the ionisation process. A lose of the chloride ion was also observed 
for all the other peaks; however the addition of a solution of silver nitrate to the 
solution showed no precipitation. The low intensity of the peak also proved that the 
haem always tend to have a sixth substitution by ligand or the different solvents. The 
peak at 709 Da represents one molecule o f haem bonded to acetonitrile, the two 
peaks at 1353 Da and 1381 Da represent respectively a molecule of water and a 
molecule of formic acid bond to two molecules of haem (Figure 4.6). This 
demonstrates that the stoichiometry of binding for acetonitrile and water and formic 
acid is different. The acetonitrile is binding to only one molecule of haem while
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water and formic acid seem to be responsible of aggregation of haem molecule 
(Figure 4.6). On the other hand, the presence of a dichloromethane-haem complex 
was not observed. This could be explained by the number of lone pair available for 
iron binding in these solvents (one on the acetonitrile nitrogen atom and two on the 
water oxygen atom, Figure 4.6).
HEME SP99 53 (0.439) 
100
VCHJ 143# 
1254 6516
709.1438
1: TOF MS ES+ 
1353.1814 5.26e3
668 1425
710.1678
1352.2589 
1254.6516
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400
Figure 4.5: Mass spectrum of TPP.
Then, titration of TPP was performed with 4 different ligands 52, 53, 53’ and 
54. These experiments were designed to provide information on the binding 
properties of these ligands with iron porphyrin. An example is shown on Figure 4.7 
with ligand 52.
On the first addition of ligand (B), the spectrum displayed two new peaks at 
299 Da and 1034 Da. The 299 Da peak is the main ligand peak corresponding to 52 
minus its imidazole ring, previous experiments have shown that loss of the imidazole 
ring (or other type of aza-ring) is often observed during the ionisation process. The 
1034 Da peak showed the formation of the haem-ligand complex.
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N; N
H3C,
N: N N N N N
Figure 4.6: Structure of TPP-solvent (CH3CN, H2O and HCOOH) complexes 
observed in the mass spectrum.
On the next addition (spectrum C), the “full” ligand peak appeared at 367 Da 
and a new complex involving a di-substitution of the haem by 52 also emerged at 
1400 Da. Spectrum D was obtained using an equal concentration of haem and ligand 
(47.61 fiM). It shows a big increase of the di-substituted species as well as new peak 
at 733 Da corresponding to the haem bound to free imidazole which is a consequence 
of the fragmentation of the ligand.
In the next spectra (spectrum E and F), equilibrium between the mono­
substituted and the di-substituted species seem to be reached. The two species seem 
to exist at more or less equivalent intensity. This could be explained by some 
decomposition of the di-substituted complex. The last two spectra (E and F) also 
showed a slow disappearance of the haem + solvent peaks (haem + H2O, haem + 
CH3CN and haem + HCOOH), although the concentration of solvent is obviously 
much higher than the concentration of ligand (E: [52] = 6 6 . 6 6  pM and F: [52] = 
104.76 pM while [H20 ] = 27.5 M, [CH3CN] = 9.5 M and [HCOOH] = 0.26 M). 
When the haem/ligand ratio gets to 1:10 (F, [52] = 104.76 pM), hardly any more 
haem + solvent species are observed, the peak at 1353 Da (water + 2 haem) has 
completely disappeared and the peaks at 709 Da (haem + acetonitrile) and 1381 Da 
(formic acid + 2 haem) are very minor compare to the two haem-ligand peaks. This
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shows that 52 is a much better ligand than acetonitrile, water and formic acid, as, 
even when its concentration is much lower than all the solvent (about 100000 fold), it 
still competes successfully for binding.
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Figure 4.7: Mass spectra of TPP titration with the imidazole ligand 52, 
concentration of haem and ligand are indicated on the right of the spectrum.
Mass spectrometry is therefore a good technique to observe the evolution of 
the formation of different species. It allowed us to draw some conclusions on the
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behaviour of the ligands and on the formation of mono or di-substituted haem 
complexes.
The evolution of the formation of the three species (free haem, mono­
substituted haem-ligand complex and di-substituted haem-ligand complex), 
depending on the ligand/haem concentration ratio, is shown on Graph 1. This graph 
displays the percentage of each of the three species without considering any other 
peaks.
haem titration by 52
120
100
haem
haem + 1 ligand 
haem + 2 ligand
60
40
20
-20
Graph 1: Percentage of haem, mono-substituted haem-ligand complex and di- 
substituted haem-ligand complex function of the ligand/haem concentration ratio for
52. Concentrations of haem and 52 for each experiment are shown in Figure 4.4.
This graph clearly shows a disappearance of free haem and formation of first 
the haem + 1 ligand complex followed by the formation of the di-substituted species. 
The percentage of the three different species seems to stay constant at high 
concentration of ligand. Also the di-substituted compound never becomes the major 
species and the free haem never completely disappears. The presence of free haem at 
high concentration of ligand might be explained by the decomposition in the mass 
spectrometer of a certain proportion of complexes.
The following graphs show the evolution of the same three species with the 
other ligands 53 (Graph 2), 53’ (Graph 3) and 54 (Graph 4).
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haem titration by 53
p ig an d ]/[h aem ]
haem
haem + 1 ligand 
haem + 2 ligand
Graph 2: Percentage of haem, mono-substituted haem-ligand complex and di- 
substituted haem-ligand complex function of the ligand/haem concentration ratio for
53. Concentrations used for this experiment are similar to concentrations of haem 
and ligand with 52 shown in Figure 4.4.
Concerning ligand 53 (Graph 2), almost no haem + 2 ligand species was 
observed, it never goes above 5 %. On the other hand the formation of the mono­
substituted complex was observed at very low concentration of ligand ([53] = 9.47 
pM). At a ligand/ haem concentration ratio of 0.5, half of the haem is already bound 
to one ligand. Then, the free ligand peak disappears completely when the 
concentration of ligand is double the concentration of haem.
The 1,3,4-triazole ligand 53’ display similar result to the imidazole 52 with 
the difference that no more free haem was observed when the concentration of ligand 
become higher than the concentration of haem (Graph 3). The presence of both 
haem-ligand species seems to stay constant after the concentration of ligand is more 
than double the concentration of haem. The chaotic curve of the percentage of haem 
+ 1 ligand and haem + 2 ligands is probably due to the ionisation dissociation 
process of the di-substituted complex and shows the limitation of the technique.
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haem titration by 53'
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Graph 3: Percentage of haem, mono-substituted haem-ligand complex and di- 
substituted haem-ligand complex function of the ligand/haem concentration ratio for 
53’. Concentrations used for this experiment are similar to concentrations of haem 
and ligand with 52 shown in Figure 4.4.
haem titration by 54
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100
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Graph 4: Percentage of haem, mono-substituted haem-ligand complex and di- 
substituted haem-ligand complex function of the ligand/haem concentration ratio for
54. Concentrations used for this experiment are similar to concentrations of haem 
and ligand with 52 shown in Figure 4.4.
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The tetrazole compound 54 displayed similarities with compound 53, but the 
formation of the haem + 2 ligand complex was not observed at all for 54 (Graph 4). 
As well as 53, an equal amount of free haem and haem + 1 ligand species was 
observed for a concentration ratio ligand/haem of 1:1. The haem is bound at 100 % 
to 54 for a haem/ligand ratio of 9:1.
In conclusion, although the techniques showed some limitations (the shape of 
the curve is occasionally chaotic), these mass spectrometry experiments provided a 
rich source of information on the binding properties of the ligands. Two different 
behaviours seem to occur. Experiments with ligand 52 and 53’ showed the formation 
of both the mono and the di-substituted complexes. Above a ligand/haem ratio of 2:1, 
the two species were present in more or less equal quantities in the gas phase. In the 
case of compound 53 and 54, the percentage o f the di-substituted complex was very 
low or even null for 54. For 53, the ligand bound species become major for a 
ligand/haem ratio of 0.25 and about 0.75 for 54. The disappearance of the haem peak 
also happened at lower concentration of ligand with compound 53. This might 
suggest that the 1,2,4-triazole compound 53 is a better ligand than the tetrazole 54. 
All compounds also appeared to be much better ligands than all the solvents present 
in solution (water, acetonitrile and formic acid).
However, as the mass spectrometry data are recorded in the gas phase and 
display the presence o f positively charged molecules in an excited state, the 
experiments do not accurately reflect what is actually happening in solution with 
ground state neutral molecules. It has been shown that false negative and false 
positive results could be obtained when the solution phase complexes dissociate prior 
to detection 195,198. It was thus not possible to draw any quantitative conclusions on 
the binding properties of our ligands, such as a binding constant calculation, using 
these mass spectrometry data But we could safely conclude that both the mono­
substituted (HL) and the di-substituted complexes (HL2) are formed and thus need to 
be considered in other experiments where the mono-substituted complex HL and the 
di-substituted complex HL2 might have similar spectra
198 Cunniff J.B. and Vouros P.; False positives and the detection of cyclodextrin inclusion complexes 
by elctrospray mass spectrometry. J. Am. Soc. Mass Spectrom., 1995, 6 ,437-447.
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3) FORMATION OF COMPLEXES AND X-RAY 
CRYSTALLOGRAPHY STUDIES
A crystal structure of hemin or TPP bound to one of our ligands would be the 
most useful source of information on the binding geometry of the ligand. It would 
provide accurate data on the distance of the axial Fe-N bond for all the different 
ligands and the stoichiometry of the reaction.
#
Figure 4.8: Stereoscopic view of the contents of one unit cell of the hemin- 
methylimidazole crystal structure193.
Although only few X-ray structures of substituted haem system were found in
1 QQthe literature, a crystal structure of imidazole bound to TPP and a crystal structure 
of methyl imidazole bound to hemin193 have been achieved. They should display 
similar binding properties to our imidazole ligand 52. The crystal structure of the 
hemin-methylimidazole complex is shown on Figure 4.8. The two axial Fe-N bond
199 Collins D.M., Countryman R. and Howard J.L.; Stereochemistry o f low-spin iron porphyrins. I. 
Bis(imidaz»le)-a^,y,<5-tetraphenylporphinatoiron(III) chloride. J. Am. Chem. Soc., 1972, 94, 2066- 
2072.
167
lengths are 1.966 A and 1.988 A and the average porphyrin Fe-N bond length is 
1.990 A. In this structure, the two propionate groups of the porphyrin core are 
connected together by a bridging water molecule.
The crystal structure of the imidazole-TPP complex (Figure 4.9) displayed
length of 1.990 A, all very similar to the hemin-methylimidazole structure. The 
complex also displays a very effective symmetry as it contains several plan of 
symmetry and the iron atom is the centre of symmetry of the complex.
In both crystals, the lengths of the two axial Fe-N bonds are non-equivalent. 
This could be explained by a small out of plane displacement of the iron atom of 
0.009 (± 0.003) A and also by the different steric interactions of the imidazole 
hydrogen atom with the porphyrin core.
Figure 4.9: Computer-drawn models of at left the imidazole-TPP (In^FeTPP)
I QQ
complex and at right the coordination group .
5 % aqueous solution of KOH and then precipitated by addition of AcOH in order to 
remove the chloride ion. After being washed thoroughly with dilute AcOH, the solid 
was dissolved in a 1:1 mixture of CHCls/MeOH containing the ligand 52. Then the 
sample was left to slowly evaporate for a few days until crystallisation occurred.
two Fe-N bond lengths of 1.957 A and 1.991 A and an average porphyrin Fe-N bond
1 02Then, Little et al. method’s for the formation of hemin-methylimidazole 
crystal was applied to the formation of a hemin-52 crystal. Hemin was dissolved in a
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After 3 days black crystals formed on the bottom of the flask, unfortunately 
none of them were suitable for X-ray analysis. Consequently, the solid was collected 
and washed with a mixture o f CHCI3 and MeOH. Elemental analysis of the solid 
confirmed the formation of the complex as well as a 1 : 2  haem/ligand stoichiometry. 
Unfortunately, the poor solubility o f the complex did not allow us to perform NMR 
and UV/VIS analysis and no conclusion could be draw from the IR analysis because 
of the poor resolution of the peaks.
Many different techniques such as layering and slow evaporation and 
different solvents (MeOH, CHCI3 , CH2CI2 , hexane, petroleum ether, diethyl ether, 
H2O) were investigated with unfortunately no success in gaining X-ray quality 
crystals both with hemin and TPP.
- Experimental procedure:
Hemin (0.4 g, 0.61 mmol) was dissolved in 40 mL of 5 % aqueous KOH and 
then precipitated by the addition of conc. AcOH. The precipitated solid was filtered 
off and washed with dilute AcOH. The dissolution and precipitation procedure was 
repeated until the filtrate was free from chloride ion, as indicated by the absence of a 
precipitate upon the addition of silver nitrate to the filtrate.
The washed, but still moist, solid was dissolved in 60 mL of a 1:1 mixture of 
CHCI3 and MeOH containing 52 (0.6 g, 1.59 mmol). The solution was filtered to 
remove any undissolved material, the volume reduced to one third and more 
methanol added. The flask was then left to slow evaporation for 3 days. Then the 
precipitated black solid was collected and washed with a mixture of CHCI3 and 
methanol. Anal, calcd. For CgoHksFeN^Oe: C, 71.21; H, 5.08; N, 12.46. Found: C, 
71.16; H, 4.81; N, 14.20. The NMR analysis of the solid was impossible because of 
its limited solubility.
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4) *H NMR STUDIES
NMR spectroscopy has become one of the most important methods for 
determining the binding constant o f two molecules in solution200. NMR has been 
the most widely used NMR technique and will be used in our study; however it is 
also possible to use 13C NMR201, 15N NMR202, 3!P NMR293 and NOESY204. This 
method uses the difference between the chemical shifts of the free ligand spectrum 
and the haem-ligand complex spectrum. Also, as paramagnetic iron atom exerts 
space effects on the relaxation rate o f nearby proton spins depending on the iron- 
proton distance194, it is possible to calculate the distance between the haem iron and 
the different proton ligand using the Solomon-Bloembergen equation205,206 (Figure 
4.10).
Tj: complex longitudinal
relaxation time
S: total electron spin
r: distance between the proton and
the paramagnetic Fe
rc: effective correlation time
200 Funasaki N., Nomura M., Ishikawa S. and Neya S.; NMR chemical shift references for binding 
constant determination in aqueous solutions. J. Phys. Chem. B, 2001,105, 7361-7365.
201 Rivera M. and Caignan G.A.; Recent developments in the 13C NMR spectroscopic analysis of 
paramagnetic hemes and heme protein. Anal. Bioanal. Chem., 2004,378,1464-1483.
Modi S., Behere D.V. and Mitra S.; 1H and 15N-NMR study o f the binding of thiocyanate to 
chemically modified horseradish peroxidase and involvement o f saly bridge. Biochim. Biophys. Acta, 
1994,1204,14-18.
203 Kabil O., Toaka S., Lo Brutto R., Shoemaker R. and Baneijee R.; Pyridoxal phosphate binding 
sites are similar in human heme-dependant and yeast heme-independant cystathionine P-synthase. J. 
Biol. Chem., 2001,276, 19350-19355.
204 Band L., Bertini I., Marconi S., Pierattelli R. and Sligar S.G.; Cytochrome P450 and aromatic 
bases: a NMRstudy. J. Am. Chem. Soc., 1994,116,4866-4873.
205 Martinez A., Olafsdottir S. and Flatmark T.; The cooperative binding o f phenylalanine to 
phenylalanine 4-monooxygenase studied by NMR paramagnetic relaxation. Eur. J. Biochem., 
1993,211,259-266.
206 Novak R.F. and Vatsis K.P.; *13 Fourier transform nuclear magnetic resonance relaxation rate 
studies on the interaction o f acetanilide with purified isozymes o f rabbit liver microsomal cytochrome 
P-450 and with cytochrome b* Mol. Pharmacol., 1982,21 ,701-709.
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ytf- nuclear gyromagnetic ratio 
ge: Lande factor for the metal ion 
Ho and Bohr magneton
Figure 4.10: Solomon-Bloembergen equation
4.1) Materials and method207
All the spectra were recorded on a Bruker DPX400 and TMS was used as the 
internal standard. The chemical shifts are given in parts per million (ppm). NMR 
samples were prepared using 500 pL o f a 1 mM solution of ligand in DMSO-d*. To 
these samples 50 or 100 pL aliquots o f a 2 mM solution of hemin in DMSO-^ were 
added. In order to keep the concentration o f ligand constant during the experiment, 
the hemin solution also contained 1 mM of ligand.
4.2) Experimental results and discussion
lH NMR spectroscopy has been shown to be a useful technique to study the 
interaction between a drug and a haem species. The broadening and the shift 
observed in the ligand peaks could be used to calculate the binding affinity of this 
ligand with the haem208. These changes in the NMR spectra are due to the influence 
of the paramagnetic iron on the ligand protons and are proof of the covalent binding 
between the haem and the ligand. It has been shown that the closer a particular 
proton on the ligand is to the Fe3+ atom, the greater the induced chemical shift194,208. 
Increasing the [ligand]/[hemin] molar ratio should also display a progressive 
modification of the chemical shift o f some protons which could be used to calculate
207 Yao Y., Qian C., Wu Y., Hu J. and Tang W.; *H NMR study of 2-methylimidazole binding to 
cytochrome c: a comprehensive investigation o f the role o f the methyl substituent on the ligand 
binding affinity and haem electronic structure in imidazole-cytochrome c complexes. J. Chem. Soc., 
Dalton Trans., 2001, 1841-1845.
208 Palma P.N., Moura I., Le Gall J., Van Beeumen J., Wampler J.E. and Moura J J.G.; Evidence for a 
ternary complex formed between flavodoxin and cytochrome c3: NMR and molecular modelling 
studies. Biochem., 1994,33 ,6397-6407.
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the ligand binding constant. Changes in the NMR spectrum of the ligand upon the 
addition of a hemin solution were consequently investigated.
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Figure 4.11: Changes in the NMR spectrum of a ImM solution of 52 upon 
the addition of hemin, concentration of hemin is respectively from the top to the 
bottom: 0 mM, 0.18 mM, 0.46 mM, 0.66 mM, 0.82 mM, 1 mM.
A spectrum of the ligand itself in DMSO-*4 was first recorded and then a 2 
mM hemin solution in DMSO-<4 also containing ImM of ligand was slowly added to 
the tube. The results undoubtedly confirmed the binding of ligand 52 to the haem 
iron. Even with a low concentration of hemin, a broadening of some peaks as well as 
a large downfield shift o f their value was observed for the imidazole ligand 52. The 
shift in the peaks concerned the NH proton at 10.75 ppm (which does not appear in 
the original ligand spectrum), the three imidazole protons and the CH singlet H-7 
which resulted in the formation o f 5 new broad singlets at 10.82 ppm, 10.35 ppm, 
10.18 ppm, 8.20 ppm and 7.96 ppm (Figure 4.11). This shows that these protons are 
the closest from the haem iron and thus confirms the coordination of the imidazole
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ring of 52 with the iron atom of the haem via a Fe-N bond. The large broadening of 
all the other peaks also confirms that all the ligand protons are relatively close from 
the haem iron. Due to the large number of aromatic proton in the ligand, it was 
unfortunately impossible for us to assign the new peaks and thus to determine the 
distance between the different protons and the haem.
The plot of the percentage of bound ligand on the concentration of hemin 
(Graph 5) shows that no evolution in the formation of the complex was observed 
when the concentration of hemin was higher than the concentration of ligand. No 
more than 75 % of the ligand binds to the haem, this can be explained by the 
formation of DMSO bridged haem or haem aggregation at high concentration of 
haem. This graph also confirms the 1:2 stoichiometry as 50 % of the ligand is bound 
to some haem at a haem/ligand concentration ratio of 1:4.
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7 0 -
6 0 -
20 -
1 0 -
0.0 0.2 0.4 0.6 0.8 1.0 1.2
[haem] mM
Graph 5: Percentage of bound ligand 52 depending on the concentration of 
haem, the concentration of ligand is constant at ImM.
The experiment was then repeated with ligand containing different azole 
rings such as the 1,2,4-triazole derivative 53, the 1,3,4-triazole derivative 53’ and the 
tetrazole 54, however no shifts or broadening of their peaks were observed. So the 
binding of these ligands with the haem iron observed in the gas phase in the mass
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spectrometry studies (Graph 2, 3 and 4) could not be confirmed in solution with *H 
NMR spectrometry.
Changes in the NMR 52 spectra upon the addition of a haem solution 
undoubtedly confirmed the binding of ligand 52 to the haem iron as well as the 1:2 
stoichiometry for the complex. However, the large number of aromatic peaks in the 
ligand did not allow us to assign all the peaks and consequently to use the Solomon- 
Bloembergen equation (Figure 4.10) to measure the distance between the different 
ligand protons and the haem iron. Another technique should therefore be used in 
order to calculate the ligand binding constant.
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5) UV/VIS ANALYSIS AND DETERMINATION 
OF THE BINDING CONSTANT
5.11 UV/VIS analysis
Another useful technique to determine the binding constant of ligands with 
haem is to measure the changes in the UV/VIS spectra of the haem upon the addition 
of ligand192. Addition of ligand to a solution of haem should lead to the formation of 
new bands characteristic o f the haem-ligand complex which can then be used to 
determine the binding constant. The UV/VIS experiments present major advantages 
compared to !H NMR. The measurement o f a UV/VIS spectrum is very fast and 
allowed us to perform a large number o f experiments in a relatively short time. The 
use of very dilute solutions (about 1000 fold more diluted than lH NMR solution) 
was also an advantage as experiments only consumed a very small amount of 
compounds.
The UV/VIS spectrum of the haem molecule is characteristic. It shows a very 
strong absorption band in the high energy region (390-450 nm) of the spectrum 
called the Soret band or B-band and a range of smaller bands in the visible region 
(450-700 nm) called the visible bands or Q-bands. These bands are susceptible to 
changes with the oxidation state and/or ligation of the haem iron atom.
Studies by Egan et ah209 on the effect of solvent on the interaction of 
quinoline antimalarials with hemin showed that a 40 % aqueous DMSO media is an 
excellent model of pure aqueous media. This solvent system also has the advantage 
of maintaining hemin in a monomeric state instead of the p-oxo dimer observed in 
pure aqueous media210. In this medium, DMSO (rather than H20 ) will be coordinated
209 Egan T.J. and Ncokazi K.K.; Effects o f solvent composition and ionic strength on the interaction of 
quinoline antimalarials with ferriprotoporphyrin IX. J. Inorg. Biochem., 2004,9 8 ,144-152.
210 Collier G.S., Pratt J.M., De Wet C.R. and Tshabalala C.F.; Studies on haemin in dimethyl 
sulphoxide/water mixtures. Biochem. «/., 1979, 779,281-289.
175
t o  t h e  h a e m  a s  a n  a x i a l  l i g a n d .  T h e  u s e  o f  D M S O  w i l l  a l s o  a l l o w  u s  t o  d i s s o l v e  b o t h  
l i g a n d  a n d  h e m i n .
T h e  c h a n g e s  i n  t h e  h e m i n  a b s o r p t i o n  s p e c t r a  w e r e  m e a s u r e d  o n  a  J A S C O  
V 5 7 0  s p e c t r o m e t e r  b y  t i t r a t i o n  o f  a  1 0 0  p M  s o l u t i o n  o f  h e m i n  w i t h  a  1 m M  s o l u t i o n  
o f  i m i d a z o l e  l i g a n d  52 b o t h  i n  4 0  % a q u e o u s  D M S O .  A s  b o t h  h e m i n  a n d  52 a r e  
i n s o l u b l e  i n  4 0  %  a q u e o u s  D M S O ,  a  1 m M  s o l u t i o n  o f  h e m i n  a n d  a  1 0  m M  s o l u t i o n  
o f  52 i n  p u r e  D M S O  h a d  t o  b e  p r e p a r e d  b e f o r e  b e i n g  d i l u t e d  w i t h  a  4 0  %  
D M S O / w a t e r  s o l u t i o n .  B e c a u s e  o f  t h e i r  d i f f e r e n t  i n t e n s i t y ,  t h e  3 0 0 - 5 0 0  n m  r e g i o n  
w a s  m e a s u r e d  i n  a  1 m m  g l a s s  U V  f l a s k  a n d  t h e  4 5 0 - 7 0 0  r e g i o n  w a s  m e a s u r e d  i n  a  1 
c m  g l a s s  U V  f l a s k  i n  o r d e r  t o  u s e  t h e  s a m e  1 0 0  p M  h e m i n  s o l u t i o n .  S p e c t r a  w e r e  
b a s e l i n e  c o r r e c t e d  a n d  d i s p l a y e d  t h e  e x t i n c t i o n  c o e f f i c i e n t  ( f r o m  t h e  B e e r - L a m b e r t  
l a w )  i n s t e a d  o f  t h e  a b s o r b a n c e  ( F i g u r e s  4 . 1 2  a n d  4 . 1 3 ) .
e :  e x t i n c t i o n  c o e f f i c i e n t  
B e e r - L a m b e r t  l a w :  A  =  e * c * l  A :  a b s o r b a n c e
c :  c o n c e n t r a t i o n  o f  a b s o r b i n g  s p e c i e s  
1: p a t h  l e n g t h  o f  t h e  c u v e t t e
hemin 1 10-4 M 
ligand 9.09 10-5 M 
ligand 1.66 10-4 M 
ligand 2.31 M 
ligand 2.85 10-4 M 
ligand 3.33 10-4 M 
ligand 3.75 10-4 M 
ligand 4.12 10-4 M 
ligand 4.44 10^1 
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ligand 5 10-4 M
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The UV/VIS spectrum of hemin displays a Soret band at 400 nm and two 
visible bands at 502 nm and 626 nm. Ligand 52 displays an intense absorbance band 
at 292 nm but no absorption at higher wavelengths. Major changes in the hemin 
spectrum were observed when 52 was added to the solution and confirmed what was 
observed by NMR spectroscopy. A massive decrease in the intensity of the Soret 
band as well as the formation of a new band corresponding to the complex at 435 nm 
was observed. The most interesting information is the emergence of an isobestic 
point at 415 nm which suggest that the equilibrium involves only two different 
absorbing species present in significant concentrations throughout the titration 
(Figure 4.12).
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Figure 4.13: Changes in absorption of a 100 pM haem solution upon the 
addition of 52 in the 450-750 nm region with ligand concentrations as given in the 
legend.
A large increase in absorbance was also observed in the visible region with 
the appearance of two new bands at 534.5 nm and 561 nm (Figure 4.13). At a 
concentration of ligand of approximately 3.33 Kf4 M, no further changes in the 
absorbance spectrum were observed across the whole hemin spectrum, indicating 
that all the haem present in solution is bound to 52.
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The experiment was also performed using TPP instead of hemin as a haem 
system. Only changes in the visible part (450-750 nm) of the spectrum were 
investigated (Figure 4.14). Though the same method and concentration of haem and 
ligand were used in this experiment, the 40 % aqueous DMSO media was replaced 
by pure dichloromethane for solubility reasons. The UV/VIS spectrum of TPP is 
different from that of hemin. It displays, in the visible region, one large band at 508 
nm and three small bands at 578 nm, 652 nm and 692 nm.
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Figure 4.14: Changes in absorption of a 100 pM TPP solution upon the 
addition of 52 in the 450-750 nm region with ligand concentrations as given in the 
legend.
The addition of 52 to the solution led to dramatic changes in the TPP 
absorption spectrum (Figure 4.14). A decrease of the bands at 508, 652 and 692 nm 
was observed as well as an increase in intensity from 531 nm to 602 nm and 
formation of two new bands at 551 nm and 578 nm. The spectra also displayed three 
isobestic points at 477 nm, 530nm and 603 nm instead of only one for the hemin 
spectra which also suggest that only two different absorbing species are present in 
solution throughout the titration. These changes in the TPP absorption spectrum are
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also very similar to those observed with the imidazole titration which displayed 
isobestic points at 533 nm and 480 nm211,212.
The experiment was then repeated with different ligands. The titration of 
haem with ligands containing different azole rings, such as 1,2,4-triazole (53), 1,3,4- 
triazole (53’) and tetrazole (54) did not display any changes in the haem absorption 
spectrum (hemin and TPP), there is thus no evidence of binding o f these ligands with 
the haem in solution which confirmed what has been observed using *H NMR 
spectroscopy. On the other hand, all the other imidazole ligands such as the methyl 
derivative 59 and the methyl ester derivative 45 displayed very similar results to 
those observed for 52, suggesting that para-substitution on the phenyl does not affect 
the binding properties of the ligand and that the difference observed in their activity 
is only due to their interactions (e.g. hydrogen bonding, hydrophobic interactions) 
with the protein residues.
UV/VIS spectroscopy is thus the technique of choice for the determination of 
binding constants for these systems. The major changes in absorbance observed both 
in the spectrum of hemin and TPP upon the addition o f 52 will allow us to measure 
the concentration of complex formed at different concentrations o f haem and ligand 
and as a result to determine the binding constant of the ligand. The presence of 
isobestic points also suggests an equilibrium involving only two species; only one 
complex is formed during the reaction.
5.2) Binding constant determination
The binding constant expresses the equilibrium between binding and 
dissociation process in a reaction and could be used to quantify the affinity of 
binding of a ligand to a metal in solution (Figure 4.2). The modification in the hemin 
and the TPP absorption spectrum upon the addition of ligand 52 should allow us to 
determine the binding constants of this ligand using the changes observed in the 
haem absorbance at different concentrations of ligand.
211 Duclos J.M.; Ligand binding to metalloporphyrin. 1. Thermodynamics constants for the association 
of imidazole with tetraphenylporphyrin iron (in ) chloride in acetone. Bioinorg. Chem., 1973, 2, 263- 
274.
212 Coyle C.L., Raison PA. and Abbott E.H.; Equilibria o f imidazole with iron(IH) 
tetraphenylporphine. Inorg. Chem., 1973,12,2007-2010.
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5.2.1) Stoichiometry o f the reaction
Prior to determining the binding constant, the determination of the 
stoichiometry o f the reaction is essential. Does binding involve one or two ligands? 
Does the reaction involve a simple equilibrium between two species or equilibrium 
between three or more species?
The mass spectrometry studies suggest a mixture of the mono-substituted, the 
di-substituted complex and free haem (Graph 1); however the presence of isobestic 
points in the UV/VIS spectra (Figure 4.12) clearly proves that only two absorbing 
species are present in detectable concentrations in solution. Literature precedent211, 
213 for the binding of imidazole compounds to different haem systems also showed 
that two imidazole compounds are bound to the haem iron atom and that there is no 
evidence for the formation of the mono-substituted complex. This was confirmed by 
elemental analysis performed on our hemin-52 complex in solid form and by the two 
crystal structures o f hemin-methylimidazole193 and imidazole-TPP199. It also suggests 
that our mass spectra results showed the mono-substituted complex HL as a result of 
a decomposition of the di-substituted complex HL2 . The equilibrium can 
consequently be described by Equation 4.1:
(Equation 4.1): K= [Haem(52)2]/[Haem][52]2
The stoichiometry of the reaction can be explained by the fact that the mono­
substituted compound is high spin (S= 5/2) while the di-substituted is low spin (S= 
1/2). The low spin Fe(III) has been shown to be smaller than the high spin Fe(III) 214, 
therefore it may drop into the porphyrin plane instead of being 0.5 A out of plane for 
the high spin Fe(IH)215 and binds the ligands more tightly. The low spin ions should 
also bind ligands better because they have fewer eg electrons which are 
antibonding210. The five electrons in the iron 3d orbitals are accommodated in the 
nonbonding t2g orbitals and the antibonding eg orbitals. The low spin complex has a
213 Cowgill R.W. and Clark W.M.; MetaOoporphyrins. VII. Coordination of imidazoles with 
ferrimesoporphyrin. J. Biol. Chem., 1952,198,33-61.
214 Hu C., Noll B.C., Schulz C.E. and Scheidt W.R.; Proton-mediated electron configuration change in 
high-spin iron(II) porphyrinates. J. Am. Chem. Soc., 2005,127, 15018-15019.
Nasri H., Ellison M.K., Shaevitz B., Gupta G.P. and Scheidt W.R.; Electronic, magnetic, and 
structural characterization of die five-coordinate, high-spin iron (II) nitrato complex 
[Fe(TpivPPXN03)]\ Inorg. Chem., 2006,45,5284-5290.
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(t2g)5(eg)° configuration while the high spin complex has a (t2g)3(eg) 2  configuration216 
(Figure 4.15). This suggests that the haem and the ligand system exhibit cooperative 
binding i.e. the binding of one ligand at one site increases the affinity of the ligand 
for the other site217. The di-substituted complex haem(52)2 will thus be far more 
stable.
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Figure 4.15: Electronic differences between the high spin (S= 5/2) and the 
low spin (S= 1/2) iron complexes.
5.2.2) Equations used
Two different equations (Equations 4.2 and 4.7), representing different types 
of binding, were used as global fitting models for the UV/VIS binding data. Equation 
4.1 is based on the mass balance equation for an equilibrium involving consecutive 
independent binding events.
K K K
H + 2L ^  HL + L HL,
K
HL,
The mass balance equation describing such equilibrium results in a quadratic 
equation, which can be solved analytically218 resulting in Equation 4.2.
(Equation 4.2):
[Li '
= background + s i g n a l + A signal-
v N  j
2 K
216 Decker A. and Solomon E.; Dioxygen activation by copper, heme and non-heme iron enzymes: 
comparison of electronic structures and reactivities. Ctar. Opinion Chem. Biol., 2005,9 ,152-163.
217 Cameron M.D., Wen B., Allen K.E., Roberts A.G., Schuman J.T., Campbell A.T., Kunze K.L. and 
Nelson S.D.; Cooperative binding of midazolam with testosterone and a-naphtoflavone within the 
CYP3A4 active site: a NMR Ti paramagnetic relaxation study. Biochem., 2005,4 4 ,14143-14151.
218 http://mathworld.wolfram.com/QuadraticFormula.html.
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Here, signalobs is the observed signal (here: absorbance), signal&& is the 
molar free haem signal, Abmdingsignal is the change in the signal upon binding, [H]t is 
the total haem concentration, [L]t is the total ligand concentration, K  is the binding 
constant which is assumed to be the same for the two consecutive binding processes 
and N  is the binding stoichiometry so that concentration of binding sites added = 
[L],IN.
The mass balance equations for the cooperative binding of 2 ligands to 1 host 
molecule: H+2L ^  HL2 result in a cubic equation (Equation 4.3).
(Equation 4.3): [L]f + (2 [H]t -[L ]t ).[L]J + yK -[L]f + = 0
This cubic equation can be solved to give the only real root (Equation 4.4)219
(Equation 4.4): [L]f = [J{r 2- Q })+\R\ f  + r .-- g
[(V(*2- e 3) + | #
Here, Q and R are given by Equations 4.5 and 4.6, respectively:
(Equation 4.5): R =
2 (2 [H ],-[L ]J -9 -(2 -[H ],-[L ],)  ^  + 2 7 -2 li3 i
________________________________________________K  J
54
f(2-[H], -[L ] , ) 2 -3->yl 
(Equation 4.6): ^  9
This results in Equation 4.7 describing the change in an observed signal for 
titrations involving equilibrium H+2L — which can then be used to fit
our UV/VIS data.
(Equation 4.7): signa,*> = back8 round + s ig n a l^  M , + ~ [L]f
219 Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.; Numerical recipes in Pascal, the 
art of scientific computing. Cambridge University Press, 1989.
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Here, signal0bS is the observed signal (absorbance), signalfree,m is the molar 
free haem signal, Abindingsignal is the change in the signal upon binding, [H]t is the 
total haem concentration, [L]t is the total ligand concentration, K  is the binding 
constant and [L]f is the free ligand concentration as calculated using Equation 4.3.
Both equations (4.2 and 4.7) were used to fit the data of the binding for our 
ligands to haem. Equation 4.7 is specific for cooperative binding of two ligands to 
one haem whereas Equation 4.2 can be used for equilibria involving an unknown 
number of independent binding sites as the stoichiometry of the reaction is one of the 
variables; however, we have here restricted N  to a value of 2. Equation 4.2 assumes 
that the monosubstituted complex HL is formed in small quantity during the reaction 
before being transformed into the di-substituted complex HL2 .
5.2.3) Fit o f  the data and binding constant determination
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Figure 4.16: Absorbance for the hemin-52 complex at different
concentrations of hemin and ligand. Lines are fitted curves using Equation 4.2. (a): 
[hemin]= 100 pM at 402 nm; (b): [hemin]= 100 pM at 420 nm; (c): [hemin]= 20 pM
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at 402 nm; (d): [hemin]= 20 pM at 420 nm. Optimised binding parameters are 
reported in Table 4.1.
Table 4.1: Optimised binding parameters (Equation 4.2) for the hemin-52 complex:
Variables (a) [hemin]= 
100 pM 
402 nm
(b) [hemin]= 
100 pM 
420 nm
(c) [hemin]— 
20 pM  
402 nm
(d) [hemin]= 
20 pM 
420 nm
Binding 
constant Km 
(M-1)
(1.69 ± 0.31).105
Stoichiometry 2
Abindingsignal 
(M^cm'1)
-7933 ±412.2 1565 ±405.7 (-5.40 ± 
0.22). 104
(4.54 ± 
0.21).104
Signal
(M^cm"1)
(1.11 ± 
0.03). 104
2572 ±312.0 (9.35 ± 
0.16).104
(3.05 ± 
0.17).104
Background 0.03 0.02 0.02 0.07
Chiz/DoF 0.0012
0.99498
The two equations 4.2 and 4.7 were used to determine the binding constants 
of 52 with both hemin and TPP. For each combination of haem and ligand, the 
binding constant was determined from global non-linear least squares fitting of four 
different sets of data at different wavelengths and concentrations using the software 
Origin . The results obtained with the two different equations were then compared 
and some conclusions were drawn about the best model and consequently about the 
type of binding.
For hemin, the decrease in absorption of the haem band at 402 nm and the 
increase in absorption of the complex at 420 nm were investigated. Two different 
concentrations of hemin were used: 100 pM and 20 pM while the ligand 
concentration was varied between 0 and 500 pM. The path length of the cuvette had
220 Origin v 7.0300 (B300), OriginLab Corporation, http://www.OriginLab.com
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to be changed from 1 mm for the measurement of the 100 fiM solution to 1 cm for 
the measurement of the 20 pM solution. With Equation 4.2, five variables had to be 
determined: the binding constant Ahi, the stoichiometry, the change in signal, the 
haem free signal and the background. The binding constant Km and the 
stoichiometry were shared between the four sets of data. As we previously 
demonstrated that there are two ligands binding to one haem, the stoichiometry was 
thus fixed as 2. The background was fixed to its measured value in each case. The 
binding constant Km and the variations in the ^mAmgsignal and the signalfoe were 
optimised to their best fit values.
In the case of Equation 4.7, the stoichiometry is already fixed in the equation 
as 2. There are consequently only four variables: the binding constant Km, the 
change in signal, the haem free signal and the background. As for the Equation 4.2, 
the binding constant Km is shared between the four sets of data, the background is 
set to its measured value and the delta signal and the haem free signal are set as 
variables.
The goodness of fit is expressed for both equations by chi2/DoF and R2. 
Chi2/DoF compares the calculated values with the experimental values (Equation 
4.8). A low value for this parameter suggests a good model.
f (calc, value -  exp. value) V
(Equation 4.8): chi2/DoF =
Here, n is the number of datapoints and DoF is the number of degrees of 
freedom which is expressed in Equation 4.9.
(Equation 4.9): DoF = ndatapoints — n
The regression coefficient R2 (Equation 4.10) corresponds to the slope of the 
straight line that most closely relates two correlated variables. It is a number between 
0 and 1 and a value close to 1 suggests a good model.
errormargin
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Figure 4.18: Absorbance for the hemin-52 complex at different
concentrations of hemin and ligand. Lines are fitted curves using Equation 4.7. (a): 
[hemin]= 100 pM at 402 nm; (b): [hemin]= 100 pM at 420 nm; (c): [hemin]= 20 pM 
at 402 nm; (d): [hemin]= 20 pM at 420 nm. Optimised binding parameters are 
reported in Table 4.2.
Table 4.2: Optimised binding parameters (Equation 4.7) for the hemin-52 complex:
Variables (a) [hemin]= 
1 0 0  p M  
4 0 2  nm
(b) [hemin]= 
1 0 0  p M  
4 2 0  nm
(c) [hemin]= 
2 0  p M  
4 0 2  nm
(d) [hemin]= 
2 0  p M  
4 2 0  nm
Binding 
constant Km  
(M-2)
(1.34 ± 0.004). 109
186
Abinding>S ignal 
(M 'W 1)
(-0.91 ± 
1.04).104
884.1 ± 5769 (-4.79 ± 
1.12).104
(4.26 ± 
1.18).104
Signal
(M^cm"1)
(1.22 ± 
0.97). 104
3113 ±5190 (8.77 ± 
0.81).104
(3.28 ± 
0.96). 104
Background 0.03 0.02 0.02 0.07
ChfVDoF 0.0A1402
R2 0.81543
Although the error on the binding constant Km {Km- (1.34 ± 0.004).109 M"2) 
with Equation 4.7 is quite small, the equation could not fit all the data points properly 
(Figure 4.17). Errors on s i g n a l and AbindmgSignal for all the graphs are also quite 
large, sometimes even bigger than the actual value. On the other hand, the fit with 
Equation 4.2 (Figure 4.16) gave better results. It displayed a binding constant Ahi= 
(1.69 ± 0.31).105 M '1 and an acceptable value for all the errors on the signal&& and 
the Abindin^ signal. Comparison of the values of both binding constants Km and Km 
showed that Km  ~ ATHi2. The difference between the values of Km and Km could be 
explained by the fact that Equation 4.2 considers the concentration of ligand and the 
concentration o f binding sites ([ligand] + [binding sites] —► [ligand-binding sites]) 
while Equation 4.7 considers the binding of two ligand to one haem ([haem] + 
2 [ligand] —► [haem-ligand2]). Consequently the units of the binding constant unit are 
different for the two equations: M_1 for AThi and M*2 for Km- As a result of the 
difference in the length o f the cuvette between experiments (a) and (b) (1 mm) and 
experiments (c) and (d) (1 cm) the values of the sig n a ls  and the Abidingsignal vary. 
For (a) and (c), which measures the changes in absorption at 402 nm, the values of 
the signal free and the Abindin^ signal for (c) are about 10 fold those for (a). This is also 
observed with (b) and (d), which measures the changes in absorption at 420 nm, 
signal free and Abindin ^ ignal for (d) are about 10 fold those for (b).
The comparison of both goodness of fit variables chi2/DoF and R2 (Equation 
4.2: chi2/DoF= 0.0012 and R2= 0.99498; Equation 4.7: chi2/DoF= 0.04402 and R2= 
0.81543) shows that Equation 4.2 is a better model for the binding of ligand 52 to 
hemin. It suggests that, though never observed, the monosubstituted complex HL is
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formed in minor quantities during the reaction prior to the formation of the 
disubstituted complex HL2 and binding of 52 to hemin follows the following 
equilibrium:
*H1 K m
H + 2 L = ^ ^=  HL + L ■ -  HL2 
Where H= hemin and L= 52
The determination of the binding constant K j with TPP followed a similar 
method as that used for hemin and both equations 4.2 and 4.7 were used for data 
analysis. The decrease in the absorbance of the TPP band at 508 nm and the increase 
of the TPP-ligand complex at 548 nm were investigated, first with a 100 pM solution 
of TPP and a ligand solution, which concentration was varied between 0 and 500 
pM, in a 1 cm cuvette and then with a 200 pM solution of TPP and a ligand solution, 
which concentration was varied between 0 and 1 mM in a 0.5 cm cuvette. The fits of 
the data with both equations are shown in Figure 4.18 (Equation 4.2) and Figure 4.19 
(Equation 4.7).
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Figure 4.19: Absorbance for the TPP-52 complex at different concentrations 
of TPP and ligand. Lines are fitted curves using Equation 4.2. (a): [TPP]= 100 pM at 
508 nm; (b): [TPP]= 100 pM at 548 nm; (c): [TPP]= 200 pM at 508 nm; (d): [TPP]= 
200 pM at 548 nm. Optimised binding parameters are reported in Table 4.3.
Table 4.3: Optimised binding parameters (Equation 4.2) for the TPP-52 complex:
Variables (a) [hemin]= 
100 pM 
402 nm
(b) [hemin]5 
100 pM 
420 nm
(c) [hemin]= 
20 pM 
402 nm
(d) [hemin]55 
20 pM 
420 nm
Binding 
constant Kj\ 
CM'1)
557.3 ± 304.6
Stoichiometry 2
A bindingSignal 
(M^cm'1)
(-4.23 ± 
1.99).104
(3.18 ± 
1.50).104
(-1.11 ± 
0.47). 104
(1.13 ± 
0.48). 104
Signalfo* 
(M^cm'1)
(1.65 ± 
0.007). 104
5154 ±65.59 8958 ± 59.23 2729 ± 40.77
Background 0.04 0.04 0.04 0.04
ChiVDoF 0.00005
R2 0.99968
Both equations (4.2 and 4.7) are able to reproduce the absorbance data for the 
formation of the TPP-52 complex. The values obtained for chi2/DoF and R2 with 
both equations (Equation 4.2: chi2/DoF= 0.00005 and R2= 0.99968; Equation 4.7: 
chi2/DoF= 0.00006 and R2= 0.99955) indicate that both binding models are suitable. 
Both binding models also displayed reasonable values for the errors of the binding 
constant K j, the AbindingS/gna/ and the signal&«.. Equation 4.2 (Figure 4.18) gave a 
binding constant Ari= 557.3 ± 304.6 M"1 and Equation 4.7 (Figure 4.19) gave a 
binding constant Kn=  (1.08 ± 0.18).107 M‘2. However, the errors with Equation 4.7 
are much lower especially on the Abidingsignal values. The difference in the path 
length of the cuvette (1 cm for (a) and (b) and 0.5 cm for (c) and (d)) acts on the
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v a l u e  o f  sign a l^  a n d  A d d i n g signal. T h e  v a l u e  o f  s ig n a ls  a n d  A d d i n g signal f o r  ( a )  i s  
2  f o l d  t h a t  o f  ( c )  a n d  t h e  v a l u e  o f  signalfree a n d  A b in d in  ^ signal f o r  ( b )  i s  2  f o l d  t h a t  o f
(d).
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F i g u r e  4 . 1 9 :  F i t  o f  t h e  a b s o r b a n c e  f o r  t h e  T P P - 5 2  c o m p l e x  a t  d i f f e r e n t  
c o n c e n t r a t i o n  o f  T P P  a n d  l i g a n d  u s i n g  E q u a t i o n  4 . 7 .  ( a ) :  [ T P P ] =  1 0 0  p M  a t  5 0 8  n m ;  
( b ) :  [ T P P ] =  1 0 0  p M  a t  5 4 8  n m ;  ( c ) :  [ T P P ] =  2 0 0  p M  a t  5 0 8  n m ;  ( d ) :  [ T P P ] =  2 0 0  p M  
a t  5 4 8  n m .  O p t i m i s e d  b i n d i n g  p a r a m e t e r s  a r e  r e p o r t e d  i n  T a b l e  4.4.
T a b l e  4.4: O p t i m i s e d  b i n d i n g  p a r a m e t e r s  f o r  E q u a t i o n  4 . 7  i n  t h e  f i t  o f  t h e  T P P - 5 2  
c o m p l e x :
Variables ( a ) (b) ( c ) ( d )
B i n d i n g  
c o n s t a n t  K n  
C M '2 )
( 1 . 0 8  ±  0 . 1 8 ) . 1 0 7
^bindingSignal
( M ^ c m ' 1)
- 6 7 2 9  ± 3 9 1 . 2 5 0 2 4  ± 3 1 1 . 9 - 2 1 7 0  ± 9 8 . 1 0 2 2 0 3  ±  9 0 . 8 7
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Signal^*
(M^cm'1)
(1.60 ± 
0.07). 104
5550 ± 63.69 8818 ±55.20 2912 ± 37.75
Background 0.04 0.04 0.04 0.04
ChfVDoF 0.00006
R2 0.99955
Therefore, Equation 4.7 is a better model for the formation of the TPP-52 
complex. In conclusion, the binding mode of ligand 52 to TPP appears to differ from 
that of 52 with hemin and follows the equilibrium.
^T2
H + 2L HL2
Where H= TPP and L= 52
In conclusion, determination of the binding constants o f ligand 52 has been 
successfully achieved using UV/VIS data both for binding with hemin and TPP. 
Unfortunately, binding constant determinations could not be done with ligands 53, 
53’ and 54. There is no evidence for the formation of the hemin and TPP complexes 
with these ligands in UV/VIS spectra, in agreement with what has been observed in 
*H NMR spectrometry. Consequently, the formation of complexes with ligands 53, 
53’ and 54 and TPP as observed in mass spectrometry studies in the gas phase has 
not been confirmed in solution.
Ligand 52 also seems to have a stronger affinity for hemin than for TPP as 
Xhi~ IOATti and Ki&z 100jKt2- This might be due to steric limitations caused by the 
orientation of the phenyl rings in TPP (Figure 4.9). Furthermore, the binding constant 
of imidazole ligand 52 ((1.69 ± 0.31).105 NT1) is comparable with the literature 
binding constant obtained for imidazole ((6.3 ± 0.9). 104 M '1)221 suggesting that there 
is no influence of the rest of the ligand on its binding properties and that the 
difference in activity is only due to the ligand interactions with the protein residues
221 Wang J.T., Yeh H.J.C. and Johnson D.F.; Proton nuclear magnetic resonance study of equilibria 
and paramagnetisms of ferriprotoporphyrin IX-ligand complexations. J. Am. Chem. S o c 1978, 100, 
2400-2405.
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of the active site. The binding constant K n  of 44 with TPP is also much lower than 
that of literature for imidazole (~ 4.8.105 M-1)190. Consequently, TPP which appeared 
to be a good model for hemin in the titration with imidazole190, is not a very accurate 
model for hemin interacting with 52.
Formation of complex with hemin and TPP also displayed different 
behaviours. With hemin, the mono-substituted complex HL is formed prior to the 
disubstituted complex HL2  and thus Equation 4.2 was found more satisfactory. With 
TPP, formation of the monosubstituted complex was never observed, the equilibrium 
followed a cooperative binding and Equation 4.7 was more suitable.
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CHAPTER 6
Conclusion
6) CONCLUSION
In order to study the binding interaction between the cytochrome P450 haem 
and some of our ligands (52, 53, 53’ and 54), different spectroscopic techniques were 
used (mass spectrometry, X-ray crystallography, *H NMR and UV/VIS), each 
providing us with different data on the nature of the binding (stoichiometry, species 
formed in solution, binding constant). Although mass spectrometry provided some 
useful data on the different species formed during the reaction (HL, HL2 and haem + 
solvents complexes), it did not provide quantitative information on the haem-ligand 
interactions in solution. [H NMR allowed us to conclude that the formation of the 
complex occurred but, because o f the large number of aromatic protons and the 
broadening of the peaks, it did not lead to any accurate quantitative data either and 
was difficult to interpret. Here, UV/VIS spectroscopy emerged as the most useful 
source of data and allowed us to determine the binding constant of the ligand 52.
Two different equations were used to fit the data from the UV/VIS study 
(Equations 4.2 and 4.7). Equation 4.2 was found to be more appropriate for 52 
binding to hemin displaying a binding constant o f Xhi= (1.69 ± 0.31).105 M'1 similar 
to that of imidazole binding to hemin ((6.3 ± 0.9). 104 M'1)221. This suggests that the 
imidazole ring, which coordinates the haem iron atom, is the only part of the ligand 
influencing the binding properties and the difference in activity observed between the 
different imidazole ligands might only be due to their interactions with the enzyme 
protein residues e.g. hydrogen bonding and hydrophobic interactions. The better fit 
observed with Equation 4.2 proves that a small amount of the mono-substituted 
complex HL is formed during the reaction before being transformed into the di­
substituted complex HL2 .
Equation 4.7 was found more suitable for TPP interaction with 52 which 
shows that there is cooperative binding; none of the monosubstituted HL complex is 
formed during the reaction. 52 displayed a binding constant K n -  (1.08 ± 0.18). 107 
M*2 with TPP which is about 100 fold lower than that of 52 interaction with hemin 
and also lower than TPP titration with imidazole (~ 4.8.105 M*1)190. Steric
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interactions between the phenyl ring of TPP and 52 might be the cause of the low 
value of Kj2.
Unfortunately, the binding constant could not be calculated for ligands 53, 
53’ and 54. There is no evidence for the formation of the complex in solution with 
these ligands and hemin and TPP. Complexes were only observed with TPP in mass 
spectrometry studies in the gas phase. It was thus not possible to correlate the 
binding constant o f the ligands to their activity. However, the fact that these ligands 
do not form a covalent bond with the haem iron could explain their poor activity (53: 
IC5o= 18 pM; 53’ and 54: IC50 > 20 pM) against CYP26 enzymes compare to 52 
(IC5o= 0.9 pM). An imidazole ring seems to be necessary in the design of future 
CYP26 inhibitors.
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Two new series of compounds the 1 -[benzofuran-2-yl-(4-
alkyl/arylphenyl)methyl]triazoles and the benzoxazol-2-yl-[phenylimidazol-1 - 
ylmethyl)phenyl]amine were successfully synthesised and biologically tested as 
CYP26 inhibitors in MCF-7 cells. The binding constant of inhibitor 52 (benzoxazol- 
2-yl-[4-imidazol-1 -ylphenylmethyl]phenyl]amine) was also calculated both with 
hemin and TPP.
The l-[benzofuran-2-yl-(4-alkyl/arylphenyl)methyl]triazoles series displayed 
a moderate activity for CYP26 inhibition. The two most active compounds, the 4- 
ethyl derivative 26, (IC5o= 4.5 pM) and the 4-phenyl derivative 27, (IC5o= 7 pM) 
displayed an activity comparable with the well-known CYP26 inhibitor liarozole 
(IC5o= 6 pM). The 4-cyclohexyl derivative (22, IC5o =5-15 pM) and the 4-r-Bu 
derivative (21, IC50 = 10-25 pM) also displayed moderate activity. All the other 
derivatives (4-Me, 4-/-Pr, 4-w-Pr and / 7-CI-C6H5) were poor inhibitors of the CYP26 
enzyme.
The benzoxazol-2-yl-[phenylimidazol-l-ylmethyl)phenyl]amine were 
designed using our homology model o f the CYP26A1 active site. In docking studies, 
they interacted closely with the haem iron and displayed multiple hydrophobic 
interactions and hydrogen bonds with the protein residues. However, they appeared 
to be only moderate inhibitors o f the CYP26 enzyme. The most potent compound of 
the series was the unsubstituted compound 52 (ICso= 0.9 pM). The methyl derivative 
(59, IC5o= 8 pM) and the hydroxy derivative (68, IC5o= 12 pM) showed activity 
comparable with that of liarozole and the l-[benzofuran-2-yl-(4- 
alkyl/arylphenyl)methyl]triazoles series. Para-substitution of the phenyl ring by 
larger substituents (45, 47 and 67) or on another position (84, 85 and 86) led to poor 
inhibitors (IC50 > 20 pM), probably because of steric constraint within the active site. 
The disappointing results observed in the activity do not confirm what was observed 
on the docking studies and show the limitations of our CYP26A1 model.
In order to study the binding interaction between the cytochrome P450 haem 
and some of our ligands (52, 53, 53’ and 54), different spectroscopic techniques were 
investigated (mass spectrometry, X-ray crystallography, *H NMR and UV/VIS). All 
the techniques gave useful information on the binding properties of our ligand to 
haem and TPP; however UV/VIS spectroscopy emerged in our case as the most
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appropriate tool and allowed us to calculate the binding constant of ligand 52 both 
with hemin (ATHi= (1.69 ± 0.31).105 M '1) and TPP (Kn= (1.08 ± 0.18).107 M'2). The 
binding constant could not be determined for the triazole ligands 53 and 53’ and the 
tetrazole ligand 54, which suggests that an imidazole ring is needed in the design of 
future CYP inhibitors.
Our future work will involve the replacement of the phenyl ring of the 
benzoxazol-2-yl-[phenylimidazol-l-ylmethyl)phenyl]amine series of inhibitors into a 
more flexible alkyl chain to enhance the activity. The disappointing results observed 
with the benzoxazole series also confirm that some improvements are needed in our 
model of the CYP26A1 enzyme.
In the binding studies, our effort should focus on the formation of a crystal 
structure of the haem-52 complex which will allow us to study in detail the Fe-N 
covalent bond. A new method should also be found to determine the binding constant 
of ligand 53, 53’ and 54 and then correlate the haem-ligand interaction of these 
ligands to their activity.
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Abstract—Methodology previously described by our group was applied to the preparation of a series of 4-alkyl/aryl-substituted 1- 
[benzofuran-2 -yl-phenylmethyI|-1 /7-triazoles. The [l,2,4]-triazole derivatives were prepared for a range of alkyl and aryl substitu­
ents, and for the 4-methyl, 4-ethyl, 4-'propyl, 4-'butyl, 4-phenyl and 4-chlorophenyl derivatives, the minor [l,3,4]-triazole isomer 
also isolated. All the triazole derivatives were evaluated for CYP26A1 inhibitory activity using a MCF-7 cell-based assay. The 4- 
ethyl and 4-phenyl-1 ,2 ,4-triazole derivatives displayed inhibitory activity (IC50 4.5 and 7 pM, respectively) comparable with that 
of the CYP26 inhibitor liarozole (IC50 7 pM). Using a CYP26A1 homology model (based on CYP3A4) template, docking experi­
ments were performed with MOE with multiple hydrophobic interactions observed in addition to coordination between the triazole 
nitrogen and the haem transition metal.
© 2006 Elsevier Ltd. All rights reserved.
1. Introduction
In humans, CYP26A1 is expressed in the liver, heart, 
pituitary gland, adrenal gland, testis, brain and placen­
ta, 1 and has been mapped to chromosome 10q23-q24.2 
It is thought that the principal role of CYP26A1 is 
homeostatic, that is, the regulation of intracellular 
ATRA steady-state levels via a negative feedback loop 
similar to that of CYP24 in the metabolism of cholecal- 
ciferol.3 The enzyme therefore may have a protective 
function, as an important regulator of differentiation 
and a possible modulator of disease states indirectly by 
controlling ATRA and other retinoid concentrations.4
Retinoic acid has been used in a number of clinical situ­
ations, especially oncology and dermatology. In oncolo­
gy, ATRA has shown spectacular success in the 
treatment of acute promyelocytic leukaemia, 5,6 although 
remission seen is followed by relapse within 4-6 months; 
this appears to be due to increased RA metabolism as a 
result of RA induction so leading to decreased clinical
Keywords: 1 -[Benzofuran-2-yl-(4-alkyl/aryI-phenyl)-methyFj-1 //-tria-
zoles; CYP26A1; Enzyme inhibition; MCF-7; Molecular modelling.
* Corresponding author. Tel.: +44 02920 876307; fax: +44 02920 
874149; e-mail: SimonsC@CardiflF.ac.uk
0968-0896/$ - see front matter © 2006 Elsevier Ltd. All rights reserved, 
doi: 10.1016/j .bmc.2006.01.018
efficacy. Although other CYPs are also induced by 
ATRA and catalyse its metabolism, it is thought that 
CYP26A1 is likely to be the most important enzyme in­
volved in its degradation7 (Fig. 1).
ATRA may improve the efficacy of other treatments 
such as radiation, cisplatin and interferon therapies.8,9 
Retinoids have been used for some time in the treatment 
of psoriasis, cystic acne, cutaneous malignancies due to 
hyperkeratinisation as well as in the treatment of photo­
damaged skin. 10,11 As CYP26A1 appears to be so 
important in the management of intracellular levels of 
ATRA and the development of resistance to its effects 
in cancer, it presents a useful target in combating the 
development of resistance. Inhibition of CYP26A1 
would elevate normal tissue levels of ATRA or maintain 
high therapeutic levels of ATRA preventing the resis­
tance that develops to treatment. This might provide a 
leap forward in the prevention and treatment of a num­
ber of diseases including hormone refractory prostate 
cancer and psoriasis.
A number of inhibitors of ATRA metabolism have been 
developed over the last fifteen years. 12-15 The discovery 
of the imidazoles as inhibitors led to further study into 
this class of compounds, resulting in the synthesis of
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Figure 1. Metabolism of all-trans retinoic acid (RA = retinoic acid).
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Figure 2. CYP26A1 metabolism inhibitors and target structures.
liarozole, which became the most studied inhibitor of 
ATRA metabolism . 1 6 - 1 8  Though more specific and effec­
tive than the other imidazoles, liarozole is still a potent 
inhibitor of aromatase, preventing its use as an oral ret­
inoic acid-mimetic for sex hormone-independent can­
cers, therefore clinical development of liarozole was 
discontinued. 3  Further development has led to the dis­
covery of the 1//-triazole derivative, R 115866, a potent 
and selective inhibitor of ATRA metabolism (Fig. 2) . 1 9
As part of our ongoing research into the development of 
CYP26A1 inhibitors, we evaluated a number of com­
pound classes for their inhibitory activity. The 4-alkyl- 
benzofuran derivatives were promising candidates 
owing to their structural similarity with liarozole as con­
firmed by molecular modelling. The synthesis, 
CYP26A1 inhibitory activity and bonding interactions 
at the CYP26A1 active site are described.
2. Chemistry
The required intermediates for the preparation of the 1- 
[(benzofuran-2 -yl)phenylmethyl] triazoles were the cor­
responding ketones, benzo[6 ]furan-2 -yl-phenylmetha- 
nones (3). The synthesis of the ketones was achieved 
by the Rap-Stoermer reaction , 2 0  and involved reaction 
of salicylaldehyde (1) with the a-bromoketones (2),21 
generated by reaction of the appropriate acetophenone 
with bromine and aluminium trichloride according to 
literature methodology2 2  (Scheme 1).
The ketones were then reduced to the respective racemic 
carbinols (4) in quantitative yields by reaction with sodi­
um borohydride. The target triazole derivatives (5-11) 
were then obtained by reaction with A,A'-thionylditriaz- 
ole, which was prepared by the reaction of 1 ,2 ,4-1//-tri­
azole with thionyl chloride at 10 °C for 1 h, for 4 days.
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Scheme 1. Reagents and conditions: (i) Br2, A1C13, E t20 ,  1 h; (ii) N aH , D M F, 80 °C, 2 h then NaOMe, 80 °C, 1 h; (iii) NaBH4, dioxane, 2 h; (iv) 
jV,V'-thionylditriazole, K2C 0 3, CH 3CN, 4 days.
In addition to the 1,2,4-triazole isomer, the minor 1,3,4- 
isomer was obtained for some of the l-[(benzofuran-2 - 
yl)phenylmethyl] triazoles. For the 1,2,4-isomers, the 
triazole protons were observed as two singlets, each 
integrating for one proton, at ~8.2 and 8.1 ppm. The 
structure of the 1,3,4-triazole isomers was confirmed by 
‘ii NMR, which gave a singlet, integrating for two pro­
tons, at ~8.30 ppm for the symmetrical triazole protons.
The 4-aryl ketone derivatives (13) were prepared from 
the 4-bromoketone (12) derivative using a Suzuki cou­
pling23 with the appropriate phenyl boronic acid. Subse­
quent reduction gave the alcohols (14), which were 
reacted with /V,iV'-thionylditriazole to generate the 
1,2,4- and 1,3,4-triazole isomers of the phenyl (15) and 
4-chlorophenyl (16) benzofurans (Scheme 2).
3. CYP26A1 Inhibitory activity
The 1 -[benzofuran-2-yl-(4-alkyl/aryl-phenyl)-methyl]- 
1//-triazoles (5-11, 15 and 16) were evaluated for their 
retinoic acid metabolism inhibitory activity using a 
MCF-7 cell assay, 13 using radiolabelled [11,12-3H] all- 
trans retinoic acid as the substrate and liarozole and 
R115866 as standards for comparison. The 4-ethyl (6 a, 
IC50 = 4.5 pM; 6 b, IC50 = 7 pM) and 4-phenyl (15a, 
IC50 = 7 pM; 15b, IC50 = 9 pM) derivatives displayed 
inhibitory activity of CYP26A1 comparable with that 
of liarozole (IC50 = 7 pM), and the cyclohexyl derivative 
(11, IC5o = 5-15pM) displayed moderate activity, the 
remaining alkyl/aryl derivatives all poor CYP26A1 
inhibitors of retinoic acid metabolism (IC50 > 20 pM) 
(Table 1). All the l-[benzofuran-2-yl-(4-alkyl/aryl-phen- 
yl)-methyl] - 1 //-triazoles were considerably less active 
than R115866 (IC50 = 5 nM).
The 4-methyl derivative (5) has previously been evaluated 
as an aromatase (CYP19) inhibitor (IC50 = 0.59 pM, cf. 
anastrazole = 0.6 pM) . 21 The 4-ethyl (6 ) and 4-phenyl 
(15) derivatives were also screened against CYP19 to 
determine selectivity, both having an inhibitory activity 
IC50 > 100 pM. The negligible CYP19 inhibitory activity 
of 6  and 15 was expected from SAR studies21 which had 
shown that only small substituents, for example, F, Cl, 
CH3 and CN were tolerated at the 4-position of the phenyl 
ring for CYP19 inhibitors.
4. Molecular modelling
In order to rationalise the results obtained, MOE 
(Molecular Operating Environment)24 docking studies 
of the inhibitors were performed using a human 
CYP26A1 model, 25 built using the recently crystallised 
human CYP3A426 as a template. Docking interactions 
at the enzyme active site were shown to be comparable 
with those of the CYP26 inhibitor liarozole with the 
benzofurans positioned above the haem with multiple 
hydrophobic interactions (Fig. 3). The inhibitor com­
pounds are all racemic therefore both enantiomers of 
all the compounds were docked to determine any prefer­
ence for (R)- or (5)-configuration; no preference was ob­
served with both enantiomers exhibiting a similar ‘fit’ in 
the active site with the nitrogen of the heterocyclic ring 
coordinating with the Fe3+ of the haem, therefore for 
comparison Figure 3 shows the (5>enantiomers of the 
4-ethyl (6 a) and the 4-phenyl (15a) 1,2,4-triazole benzo- 
furan derivatives.
Docking of the 4-alkyl derivatives with a chain length 
of > 2  indicated that steric hindrance was encountered 
preventing close (2.5-3.5 A) interaction with the haem.
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Y-N 14a, R -  H 
14b, R = Cl
15a, R * H, X=N, Y=CH 
15b, R = H, X=CH,Y=N 
16a, R = Cl, X=N, Y=CH 
16b, R = Cl, X=CH,Y=N
Scheme 2. Reagents and conditions: (i) Pd(PPh3)4, N a2C 0 3(aq) toluene, 100 °C, 5 h, then H 20 2, rt, 1 h (60-70 %); (ii) NaBH4, dioxane, 2-6 h; (iii) 
N ,N '-thionylditriazole, K 2C 0 3, C H 3CN , 4 days.
Table 1. IC50 data for the novel benzofuran derivatives using CYP26A1 MCF-7 assays
Compound R X Y IC50 (pM)
5a c h 3 N CH >40
5b c h 3 CH N >40
6 a c h 2c h 3 N CH 4.5
6 b c h 2c h 3 CH N 5
7 c h 2c h 2c h 3 N CH 50-100
8 a C H (C H 3) 2 N CH 20-40
8 b C H (C H 3) 2 CH N 50-100
9 C (C H 3) 3 N CH 10-25
1 0 C H 2C H (C H 3) 2 N CH 40-50
11 Cyclohexyl N CH 5-15
15a Q H 5 N CH 7
15b c 6h 5 CH N 9
16a p -C l-Q H s N CH 20-40
16b p-Cl-CfrHs CH N 20-40
Ketoconazole — — — 12
Liarozole — — — 7
R115866 — — — 0.005
IC50 values are the average (±5%) o f two experiments.
The phenyl derivative (15, IC 50  = 7-9  pM ) has a  greater 
inhibitory activity despite its size owing to  favourable 
conformation and  enhanced hydrophobic bonding. This 
may strengthen the in teraction  o f  the phenyl derivative 
increasing its potency as an  inhibitor o f  the enzyme; 
however, the unsubstitu ted  phenyl was the limit with
the introduction o f the chloro substituent (16, 
IC 50 = 20-40 pM ) resulting in a reduction o f inhibitory 
activity owing to  steric/electronic factors.
The docking studies however fail to shed any light on 
the poor results obtained for the methyl compound (5 ,
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Figure 3. Active site region of CYP26A1 model showing (a) 5-6a and (b) S-15a in ball and stick form. The distance from the haem is indicated with a 
green line, transition metal interaction with a purple line. Amino acid residues identified are involved in hydrophobic interactions.
IC5 0  > 40 pM), which was expected to possess potency 
similar to that of the ethyl derivative (6 , IC 5 0  = 4.5- 
5 |iM).
A series of 4-alkyl/aryl benzofuran phenyl triazole deriv­
atives has been prepared with the ethyl and phenyl 
derivatives shown to possess comparable inhibitory 
activity with that of the known CYP26 inhibitor 
liarozole.
5. Experimental
5.1. Materials and methods: chemistry
]H and 13C NMR spectra were recorded with a Brucker 
Avance DPX500 spectrometer operating at 500 and 
125 MHz, with Me4Si as internal standard. Mass spectra 
were determined by the EPSRC Mass Spectrometry 
Centre (Swansea, UK). Microanalyses were determined 
by Medac Ltd (Surrey, UK). Flash column chromatog­
raphy was performed with silica gel 60 (230-400mesh) 
(Merck) and TLC was carried out on precoated silica 
plates (kiesel gel 60 F 2 5 4 , BDH). Melting points were 
determined on an electrothermal instrument and are 
uncorrected.
5.1.1. General method for the preparation of the ketones
3. To a solution of sodium hydride (60%, 11 mmol) in 
dry A^Af-dimethylformamide (10 mL) was added a solu­
tion of salicylaldehyde (1,10 mmol) in dry Ar,Ar-dimeth- 
ylformamide ( 6  mL) dropwise. Hydrogen gas was 
liberated to give a yellow solution of the sodium salt. A 
solution of the a-bromoketone 2  ( 1 0  mmol) in dry 
iV,A/-dimethylformamide (10 mL) was then added drop- 
wise and the reaction mixture was heated under nitrogen 
at 80 °C for 1.5 h. Sodium methoxide (2.5 mmol) was 
added to the mixture and heating was continued for 
another hour (TLC system: petroleum ether/ethyl acetate 
4:1 v/v). After cooling, the reaction mixture was evapo­
rated to about a third of its volume, diluted with dichlo- 
romethane (100 mL), washed with water (100 mL), dried 
(MgSQ4) and concentrated under reduced pressure.
5.1.1.1. Benzofur an-2-y l-(4-ethy 1-pheny l)-methanone 
(3a, R = C H 2CH 3). Brown solid (34%) after recrystalli­
sation from methanol, mp 60-62 °C. *H NMR (CDC13): 
3 8.05 (d, 7  = 8.1 Hz, 2H, Ar), 7.78 (d, 7  = 7.7 Hz, 1H, 
Ar), 7.70 (d, 7 = 7 .9 , 1H, Ar), 7.55 (m, 2H, Ar), 7.37 
(m, 3H, Ar), 2.81 (q, 7 =7.6 Hz, 2H, C //2), 1.36 (t, 
J  =7 .6  Hz, 3H, CH3). ,3C NMR (CDC13): 3 184.56 
(0 = 0 ) ,  156.35 (C, C-7a), 152.83 (C, C-4'), 150.43 (C, 
C-F), 135.22 (C, C-2), 130.19 (2 x CH, CH-2' and CH- 
60, 128.66 (CH, CH-6 ), 128.52 (2x CH, CH-3' and 
CH-50, 127.48 (C, C-3a), 124.36 (CH, Ar), 123.70 
(CH, Ar), 116.62 (CH, CH-3), 112.98 (CH, CH-7), 
29.46 (CH2), 15.71 (CH3). Anal. Calcd for Ci7 H 1 4 0 2  
(250.296): C, 81.58; H, 5.64. Found: C, 81.44; H, 5.84.
5.1.1.2. Benzofuran-2-yl-(4-propyl-phenyl)-methanone 
(3b, R = C H 2CH 2CH 3). Cream crystalline solid (42%) 
after recrystallisation from methanol, mp 64-66 °C. 'H 
NM R (CDCI3 ): 3 7.92 (d, 7  = 8.2 Hz, 2H, Ar), 7.65 (d, 
7  =7 .9  Hz, 1H, Ar), 7.57 (dd, 7=0.40, 8.5 Hz, 1H, 
Ar), 7.46 (d, 7 =0.6  Hz, 1H, Ar), 7.42 (m, 1H, Ar), 
7.26 (m, 3H, Ar), 2.62 (m, CH2, propyl), 1.64 (dt, 
7 =  7.4, 8.5 Hz, CH2, propyl), 0.91 (t, 7 =  7.3 Hz, CH3, 
propyl). ,3C NMR (CDC13): <5 184.09 (C =0), 155.95 
(C, C-7a), 152.51 (C, C-40, 148.50 (C, C-F), 134.84 
(C, C-2 ), 129.67 (2 x CH, CH-2' and CH-6 ') and 
128.68 (2 x CH, CH-3' and CH-50, 128.19 (CH, Ar),
127.08 (C, C-3a), 123.92 (CH, Ar), 116.07 (CH, CH- 
3), 112.56 (CH, CH-7), 38.12 (CH^, 24.25 (CH2),
13.75 (CH3). HRMS (EI+) mlz Calcd for C ,8 H 1 6 0 2  
(M+H)+ 265.1223. Found 265.1224.
5.1.1.3. Benzofur an-2-yl-(4-isopropy 1-pheny I)-metha- 
none (3c, R = CH(CH3)2). Pale orange solid (44%) after 
recrystallisation from methanol, mp 93-95 °C. 'H  NMR 
(CDCI3 ): 3 7.85 (m, 2H, Ar), 7.53 (m, 2H, Ar), 7.35 (m, 
2H, Ar), 7.34 (s, 1H, H-7), 7.32 (m, 2H, Ar) 3.05 (septet, 
1H, CH, isopropyl), 1.32 (s, 6 H, isopropyl). 13C NMR 
(CDCI3 ): 3 186.36 (C =0), 155.81 (C, C-7a), 154.60 (C, 
C-2), 154.39 (C, C-4'), 152.39 (C, C-1'), 134.89 (C, C- 
3a), 131.15 (2x CH, CH-2' and CH-6 '), 129.74 (2x 
CH, CH-3' and CH-5'), 126.62 (CH, Ar), 124.22 (CH, 
Ar), 123.27 (CH, Ar), 115.76 (CH, CH-3), 111.20 (CH,
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CH-7), 34.24 (CH, isopropyl), 23.82 (CH3, isopropyl). 
Anal. Calcd for C18H 160 2 (264.318): C, 81.79; H, 6.10. 
Found: C, 81.58; H, 6.07.
5.1.1.4. Benzofur an-2-yl-(4-terf-butyl-phenyI)-metlia- 
oooe (3d, R = C(CH3)3). Yellow solid (32%) after recrys­
tallisation from methanol, mp 103-105 °C. 'H NMR 
(CDC13): <5 7.87 (m, 2H, Ar), 7.67 (m, 2H, Ar), 7.53 (m, 
2H, Ar), 7.34 (s, 1H, H-7), 7.32 (m, 2H, Ar), 1.35 (s, 
9H, 'butyl). l3C NMR (CDC13): 3 184.08 (C=0),
167.76 (C, C-7a), 156.77 (C, C-2), 155.95 (C, C-4'),
155.95 (C, C-l'), 134.54 (C, C-3a), 130.89 (2x CH, 
CH-2' and CH-60, 129.51 (2 x CH, CH-3' and CH-50,
127.09 (CH, Ar), 125.55 (CH, Ar), 123.92 (CH, Ar), 
116.14 (CH, CH-3), 112.57 (CH, CH-7), 68.17 (C, 'butyl),
31.15 (CH3, 'butyl). Anal. Calcd for C19Hi8O2 0.6H2O 
(289.159): C, 78.92; H, 6.69. Found: C, 79.17; H, 7.06.
5.1.1.5. B«nzofuran-2-yl-(4-isobutyl-phenyI)-metha- 
none (3e, R = CH2CH(CH3)2 ). White solid (50%) after 
recrystallisation from methanol, mp 62-63 °C. *H 
NMR (CDC13): 3 7.90 (m, 2H, Ar), 7.59 (m, 2H, Ar),
7.52 (m, 2H, Ar), 7.34 (m, 2H, Ar), 7.32 (s, 1H, H-7),
2.56 (d, 2H, H-16), 1.96 (m, 1H, H-17), 1.01 (d, 6 H, 
H-18, H-19). 13C NMR (CDC13): 3 184.08 (C =0),
155.95 (C, C-7a), 152.50 (C, C-2), 147.55 (C, C-40,
134.86 (2x C, C-l' and C-3a), 129.63 (2x CH, CH-2' 
and CH-6 '), 129.30 (2x CH, CH-3' and CH-5'), 128.19 
(CH, Ar), 127.08 (CH, Ar), 123.92 (CH, Ar), 123.25 
(CH, Ar), 116.09 (CH, CH-3), 112.55 (CH, CH-7), 
45.48 (CH2, isobutyl), 30.16 (CH, isobutyl), 22.39 
(CH3, isobutyl). Anal. Calcd for C 19H 180 2 (278.345): 
C, 81.99; H, 6.52. Found: C, 81.55; H, 6.45.
5.1.1.6. Benzofuran-2-yl-(4-cyclohexyLpheiiyI)-ii»etha- 
uone (3f, R = CC6H12) . 27 Light yellow solid (29%) after 
recrystallisation from ethyl acetate. Mp 92-94 °C. 
NMR (CDC13): 3 7.93 (m, 2H, Ar), 7.24 (m, 2H, Ar), 
7.19 (m, 4H, Ar), 6.62 (s, 1H, H-7), 2.51 (quintet, 1H, 
C//-cyclohexyI), and 1.56 (m, 10H, cyclohexyl).
5.1.2. General method for the preparation of the biphenyl 
ketones 13. Two molar aqueous Na2C 03 (11.65 mL) was 
added to a solution of benzo[£]furan-2-yl(4-bromophe- 
nyl)methanone21 (1.0 g, 3.32 mmol) in toluene (20 mL). 
TTie mixture was bubbled with nitrogen for one minute 
and then Pd(PPh3)4 (0.20 g, 0.166 mmol) was added to 
the mixture. Phenyl- or 4-phenyl-boronic acid 
(6.64 mmol) in ethanol (5 mL) was added to the above 
mixture and the reaction was refluxed at 100 °C for 4 h. 
After the reaction was complete, the residual borane 
was oxidised by the addition of H20 2 (30%, 2.5 mL) at 
room temperature for 1 h. The crude product was extract­
ed with CH2C12 (100 mL) and water (3x 100 mL). The 
organic layer was dried with MgS04, filtered and reduced 
in vacuo to give a light yellow oily residue. Purification by 
flash column chromatography (petroleum ether/ethyl 
acetate 95:5 v/v increasing to 80:20 v/v) gave the product, 
which was recrystallised from petroleum ether.
5.I.2.I. Benzo|6]furan-2-yl-biphenyl-4-yI-methanone 
(13a). Light yellow fine crystals (58%), mp 150-152 °C 
(lit.28 153-155 °C). TLC system: petroleum ether/ethyl
acetate, 1:1 v/v, R{: 0.63. lK  NMR (CDC13): 3 8.21 
(dd, / =  1.6, 8.2 Hz, 2H, Ar), 7.82 (m, 3H, Ar), 7.73 
(m, 3H, Ar), 7.65 (s, 1H, H-3), 7.46 (m, 5H, Ar). 13C 
NMR (CDC13): 3 184.33 (0= 0), 156.43 (C, C-7a),
152.80 (C, C-4'), 146.16 (C, C-l"), 140.29 (C, C-l'), 
136.31 (C, C-2), 130.58 (2 x CH, CH-2' and CH-60,
129.46 (2x CH, CH-3" and CH-5"), 128.83 (2x CH, 
CH-3' and CH-50, 128.76 (CH, Ar), 127.77 (2x CH, 
CH-2" and CH-6 "), 127.66 (CH, Ar), 127.48 (t, C-3a),
124.46 (CH, Ar), 123.78 (CH, Ar), 116.83 (CH, CH-3),
113.03 (CH, CH-7).
5.I.2.2. Benzol AJfuran-2-y 1(4'-chlorobiphenyl-4-
yl)methanone (13b). Light yellow solid (73%), mp 76- 
78 °C. TLC system: petroleum ether/ethyl acetate, 4:1 
v/v, Rr: 0.50. *H NMR (CDC13): 3 8.25 (dd, J=  1.7,
6 .6  Hz, 2H, Ar), 7.81 (m, 4H, Ar), 7.69 (m, 2H, Ar),
7.52 (m, 5H, Ar). 13C NMR (CDC13): 3 184.18 (C=0),
156.44 (C, C-7a), 152.75 (C, C-40, 144.82 (C, C-10,
138.71 (C, C-2 ), 136.57 (C, C-l"), 134.96 (C, C-4"), 
130.67 (2 x CH, CH-2' and CH-60, 129.64 (2x CH, 
CH-3" and CH-5"), 128.89 (2 x CH, CH-3' and CH-5'),
128.65 (CH, CH-6 ), 127.49 (2x CH, CH-2" and CH- 
6 "), 127.44 (C, C-3a), 124.49 (CH, Ar), 123.79 (CH, 
Ar), 116.87 (CH, CH-3), 113.02 (CH, CH-7). Anal. 
Calcd for C2 ,H ,3C102 (332.785): C, 75.79; H, 3.94. 
Found: C, 76.14; H, 4.00.
5.1.3. General method for the preparation of the alcohols
4 and 14. To a cooled (0 °C) solution of benzofuran-2-yl- 
(4-alkyl/aryl-phenyl)-methanone (5 mmol) in anhydrous 
dioxan (15 mL) was added sodium borohydride 
(5 mmol) and then the mixture was allowed to stir at 
room temperature under nitrogen for 2 h. The solvent 
was concentrated under reduced pressure and aqueous 
hydrochloric acid (1 M, 10 mL) was added to the resi­
due. The oil formed was extracted with diethyl ether 
(2x 50 mL) and washed with water (2x 25 mL), the 
organic layers were combined and dried with MgS04 
and the solvent concentrated under reduced pressure.
5.13.1. Benzofnran-2-yl-(4-eti)yl-phenyl)-methanol 
(4a, R = CH2 CH3 ). White solid (83%), mp 45-47 °C. 
TLC system: petroleum ether/ethyl acetate, 3:2 v/v, Rf. 
0.64. H NMR (CDC13): 7.60 (m, 1H, Ar), 7.50 (m, 
3H, Ar), 7.32 (m, 4H, Ar), 6.61 (s, 1H, H-3), 5.96 (d, 
/  = 4.6 Hz, 1H, CH-OH), 2.91 (d, /  = 4.6Hz, 1H, 
OH), 2.76, (q, J  = 7.6 Hz, 2H, CH2), 1.34 (t, 
J  = 7.6 Hz, 3H, CH3). 13C NMR (CDC13): 3 160.31 
(C, C-2), 159.21 (C, C-7a), 155.54 (C, C-4'), 144.97 (C, 
C-l'), 138.12 (C, C-3a), 128.58 (2x CH, CH-3' and 
CH-50, 127.34 (2 x CH, CH-2' and CH-6 '), 124.67 
(CH, Ar), 123.25 (CH, Ar), 121.58 (CH, Ar), 111.81 
(CH, CH-7), 104.35 (CH, CH-3), 71.02 (CH, CH-OH), 
29.08 (CH2), 16.05 (CH3). LRMS (EI+) m/z: 252.1 
(M+). Anal. Calcd for C17H160 2 (252.311): C, 80.93; 
H, 6.39. Found: C, 80.73; H, 6.41.
5.13.2. Benzoforan-2-yl-(4-propyl-phenyl)-methanol 
(4b, R =  C H 2C H 2C H 3). Yellow syrup (60%). TLC sys­
tem: petroleum ether/ethyl acetate, 4:1 v/v, Rf: 0.64. H 
NMR (CDC13): 3 7.50 (m, 4H, Ar), 7.26 (m, 4H, Ar), 
5.70 (d, J =  9.5 Hz, 1H, CH-OH), 2.64 (m, CH2, pro­
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pyl), 2.50 (s, 1H, OH), 1.69 (m, CH2, propyl), 0.10 (dt, 
/=  3.5, 7.3 Hz, CH3, propyl). 13C NMR (CDC13): <5 
157.20 (C, C-2), 155.25 (C-7a), 142.95 (C, C-47),
135.72 (C, C-l'), 128.76 (2 x CH, CH-37 and CH-5'),
128.15 (2 x CH, CH-2' and CH-6 '), 127.57 (C, C-3a),
126.78 (CH, Ar), 124.25 (CH, Ar), 122.82 (CH, Ar), 
121.13 (CH, Ar), 111.48 (CH, CH-7), 105.09 (CH, 
CH-3), 75.22 (CH, CH-OH), 37.85 (CH2), 24.51 
(CHz), 13.93 (CH3). Anal. Calcd for Ci8H180 2 
(266.339): C, 81.17; H, 6.81. Found: C, 80.87; H, 6.92.
5.1.3.3. Benzofuran-2-yl-(4-isopropyl-phenyl)-metha- 
nol (4c, R = CH(CH3)2 ). White solid (96%), mp 69- 
70 °C. TLC system: petroleum ether/ethyl acetate, 4:1 
v/v, Rf: 0.74. !H NMR (CDC13): 5 7.42 (m, 2H, Ar),
7.34 (m, 2H, Ar), 7.16 (m, 2H, Ar), 7.11 (s, 2H, Ar), 
6.45 (s, 1H, H-7), 5.81 (s, 1H, Ctf-OH), 2.82 (m, 1H, iso­
propyl), 2.59 (s, 1H, OH), 1.18 (s, 6 H, isopropyl). 13C 
NMR (CDC13): 8 157.64 (C, C-2), 154.03 (C, C-7a),
148.10 (C, C-47), 136.71 (2x CH, CH-37 and CH-57),
127.03 (2x CH, CH-27 and CH-6 7), 125.81 (CH, Ar),
125.65 (CH, Ar), 123.16 (CH, Ar), 110.28 (CH, CH-7),
102.82 (CH, CH-3), 69.54 (CH, CH-OH), 32.84 (CH, 
isopropyl), 22.93 (CH3, isopropyl). Anal. Calcd for 
C18H19O2-0.5H2O (276.3545): C, 78.23; H, 7.29. Found: 
C, 78.14; H, 7.05.
5.1.3.4. Benzofuran-2-yl-(4-terf-butyl-phenyl)-inetha- 
doI (4d, R = C(CH3)3). White solid (99%), mp 87- 
88 °C. TLC system: petroleum ether/ethyl acetate, 4:1 
v/v, Rf: 0.72. lH NMR (CDC13): 5 7.39 (m, 2H, Ar),
7.34 (m, 2H, Ar), 7.30 (m, 2H, Ar), 7.12 (m, 2H, Ar), 
6.41 (s, 1H, H-7), 5.78 (s, 1H, C//-OH), 2.58 (s, 1H, 
OH), 1.21 (s, 9H, 'butyl). 13C NMR (CDC13): S 158.74 
(C, C-2), 155.14 (C, C-7a), 151.24 (C, C-47), 130.72 (2x 
CH, CH-37 and CH-57), 129.36 (2x CH, CH-27 and 
CH-6 7), 128.15 (CH, Ar), 126.64 (CH, Ar), 125.93 
(CH, Ar), 111.39 (CH, CH-7), 103.92 (CH, CH-3),
70.57 (CH, CH-OH), 34.66 (C, 'butyl), 31.39 (CH3, 'bu­
tyl). Anal. Calcd for C l9H2o02 (280.361): C, 81.40; H, 
7.19. Found: C, 81.22; H, 7.01.
5.1.3.5. Benzofuran-2-yl-(4-isobutyl-phenyl)-inethanol 
(4e, R = CH2CH(CH3)2 ). Yellow syrup (99%), mp 87- 
88 °C. TLC system: petroleum ether/ethyl acetate, 4:1 
v/v, Rf: 0.73. *H NMR (CDC13): 5 7.53 (m, 1H,
Ar), 7.48 (m, 1H, Ar), 7.41 (m, 2H, Ar), 7.20 (m,
4H, Ar), 6.57 (s, 1H, H-7), 5.95 (s, 1H, C//-OH),
3.72 (s, 1H, OH), 2.52 (s, 2H, isobutyl). 1.91 (m,
1H, isobutyl), 0.96 (s, 6 H, isobutyl). 3C NMR 
(CDC13): 8 158.74 (C, C-2), 155.12 (C, C-7a), 142.05 
(C, C-47), 137.66 (C, C -l7), 129.38 (2x CH, CH-37 
and CH-57), 128.10 (CH, Ar), 126.63 (2x CH, CH-27 
and CH-6 7), 124.23 (CH, Ar), 122.81 (CH, Ar), 
121.12 (CH, Ar), 111.34 (CH, CH-7), 103.89 (CH, 
CH-3), 70.66 (CH, CH-OH), 45.16 (CH2, isobutyl), 
30.21 (CH, isobutyl), 22.38 (CH3, isobutyl). Anal. 
Calcd for Ci9H20O2 (280.361): C, 81.40; H, 7.19. 
Found: C, 81.07; H, 7.43.
5.1.3.6. Benzofuran-2-yl-(4-cyclohexyl-phenyl)-inetha-
nol (4f, R = XgHjx). White solid (98%), mp 67-68 °C. 
TLC system: petroleum ether/ethyl acetate, 4:1 v/v, Rf:
0.63. *H NMR (CDC13): 8 7.59 (m, 1H, Ar), 7.48 (m, 
3H, Ar), 7.25 (m, 4H, Ar), 6.58 (s, 1H, H-7), 5.89 (s, 
1H, CH-OH), 3.72 (s, 1H, OH), 2.61 (m, 1H, cyclohex- 
yl), 1.58 (m, 10H, cyclohexyl). 13C NMR (CDC13): 8
159.28 (C, C-2), 155.46 (C, C-7a), 144.09 (C, C-47),
134.90 (C, C-l7), 128.72 (2x CH, CH-37 and CH-57), 
128.59 (2x CH, CH-27 and CH-60, 124.00 (CH, Ar), 
122.77(CH, Ar), 120.91 (CH, Ar), 111.25 (CH, Ar),
103.24 (CH, Ar), 67.63 (CH, CH-OH), 45.00 (CH, 
C//-cyclohexyl), 35.40 (CH2, cyclohexyl), 27.65 (CH2, 
cyclohexyl), 26.95 (CH2, cyclohexyl). HRMS (El ) m/z 
Calcd for C21H22Q2 (M+H)+ 358.1914. Found 358.1910.
5.1.3.7. Benzo[AJfuran-2-yl-biphenyl-4-yl-methanol 
(14a, R = phenyl). White solid (90%), mp 121-123 °C 
(lit.28 123-125 °C). TLC system: petroleum ether/ethyl 
acetate, 1:1 v/v, Rf: 0.63. *H NMR (CDC13): 8 7.63 
(m, 6 H, Ar), 7.46 (m, 4H, Ar), 7.30 (m, 3H, Ar), 6.64 
(d, J = 0.6 Hz, 1H, H-3), 6.04 (d, J -  3.1 Hz, 1H, CH- 
OH), 2.73, (d, J  = 3.9 Hz, 1H, OH). I3C NMR (CDC13): 
8 158.84 (C, C-2), 155.57 (C, C-7a), 141.76 (C, C-l7),
141.10 (C, C-l77), 139.69 (C, C-40, 129.28 (2x CH, 
CH-377 and CH-570, 128.47 (C, C-3a), 127.92 (2x CH, 
CH-27 and CH-6 7), 127.83 (2x CH, CH-37 and CH-50,
127.72 (2x CH, CH-277 and CH-6 77), 127.60 (CH, Ar),
124.82 (CH, Ar), 123.34 (CH, Ar), 121.64 (CH, Ar),
111.83 (CH, CH-7), 104.57 (CH, CH-3), 70.91 (CH- 
OH).
5.1.3.8. Benzof A]furan-2-yl-(4 '-chlorobiphenyl-4- 
y!)methanol (14b, R = 4-chlorophenyI). White solid 
(75%), mp 76-78 °C. TLC system: petroleum ether/ethyl 
acetate, 1:1 v/v, Rf: 0.60. *H NMR (CDC13): 8 7.54 (m, 
7H, Ar), 7.44 (m, 3H, Ar), 7.25 (m, 2H, Ar), 6.59 (s, 1H, 
H-3), 6.00 (d, /  = 4.5 Hz, 1H, CH-OH), 2.65 (d, 
/ =  4.6 Hz, 1H, OH). 13C NMR (CDC13): <5 158.69 (C, 
C-2), 155.55 (C, C-7a), 140.48 (C, C-l7), 140.31 (C, C- 
47), 139.51 (C, C-l77), 134.02 (C, C-477), 129.42 (2x CH, 
CH-377 and CH-577), 128.81 (2x CH, CH-277 and CH- 
6 "), 128.41 (C, C-3a), 127.80 (2x CH, CH-27 and CH- 
60, 127.64 (2x CH, CH-37 and CH-57), 124.87 (CH, 
Ar), 123.36 (CH, Ar), 121.65 (CH, Ar), 111.82 (CH, 
CH-7), 104.59 (CH, CH-3), 70.82 (CH-OH). Anal. 
Calcd for C2iH15C102 (334.800): C, 75.20; H, 4.45. 
Found: C, 75.34; H, 4.52.
5.1.4. General method fw  the preparation of the triazole 
compounds 5-11, 15 and 16. Thionyl chloride (4 mmol) 
in anhydrous acetonitrile (10.0 mL) was added dropwise 
to a stirred solution of 1,2,4-triazole (16 mmol) in anhy­
drous acetonitrile (10.0 mL) at a temperature of 10 °C. 
The white suspension formed was stirred for 1 h at 
10 °C. A solution of benzo[Z>]furan-2-yl-(4-alkyl/arylphe- 
nyl)methanol (4a-f, 14) (1.0 g, 4 mmol) in anhydrous 
acetonitrile (10.0 mL) was added to the mixture fol­
lowed by activated potassium carbonate (1 .1 0  g, 
8  mmol). The suspension was stirred under nitrogen at 
room temperature for 4 days. The resulting suspension 
was filtered and the filtrate was evaporated in vacuo to 
yield a light brown oil. The oil was extracted with 
CH2C12 (150 mL) and water (3x 100 mL). The organic 
layer was dried with MgS04, filtered and reduced 
in vacuo.
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5.1.4.1. 1 -(BenzoI£]furan-2-yl-(4-inethylphenyI)ineth- 
yl]-l//-ll,2,4]triazole (5a) and 4-(benzo|AJ furan-2-yl-(4- 
methylphenyl)methyl]-4//-[l,3,4]triazole (5b). Purified by 
column chromatography (petroleum ether/ethyl acetate, 
1:1 v/v) to give the [l,2,4]triazole 5a, further elution 
(dichloromethane/methanol, 95:5 v/v) gave the [l,3,4]tri- 
azole 5b.
Data for 5a: orange crystals (28%), mp 106-108 °C. TLC 
system: petroleum ether/ethyl acetate, 4:1 v/v, Rf 0.14. 
*H NMR (CDC13): 5 8.14 (s, 1H, H-3'"), 8.05 (s, 1H, 
H-5'"), 7.56 (d, /  = 7.7 Hz, 1H, Ar), 7.48 (d, 
7=8.3 Hz, 1H, Ar), 7.34 (m, 1H, Ar), 7.25 (m, 5H, 
Ar), 6.84 (s, 1H, H-l), 6.59 (s, 1H, H-3), 2.40 (s, 3H, 
CH3). 13C NMR (CDCI3): <5 155.34 (C, C-2), 152.93 
(C, C-7a), 152.21 (CH, CH-57"), 143.21 (CH, CH-3W),
139.24 (C, C-3a), 132.61 (C, C-l'), 129.80 and 127.67 
(CH, Ar), 127.55 (C, C-4'), 125.17, 123.30 and 121.49 
(CH, Ar), 111.54 (CH, CH-7), 107.58 (CH, CH-3),
62.10 (CH, CH-1), 21.19 (CH3).
Data for 5b: white solid (12%), mp 64-66 °C. TLC sys­
tem: dichloromethane/methanol, 9:1 v/v, Rf. 0.27. H 
NMR (CDCI3): 5 8.21 (s, 2H, H-2'" and H-5'"), 7.57 
(d, J=  7.7 Hz, 1H, Ar), 7.48 (d, J  =8.3 Hz, 1H, Ar),
7.36 (m, 1H, Ar), 7.28 (m, 3H, Ar), 7.17 (d, 
J=  8.1 Hz, 2H, Ar), 6.64 (s, 1H, H-l), 6.59 (s, 1H, H- 
3), 2.41 (s, 3H, CH3). 13C NMR (CDC13): 6 155.39 (C, 
C-2), 152.42 (C, C-7a), 142.43 (2x CH, CH-2"' and 
CH-5'"), 139.72 (C, C-l'), 132.27 (C, C-4'),130.08 and 
127.38 (CH, Ar), 127.22 (C, C-3a), 125.56, 123.56 and
121.57 (CH, Ar), 111.62 (CH, CH-7), 107.60 (CH, 
CH-3), 58.00 (CH, CH-1), 21.18 (CH3). HRMS (EI+) 
m!z Calcd for C18H 15N30  (M+H)+ 290.1288. Found 
290.1287.
5.1.4.2. 1 -|Benzo|61furan-2-yl-(4-ethylphenyl)methyI]- 
1//-11,2,41 triazole (6a) and 4-{benzo(6] furan-2-yl-(4-eth- 
y!phenyI)niethyl}-4//-| 1 ,3,4Itriazole (fib). Purified by col­
umn chromatography (petroleum ether/ethyl acetate, 
7:3 v/v) to give the [l,2,4]triazole 6a, further elution 
(dichloromethane/methanol, 99:1 v/v) gave the [l,3,4Jtri- 
azole 6b.
Data for 6a: yellow syrup (67%). TLC system: petroleum 
ether/ethyl acetate, 1:1 v/v, Rf. 0.42. *H NMR (CDC13): 
S 8.19 (s, 1H, H-3'"), 8.09 (s, 1H, H-5'"), 7.58 (d, 
/  = 8.4 Hz, 1H, Ar), 7.51 (d, /= 9 .3 H z , 1H, Ar), 
7.39-7.27 (m, 6 H, Ar), 6.89 (s, 1H, H-l), 6.63 (s, 1H, 
H-3), 2.73 (q, /= 7 .6 H z , 2H, CHZ), 1.30 (t,
J =7.6 Hz, 3H, C //3). I3C NMR (CDC13): 5 155.75 
(C, C-2), 153.342 (C, C-7a), 152.65 (CH, CH-5'"),
145.91 (C, C-4'), 143.67 (CH, CH-3'"), 133.20 (C, C- 
1'), 129.06 (2x CH, CH-2' and CH-6 '), 128.16 (2x CH, 
CH-3' and CH-5'), 127.96 (C, C-3a), 125.59 (CH, Ar),
123.73 (CH, Ar), 121.93 (CH, Ar), 111.97 (CH, CH-7),
108.06 (CH, CH-3), 62.51 (CH, CH-1), 28.99 (CH2), 
15.85 (CH3). HRMS (EI+) m /z  Calcd for C19H17N30  
(M+H)+ 304.1444. Found 304.1442.
Data for 6b: White solid (13%), mp 126-128 °C. TLC 
system: dichloromethane/methanol, 9:1 v/v, Rf 0.31. 
*H NMR (CDCI3): 5 8.25 (s, 2H, H-2'" and H-5'"),
7.57 (d, J  = 6 .8  Hz, 1H, Ar), 7.46 (d, J  = 8.4 Hz, 1H, 
Ar), 7.37-7.19 (m, 6 H, Ar), 6.75 (s, 1H, H-l), 6.62 (s, 
1H, H-3), 2.70 (q, / =  7.6 Hz, 2H, CH& 1.26 (t, 
/  = 7.6 Hz, 3H, CH3). 13C NMR (CDC13): <5 155.76 
(C, C-2), 152.90 (C, C-7a), 146.26 (C, C-4'), 142.95 (2x 
CH, CH-2'" and CH-5'"), 132.98 (C, C-l'), 129.27 (2x 
CH, CH-2' and CH-6 '), 127.89 (2x CH, CH-3' and 
CH-5'), 127.67 (C, C-3a), 125.91 (CH, Ar), 123.94 
(CH, Ar), 122.01 (CH, Ar), 112.01 (CH, CH-7), 108.04 
(CH, CH-3), 58.28 (CH, CH-1), 28.95 (CH2), 15.83 
(CH3). Anal. Calcd for C19H17N30  (303.362): C, 
75.23; H, 5.65; N, 13.84. Found: C, 75.19; H, 5.74; N, 
13.61.
5.1.4.3. l-[Benzo[£]furan-2~yl-(4-propylphenyI)meth- 
y lj-l//-[l ,2,4]triazole (7). Purified by column chromatog­
raphy (petroleum ether/ethyl acetate, 1:1 v/v) to give the
[l,2,4]triazole 7 as a yellow syrup (2%). TLC system: 
petroleum ether/ethyl acetate, 4:1 v/v, Rf 0.25. !H 
NMR (CDCI3): S 8.03 (s, 1H, H-3'"), 7.94 (s, 1H, H- 
5'"), 7.46 (d, / =  7.7 Hz, 1H, Ar), 7.38 (d, J=  8.3 Hz, 
1H, Ar), 7.23 (m, 1H, Ar), 7.16 (m, 5H, Ar), 6.74 (s, 
1H, H-l), 6.49 (s, 1H, H-3), 2.53 (t, J=  7.6 Hz, CH2, 
propyl), 1.57 (dt, J  = 7.5, 15 Hz, CH2, propyl), 0.87 (t, 
/ =  7.3 Hz, CH3, propyl). 13C NMR (CDC13): 5 154.32 
(C, C-2), 151.92 (C, C-7a), 151.17 (CH, CH-5'"),
142.96 (C, C-3a), 131.77 (C, C-l'), 128.17 (2x CH, 
CH-2' and CH-60, 126.61 (2x CH, CH-3' and CH-5'),
126.53 (C, C-4'), 124.13, 122.27 and 120.46 (CH, Ar),
110.52 (CH, CH-7), 106.55 (CH, CH-3), 61.11 (CH, 
CH-1), 36.68 (CHj), 23.34 (CH2), 12.79 (CH3). HRMS 
(EI+) mtz Calcd for C ^ H ^ O  (M+H)+ 318.1601. 
Found 318.1601.
5.1.4.4. 1 -(BenzolA]furan-2-yl-(4-isopropylplienyl)-
methylj-l //-|1 ,2,41triazole (8a) and 4-Jbenzo(Al fivan-2- 
yH4-isopropylplieiiyl)metbyI]-4//-{l,3,4]triazole (8b).
Purified by column chromatography (hexane/ethyl ace­
tate, 9:1 v/v) to give the [l,2,4]triazole 8a, further elution 
(dichloromethane/methanol, 9:1 v/v) gave the {l,3,4]tria- 
zole 8b.
Data for 8a: yellow syrup (78%). TLC system: petroleum 
ether/ethyl acetate, 1:1 v/v, Rf 0.72. ‘H NMR (CDC13): 
5 8.42 (s, 1H, H-3'"), 8.33 (s, 1H, H-5'"), 7.31 (m, 1H, 
Ar), 7.24 (m, 2H, Ar), 7.06 (m, 5H, Ar), 6.62 (s, 1H, 
H-l), 6.37 (s, 1H, H-3), 2.73 (septet, 1H, isopropyl), 
1.05 (d, 6 H, isopropyl). 13C NMR (CDC13): 5 155.25 
(C, C-2), 153.15 (CH, C-7a), 152.11 (CH, CH-5'"),
149.79 (C, C-3a), 143.35 (C, C-l'), 133.09 (C, C-40,
127.76 (2 x CH, CH-2' and CH-60, 126.84 (2x CH, 
CH-3' and CH-5'), 125.04 (CH, Ar), 123.22 (CH, Ar),
112.44 (CH, Ar), 111.42 (CH, CH-7), 107.07 (CH, 
CH-3), 62.03 (CH, CH-1), 34.47 (C, isopropyl), 24.16 
(CH3, isopropyl). HRMS (EI+) mtz Calcd for 
C2oH 19N 30  (M)+ 318.1601. Found 318.1601.
Data for 8b: yellow syrup (7%). TLC system: petroleum 
ether/ethyl acetate, 1:1 v/v, Rf 0.11. *H NMR (CDC13): 
5 8.12 (s, 2H, H-2'" and H-5'"), 7.47 (m, 1H, Ar), 7.39 
(m, 1H, Ar), 7.27 (m, 1H, Ar), 7.20 (m, 4H, Ar), 7.13 
(m, 3H, Ar), 6.56 (s, 1H, H-l), 6.49 (s, 1H, H-3), 2.75 
(septet, 1H, isopropyl), 1.18 (d, 6 H, isopropyl). I3C
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NMR (CDC13): S 155.39 (C, C-2), 152.30 (C, C-7a),
150.63 (2x CH, CH-2'" and CH-5'"), 142.47 (C, C-4'),
132.46 (C, C-l'), 127.72 (C, C-3a), 127.52 (2 x CH, 
CH-2' and CH-6 '), 127.21 (2x CH, CH-3' and CH-5'),
125.58 (CH, Ar), 123.58 (CH, Ar), 121.59 (CH, Ar),
111.64 (CH, CH-7), 107.67 (CH, CH-3), 58.08 (CH, 
CH-1), 33.89 (C, isopropyl), 23.85 (CH3, isopropyl). 
HRMS (EI+) m/z Calcd for C2oH19N30  (M+H)+ 
318.1601. Found 318.1603.
5.1.4.5. l-|Benzo(61furan-2-yl-(4-ferf-batyLphenyI)- 
methyl}-l//-IL2,4|triazole (9). Purified by column chro­
matography (hexane/ethyl acetate, 9:1 v/v) to give the
[1.2.4]triazole 9, as a yellow syrup (62%). TLC system: 
petroleum ether/ethyl acetate, 1:1 v/v, Rf. 0.61. !H 
NMR (CDC13): S 8.15 (s, 1H, 1H, H-3'"), 8.01 (s, 1H, 
H-5'"), 7.49 (m, 1H, Ar), 7.40 (m, 3H, Ar), 7.25 (m, 
3H, Ar), 7.19 (m, 3H, Ar), 6.76 (s, 1H, H-l), 6.57 (s, 
1H, H-3), 1.32 (s, 9H, 'butyl). 13C NMR (CDC13): 8 
156.98 (C, C-2), 154.16 (CH, CH-5'"), 150.30 (C, 
C-7a), 148.52 (CH, CH-3'"), 136.47 (C, C-4'), 132.56 
(2x CH, CH-2' and CH-6 '), 129.94 (C, C-l'), 129.08 
(C, C-3a), 127.92 (2x CH, CH-3' and CH-5'), 123.37 
(CH, Ar), 122.14 (CH, Ar), 120.55 (CH, Ar), 110.82 
(CH, CH-7), 101.37 (CH, CH-3), 61.90 (CH, CH-1),
34.80 (C, 'butyl), 31.41 (CH3, 'butyl). HRMS (EI+) ml 
z Calcd for C2 iH2iN30  (M)+ 332.1757. Found 332.1761.
5.1.4.6. l-{Benzo|A]furan-2-yl-(4-isobutylphenyl)meth- 
ylj-l //-| 1,2,4]triazole (10). Purified by column chroma­
tography (hexane/ethyl acetate, 9:1 v/v) to give the
[1.2.4]triazole 10 as a yellow syrup (56%). TLC system: 
petroleum ether/ethyl acetate, 1:1 v/v, R f  0.63. *H 
NMR (CDC13): 8 8.28 (s, 1H, 1H, H-3'"), 8.22 (s, 1H, 
1H, H-5'"), 7.60 (m, 2H, Ar), 7.40 (m, 2H, Ar), 7.31 
(m, 2H, Ar), 7.23 (m, 2H, Ar), 6.82 (s, 1H, H-l), 6.54 
(s, 1H, H-3), 2.54 (d, 2H, CH2, isobutyl), 1.95 (m, 1H, 
CH, isobutyl), 1.02 (s, 6 H, isobutyl). 13C NMR 
(CDC13): 8 155.27 (C, C-2), 153.21 (CH, CH-5'"), 
152.11 (CH, CH-3'"), 136.47 (C, C-7a), 132.51 (2x CH, 
CH-2' and CH-6 '), 131.47 (2x CH, CH-3' and CH-5'),
131.36 (C, C-4'), 129.94 (C, C-l'), 128.88 (C, C-3a),
123.37 (CH, Ar), 122.14 (CH, Ar), 120.55 (CH, Ar), 
110.89 (CH, CH-7), 101.37 (CH, CH-3), 56.50 (CH, 
CH-1), 45.54 (CH2, isobutyl), 27.57 (CH, isobutyl), 
22.23 (CH3, isobutyl). Anal. Calcd for C2 jH2 iN3O0.3- 
H20  (336.821): C, 74.89; H, 6.46; N, 12.48. Found: C, 
74.87; H, 6.45; N, 12.15.
5.1.4.7. l-|Benzo[AJfuran-2-yl-(4-cyclohexylphenyl> 
methylJ-l/Z-Il ,2,4]triazole (11). Purified by column chro­
matography (hexane/ethyl acetate, 9:1 v/v) to give the
[1.2.4]triazole 11 as a yellow syrup (14%). TLC system: 
petroleum ether/ethyl acetate, 1:1 v/v, Rf: 0.70. *H 
NMR (CDC13): <5 8.28 (s, 1H, 1H, H-3'"), 8.22 (s, 1H, 
1H, H-5'"), 7.60 (m, 2H, Ar), 7.40 (m, 2H, Ar), 7.31 
(m, 2H, Ar), 7.23 (m, 2H, Ar), 6.82 (s, 1H, H-l), 6.54 
(s, 1H, H-3), 2.54 (m, 1H, CH, cyclohexyl), 1.48 (m, 
10H, cyclohexyl). 13C NMR (CDC13): 8 156.98 (C, C- 
2), 154.16 (CH, C-7a), 148.52 (CH, CH-5'"), 143.74 
(CH, CH-3'"), 136.47 (C, C-4'), 131.56 (2 x CH, CH-2' 
and CH-6 '), 129.81 (2x CH, CH-3' and CH-5'), 128.64 
(C, C-3a), 123.37 (CH, Ar), 122.14 (CH, Ar), 120.55
(CH, Ar), 110.89 (CH, CH-7), 101.37 (CH, CH-3), 
56.50 (CH, CH-1), 45.00 (CH, cyclohexyl), 35.40 (2x 
CH2, cyclohexyl), 27.65 (2x CH2, cyclohexyl), 26.95 
(lx  CH2, cyclohexyl). HRMS (EI+) m/z Calcd for 
C23H23N30 2 (M+H)+ 358.1914. Found 358.1910.
5.1.4.8. l-(Benzo[£]furan-2-yl-biphenyl-4-yI-methyI)- 
l//-[l,2,4]triazole (15a) and 4-(benzof£]fiiran-2-yl-biphe- 
ny 1-4-yl-methyI)-4/y-[l ,2,4]triazole (15b). Purified by col­
umn chromatography (petroleum/ethyl acetate, 9:1 v/v 
increasing to 65:35 v/v) to give the (l,2,4]triazole 15a, 
further elution (dichloromethane/methanol, 99:1 v/v) 
gave the [l,3,4]triazole 15b.
Data for 15a: White solid (53%), mp 130-132 °C. TLC 
system: petroleum ether/ethyl acetate, 1:1 v/v, Rf 0.41. 
‘H NMR (CDC13): 8 8.24 (s, 1H, H-3'"), 8.12 (s, 1H, 
H-5'"), 7.68 (d, J -  8.3 Hz, 2H, Ar), 7.63 (m, 3H, Ar),
7.53 (m, 3H, Ar), 7.45-7.31 (m, 5H, Ar), 6.96 (s, 1H, 
H-l), 6.69 (s, 1H, H-3). 13C NMR (CDC13): 8 155.80 
(C, C-2), 152.99 (C, C-7a), 152.78 (CH, CH-5'"),
143.76 (CH, CH-3'"), 142.6.1 (C, C-l"), 140.55 (C, C- 
1'), 134.92 (C, C-4'), 129.36 (2x CH, CH-2' and CH- 
60, 128.58 (2 x CH, CH-3" and CH-5"), 128.27 (2x 
CH, CH-2" and CH-6 "), 128.23 (2x CH, CH-3' and 
CH-50, 127.92 (C, C-3a), 127.60 (CH, CH-4"), 125.75 
(CH, Ar), 123.83 (CH, Ar), 122.02 (CH, Ar), 112.02 
(CH, CH-7), 108.34 (CH, CH-3), 62.41 (CH, CH-1). 
Anal. Calcd for C23H17N30  (351.406): C, 78.61; H, 
4.88; N, 11.95. Found: C, 78.38; H, 4.74; N, 11.89.
Data for 15b: Light yellow solid (6%), mp 56-58 °C. 
TLC system: dichloromethane/methanol, 9:1 v/v, Rf 
0.31. *H NMR (CDC13): 8 8.41 (s, 2H, H-2'" and H- 
5"0, 7.79 (d, J  = 8.4 Hz, 2H, Ar), 7.72 (m, 3H, Ar), 
7.61 (m, 3H, Ar), 7.58-7.40 (m, 5H, Ar), 6.87 (s, 1H, 
H-l), 6.79 (s, 1H, H-3). 13C NMR (CDC13): 8 155.85 
(C, C-2), 152.44 (C, C-7a), 143.02 (C, C-l"), 142.93 
(2x CH-2'" and CH-5'"), 140.23 (C, C-l'), 134.50 (C, 
C-4'), 129.42 (2x CH, CH-2' and CH-6 '), 128.51 (2x 
CH, CH-3" and CH-5"), 128.41 (2x CH, CH-2" and 
CH-6"), 128.31 (CH, CH-4"), 127.59 (2x CH, CH-3' 
and CH-5' and C, C-3a), 126.12 (CH, Ar), 124.07 
(CH, Ar), 122.09 (CH, Ar), 112.10 (CH, CH-7), 108.34 
(CH, CH-3), 58.33 (CH, CH-1). Anal. Calcd for 
C23H17N30  (351.406): C, 78.61; H, 4.88; N, 11.95. 
Found: C, 78.77; H, 4.62; N, 11.79.
5.1.4.9. l-[Benzo[£]fiiran-2-yl-(4'-ch]or<>-bipheny]-4-yl)- 
methyl]-l//-[l ,2,4]triazole (16a) and 4-{benzo[£jfuran-2-yl- 
(4'cMoro-biphenyl-4-yl)-inethylj-4//-[l,2,41triazole (16b).
Purified by column chromatography (petroleum/ethyl 
acetate, 9:1 v/v increasing to 65:35 v/v) to give the
[l,2,4]triazole 16a, further elution (dichloromethane/ 
methanol, 99:1 v/v) gave the [l,3,4]triazole 16b.
Data for 16a: white solid (67%), mp 34-36 °C. TLC sys­
tem: petroleum ether/ethyl acetate, 1:1 v/v, Rf 0.26. H 
NMR (CDC13): 8 8.24 (s, 1H, H-3'"), 8.11 (s, 1H, H- 
5"'), 7.64 (d, J = 8.3 Hz, 2H, Ar), 7.60-7.52 (m, 3H, 
Ar), 7.49-7.29 (m, 7H, Ar), 6.95 (s, 1H, H-l), 6.69 (s, 
1H, H-3). 13C NMR (CDC13): 8 155.80 (C, C-2),
152.80 (CH, CH-5'" and C, C-7a), 143.74 (CH, CH-
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3'"), 141.36 (C, C-l'), 138.97 (C, C-l"), 135.32 (C, C-47),
134.38 (C, C-4"), 129.52 (2 x CH, CH-2' and CH-6 7),
128.83 (2x CH, CH-3" and CH-5"), 128.67 (2x CH, 
CH-2" and CH-6 "), 128.10 (2x CH, CH-37 and CH-57),
127.87 (C, C-3a), 125.80 (CH, Ar), 123.86 (CH, Ar), 
122.02 (CH, Ar), 112.02 (CH, CH-7), 108.40 (CH, 
CH-3), 62.35 (CH, CH-1). Anal. Calcd for C23H16 
C1N30  (385.852): C, 71.60; H, 4.18; N, 10.89. Found: 
C, 71.45; H, 4.10; N, 10.62.
Data for 16b: Light yellow solid (13%), mp 68-70 °C. 
TLC system: dichloromethane/methanol, 9:1 v/v, Rf:
0.50. *H NMR (CDCI3): 5 8.31 (s, 2H, H-27" and H- 
5/7/), 7.65 (d, J — 8.3 Hz, 2H, Ar), 7.61-7.43 (m, 6 H, 
Ar), 7.41-7.31 (m, 4H, Ar), 6.79 (s, 1H, H-l), 6.70 (s, 
, 1H, H-3). 13C NMR (CDCI3): 3 155.85 (C, C-2),
152.29 (C, C-7a), 142.89 (2x CH, CH-27" and CH-57"),
141.75 (C, C-l7), 138.66 (C, C-l"), 134.93 (C, C-47),
134.58 (C, C-4"), 129.59 (2x CH, CH-27 and CH-6 7),
128.82 (2x CH, CH-3" and CH-5"), 128.42 (2x CH, 
CH-2" and CH-6 "), 128.35 (2x CH, CH-37 and CH-57),
127.56 (C, C-3a), 126.16 (CH, Ar), 124.10 (CH, Ar),
122.10 (CH, Ar), 112.10 (CH, CH-7), 108.37 (CH, 
CH-3), 58.26 (CH, CH-1). Anal. Calcd for
C23H16C1N30  0.1H20  (387.653): C, 71.26; H, 4.21; N, 
10.83. Found: C, 71.05; H, 4.09; N, 10.75.
5.2. MCF-7 (CYP26A1) assay for inhibition of metabo­
lism of atRA
Human MCF-7 breast cancer cells were cultured in phe­
nol red free RPMI1640 medium supplemented with 5 % 
(v/v) charcoal free foetal calf serum, antibiotics (penicillin 
and streptomycin) and fungizone at the same concentra­
tion of 10 iU/mL. Cells were grown in a humidified incu­
bator (5% C 02, 95% air) at 37 °C. MCF-7 cells were 
seeded in 12-well cell culture plates (Comings Inc., New 
York, USA) at 2.5 x 105 cells per well in a total volume 
of 1.5 mL. Cells were allowed to adhere to the well for 
24 h. After 24 h, the medium from each well was re­
moved, washed once with phosphate-buffered saline 
(PBS) and replaced by fresh medium plus 10 pL inhibi­
tor/solvent (acetonitrile) and 10 pL of atRA (to give a fi­
nal concentration of 1 x 1 0 - 7 M atRA and 0.1 pCi 
[11,12-3H] all-trans retinoic acid). The plates were foil 
wrapped and incubated at 37 °C for 9 h. Each treatment 
was performed in duplicate. The incubation was stopped 
by addition of 1% acetic acid (100 pL/well), the medium 
removed into separate glass tubes. Two hundred microli­
tres of distilled water was added to each well and the cells 
were scrapped off and the contents added to the appropri­
ate glass tube. This procedure was repeated with a further 
4Q0 pL water but without scraping. Ethyl acetate con­
taining 0.05% (w/v) butylated hydroxyanisole (2x 2 mL) 
was added to each tube. After vortexing for 15 s, the tubes 
were spun down at 3000 rpm for 15min. The organic 
layer was then evaporated using a Christ centrifuge con­
nected to a vacuum pump and a multitrap at —80 °C.
5.3. High performance liquid chromatography (HPLC)
The HPLC system was equipped with a high pressure 
pump (Milton-Roy pump), injector with a 50 pL loop
connected to a fJ-RAM radioactivity detector, connected 
to a Compaq™ computer running Laura® data acquisi­
tion and analysis software. This enabled on-line detec­
tion and quantification of radioactive peaks. The 
HPLC column (10 pM Qg pBondapak™ 3.9 x 300 mm 
HPLC column from Waters, UK) operating at ambient 
temperature was used to separate the metabolites which 
were eluted with acetonitrile/1% ammonium acetate in 
water/acetic acid (75:25:0.1 v/v/v) at a flow rate of
1.9 mL/min. Ecoscint™ was used as the flow scintilla­
tion fluid.
5.4. Molecular docking
All molecular modelling studies were performed on a 
RM Innovator Pentium IV 2.4 GHz running either Li­
nux Fedora Core 3 or Windows XP using Molecular 
Operating Environment (MOE) 2004.0324 software. All 
the minimisations were performed with MOE a until a 
RMSD gradient of 0.05 Kcal mol- 1  A -1  with the force- 
field specified and the partial charges were automatically 
calculated.
Ligands were docked within the active site of the 
CYP26A1 homology model25 using the MOE-Dock 
with simulated annealing used as the search protocol 
with a total of 5 runs, 10 cycles per run, 8000 steps 
per cycle and an initial temperature of 1000 K. Molecu­
lar dynamics was performed with MOE using the NVT 
environment for 1 0 0  ps and constant temperature of 
300 K using the MMFF94X forcefield with all other de­
fault settings in MOE-dynamics chosen. The lowest 
energy conformation was selected and subjected to an 
energy minimisation using the MMFF94X forcefield. 
The scoring.svl script was used to identify interaction 
types between ligand and protein.
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